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The heat shock proteins are a highly conserved protein family that are constitutively 
expressed and function as molecular chaperones.  Molecular chaperones 90kDa Heat Shock 
Protein  (Hsp90) and 70kDa Heat Shock Protein (Hsp70) have emerged as promising therapeutic 
targets for both cancer and neurodegenerative diseases.  Hsp90 is responsible for the maturation 
of more than 300 nascent polypeptides, “clients”. These client proteins are involved in the 
oncogenic process, as many are associated with all 10 hallmarks of cancer.  Hsp70 is involved in 
protein folding and maintenance of protein homeostasis.  Targeting molecular chaperones, 
Hsp70 and Hsp90, is a viable therapeutic strategy for various neurodegenerative diseases as they 
prevent protein aggregation via refolding denatured proteins and solubilizing protein aggregates.  
Therefore, small molecules that interact with Hsp90 are sought, as modulation of Hsp90 can 
impact the cellular function of Hsp70.   
 Hsp90 contains a traditional N-terminal ATP-binding site and a C-terminal dimerization 
domain, which contains an additional binding site.  Targeting the Hsp90 C-terminus with 
inhibitors derived from novobiocin is one approach to modulating molecular chaperones.  
Structure activity relationship studies on novobiocin have led to the development of either 
neuroprotective or cytotoxic compounds.  Segregation of the pro-survival heat shock response 
from a cytotoxic response due to client protein degradation is unique to C-terminal inhibitors.  
Described herein is the design, synthesis and biological evaluation of small molecules that target 
the C-terminus of Hsp90, for the continued development of potential therapeutics for the 
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1. Introduction to Hsp90 Structure, Function, and Modulation 
 
Introduction 
Molecular chaperones are an evolutionarily conserved class of proteins that prevent 
aggregation and assist in the conformational maturation of other cellular proteins (referred to as 
client proteins). Heat shock proteins (Hsps) are a group of molecular chaperones that are 
ubiquitously expressed under non-stressed conditions and can be upregulated upon exposure to 
cellular stress, including elevated temperature. Hsp90 is the most abundant heat shock protein 
and represents 1-2% of the cellular protein in unstressed cells.1-3 There are four human isoforms 
of Hsp90: the cytosolic isoforms Hsp90α and β, Grp94 (localized to the endoplasmic reticulum), 
and TRAP1 (localized to the mitochondria). Hsp90 facilitates the conformational maturation of 
Hsp90-dependent proteins via the Hsp90 chaperone cycle, in which the Hsp90 homodimer forms 
a large, multiprotein complex that relies upon co-chaperones, immunophilins, and partner 
proteins to fold nascent polypeptides, as well as the rematuration of denatured proteins.4-6 The 
Hsp90 heteroprotein complex folds these substrates through a series of conformational 
transitions at the middle and N-terminal domain of Hsp90 that facilitate ATP hydrolysis at the N-
terminus.7-8 Inhibition of the Hsp90 protein folding machinery results in client protein 
ubiquitinylation and subsequent degradation by the proteasome, which can ultimately result in 
cell death.9-12 Many Hsp90-dependent client proteins (e.g., ErbB2, B-Raf, Akt, steroid hormone 
receptors, mutant p53, HIF-1, survivin, telomerase, etc.) are associated with the ten hallmarks of 
cancer: self sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, 




and tumor-promoting inflammation.13-14 Therefore, oncogenic client protein degradation via 
Hsp90 inhibition represents a promising approach toward anticancer drug development.15-17 
Additionally chaperones interact with protein degradation pathways to control constitutive 
protein turnover and to facilitate the elimination of misfolded proteins.18   
Originally, small molecule inhibitors of Hsp90 were designed to perturb the ATPase 
activity located at the N-terminus and include derivatives of geldanamycin, radiciol, and purine.19 
N-terminal Hsp90 inhibitors are effective at inhibiting Hsp90 function and lead to anti-
proliferative activity through client protein degradation; however, Hsp90 N-terminal inhibition 
also leads to induction of the Heat Shock Response (HSR).20-22 The consequence of inducing a 
pro-survival response concomitantly with inducing client protein degradation is typically, 
cytostatic activity. However, this induction also leads to dosing and scheduling problems in the 
clinic, as N-terminal inhibitors induce expression of the target they inhibit. Therefore, Hsp90 
inhibitors with novel mechanisms of action are sought to take advantage of the dependence that 
client protein-driven cancers have upon Hsp90, without concomitant induction of the pro-
survival, heat shock response.    
Two alternative strategies for inhibiting the function of Hsp90 include disruption of the 
Hsp90 heteroprotein complex and disruption of the Hsp90 C-terminal dimerization domain. 
Disruption of the Hsp90 heteroprotein complex has emerged as an effective strategy to prevent 
client protein maturation without induction of the HSR.23 More specifically, disruption of 
interactions between Hsp90 and co-chaperones, such as Cdc37, or direct inhibition of co-
chaperones and immunophilins, such as p23, F1F0 ATP synthase and FKBP52, prevent the 




Alternatively, novobiocin was the first Hsp90 C-terminal inhibitor identified, and was 
found to inhibit Hsp90 in SKBr3 cells at approximately 700 μM concentration.28 As a result, 
derivatives of the coumarin-containing natural product have been intensely sought and 
compounds manifesting improved activity identified. These C-terminal inhibitors prevent cancer 
cell proliferation at concentrations similar to N-terminal inhibitors and induce degradation of 
Hsp90-dependent client proteins without induction of the HSR.29-30 In addition to novobiocin and 
novobiocin analogs, epilgallocatechin-3-gallate (EGCG), silybin and cisplatin have been 
reported to bind the Hsp90 C-terminus.31  
Herein, recent progress in Hsp90 structural elucidation and the dynamic aspects of the 
Hsp90 chaperone cycle will be discussed. Alternative strategies for Hsp90 inhibition that include 
direct and indirect targets of Hsp90, as well as the current state of traditional small molecule 
Hsp90 inhibitors will be summarized. Lastly, post-translational modifications to Hsp90 and 
partner proteins will be described as well as the effect of these modifications on client protein 
maturation, stability and activity in normal and transformed cells. 
 
Hsp90 Chaperone Cycle 
Hsp90 exists primarily as a homodimer. Each monomer contains three domains; an N-
terminal domain with an ATP-binding pocket, a C-terminal domain responsible for dimerization, 
and a middle domain that connects the N- and C-termini through a highly-charged and flexible 
linker.  The Hsp90 protein folding cycle is complex and illustrated in Figure 1.  Many 
conformational switches and changes are needed to obtain the catalytically active state of Hsp90, 
and various co-chaperones are needed to regulate the protein folding cycle.32 Most of the co-




motif located at the C-terminus.  Co-chaperone Hsp90-Hsp70 organizing protein (HOP) is 
responsible for delivering substrates from Hsp70 to Hsp90, and binds Hsp90 to stabilize the open 
conformation (A brief overview of co-chaperone binding to Hsp90, and its effects are 
highlighted in Table 1).33 HOP interacts directly with the EEVD motif through its 
tetratricocpeptide repeat (TPR) domain.  
After the binding of HOP, Hsp70 and the bound client protein stabilize the open 
conformation of Hsp90, and then various immunophilins (specifically, those with prolyl 
isomerase activity), co-chaperones, and other partner proteins bind to form a heteroprotein 
complex.  When the immunophilins, containing peptidyl-prolyl isomerase activity (e. g. 
FKBP51, FKBP52, etc.) bind Hsp90, an asymmetric complex is formed.33   This asymmetric 
structure is often referred to as the ‘late complex’ and promotes the chaperone cycle through 
stabilization of the open conformation.34 After formation of the late complex, the activator of 
Hsp90 ATPase, Aha1, assembles with the heteroprotein complex to dissociate co-chaperones, 
such as HOP and Hsp70.34 Buchner and coworkers demonstrated that Aha1, the most effective 
activator of ATPase activity, is needed for HOP release, but not p23, which had been previously 
reported.34 They found that Aha1 and the co-chaperone Cpr6 bind Hsp90 in a synergistic manner 





Figure 1 Hsp90 catalytic chaperoning cycle, highlighting the two closed 
conformations.  The first closed conformation is stabilized by Aha1.  p23 then displaces 




Hsp90-catalyzed ATP hydrolysis is not only required for folding the bound substrate, but also for 
release of the properly folded substrate.  In order to achieve ATP hydrolysis, Hsp90 must adopt a 
closed conformation.32 To form the closed state, Aha1 binds in a sequential manner, followed by 
ATP.  Structural reorganization ensues to facilitate closure of the N-terminal ATP lid.  Lid 
closure stabilizes the catalytic loop, which is required for ATP hydrolysis.  In addition, the ATP 
lid establishes contacts between specific residues of the catalytic loop and ATP, in addition to the 
adjacent Hsp90 monomer, resulting in further stabilization of the Hsp90 complex.  This 
conformational change represents the rate-limiting step in the protein folding cycle, which is not 
ATP hydrolysis.32   
In addition to establishing that Aha1 and Cpr6 bind Hsp90 in a synergistic manner, it was 
demonstrated that Aha1 association with Hsp90 accelerates the conformational change required 
for attainment of the closed state.  In fact, the conformation formed upon Aha1 binding is 
different from the state wherein ATP hydrolysis occurs, as illustrated in Figure 1.34 In the closed 
state with Aha1, ATP can exchange readily.  However, upon p23 displacement of Aha1, a 
second closed conformation is formed, which is followed by p23 dissociation and ATP 
hydrolysis.34 The resulting complex disassembles and the folded substrate is released to 
propagate of the catalytic cycle.  
p23 is a well-established regulator of Hsp90 ATPase activity and has been shown to 
inhibit ATP hydrolysis and client release.35-36 McLaughlin et. al demonstrated that p23 interacts 
with Hsp90 in the presence and absence of ATP; however, affinity for the p23-Hsp90 complex 
increased when ATP was present. Mass spectral analysis determined that one molecule of p23 
bound to each Hsp90 monomer and p23 interacted with truncated fragments that lack a C-




Collectively, these data suggest that p23 locks Hsp90 subunits during the ATP-bound state, 
which exhibits a high affinity for protein substrates.  
 Another co-chaperone, carboxyl terminus of Hsp70-interacting protein (CHIP), regulates 
the release of properly folded client proteins, or can target them for degradation.37-38 CHIP 
contains a ubiquitin ligase domain and thus, provides a direct link to protein degradation via the 
proteasome.39 CHIP interacts with Hsp90 or Hsp70 through its TPR domain, and when bound to 
Hsp90, CHIP can displace HOP and p23. In the presence of Hsp90 inhibitors, CHIP mediates 
ubiquitinylation of substrates and ultimately directs them for degradation via the proteasome.40  
 













Hop/Sti1 TPR2A, TPR2B N, M, C 
Stabilizes open 
state Inhibition 
Cdc37 M, C N Stabilizes open state Inhibition 
Sgt1 CS domain N Not determined No effect 





Aha1 N, C N, M Stabilizes closed state Acceleration 
Ppt/PP5 TPR1, TPR2, TPR3 C Not determined No effect 
Cpr6, 




P52 TPR C Not determined No effect 
p23/Sba1 N N 
Stabilizes 





Other co-chaperones have less defined roles in the inhibition or promotion of Hsp90 
ATPase activity; however, proper function of these co-chaperones and direct interaction with 
Hsp90 appears important for client protein maturation. Small glutamine-rich tetratricopeptide 
repeat-containing protein α (SGTA) is linked to several cellular processes including cell 
division, mitosis, cell cycle checkpoint activation, and viral infection. SGTA interacts directly 
with Hsp70 and may interact with Hsp90 via its TPR domain to facilitate maturation of the 
growth hormone and androgen receptors.41 It has also been proposed that SGTA participates in 
the sequestration of client proteins in an inactive state.  
F1F0 ATP synthase was proposed to possess co-chaperone function by interacting with 
Hsp90 in several different cancer cell lines.27, 42 Furthermore, inhibition of F1F0 ATP synthase 
directly affected client protein maturation. F1F0 ATP synthase is a macromolecular machine that 
produces the majority of cellular ATP and is localized to the mitochondria and the cell surface in 
certain cancers.43-46 F1F0 ATP synthase was shown to directly interact with Hsp90, specifically 
the Hsp90α isoform.47 A selective inhibitor of F1F0 ATP synthase, as well as general inhibitors of 
ATP synthases, have been shown to disrupt interactions between F1F0 ATP synthase and 
Hsp90α, and ultimately produce client protein Hsp90-dependent degradation.47-48  
 
Heat Shock Response 
Traditional discussion of the pro-survival heat shock response (HSR) typically is as 
follows: “In the presence of degraded client proteins or upon treatment with a N-terminal 
TPR tetratricocpeptide repeat, CS = CHORD (cysteine and histidine-rich domain)-containing 




inhibitor Hsp90-bound transcription factor Heat Shock Factor-1 (HSF-1) is displaced.49-50 Upon 
displacement, HSF-1 trimerizes, translocates to the nucleus and binds the Heat Shock Regulatory 
Elements, which are evolutionarily conserved sequences throughout the genome that lead to 
increased levels of the heat shock proteins. The HSR is a pro-survival response to cellular stress 
that cause conditions which induce the denaturation of proteins. Hsp27, Hsp40, Hsp70, and 
Hsp90, amongst other HSPs, are over-expressed to refold denatured proteins.”  While this 
description is accurate, it is an over-simplification of a complex biological process.  HSF-1, the 
small but mighty player in the heat shock response, has been heavily studied in the last decade 
and consequently has been found to be involved in many different disease states.  HSF-1 is often 
activated in cancer cells and has been shown to be important in cancer progression.51 
Alternatively, a lack of HSF-1 is connected to neurodegenerative diseases as proteins 
aggregate.52-53 Recently, HSF-1 was implicated in diabetes as HSF-1 expression was altered in 
islets from diabetic rats and restoring HSF-1 activity prevented glucolipotoxicity-induced 
endoplasmic reticulum stress and apoptosis.54 While it is becoming more apparent how HSF-1 is 
implicated in many diverse cellular processes, it is still unclear how HSF-1 regulates the heat 
shock response.      
Currently there are two hypotheses in the literature to explain how HSF-1 regulates the 
heat shock response. The first is the chaperone titration theory and the second is the heat shock-
dependent phosphorylation theory.  The chaperone titration theory suggests that HSF-1 is bound 
to chaperones in an inhibitory complex.  When cellular stress occurs, HSF-1 dissociates from the 
inhibitory complex as the chaperones are titrated away by misfolded and unfolded proteins.  
HSF-1 then forms trimers and localizes to the nucleus to activate transcription. Once proteostasis 




studies have determined what chaperone and co-chaperones interact biochemically and 
pharmacologically with HSF-1.  However, due to the observed switching dynamics of HSF-1, 
direct unequivocal evidence is difficult to obtain.   
Bharadwaj and co-workers investigated the Hsp90 chaperone complex and the regulation 
of HSF-1.56 Using electrophoretic mobility shift assay/super shift technique they found that 
elevated levels of Hsp90, Hsp70, Hip, and Hop decreased the time of HSF-1 deactivation to the 
non-DNA-binding state.  Interestingly, they found that immunophilins had the opposite effect. 
Thus, they proposed that nascent co-chaperones exert their effect via remodeling existing 
chaperone complexes and Hip, Hop and Hsp70/90 promote formation of additional chaperone 
complexes.56 Subsequent experiments also evaluated the interaction between various co-
chaperones and chaperones and stress-activated HSF-1 to find that Hsp90, p23, and FKBP52 
form a heterocomplex with the regulatory domain of HSF-1.  Disruption of this complex 
promotes HSF-1 DNA binding as a heat shock promoter.57 Interestingly these co-chaperones are 
also involved in the chaperone machine that is important for folding the steroid receptors, 
indicating that HSF-1 oligomerization is regulated by a similar foldosome-type mechanism.    
The second theory for HSF-1 regulation is the phosphorylation theory, which simply 
states that upon site dependent phosphorylation, HSF-1 activates the transcription of chaperone 
genes.58 Unfortunately, recent studies have found that mutation of 15 phosphorylation sites failed 
to prevent HSF-1 activation during heat shock.  Even though phosphorylation of HSF-1 is a 
hallmark of the heat shock response pathway, no direct evidence of the specific role HSF-1 
phosphorylation provides has yet emerged.59 Recent studies by Zheng and co workers attempted 
to link the two theories by studying over 70 phosphorylation sites and examining Hsp70 and 




model, as Hsp70 and HSF-1 form a feedback loop controlled by heat shock response and 
activation. Additionally Zheng and co workers identified that phosphorylation amplifies 
transcriptional activation of HSF-1, as opposed to phosphorylation triggering the activation of 
HSF-1.60 They hypothesized that introduction of a negative charge via phosphorylation increases 
the transcription initiated by HSF-1.60-61 Based on these findings both theories are correct as 
HSF-1 uses both phosphorylation and a chaperone switch to regulate the heat shock response.  
Control over the pro-survival heat shock response is vital for neuroprotection.  Induction 
of the pro-survival heat shock response occurs in a different manner for N-terminal and C-
terminal Hsp90 inhibitors.  Pan Hsp90 N-terminal inhibition results in induction of the HSR, 
however C-terminal inhibition can segregate these activities.  Treatment with C-terminal 
inhibitors can result in either client protein degradation or induction of heat shock proteins, but 
not both.   
The pro-survival heat shock response can be beneficial for neuroprotection. Partial 
folding of proteins leads to a functionally inactive state of the protein, which may lead to toxic 
insults within the cell, leading to cell death.  This partial or inaccurate folding occurs in 30% of 
nascent proteins, which typically leads to their degradation.62-63 It is likely that the toxicity of 
different neurodegenerative disorders result from an imbalance between normal chaperone 
activity and misfolded protein species.64 HSF-1 protects neuronal cells from death caused by the 
accumulation of misfolded proteins, which is essential because neurons are post-mitotic and are 
unable to dilute misfolded or aggregated proteins through cell division. 65-66 Consequently HSF-1 
has been found to be essential for the survival of rat neurons, and HSF-1 protein expression 
levels are reduced as cell death is approached.67 Verma and co-workers found that 




a novel mechanism of action wherein HSF-1 is not a trimer.67 While the levels of HSF-1 
typically do not change and are tightly regulated, HSF-1 levels in neurons are reduced well 
before degeneration.  This strongly indicates that reduction in HSF-1 expression is a precursor to 
neurodegeneration.  Verma and co workers propose that HSF-1 has an alternate mechanism of 
action for neuroprotection in which monomer HSF-1 binds non-HSE sequences in conjunction 
with other transcription factors.67-69  
Additional neuroprotection via modulators of HSF-1 have been investigated. 
Hydroxylamine derivatives like arimoclomol are known to be co-inducers of the HSR and are 
thought to prolong the binding of HSF-1 to HSE. Additionally, these molecules are thought to 
cause HSF-1 activation via affecting plasma membrane fluidity.70 These compounds are thought 
to weaken the interactions between lipid chains that can induce disorder effects in membranes, 
similar to heat shock, ultimately leading to HSF-1 activation.71-72    
Current studies have begun to unveil that HSF-1 can segregate its proteostatic activity 
from its other activities, like metabolic control.  For example Qiao and co-workers have reported 
that HSF-1 is involved with metabolic control via interaction with the Nampt promoter, which 
controls intracellular NAD+ levels. Heat shock is known to increase the cellular NAD+/NADH 
ratio. Sitruin enzymes (SIRT1 and SIRT3) require NAD+ as a cofactor for metabolic regulation 
and are known to play a critical role in the maintenance of mitochondrial function. They found 
that SIRT1/3 levels are affected in HSF-1 deficient cells. SIRT1 is responsible for the 
deacetylation of HSF-1, and can prolong HSF-1 DNA binding by deacetylation.  HSF-1 removal 
from chromatin is facilitated by acetylation of K80, which is in direct contact with DNA. This 
study clearly ties HSF-1 to metabolic control. HSF-1 undoubtedly has many important rolls to 





Client-specific Hsp90 Co-chaperones 
While Hsp90-co-chaperone interactions continually change throughout the chaperone 
cycle to either inhibit or promote ATP hydrolysis, co-chaperones also exhibit client specificity 
during the chaperone cycle and promote the maturation of client protein classes.73 The 
mechanism by which co-chaperones assist in the delivery of clients to Hsp90 occurs via 
interactions between specific clients or through interactions with Hsp90 that prime the chaperone 
machinery for the loading of protein substrates.  
The co-chaperone activity manifested by cell division cycle 37 homolog, or Cdc37, is 
required for the maturation of all Hsp90-dependent kinases.24, 74 This co-chaperone inhibits 
ATPase activity, but does not affect accessibility to the ATP binding site.75-77 Sgt1 (suppressor of 
G2 allele of skp1) is required for activation of nucleotide-binding leucine-rich repeat receptors 
(NLRs).78 The co-chaperones Tah1 (TRP-containing protein associated with Hsp90) and Pih1 
(protein interacting with Hsp90) are associated with chromatin remodeling and temporarily halt 
the Hsp90 ATPase cycle to prepare Hsp90 for the maturation of small nuclear 
ribonucleoproteins.79  
Other co-chaperones that exhibit client protein specificity are the peptidyl-prolyl 
isomerases (PPIases), and include FK506 binding protein (FKBP) 51, FKBP52, and cyclophylin 
(Cyp) 40.80-81 These remodeling PPIases are commonly utilized in Hsp90-steroid hormone 
receptor complexes. Interestingly these PPIases are specific hormone receptor clients, for 
example, FKBP51 in concert with protein phosphatase 5 (Pp5), is responsible for the maturation 
of the glucocorticoid receptor complexes; however, isolated FKBP51 is found associated with 




While it remains unknown as to how co-chaperones selectively interact with clients, co-
chaperones involved in the maturation of certain clients, or substrate classes, provide an 
opportunity to selectively prevent the maturation of these client(s) by targeting interactions 
between Hsp90 and the co-chaperone.  
 
Disrupting Hsp90-co-chaperone Interactions 
Disruption of the interactions between Hsp90 and co-chaperones has been a successful 
strategy for selective and non-selective degradation of client protein substrates. Small molecules 
can disrupt these interactions and manifest properties unlike N-terminal Hsp90 inhibitors. 
Celastrol and gedunin (Figure 2) were originally suspected to disrupt interactions between Hsp90 
and Cdc37 and induce degradation of kinase client proteins.82-84 The mechanism by which these 
compounds affect the Hsp90 chaperone cycle has since been explained. Celastrol is a natural 
product that exerts potent anti-cancer activity via multiple mechanisms of action. One of these 
mechanisms is to disrupt Hsp90-Cdc37 interactions. The natural product gedunin was shown to 
disrupt Hsp90-p23 interactions.  
  
 
Figure 2 Structures of celastrol and gedunin. 
 
NMR studies by Sreeramulu, et. al. demonstrated that celastrol binds and covalently 




therefore, does not directly bind Hsp9085. In addition, Chadli, et. al. report that celastrol inhibits 
the Hsp90 chaperone cycle by destabilizing p23, which results in the degradation of steroid 
hormone receptors.86 Therefore, celastrol appears to exhibit a multi-faceted mechanism for 
inhibition of the Hsp90 protein folding cycle. In addition, it was reported that gedunin binds the 
co-chaperone, p23, and inhibits p23 chaperone activity while blocking interactions between p23 
and Hsp90.26 Gedunin inactivated p23 via caspase 7 activation, which led to cleavage of the p23 
C-terminus and induction of apoptosis. Interestingly, treatment with gedunin did not increase 
Hsp27 levels and only slightly elevated Hsp70 levels were observed, suggesting this approach 
may not induce the HSR. 
Hsp90 requires ATP for chaperone activity and inhibition of ATP synthase with pan ATP 
synthase inhibitors such as oligomycin A, 2-deoxy-D-glucose, antimycin A and efrapeptins 
prevent Hsp90-dependent client maturation, (Figure 3).42, 47-48 ATP synthase inhibitors do not 
induce the HSR, as oligomycin A and efrapeptins manifest little to no increase in Hsp90, Hsp70 
and Hsp27 levels. Furthermore, inhibition of the singular ATP synthase, F1F0 ATP synthase, with 
the selective inhibitor, cruentaren A, retained this activity and resulted in client protein 
degradation through destabilization of F1F0 ATP synthase-Hsp90α interactions (Figure 3).47, 87-88  
Hsp90 and p23 in complex with hTERT, the catalytic subunit of telomerase, is required 
for the nuclear localization of telomerase, a protein whose unregulated function contributes to 
unlimited replicative potential. The promiscuous natural product, curcumin, induced cytoplasmic 
accumulation and degradation of hTERT through disruption of p23-hTERT interactions as one of 
its many mechanisms of action (Figure 3).89 Curcumin decreased association between p23 and 
hTERT, but did not prevent hTERT from interacting with Hsp90. In contrast, the N-terminal 






Figure 3 Structures of allosteric modulators of the Hsp90 chaperone 
cycle. 
 
San A-amide, a derivative of the natural product sansalvamide A, induces apoptosis in 
various cancer cell lines, including pancreatic, colon, breast and prostate (Figure 3).90-91 Vasko et. 
al. reported that San A-amide-mediated apoptosis in the HCT-116 colon cancer cell line occurred 
through displacement of inositol hexakisphosphate kinase-2 (IP6K2) and FKBP52 from the 
Hsp90 C-terminus.92San A-amide binds the N-middle domain of Hsp90 and appears to disrupt 
the structural equilibrium of this region, which appears to alter the substrate-binding site. In 
contrast, San A-amide has no effect on the N-terminal client, Her2. This mechanism of action is 




AAG) does not affect IP6K2 and FKBP52 binding, but does affect Her2 maturation. 
Furthermore, San A-amide exhibits no effect on Hsp90 ATPase activity, which supports its role 
as an allosteric modulator and its potential to selectively disrupt Hsp90 C-terminal binding 
interactions. 
 
N-Terminal Hsp90 Inhibitors 
Hsp90 inhibitors that bind the N-terminus compete with ATP and perturb ATPase 
activity, thereby disrupting client protein maturation. ATP adopts a unique conformation when 
bound to Hsp90, due to the presence of a Bergerat fold in the protein structure, which is 
characteristic of the GHKL (Gyrase, Hsp90, Histidine, Kinase, MutL) subgroup within the 
ATPase/kinase superfamily.93-94 Compounds that bind the N-terminal ATP-binding pocket adopt 
a bent conformation and afford selectivity for Hsp90 over other ATP-binding proteins. All 
Hsp90 inhibitors under clinical investigation are N-terminal inhibitors and include derivatives of 
geldanamycin (GDA), radiciciol (RDC), and purine (Figure 4). N-terminal inhibitors have been 
studied in great detail and comprehensive reviews are present throughout the Hsp90 literature.95-
99 
GDA belongs to the benzoquinone class of ansamycins and was originally pursued as an 
antibiotic until it was shown to reverse v-src oncogenic transformation by destabilization of the 
Hsp90-src complex.100 Although GDA is a potent anticancer agent, it did not undergo clinical 
evaluation due to its poor drug-like properties. However, several derivatives of GDA have 
entered clinical investigation and include 17-allyl-17-demethoxygeldanamycin (17-AAG), 17-
desmethoxy-17-N,N-dimethylaminoethylaminogeldanamycin (17-DMAG), 17-allylamino-17-




aminogeldanamycin (IPI-493) (Figure 4 A). RDC is a macrocyclic lactone that contains a 
resorcinol moiety as well as an allylic epoxide and an α,β,γ,δ-unsaturated ketone. Although 
RDC is unstable in serum, the resorcinol moiety of RDC has been utilized to develop several 
compounds that remain under clinical investigation, such as STA-9090, NVP-AU922/VER-
52269, KW-2478, and AT-13387 (Figure 4 B). The crystal structure of ADP bound to Hsp90 
provided an opportunity to design inhibitors that take advantage of the unique Bergerat fold. 
Purine-containing compounds, such as PU-3, CNF 2024/BIIB021, MPC-3100, Debio 0932 





Figure 4 Structures of geldanamycin and derivatives (A), radiciciol and derivatives 
(B), as well as PU-3 and purine-containing analogs (C). 
 
Despite the effectiveness of N-terminal inhibitors as anticancer agents, several concerns 
have emerged as a consequence of N-terminal inhibition. Induction of the HSR has resulted in 
dosing and scheduling problems during clinical trials and spurred the development of Hsp90 
inhibitors that are devoid of this response, such as C-terminal inhibitors and allosteric modulators 
of the chaperone cycle. In addition, gastrointestinal distress, hepato- and ocular toxicities have 
been observed during pre-clinical and clinical trials.101 This may result from off-target affects, 
metabolic instability and/or on-target effects from pan inhibition of all four Hsp90 isoforms. 




maturation.102 Hsp90 inhibitors have been shown to disrupt the proper trafficking and function of 
hERG.103 Therefore, cardiotoxicity has also been observed during the development of Hsp90 
inhibitors. All Hsp90 N-terminal inhibitors in the clinic exhibit pan Hsp90 inhibitory activity and 
target all four isoforms. It appears that other clients (oncogenic or not) may also exhibit a 
preference for individual Hsp90 isoforms,102, 104-105 Therefore, deciphering the role played by each 
isoform will be important for the development of future Hsp90 inhibitors.  
Despite the high sequence similarity and identity possessed among the N-termini of each 
Hsp90 isoform, inhibitors have recently been developed that manifest selective inhibition. An 
inhibitor derived from the ansamycin scaffold has been developed that targets Hsp90α and β, but 
not Grp94 (Figure 5 A).106 Likewise, resorcinol- and purine-containing inhibitors have also been 
reported to selectively inhibit Grp94 based on subtle differences within the N-terminus of Grp94 
(Figure 5 B and C).104-105 
 
Figure 5 Structures of Hsp90α/β inhibitor (A), resorcinol-
containing Grp94 inhibitor (B), and purine-containing Grp94 
inhibitor (C). 
 
C-Terminal Binding Pocket 
The C-terminus of Hsp90 contains a second nucleotide-binding site. Matts and 
coworkers, were the first to note that molybdate inhibited geldanamycin binding to the N-




for a second binding site was presented by Neckers and coworkers, when they determined that 
novobiocin, a coumarin antibiotic, bound the C-terminus of Hsp90.28 The researchers found that 
novobiocin bound a carboxy-terminal Hsp90 fragment. 28 Later, they were able to demonstrate 
that the same C-terminal binding site bound ATP and novobiocin, both within amino acids 542-
732.  More specifically, they found amino acids 657-677 to be essential, as removal of these 
residues resulted in diminished affinity for novobiocin.108 In addition, these amino acids revealed 
that novobiocin bound to a site that is important for Hsp90 dimerization and co-chaperone 
binding.108 The ability to interrupt dimerization was therefore, proposed as a useful strategy to 
prevent client protein maturation.   
Matts and coworkers demonstrated that novobiocin binding altered the EEVD motif and 
consequently impacted Hsp90 interactions with various co-chaperones.109 Upon further 
exploration, they showed that novobiocin binding resulted in a conformational change that 
ultimately led to the dissociation of bound kinases and cochaperones.109 Csermely and coworkers 
found the anticancer drug, cisplatin, also bound the C-terminus and strengthened interactions 
between Hsp90 and Hsp70.110 Their studies suggested that the C-terminal ATP binding site only 
opens after occupancy of the N-terminal binding site.110 Peyrot and coworkers provided 
additional evidence for a C-terminal nucleotide binding site using isothermal calorimetry, 
scanning differential calorimetry, and fluorescence spectroscopy.111  
It was proposed that the C-terminus contains a Rossmann fold between amino acids 490 
and 630, which could also exhibit NADH reductase activity.111 However, Csermely, and 
coworkers demonstrated that nicotinamide adenine dinucleotides only interacted with the N-
terminus and therefore, no such NAD-binding site existed.112   It was found that both purine and 




site that only binds nicotinamide adenine dinucleotides and diadenosine polyphosphate.  In fact, 
GTP and UTP also bind to the C-terminal binding site.112 In addition to exploring the differences 
in nucleotide specificity of the C-terminal binding site, they determined that a ligand must 
contain both a charged group as well as a large hydrophobic moiety to effectively bind this 
region.112 
Agard and coworkers further examined the intra and intermonomer interactions of Hsp90, 
and demonstrated that dimerization is required for ATP hydrolysis.113 Removal of the C-terminal 
dimerization domain resulted in reduced ATPase activity (approximately 6-10 fold).  However, it 
was shown that dimerization could be replaced via a disulfide bond between two monomers, 
which restored ATPase activity.113 Additional work by Buchner and coworkers identified a 
switch point at the C-terminus, in which mutants of alanine 577 caused both higher ATPase 
activity and increased activation of client proteins.114 Interestingly, these results are consistent 
with amino acids that are known to stabilize β-sheets.  In support of this observation, they 
showed that mutant A577N produced lower affinity for N-terminal nucleotides, as asparagine is 
known to destabilize β-sheets.114 
Most recently, Matts and Blagg provided additional information about the location of the 
C-terminal binding site by the use of proteolytic fingerprinting and photoaffinity labeling.115 
They showed that Hsp90 C-terminal inhibitors stall the complex into an open confirmation, 
which results in protection from proteolytic cleavage via trypsin (Arg620 and Lys615), and 
prevention of N-terminal occupation.  Importantly, these results were in agreement with the work 
of Hugel and coworkers as discussed below.115-116 These findings were further supported by 
Retzlaff and coworkers, who demonstrated that C-terminal inhibitors interact with and stabilize a 




chaperone activity.114-115 This work demonstrated that binding to the C-terminus prevents 
formation of the closed conformation.115   
 
 
Figure 6. Effect of nucleotide binding to the N-terminus on the C-terminal dimerization.  
The percentages reflect the likelihood of the C-terminus being either opened or closed.  
 
Recent investigation of the Hsp90 dynamic cycle by Hugel and coworkers highlighted 
conformational activity within the C-terminus that may explain the different biological outcomes 
observed with C-terminal inhibitors.116 They observed that the Hsp90 C-terminus opens and 
closes, which is in contrast to prior models.  They noted an inverse correlation between the N-
and C-terminal domains, in which the Hsp90 dimer was found to open and close several times 
before dimer dissociation.  Interestingly, their data demonstrated that the C-terminus opens and 
closes regardless of the N-terminal state, which was confirmed by the use of AMP-PNP and 
caused Hsp90 to remain in the closed state. Their results, as illustrated in Figure 6, showed that 
when no nucleotide is bound to the N-terminus, the C-terminus exists in an open conformation 
43% of the time, and in a closed conformation 57% of the time.  However, when ATP is bound 
to the N-terminus, the C-terminal states reversed.  Reversal of the C-terminus state upon ATP 
binding is caused by destabilization of the C-terminus.  Since the N-terminal ATP-binding 




which is important when considering the implication of C-terminal inhibition.116 With Hugel’s 
data and model, one could propose that binding to the C-terminus can occur when the domain is 
open, which would prevent dimerization, or after dimerization, which would prevent occupation 
of the N-terminal binding pocket.    
 
Hsp90 C-Terminal Inhibitors: Novobiocin and Novobiocin analogs 
Since both Hsp90 and DNA gyrase bind ADP and geldanamycin in a bent conformation, 
it was proposed that a DNA gyrase inhibitor could also inhibit Hsp90.28 Originally, it was 
proposed that the coumermycin antibiotics—specifically novobiocin (structure illustrated in 
Figure 7), chlorobiocin, and coumermycin A1—could bind the N-terminal nucleotide-binding 
pocket due to structural similarities within the binding site.  Indeed, novobiocin was able to 
compete with radiciol and geldanamycin for Hsp90 binding, but neither geldanamycin nor 
radiciciol could compete with novobiocin.28 Amino-terminal and carboxy-terminal fragments of 
Hsp90 were prepared for further investigation.  As expected, geldanamycin bound the N-terminal 
fragment, however, novobiocin was found to bind the C-terminal fragment.28  
Although novobiocin was found to bind the C-terminus, it manifested low efficacy in 
cellular models (~700 μM in SkBr3).  To improve upon this low activity, structure-activity 
relationship studies were pursued.  The first novobiocin analog reported was A4 (illustrated in 
Figure 7), in which the benzamide side chain was replaced with an acetamide and lacked the 4-
hydroxyl and the 3’-carbamate.117 A4 induced client protein degradation at approximately 10μM 
in the LNCaP prostate cancer cell line (a mutated androgen receptor-dependent prostate cancer 
cell line).117 However, A4 induced a robust HSR at concentrations approximately 1000-fold 




protein degradation had not been previously observed.  Recall that, N-terminal inhibitors induce 
client protein degradation at the same concentration they induce the HSR.  Since A4 exhibited 




Figure 7 C-terminal Inhibitors of Hsp90. 
 
4-Deshydroxynovobiocin (DHN1) and 3’-descarbamoyl-4-deshydroxynovobiocin 
(DHN2), as illustrated in Figure 7, were synthesized to examine whether the 4-hydroxy was 
detrimental to Hsp90 inhibitory activity.118 These studies confirmed that removal of the 4-
hydroxy resulted in decreased DNA gyrase activity, but improved Hsp90 inhibitory activity.118 
Importantly, these compounds induced client protein degradation at concentrations in which no 
HSR was observed.   Further modifications to the coumarin core were designed to mimic the 
guanosine nucleus via the addition of hydrogen bond acceptors placed at the 5-, 6-, and 8-




compound, KU-174 (illustrated in Figure 7), was subjected to a NCI60 screen and showed 
activity against multiple cancer cell lines.120 Other investigational studies on the coumarin core 
(compound 2) are illustrative of work in this area.29, 119, 121-123 Most recently, it was demonstrated 
that the coumarin core could be replaced with a biphenyl moiety (compound 3 represents such an 
example).  Analogs containing the biphenyl moiety manifest good activity against the SkBr3 and 
MCF-7 cell lines, and represent a new scaffold for further exploration of the Hsp90 C-terminal 
binding site.124       
In addition to the coumarin core, novobiocin contains a noviose sugar and a benzamide 
side chain.  A biaryl ring system that contains a meta-methoxy was found to exhibit comparable 
activity to the benzamide side chain present in KU-174.125 Additional studies to replace the 
benzamide side chain have also been reported.125,30, 126-127 Extensive SAR studies have been 
carried out on the noviose sugar.128-132 It was determined that the 2’- and 3’-hydroxy moieties are 
essential for activity, whereas, the 6’-gem-dimethyl group and the 5’-methoxy are not.128 
Additional SAR demonstrated that N-methyl piperidine represents a suitable replacement for the 
noviose sugar (compound 1 in Figure 7).  
 
EGCG and Silybin 
There are two other natural products that have been shown to bind the Hsp90 C-terminus, 
(-)-Epigallocatechin-3-gallate (EGCG) and silybin (Figure 7).  EGCG is the major component of 
green tea and silybin is the major component of silymarin, which is extracted from the seed of 
milk thistle.133,134  Through the use of proteolytic footprinting, immunoprecipitation, and an ATP-
argarose pull-down assay, Gasiewicz and coworkers demonstrated that EGCG binds the same 




protein degradation (telomerase, multiple kinases, and the aryl hydrocarbon receptor), and 
therefore anti-cancer activity.135,136   
Historically, silybin has been used for the treatment of liver and gallbladder disorders.137 
However, silybin was also shown to manifest cytotoxic activity against various cancer cell lines 
in addition to enhancing the efficacy of other chemotherapeutic agents.  Silybin was identified as 
an Hsp90 C-terminal inhibitor and Hsp90-dependent client proteins were degraded in a 
concentration-dependent manner, while Hsp90 levels remained constant.138 Overlay of silybin 
and novobiocin suggest the coumarin and flavonone ring could be interchanged, which led to 
compounds that exhibited improved Hsp90 inhibitory activity.139           
 
Post-translational Modifications of the Hsp90 Chaperone Cycle 
The Hsp90 chaperone cycle can be fine-tuned to quickly adapt to changes in the 
intracellular environment through post-translational modifications (PTMs). Several 
comprehensive reviews describe these covalent modifications, which include phosphorylation, 
acetylation, S-nitrosylation, oxidation, ubiquitinylation, and SUMOylation. These PTMs can 
affect ATPase activity, stabilization of Hsp90-client interactions, co-chaperone interactions, and 
in some cases, target client proteins for maturation or degradation.140-142 A summary of some 
Hsp90 PTMs and original references are provided in Table 2. PTMs of the Hsp90 chaperone 
cycle can enhance or diminish the effects of small molecule Hsp90 inhibitors, such as GDA. 
Targeting these PTMs can provide an opportunity to enhance the efficacy of Hsp90 inhibitors 





Co-chaperones Cdc37, Sgt1, p23, and FKBP52 are susceptible to phosphorylation by 
casein kinase 2 (CK2).143-148 CK2 phosphorylates ser-13 of Cdc37. This modification is required 
for Cdc37’s chaperoning of numerous kinase clients as well as for the binding of Cdc37 to 
Hsp90. De-phosphorylation of Cdc37 at ser-13 by the phosphatase, PP5/Ppt1, negatively affects 
the chaperone cycle and prevents maturation of these clients. Phosphorylation of Sgt-1 at ser-361 
negatively impacts Sgt-1 dimerization and prevents kinetochore assembly, a process required for 
chromosome segregation during eukaryotic cell division. CK2-mediated phosphorylation of p23 
at ser-113 and -118 was shown to be important for prostaglandin synthase activity and required 
for formation of the Hsp90-p23-CK2 complex. CK2 also phosphorylated thr-143 of FKBP52. 
While this modification does not affect FKBP52 from binding FK506, phosphorylated FKBP52 
does not bind Hsp90.  
Several kinases are capable of phosphorylating Hsp90 and have varying effects on the 
chaperone cycle. Double-stranded DNA protein kinase (DNA-PK) phosphorylates thr-5 and -7 of 
the Hsp90α N-terminal domain and may play a role in DNA damage. Client kinases also 
phosphorylate Hsp90 and may regulate their own chaperoning via a feedback mechanism. B-Raf 
was shown to phosphorylate ser-263 of Hsp90 in melanoma and Akt to phosphorylate Hsp90α 
and Hsp90β, Grp78 and Grp94, Hsp70, and protein disulfide isomerase (PDI). c-Src 
phosphorylates Hsp90β at tyr-301 in response to vascular endothelial growth factor receptor-2 
(VEGFR-2) activation and increases association between Hsp90β and eNOS. Protein kinase A 
(PKA) phosphorylates thr-90 of Hsp90α and reduces association with eNOS, which results in 
both diminished eNOS activity and nitric oxide production. Phosphorylation of thr-90 of Hsp90α 
via PKA was also shown to mediate cellular secretion of Hsp90α and may play a role in wound 




when Hsp90 is in the “open conformation” and positively affects the ability of Hsp90 to 
chaperone a select group of client kinases (ErbB2, Raf-1, and Cdk4). However, phosphorylation 
of this residue also negatively affects GDA binding to the Hsp90 N-terminus.  
CK2 phosphorylation of ser-231 and-263 in the charged linker of Hsp90α, as well as the 
equivalent residues in Hsp90β (ser-226 and -255) occurs in normal cells, but not leukemic cells. 
Several leukemogenic kinases, such as Bcr-abl, FLT3/D835Y, and Tel-PDGFRβ, suppressed 
phosphorylation of Hsp90β at these residues, which resulted in stable interactions between 
Hsp90β and apoptotic peptidase activating factor-1 (Apaf-1). Ultimately, this activity led to 
inhibition of apoptosome function and may contribute to resistance in leukemia. CK2 
phosphorylation at these sites also disrupts the Hsp90-aryl hydrocarbon complex and destabilizes 
the aryl hydrocarbon receptor protein. CK2 was also shown to phosphorylate thr-36 of Hsp90α. 
Mutation of this residue to a phospho-mimetic, aspartate, resulted in decreased chaperoning of 
several clients and reduced interactions between Hsp90α with Aha1.  
Acetylation/deacetylation of Hsp90 has been investigated using HDAC inhibitors.149-
151Acetylation of Hsp90 by p300 resulted in diminished interactions between Hsp90 and clients 
and ultimately, resulted in client instability and degradation. Mutation of lysine to acetylated 
lysine was shown to decrease interactions between Hsp90 and several clients/co-chaperones as 
well as to reduce ATP-binding. De-acetylation of Hsp90 has been shown to occur via several 
HDACs including HDAC6, HDAC1 and HDAC10, which correlate with the stabilization of 
Hsp90-client interactions and increased chaperone activity.152-155 
Other PTMs include S-nitrosylation of Hsp90α at cys-597 via nitric oxide, oxidation of 
cys-572 by the oxidized lipid, 4-hydroxy-2-nonenal (4-HNE; is formed during cellular oxidative 




ubiquitinylation decrease chaperone function by perturbing ATPase activity or destabilizing 
Hsp90-client interactions, which results in client degradation. Alternatively, SUMOylation of the 
conserved lysine reside, lys-191, initiated recruitment of the ATPase activating co-chaperone, 
Aha1. In addition, SUMOylation facilitated binding of several Hsp90 N-terminal inhibitors and 














DNA-PK Thr-5 and -7 phosphorylation156 Unknown 
B-Raf Ser-263 phosphorylation of Hsp90α157 Unknown 
Akt 
Thr and ser 
phosphorylation of Hsp90α, 
Hsp90β, and Grp94158 
Unknown 
c-Src Try-301 phosphorylation 
of Hsp90β159 
Increased eNOS 








eNOS activity and NO 
production. Also 
stimulates cellular 
secretion of Hsp90α. 
CK2 
Phosphorylation of ser-
231 and -263 of Hsp90α 
and ser-226 and -255 of 
Hsp90β in untransformed 




dissociation of Hsp90 







chaperoning activity of 
select clients. Decreased 
GDA binding to Hsp90. 





Oxidation 4-HNE Cys-572 oxidation167 Decreased chaperone activity 
Ubiquitinylation Ubiquitin pathway Lys ubiquitinylation
168-169 
Destabilized Hsp90 
client interactions and 
resulted in client 
degradation. 




pathway of Aha1 and facilitated 




Tumor dependency on pathways regulated by Hsp90 provides clear rationale for the 
development of Hsp90 inhibitors. Hsp90 inhibition offers a multifaceted treatment strategy, 
which is in contrast to current cancer therapies that target a single signaling pathway. Despite the 
potential of Hsp90 as a drug target, no Hsp90 inhibitor has been FDA approved. Alternative 
methods to target Hsp90 include inhibition of the C-terminus or allosteric modulation of the 
chaperone machinery.  
Recent advances toward elucidation of the Hsp90 structure and intricacies of the 
chaperone cycle have provided details on the conformational changes required for heteroprotein 
complex formation during various stages of the chaperone cycle. PTMs of proteins involved in 
the chaperone cycle have shed light on how quickly Hsp90 adapts to changes in the cellular 
environment. Alternative methods to modulate Hsp90 may provide an opportunity to select for 
oncogenic client degradation, while avoiding some of the negative consequences of N-terminal 
inhibition. In conclusion, the Hsp90 chaperone cycle and inhibitor development have become a 
diverse and dynamic field of study. As details of the chaperone cycle emerge, more information 
regarding the regulation of chaperone machinery in normal versus transformed cells will be 
discovered. Such studies will lead to the development of tailored strategies for modulation of the 
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2. Development of Noviomimetics that Modulate Molecular Chaperones 
and Manifest Neuroprotective Effects 
 
Introduction 
Molecular chaperones represent promising therapeutic targets for both cancer and 
neurodegenerative diseases.1-4  The 90kDa Heat Shock Protein 90 (Hsp90) is a molecular 
chaperone that is responsible for the folding and maturation of more than 300 client protein 
substrates.5  Hsp90 modulates client protein substrates associated with all 10 hallmarks of cancer, 
supporting that inhibition of this chaperone may be useful for the treatment of cancer.6-8  
However, Hsp90 is also a target for neurodegenerative diseases since molecular chaperones can 
refold denatured proteins and resolubilize protein aggregates.3, 9-14 The N-terminus of Hsp90 
contains an ATP-binding site, and ATP hydrolysis provides the requisite energy needed to fold 
client protein substrates.15-16 Currently, there are six N-terminal inhibitors undergoing clinical 
evaluation for the potential treatment of cancer.17-18 Unfortunately, inhibition of the N-terminus 
and subsequent client protein degradation also leads to induction of the heat shock response 
(HSR), which results in the overexpression of the heat shock proteins, Hsp27, Hsp40, Hsp70 and 
Hsp90. 19-21 In contrast to N-terminal inhibitors, C-terminal inhibitors can segregate client protein 
degradation from induction of the pro-survival heat shock response.22  
The DNA gyrase inhibitor, novobiocin (2.1), was the first Hsp90 C-terminal inhibitor 
discovered.23 Through extensive structure-activity relationships, the natural product was 
modified to exhibit anti-proliferative activity.24-26 Continued development of the potential cancer 
therapeutics led to the identification of cytotoxic replacements of the noviose sugar,27-29 which 




could be used in lieu of the coumarin core.30-33 These cytotoxic compounds provide an excellent 
platform for the treatment of cancer, as these analogs cause degradation of Hsp90-client proteins 
and leads to the disruption of multiple oncogenic pathways.2    
Concurrently, structure-activity relationship studies identified KU-32 (2.2), which was 
shown to manifest neuroprotective activity in cellular models of Alzheimer’s disease.34-35  
Inhibition of Hsp90 by 2.2 results in induction of Hsp70, which decreases the levels of abnormal 
proteins, prevents aggregation of proteins, and ultimately alleviates the phenotype of many 
neurodegenerative disorders.36 Subsequent studies demonstrated that 2.2 reversed clinical 
symptoms of Diabetic Peripheral Neuropathy (DPN) in vivo and protected against neuronal 
glucotoxicity.37-39  A homology model of the Hsp90 C-terminus was utilized to design a second 
generation of analogues, termed novologues (novobiocin analogues), which exchanged the 
coumarin core of 2.2 with a biphenyl ring system, and ultimately produced 2.3 (Figure 2.1A: 
Previous studies).40-41 Although 2.3 exhibits promising activity and is undergoing pre-clinical 
evaluation, modeling studies with 2.3 identified unexplored regions within the C-terminal 
binding site ultimately led to the identification of noviomimetics (a non-noviosylated compound) 
2.4.42 Preliminary studies with 2.4 confirmed that these noviomimetics maintained the desired 
biological activity of 2.3, but are more synthetically desirable due to removal of the complex 
noviose sugar.42-46  As a result, a new library of novologues and noviomimetics was designed in 
which modifications were incorporated to gain additional interactions with the binding pocket 
(Figure 2.1A: Current Study). Several compounds obtained from this third generation library 






Results and Discussion  
A homology model of the Hsp90 C-terminus was utilized for the design of new 
novologues, and demonstrated the potential for a binding pocket adjacent to the noviose sugar of 
2.3 as illustrated in Figure 2.1B.  During prior studies wherein replacements of the noviose sugar 
were explored, 2.4 was identified as a simplified novologue that exhibited similar biological 
activity to 2.3.42  As shown in Figure 2.1B, the noviose surrogate could project into this 
previously unexplored binding pocket and therefore modifications to the benzyl ring on 2.4 were 
explored to identify improved modulators.  Modifications at the ortho- position were 
 
Figure 2.1. A). A summary of prior and current studies presented 
herein. B).  Compounds 2.3 (KU-596), 2.4, and 2.30 docked to 




investigated to determine whether hydrogen bonding interactions could be established with 
GLU537, GLN682, or nearby amino acids (Figure 2.1B).  Substituents at the meta- and para- 
positions were explored to identify potential hydrophobic interactions at this location. In 
addition, modification to the central ring of 2.3 was sought to determine whether hydrogen bond 
donors or acceptors would enhance interaction with the binding pocket (Figure 2.1B).  
Substituents chosen for these studies included both electronic and steric functionalities to 
establish preliminary structure-activity relationships. 
Synthesis of phenol 2.941 (Scheme 2.1A) commenced by benzyl protection of 2,4-
dihydroxybenaldehyde, 2.5. The resulting benzyl ether was converted to 
trifluoromethanesulfonate 2.6, in the presence of N-Phenyl bis-trifluoromethane sulfonimide and 
potassium carbonate using microwave conditions.47 A subsequent Suzuki coupling reaction with 
commercially available 3-fluorophenyl boronic acid was employed to generate the biaryl ring 
system found in 2.7, which was then subjected to a Henry reaction, followed by simultaneous 
reduction of both the nitro and olefin functionalities with lithium aluminum hydride to yield 
amine 2.8. Acylation of 2.8 was followed by cleavage of the benzyl ether under hydrogenolysis 







Compounds 2.14b-u were obtained via an SN2 substitution reaction between phenol 2.9 
and the toluenesulfonates of the corresponding sugar surrogates (Scheme 2.1B).48 Compound 
2.18 was obtained by a Mitsunobu reaction between phenol 2.9 and the corresponding sugar 
mimic.  Novologue 2.18 was then subjected to an osmium tetroxide catalyzed dihydroxylation to 
obtain the corresponding diol, 2.19 (Scheme 2.1C). 
 
 
Scheme 2.1. A). Synthesis of phenol 2.9. Reagents and Conditions: a. BnBr, 
NaHCO3, CH3CN, 75%; b. (CF3SO2)2O, Et3N, DCM, 60%; c.3-fluoro-
phenylboronic acid, Pd(PPh3)4, K2CO3, DMF, 90%; d.CH3NO2, NH4OAc, 
98%; e.LiAlH4, THF, 30 min, f. Ac2O, Et3N, 72% over 2 steps, g. H2, Pd/C, 
MeOH, 90%. B). Synthesis of Noviomimetics 2.14b-u. Reagents and 
Conditions: h. TsCl, Pyridine, 0 oC-rt, on CHCl3, 45%; i. NaH, Acetonitrile, 
rt, 16hr, 60-70%; j. K2CO3, DMF, 80oC, 2d, 55-80%; b: x = o-OCH3; c: x = 
o-CH3; d: x = p-Br; e: x = p-Cl; f: x = o-F; g: x = o-Br; h: x = o-Cl; i: x = m-
Br; j: x = m-Cl; k: x = m-OCH3, l: x = p-F; m: x = p-OCH3; n: x = p-CH3; o: 
x = p-CF3; p: x = p-tBu; q: x = 2, 6-dichloro; r: x = 2-OCH3, 4-Cl; s: x = 2-
Br, 4-Cl; t: x = 2-naphthalene; u: x = 2-OCH3, 4-CH3. C). Synthesis of 
compounds 2.18 and 2.19. Reagents and Conditions: k. NaH, DMF, rt, on, 








Scheme 2.2. A). Synthesis of 2.27. Reagents and Conditions: 
a.AgOTf, Cl2CHOMe, DCM, 40% b. NaHCO3, BnBr, MeCN, 45-
70%; c.N-PhTf2, K2CO3, THF, 120 oC, microwave, 95%; d. 3-
fluoro-phenylboronic acid, Pd(PPh3)4, K2CO3, DMF, 90%; 
e.CH3NO2, NH4OAc, 98%; f. LiAlH4, THF, 30 min; g. Ac2O, Et3N, 
72%;  h. H2, Pd/C, EtOAc, 90%; i. BF3OEt, DCM, 40%; j. Et3N, 
MeOH, 85%. B). Synthesis of 2.30. Reagents and Conditions: k. 
Me2SO4, K2CO3, H2O/Acetone (1/1), 55%; C). Synthesis 2.32. 
Reagents and Conditions: l. MOMCl, DIPA, DCM, 65%; D). 
Synthesis of 2.35. Reagents and Conditions: m. MOMCl, DIPEA, 
DCM, 70%; E). Synthesis of 2.38. Reagents and Conditions: n. 
Hexamethylenetetramine, Trifluoroacetic Acid, 25%; o. NaHCO3, 





Synthesis of each derivative that contained a modified core began via different starting 
materials. Synthesis of compound 2.27 commenced by reduction of commercially available 2,4-
dihydroxybenzaldehyde with sodium cyanoborohydride in the presence of HCl (Scheme 2.2A).49 
The resulting methylbenzene (2.20) was formylated to obtain 2,4-dihydroxy-5-
methylbenzaldehyde, which was then benzyl protected to produce 2.21.50  Compound 2.21 was 
then subjected to the same conditions utilized to produce phenol 2.9, and ultimately yielded 
phenol 2.25 (Scheme 2.2A).  The noviose sugar was synthesized using a previously reported 
procedure.43-46  The protected sugar was activated (2.26)51-52 and then coupled with 2.25 using 
Schmidt conditions.53  Solvolysis of the carbonate with triethylamine and methanol provided the 
final product, 2.27.   Synthesis of 2.30 and 2.32 began by formylation of phloroglucinol, 
followed by benzyl protection of 2,4,6-trihydroxybenzaldehyde using potassium carbonate and 
benzyl bromide to yield 2.28.  To achieve the final product 2.30, 2.28 was subjected to dimethyl 
sulfate in water and acetone to yield the methyl ether, 2.29 (Scheme 2.2B).54  This key 
intermediate was then subjected to the conditions previously described in Scheme 2.2B, to obtain 
2.30. 
Compound 2.32 was obtained by the treatment of 2.28 with chloromethyl methyl ether to 
produce the mono-protected phenol 2.31 (Scheme 2.2C),55-56 which was then subjected to the 
conditions previously described to give 2.32.  Synthesis of compound 2.35 began by selective 
benzylation of 2,3,4-trihydroxybenzyaldehyde, which was then subjected to methoxy methyl 
ether formation to produce intermediate 2.34.  Similarly, compound 2.34 was subjected to 
conditions previously described to achieve the free phenol, which was then coupled with the 
trichloroacetamide of noviose carbonate and upon solvolysis, gave 2.35. Synthesis of compound 




product was then benzyl protected to yield compound 2.37, which was modified according to the 
conditions highlighted in Scheme 2.2E to obtain the final product, 2.38.  
We have previously shown that the cytoprotective activity manifested by KU-32 and KU-
596 requires Hsp70 induction. Therefore, upon construction of the library of noviomimetics, we 
evaluated Hsp70 induction via a luciferase reporter assay (Figure 2.2A).  
 
Figure 2.2. A). Evaluation of Hsp70 induction via noviomimetics in 
a Luciferase Reporter Assay.  Results are mean ±SEM. (n = 3-9). c: 
R = o-CH3; d: R = p-Br; e: R = p-Cl; f: R = o-F; g: R = o-Br; h: R = 
o-Cl; j: R = m-Cl; k: R = m-OCH3, l: R = p-F; m: R = p-OCH3;n: R 
= p-CH3; o: R = p-CF3; p: R = p-tBu; q: R = 2, 6-dichloro; r: R = 2-
OCH3, 4-Cl; s: R = 2-Br, 4-Cl; t: R = 2-naphthalene; u: R = 2-
OCH3, 4-CH3. B). Induction of Hsp70 protein expression by select 
noviomimetics. 50B11 cells were treated for 24hr with 1 µM of the 
indicated Novologues or 250 nM geldanamycin (GDA) as a positive 
control. Immunoblot analysis was performed and densitometry was 




As shown in Figure 2.2A, 2.14e induced the most robust Hsp70 levels for the new 
noviomimetics. Generally, the noviomimetics with substitutions at the para- and ortho-positions 
manifest increased Hsp70 levels in the luciferase reporter assay, Figure 2.2A. Whereas, in the 
luciferase reporter assay noviomimetics with substitutions at the meta-position (2.14i-k) appear 
less favorable as Hsp70 induction was less robust when compared to the similarly substituted 
ortho- and para-noviomimetics.  The para-substituted noviomimetics showed greater induction 
of Hsp70 than the corresponding ortho-noviomimetics (2.14c, 2.14f-h).  Generally, electron-
withdrawing groups at the para- position produced the most Hsp70 induction, followed by 
electron donating groups at the ortho- position. Similarly, para-substituted noviomimetic 2.19 
contains a cyclohexyl cis-diol and also activated the luciferase promoter.  The cis-diol of 2.19 
mimics the noviose sugar more than the unsubstituted cyclohexane ring, which may explain its 
enhanced activity, Figure 2.2A.  
Immunoblot analyses were then performed to further examine the effect of select 
noviomimetics on Hsp70 protein expression.  Compounds 2.4, 2.14b, 2.14g, and 2.14h resulted 
in Hsp70 induction, Figure 2.2B. Meta-substituted noviomimetics resulted in decreased Hsp70 
levels as compared to the similarly substituted ortho- and para-noviomimetics, 2.14q and 2.14o.  
Dually modified, 2.14r, demonstrated the least amount of Hsp70 induction, suggesting that the 
binding pocket does not tolerate modifications at both the ortho- and para-positions.  
Surprisingly, 2.19 was less effective in the immunoblot assay, despite promising luciferase 
activity. Taking the biological activity in both assays into account, noviomimetic side chains on 
(2.4 and 2.14 b-e) were selected for further investigation. 
Comparison studies between the noviomimetic side chains and the original KU-32 




comparison studies were conducted to determine the core that provides the greatest Hsp70 
induction. The coumarin containing noviomimetics (2.56a and 2.56c-2.56e) were synthesized 
(Figure 2.3A) with selected noviomimetic side chains.  Using the luciferase reporter assay, the 
phenol for each scaffold and noviomimetics 2.56a and 2.56c-2.56e, were evaluated (Figure 
2.3B). Scaffolds 2.9 and 2.55 did not contain any sugar moiety/surrogate and were found to be 
inactive. Noviomimetics containing the KU-32 coumarin scaffold exhibited similar or decreased 





The similar or decreased induction of Hsp70 by 2.56a and 2.56c-2.56e could result from 
the rigid coumarin core.  The biphenyl core offers enhanced flexibility that is not available with 
the coumarin core, which may allow for improved interactions within the binding pocket.  
Increasing flexibility may also be important due to the increase in length of the noviomimetic 
side chain as compared to noviose sugar.  Substitutions on the central ring were evaluated using 
immunoblot analysis to observe Hsp70 levels and to support improved interactions with the 
 
Figure 2.3.  A. Synthesis of 2.56a and 2.56c-d. Reagents and Conditions: a. 
Bredereck's Reagent, Toluene, 100oC, 75%; b. AcOH, 130oC, 60%; c. H2, Pd/C, 
MeOH, 90%; d. Ac2O, Pyridine, DCM, 75%; e. K2CO3, MeOH, 55%;  f. K2CO3, 
DMF, 80oC, 2d, 55-80%. B. Evaluation of Hsp70 induction via coumarin 
containing noviomimetics 2.56a and 2.56c-e, unsubstituted scaffolds 2.9 and 
2.55, and biaryl noviomimetics 2.4 and 2.14c-e in a Luciferase Reporter Assay.  





binding pocket. The novologues were analyzed at varying concentrations (30, 100, 300, 1000, 
and 3000nM) as shown in Figure 2.4A.  
 
Novologues containing substituted central rings produced improved Hsp70 induction as 
compared to 2.3 (Figure 2.4A).  Novologues 2.27 and 2.35 resulted in the largest induction of 
Hsp70.  It is possible that the methyl substituent present in 2.27 overlays in three-dimensional 
space with 2.2, and reinstates interactions that are lost upon moving from the coumarin to the 
biphenyl ring system.  Furthermore, the data supports the importance of having a hydrophobic 
substitution on the central core, as 2.27 resulted in the greatest induction of Hsp70.  In 
 
Figure 2.4. A). Immunoblot analysis of Hsp70 induction of novologues in 
nontransfected 50B11 cells. 50B11 cells were treated for 24hr with the indicated 
Novologues or DMSO as the negative control. Immunoblot analysis was 
performed and densitometry was used to report fold induction of Hsp70. B). 
Immunoblot analysis of Hsp70 induction of dually modified noviomimetics in 
nontransfected 50B11 cells. 50B11 cells were treated for 24hr with the indicated 
Noviomimetic or DMSO as the negative control. Immunoblot analysis was 





continuation, the novologues containing central core substituents were coupled with selected 
noviomimetics (2.13a-e). These noviomimetics were synthesized as described in Scheme 2.2 and 
then analyzed via immunoblot analysis to evaluate Hsp70 induction.        
As shown in Figure 2.4B, noviomimetics 2.40a, 2.40d, 2.41a, and 2.42d resulted in the 
greatest Hsp70 induction.  Noviomimetics with a methoxy group at the 3-position (2.40a-e) 
generally resulted in increased Hsp70 levels when compared to noviomimetics with other central 
ring modifications and the same noviomimetic side chain. Interestingly, none of the methyl 
containing noviomimetics (2.39a-d) resulted in improved Hsp70 induction, which was 
unexpected since 2.27 resulted in the greatest induction of all of the central ring modifications.  It 
is likely that switching from the noviose sugar to a noviomimetic alters binding, and ultimately 
leads to a decrease in Hsp70 levels. Noviomimetics containing a phenol on the central ring were 
similarly active when located at the 3- or 6- positions  (2.41a-e and 2.42a-e), and only the 
noviomimetic side chain seemed to impact induction of Hsp70.  Noviomimetic side chains a and 
d appear to produce the most robust induction of Hsp70, regardless of the central ring 
modification.  
 






   
Further assessment of the neuroprotective activity of select noviomimetics was carried 
out after establishment that the desired cytoprotective response, induction of Hsp70, occurred 
upon treatment with Hsp90 inhibitors.  Noviomimetics 2.30, 2.32, 2.40d, 2.40e, 2.41a, 2.41b, 
and 2.42d were selected for further biological evaluation in an assay that evaluates c-jun levels.   
  Hsp70 regulates c-jun levels by increasing its degradation via the proteasome (Figure 
2.5).58  Therefore, induction of Hsp70 via noviomimetics results in the degradation of c-jun. The 
assay was carried out by treating 50B11 cells with serum free media for 24 hours, resulting in 
cell cycle arrest and a decrease in the expression of c-jun.  The cells were then treated with 
vehicle or 1μM of the indicated noviomimetic, and c-jun was induced by placing the cells in 
medium containing 10% FBS for 2 hours.  The protein was harvested and c-Jun levels were 
evaluated.  
Figure 2.5.  c-Jun levels in 50B11 cells upon treatment with 
1µM of noviomimetic for 24 hours.  A). c-Jun levels 
normalized to the SF Serum.  B). Representative immunoblot 




All of the selected noviomimetics decreased c-Jun levels when compared to the untreated 
control, SF Serum (Figure 2.5).  Importantly, most noviomimetics exhibited improved activity 
when compared to 2.3, and a few had improved activity as compared to 2.4.  The general trend of 
the data illustrates that noviomimetics with a free phenol at the 3-position were more effective 
than noviomimetics with a methoxy at the 3-position.  Excitingly, noviomimetic 2.41a resulted 
in the greatest reduction in c-Jun levels. Reduction of c-Jun levels by all noviomimetics suggests 
that the mechanism of action occurs via induction of Hsp70.  
Prior work indicated that the neuroprotective efficacy manifested by KU-32 to improve 
the symptoms of diabetic peripheral neuropathy was associated with an increase in mitochondrial 
respiration. To determine whether the increase in Hsp70 expression correlated with 
mitochondrial respiration, 50B11 cells were treated with various noviomimetics for 24 hours 
 
Figure 2.6. Noviomimetics enhance mitochondrial function. A). 50B11 cells were seeded 
into the 96 well plates, maintained in high glucose DMEM supplemented with 10% fetal 
bovine serum. After 12 hours, 50B11 cells were changed into high glucose DMEM 
medium with 1% FBS, treated together with 1 µM 2.3, 2.4, 2.40d, 2.40e, 2.41a, 2.32. 
After 24 hr, the cells were stressed with 0.5mM H2O2 for 2hr. H2O2 can largely inhibit 
50B11 mitochondrial bioenergetics, indicated by largely decreased response to FCCP. 
1µM 2.3,2.4 and 2.40e can significantly increase cellular Maximal Respiratory Capacity 
(MRC) of oxidative stress. 50B11 cells were treated for 16 hr with DMSO, 2.3, 2.4, 2.32, 





(Figure 2.6). Mitochondrial respiration was then measured in intact cells using an XF96 
extracellular flux analyzer, which provides concurrent measures of mitochondrial oxygen 
consumption rates (OCR) and extracellular acidification rates (ECAR) as an indication of 
glycolytic activity.  A variety of noviomimetics were selected to examine this correlation 
between Hsp70 expression and mitochondrial respiration effects on mitochondrial respiration.     
Hydrogen peroxide can induce cellular apoptosis through mitochondrial dysfunction. 
0.5mM hydrogen peroxide can cause mitochondrial bioenergetics (mtBE) loss, indicated by 
largely decreased response to FCCP. 2.3 and 2.4 effectively improved mtBE, however the dually 
modified noviomimetics resulted in decreased maximal respiratory capacity (Figure 2.6). 
Surprisingly, noviomimetic 2.40e was the most effective at increasing the MRC, even though it 
was not as efficacious in the c-jun assay as the other noviomimetics.  The different results 
obtained from these two assays are due to each assay relying upon a different cellular mechanism 
for the analyzed biological result.  
 
Conclusion 
In conclusion, a library of novologues was designed with the goal of replacing the 
synthetically complex noviose sugar with simplified sugar surrogates. The data support that 
noviomimetics can successfully retain the ability to increase Hsp70 expression and 
mitochondrial function, two mechanistic features that are associated with the neuroprotective 
efficacy of both biaryl-based novologues such as 2.4 and novobiocin-based compounds such as 
2.3. Noviomimetic 2.41a exhibited promising effects in the c-Jun assay, while 2.40e was 








We have observed that the major metabolite for both KU-32 and KU-596 lacks the 4’-
methyl ether on the noviose sugar and exhibits inconsistent neuroprotective activity (Figure 
2.7A). Initial efforts to overcome this short half-life led to the development of noviomimetics 
like 2.4, and those investigated in this chapter.  Additional efforts can proceed to explore other 




   
Preliminary exploration led to the synthesis of noviomimetics 2.45-2.47 (Figure 2.7B), which 
contain a cyclohexylamine group in lieu of the cyclohexane ring. The cyclohexylamine ring was 
selected because a di-benzylated amine would quickly illustrate how much bulk could be 
tolerated in the binding pocket while maintaining biological activity.  Additionally a di-
benzylated amine would be metabolized more slowly than its mono-substituted counterpart, 
Figure 2.7. A). Illustration of the major metabolite of KU-32 and KU-596. 
B). Synthesis of 2.45-2.47. Reagents and Conditions: a. NaHCO3, BnBr, 
MeCN, 90%; b. PPh3, DIAD, THF, rt, 3h, 58%; c. H2, Pd/C, EtOAc, 90%; d. 
K2CO3, BnBr, MeCN, 40%. C). Immunoblot analysis of Hsp70 induction of 
novologues in nontransfected 50B11 cells. 50B11 cells were treated for 24hr 
with the indicated Novologues or DMSO as the negative control. 
Immunoblot analysis was performed and densitometry was used to report 




which is desirable.  Immunoblot analysis was used to evaluate Hsp70 induction in 50B11 cells 
for 2.45-2.47 (Figure 2.7C).  Following the trend identified with initial noviomimetics42,  mono-
benzylated 2.47 is more efficacious than non-benzylated 2.46.  Excitingly, 2.45 resulted in the 
greatest amount of Hsp70 induction.  This result highlights that bulk is tolerated within the 
binding pocket, creating further opportunities to explore different di-substituted amines. These 
initial results provide an excellent starting point for further exploration of new noviomimetics 
that contain different di-substituted cyclohexylamine groups and other functional groups that 
would result in decreased metabolism.     
 
Materials and Methods 
Luciferase Reporter Assay, Immunoblot Analysis and Client Protein Degradation  
 The luciferase reporter assay was performed using a 1.5 kb region upstream of the start 
codon of the human HSPA1A gene to drive luciferase expression as previously described. 50B11 
cells59 were grown in 10 cm dishes in maintenance medium and the cells were transfected using 
lipofectamine. Twenty-four hours after transfection, the cells were re-seeded into 24 well plates 
at a density of 2 x 105 cells per well. After a 6 hour period to permit attachment, the cells were 
treated with the indicated compounds for 16 hour. Luciferase activity was assessed and 
normalized to the total protein concentration of each well.  
50B11 cells were treated with the indicated compounds for 24 hours and were scraped 
into lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 
0.5 mM sodium orthovandate, 40 mM NaF, 10 mM b-glycerophosphate, and Complete Protease 
Inhibitors (Roche Diagnostics). After 15 minutes on ice, the lysates were sonicated then 




estimated using a Bio-Rad protein assay and bovine serum albumin as the standard. Following 
SDS-PAGE, the proteins were transferred to nitrocellulose and the membrane incubated with 5% 
non-fat dry milk in phosphate buffered saline containing 0.1% Tween 20 (PBST) for 1-2hr at 
room temperature. The blots were probed with primary antibodies recognizing Hsp70 or b-actin 
at 4ºC overnight.  The membranes were washed with PBST and subsequently incubated with 
HRP-conjugated secondary antibodies and immunoreactive proteins were visualized using 
chemiluminescence detection  (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, 
UK). The films were digitally scanned and densitometrically analyzed using ImageJ (NIH) 
software. Client protein degradation in MCF-7 cells was performed as previously described.60  
 
C-jun assay 
Immortalized sensory neurons 61 were rendered quiescent to decrease c-jun levels by 
placing them in serum free medium for 24 hours. During this interval, the cells were treated with 
vehicle (DMSO or Captisol) or 1 µM of the indicated compound. C-jun was then upregulated by 
placing the cells in medium containing 10% serum for 2 hour and cell lysates were collected for 
western blot analysis. All the data were normalized to c-jun levels in the presence of serum plus 
vehicle. 
 
Mitochondrial Bioenergetic (mtBE) Assessment  
Oxygen consumption rate (OCR) was assessed in the 50B11 transformed sensory neuron 
cell line, using an XF96 Extracellular Flux Analyzer (Seahorse Biosciences, North Billerica, 
MA). 50B11 cells were seeded into the 96 well plates at 40,000 cells per well and maintained in 




CO), 5 µg/ml blasticidin and antibiotics at 37 °C. The maintenance media was changed to serum 
free unbuffered DMEM supplemented with 1mM pyruvate and 5.5 mM D-glucose and the cells 
incubated at 37 °C in room air for one hour before starting the assay. After introducing the plate 
into the XF96 analyzer, the basal oxygen consumption rate (OCR) was measured prior to the 
addition of 1 µg/ml oligomycin to inhibit the ATP synthase to measure the portion of the basal 
OCR that was coupled to ATP synthesis; residual OCR after oligomycin treatment is from 
uncoupled respiration (proton leak). Next, 1 µM of the protonophore FCCP was injected to 
dissipate the proton gradient across the inner mitochondrial membrane to measure maximal 
respiratory capacity (MRC). The final injection of 1µM rotenone + 1µM antimycin A was used 
to assess non-mitochondrial respiration. The XF96 analyzer also measures the rate of 
extracellular acidification as a marker of glycolytic activity coincident with the assessment of 
mitochondrial OCR.  
After the respiratory measures, the cells were harvested and the protein content of each 
well determined using a Bradford protein assay. OCR values were normalized to the total protein 
content of each well and ATP-linked respiration, proton leak, maximal respiratory capacity, 
spare respiratory capacity and respiratory control ratio were determined as described.60, 62 
 
Chemistry General.  
1H NMR were recorded at 500 MHz (Avance AVIII 500 MHz spectrometer with a dual 
carbon/proton cryoprobe) or 400 (Bruker AVIIIHD 400 MHz NMR with a broadband X-channel 
detect gradient probe) and 13C NMR were recorded at 125 MHz (Bruker AVIII spectrometer 
equipped with a cryogenically cooled carbon observe probe).   Chemical shifts are reported in δ 




recorded with a LCT Premier with ESI ionization. 1H and 13C NMR was used to verify that all 
tested compounds were >95% pure. TLC analysis was performed on glass backed silica gel 
plates and visualized by UV light. All solvents were reagent grade and used without further 
purification. 
 
Synthesis and Compound Characterization 
 
N-(2-(3'-Fluoro-5-hydroxy-[1,1'-biphenyl]-2-yl)ethyl)acetamide (2.9).  




This compound and the similar side chains were synthesized following a previously reported 



















Potassium carbonate (30 mg, 0.19 mmol) was added to a solution of 2.9 (45 mg, 0.16 mmol) 
in DMF (1 mL) and stirred at rt for 30 min, before 4-(benzyloxy)cyclohexyl 4-
methylbenzenesulfonate (75 mg, 0.19 mmol) were added. The solution was heated to 80 °C for 
16h. Distilled water (3x 5 mL) was added to the mixture and the organic layer extracted with 
ethyl acetate. After removal of the solvent on a Rotovap, the crude mixture was purified by 
column chromatography (Silica gel, 40% EtOAc in hexane) to give 2.4 (8 mg) as a white solid in 
75% yield: 1H NMR (500 MHz, CDCl3) δ 7.67-7.58 (m, 1H), 7.50-7.46 (m, 1H), 7.41-7.38 (m, 
1H), 7.30-7.27 (m, 3H), 7.12 (d, J = 5 Hz, 1H), 7.01-6.92 (m, 3H), 6.82-6.79 (dt, J1 = 10 Hz, J2 = 
5 Hz, 1H), 6.70-6.67 (dd, J1 = 10 Hz, J2 = 5 Hz, 1H), 5.24 (s, 1H), 4.48 (s, 2H), 4.25 (m, 1H), 
3.44 (m, 1H), 3.33−3.15 (q, J = 6.7 Hz, 2H), 2.78−2.66 (t, J = 7.2 Hz, 2H), 2.07-1.80 (m, 4H), 
1.79 (s, 3H), 1.69-1.61 (m, 2H), 1.50-1.46 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 169.8, 163.4, 
156.1, 142.0, 139.0, 132.0, 130.8, 129,8, 128.5, 128.4, 128.3, 128.1, 128.0, 127.4, 124.8, 117.5, 
116.0, 115.5, 114.2, 114.1, 74.3, 72.8, 70.1, 40.5, 31.8, 30.9, 28.4, 28.3, 27.4, 23.3. HRMS 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 










Hz, 2H), 7.23 – 7.06 (m, 2H), 7.04 – 6.85 (m, 4H), 6.79 (dd, J = 8.0, 5.7 Hz, 2H), 6.69 (dd, J = 
5.3, 2.2 Hz, 1H), 5.23 (t, J = 5.5 Hz, 1H), 4.51 (s, 2H), 4.31 – 4.17 (m, 1H), 3.75 (s, 3H), 3.45 
(td, J = 7.9, 7.2, 3.5 Hz, 1H), 3.19 (d, J = 6.7 Hz, 2H), 2.65 (t, J = 7.1 Hz, 2H), 2.04 (t, J = 4.1 
Hz, 2H), 1.90 (ddd, J = 28.1, 12.7, 6.2 Hz, 2H), 1.79 (s, 3H), 1.67 – 1.58 (m, 2H), 1.55 – 1.41 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 168.92, 162.45, 160.49, 155.11, 142.58, 141.00, 129.76, 
128.84, 127.41, 127.19, 127.02, 126.89, 126.36, 123.81, 119.42, 116.53, 114.46, 112.99, 109.04, 
74.57, 73.58, 63.86, 54.26, 39.52, 30.81, 27.44, 26.43, 22.19. HRMS (ESI+), m/z [M+Na+] 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.36 (dddd, J = 14.7, 
10.8, 6.6, 2.0 Hz, 2H), 7.21 – 7.13 (m, 4H), 7.09 – 7.03 (m, 2H), 7.00 (dq, J = 9.5, 1.1 Hz, 1H), 
6.88 (ddd, J = 8.5, 4.1, 2.7 Hz, 1H), 6.76 (dd, J = 5.8, 2.7 Hz, 1H), 5.32 – 5.26 (m, 1H), 4.53 (s, 
2H), 4.36 (dt, J = 6.6, 3.4 Hz, 1H), 4.30 (dq, J = 8.5, 5.0, 4.1 Hz, 1H, minor diast.), 3.52 (tt, J = 
6.0, 3.4 Hz, 1H), 3.27 (td, J = 7.2, 5.9 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.34 (d, J = 2.4 Hz, 3H), 
2.11 (qt, J = 6.5, 3.9 Hz, 2H), 1.97 (m, 3H), 1.92 (tdd, J = 7.5, 4.2, 2.0 Hz, 2H), 1.77 – 1.67 (m, 










141.87, 136.64, 136.37, 130.03, 129.67, 128.25, 127.89, 127.49, 125.71, 125.68, 124.73, 117.40, 
115.52, 114.08, 113.88, 74.39, 68.66, 68.27, 40.39, 31.74, 30.49, 28.30, 27.40, 27.27, 23.18, 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.49-7.46 (m, 2H), 7.41-7.36 
(m, 1H), 7.26-7.19 (m, 3H) 7.09−6.99 (m, 3H), 6.09-6.87 (m, 1H), 6.77 (dd, J1 = 10 Hz, J2 = 5 
Hz, 1H), 5.30 (br, s, 1H), 4.50 (s, 2H), 4.38-4.36 (m, 1H), 4.35-4.30 (m, 1H, minor diast.), 3.52-
3.48 (m, 1H), 3.28 (q, J = 3 Hz, 2H), 2.73 (t, J = 3 Hz, 2H), 2.13-1.88 (m, 4H), 1.87 (s, 3H). 
1.73-1.67 (m, 2H), 1.59-1.51 (m, 2H), 13C NMR (125 MHz, CDCl3) δ 170.09, 161.80, 156.34, 
143.87, 142.32, 138.30, 131.73, 131.09, 130.14, 129.35, 128.46, 125.14, 121.53, 117.82, 116.30, 
115.90, 114.48, 74.64, 73.05, 69.71, 40.78, 32.15, 28.58, 27.73, 23.57. HRMS (ESI+), m/z 














The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.37-7.32 (m, 1H), 7.29-7.22 
(m, 4H), 7.16 (d, J = 5 Hz, 1H), 7.05−6.95 (m, 3H), 6.86-6.83 (m, 1H), 6.73-6.71 (m, 1H), 5.33 
(br, s, 1H), 4.49 (s, 2H), 4.35-4.26 (m, 1H), 3.49-3.44 (m, 1H), 3.24 (q, J = 5 Hz, 2H), 2.71 (t, J = 
5 Hz, 2H), 2.09-1.81 (m, 4H), 1.84 (s, 3H), 1.71-1.63 (m, 2H), 1.57-1.46 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ 170.15, 161.79, 156.33, 143.91, 142.32, 137.79, 133.42, 131.07, 130.15, 129.01, 
128.85, 128.78, 128.45, 125.14, 117.82, 116.46, 115.89, 114.47, 75.84, 74.65, 73.05, 69.68, 
40.80, 32.14, 27.73, 23.53. HRMS (ESI+), m/z [M+Na+] calculated for C29H31ClFNO3Na 




















The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H NMR (400 MHz, CDCl3) δ 7.50-7.36 (m, 2H), 7.28-7.24 
(m, 1H), 7.21-7.13 (m, 2H), 7.09-7.00 (m, 4H), 6.91-6.76 (m, 2H), 5.32 (br, s, 1H), 4.62 (s, 2H), 
4.38-4.36 (m, 1H), 4.32-4.31 (m, 1H, minor diast.), 3.56-3.52 (m, 1H), 3.27 (q, J = 5 Hz, 2H), 
2.75-2.71 (t, J = 7.2 Hz, 2H), 2.14-1.89 (m, 4H), 1.87 (s, 3H), 1.76-1.53 (m, 4H). 13C NMR (100 
MHz, CDCl3) δ 170.1, 163.7, 159.8, 156.2, 142.3, 131.0, 130.6, 130.0, 129.4, 129.2, 126.4, 
126.2, 125.1, 124.3, 117.8, 116.4, 115.7, 114.4, 114.2, 74.6, 73.1, 63.9, 40.7, 32.1, 28.5, 27.6, 




yl)ethyl)acetamide (2.14g).  
The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.57-7.47 (m, 2H), 7.42-7.30 
(m, 2H), 7.21−7.12 (m, 2H), 7.10-7.00 (m, 3H), 6.91-6.88 (m, 1H), 6.78-6.76 (m, 1H), 5.33 (br, 
s, 1H), 4.60 (s, 2H), 4.39-4.33 (m, 1H), 3.60-3.56 (m, 1H), 3.29 (q, J = 5 Hz, 2H), 2.74 (t, J = 5 
Hz, 2H), 2.15-1.92 (m, 4H), 1.88 (s, 3H), 1.78-1.56 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 










128.35, 128.06, 127.06, 125.67, 117.43, 116.38, 115.62, 114.88, 72.06, 71.26, 68.56, 40.81, 
32.45, 27.79, 23.38.  HRMS (ESI+), m/z [M+Na+] calculated for C29H31BrFNO3Na 562.1369, 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.57-7.51 (m, 1H), 7.14-7.34 
(m, 2H), 7.30-7.26 (m, 1H), 7.24-7.19 (m, 2H), 7.09-7.00 (m, 3H), 6.91-6.88 (m, 1H), 6.78-
6.6.76 (m, 1H), 5.31 (br, s, 1H), 4.64 (s, 2H), 4.39-4.32 (m, 1H), 3.59-3.56 (m, 1H), 3.27 (q, J = 
5 Hz, 2H), 2.74 (t, J = 5 Hz, 2H), 2.16-1.92 (m, 4H), 1.88 (s, 3H), 1.78-1.55 (m, 4H). 13C NMR 
(125 MHz, CDCl3) δ 170.13, 163.77, 156.38, 142.35, 137.02, 132.99, 131.10, 130.16, 130.09, 
129.48, 129.39, 129.07, 128.67, 128.33, 127.06, 125.15, 117.83, 116.48, 115.92, 114.48, 74.66, 
73.23, 67.25, 40.79, 32.15, 27.77, 23.58. HRMS (ESI+), m/z [M+Na+] calculated for 













yl)ethyl)acetamide (2.14i).  
The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.53-7.51 (m, 1H), 7.43-7.36 
(m, 2H), 7.30-7.26 (m, 1H), 7.23−7.19 (m, 2H), 7.10-7.05 (m, 2H), 7.03-6.99 (m, 1H), 6.91-6.86 
(m, 1H), 6.79-6.76 (m, 1H), 5.30 (br, s, 1H), 4.52 (s, 2H), 4.39-4.29 (m, 1H), 3.53-3.49 (m, 1H), 
3.29 (q, J = 5 Hz, 2H), 2.74 (t, J = 5 Hz, 2H), 2.15-1.87 (m, 4H), 1.87 (s, 3H), 1.67-1.44 (m, 4H). 
13C NMR (125 MHz, CDCl3) δ 170.12, 163.77, 156.16, 143.92, 141.70, 131.10, 130.77, 130.72, 
130.62, 130.22, 130.10, 128.45, 127.81, 126.14, 125.15, 117.84, 116.48, 115.91, 115.36, 71.54, 
69.63, 69.24, 40.79, 32.15, 28.46, 27.74, 27.59, 23.58. HRMS (ESI+), m/z [M+Na+] calculated 





















The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.36 (m, 2H), 7.29-7.19 
(m 4H), 7.07−7.00 (m, 3H), 6.91-6.87 (m, 1H), 6.78-6.76 (m, 1H), 5.31 (br, s, 1H), 4.53 (s, 2H), 
4.39-4.36 (m, 1H), 3.53-3.49 (m, 1H), 3.28 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.14-2.1.87 
(m, 4H), 1.87 (s, 3H), 1.75-1.52 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 170.10, 161.80, 156.34, 
143.92, 142.34, 134.56, 131.09, 130.16, 129.91, 128.46, 128.36, 127.78, 127.69, 125.64, 125.14, 
117.83, 116.47, 115.90, 114.47, 75.98, 74.62, 69.68, 40.78, 32.15, 28.55, 27.73, 23.57. HRMS 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.36 (m, 1H), 7.28-7.25 
(m, 1H), 7.10 (d, J = 5 Hz, 1H), 7.09-7.00 (m, 3H), 6.95-6.87 (m, 3H), 6.84-6.81 (m, 1H), 6.78-
6.75 (m, 1H), 5.35 (br, s, 1H), 4.54 (s, 2H), 4.37-4.30 (m, 1H), 3.82 (s, 3H), 3.53-3.49 (m, 1H), 
3.28 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.14-1.88 (m, 4H), 1.88 (s, 3H), 1.78-1.51 (m, 4H). 










130.16, 129.67, 128.40, 125.14, 119.97, 117.83, 116.47, 115.78, 114.47, 114.30, 113.17, 75.66, 
74.77, 70.29, 55.49, 40.80, 32.13, 28.58, 27.71, 27.62, 23.54. HRMS (ESI+), m/z [M+Na+] 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.30 (m, 3H), 7.20 (d, J 
= 5 Hz, 1H), 7.10−6.99 (m, 5H), 6.90-6.87 (m, 1H), 6.78-6.75 (m, 1H), 5.33 (br, s, 1H), 4.51 (s, 
2H), 4.39-4.29 (m, 1H), 3.53-3.49 (m, 1H), 3.28 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.14-
1.87 (m, 4H), 1.88 (s, 3H), 1.74-1.48 (m, 4H). 13C NMR (125 MHz, CDCl3) δ170.14, 163.76, 
161.79, 156.16, 143.92, 142.30, 131.09, 130.14, 129.47, 128.34, 125.14, 125.12, 117.79, 116.47, 
115.91, 115.53, 115.36, 114.47, 74.80, 73.06, 69.37, 40.79, 32.14, 27.74, 27.71, 27.60, 23.56. 














The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.61-7.51 (m, 2H), 7.49-7.46 
(m, 2H), 7.41-7.35 (m, 1H), 7.20 (d, J = 5 Hz, 1H), 7.09−6.99 (m, 3H), 6.91-6.87 (m, 1H), 6.77-
6.75 (m, 1H), 5.38 (br, s, 1H), 4.61 (s, 2H), 4.37-4.31 (m, 1H), 3.83 (s, 3H), 3.55-3.51 (m, 1H), 
3.28 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.15-1.86 (m, 4H), 1.87 (s, 3H), 1.75-1.53 (m, 4H). 
13C NMR (125 MHz, CDCl3) δ 170.21, 161.80, 159.34, 156.40, 143.88, 142.33, 131.08, 130.16, 
129.34, 128.37, 125.14, 117.84, 116.48, 116.31, 115.78, 114.31, 114.07, 75.39, 74.85, 70.11, 
55.57, 40.83, 32.13, 28.75, 23.52. HRMS (ESI+), m/z [M+Na+] calculated for C30H34FNO4Na 




















The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.41 – 7.34 (m, 1H), 
7.26 – 7.21 (m, 3H), 7.20 – 7.11 (m, 2H), 7.10 – 7.04 (m, 2H), 7.00 (ddd, J = 9.6, 2.6, 1.6 Hz, 
1H), 6.87 (ddd, J = 8.6, 6.0, 2.7 Hz, 1H), 6.75 (dd, J = 7.6, 2.7 Hz, 1H), 5.33 – 5.28 (m, 1H), 
4.51 (s, 2H), 4.35 (dt, J = 6.7, 3.4 Hz, 1H), 4.29 (tt, J = 8.2, 3.4 Hz, 1H, minor diast.), 3.53 – 
3.45 (m, 1H), 3.27 (tdd, J = 7.3, 5.9, 1.4 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.34 (s, 3H), 2.15 – 
2.02 (m, 2H), 2.00 (dtd, J = 12.6, 6.7, 2.4 Hz, 2H), 1.87 (s, 3H), 1.68 (tq, J = 8.7, 3.9 Hz, 2H), 
1.54 (dddd, J = 20.1, 15.8, 10.5, 2.8 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.08, 161.65, 
156.24, 143.73, 142.12, 137.29, 137.20, 136.05, 130.01, 129.93, 129.19, 128.23, 128.10, 127.72, 
125.00, 124.98, 117.68, 116.33, 115.78, 114.30, 74.68, 70.14, 69.72, 40.65, 31.98, 28.57, 28.48, 















The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.61 (d, J = 5 Hz, 2H), 7.48 (t, 
J = 5 Hz, 2H), 7.42-7.37 (m, 1H), 7.20 (d, J = 5 Hz, 1H), 7.09 (d, J = 5 Hz, 1H), 7.09−7.00 (m, 
2H), 6.92-6.86 (m, 1H), 6.80-6.75 (m, 1H), 5.38 (br, s, 1H), 4.61 (s, 2H), 4.40-4.30 (m, 1H), 
3.55-3.50 (m, 1H), 3.29 (q, J = 3 Hz, 2H), 2.74 (t, J = 3 Hz, 2H), 2.15-1.87 (m, 4H), 1.88 (s, 3H), 
1.77-1.52 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 170.21, 163.77, 161.81, 156.34, 156.16, 
143.91, 143.44, 142.35, 131.11, 130.17, 128.45, 128.36, 127.62, 125.63, 125.14, 117.82, 116.47, 
115.90, 114.50, 76.11, 74.56, 69.68, 69.30, 40.84, 32.15, 28.52, 28.41, 27.73, 27.61, 23.53. 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.40-7.36 (m, 3H), 7.31-7.27 
(m, 2H), 7.20 (d, J = 5 Hz, 1H), 7.09-6.99 (m, 3H), 6.91-6.87 (m, 1H), 6.78-6.76 (m, 1H), 5.30 
(br, s, 1H), 4.53 (s, 2H), 4.36 (dt, J = 6.7, 3.4 Hz, 1H), 4.29 (dt, J = 8.4, 4.5 Hz, 1H, minor 
diast.), 3.54-3.51 (m, 1H), 3.29 (q, J = 5 Hz, 2H), 2.74 (t, J = 5 Hz, 2H), 2.14-1.88 (m 4H), 1.88 










156.25, 150.58, 143.74, 142.13, 135.97, 130.94, 129.95, 128.25, 127.49, 125.46, 124.98, 117.70, 
116.34, 115.63, 114.34, 74.70, 70.10, 69.67, 40.64, 34.66, 32.00, 31.51, 28.56, 27.60, 27.49, 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.36 (m, 1H), 7.33-7.31 
(m, 1H), 7.20-7.16 (m, 2H) 7.09−6.99 (m, 3H), 6.90-6.87 (m, 1H), 6.78-6.76 (m, 1H), 5.29 (br, s, 
1H), 4.77 (s, 2H), 4.38-4.35 (m, 1H), 4.33-4.28 (m, 1H, minor diast.), 3.61-3.56 (m, 1H), 3.27 (q, 
J = 3 Hz, 2H), 2.73 (t, J = 3 Hz, 2H), 2.16-1.89 (m, 4H), 1.87 (s, 3H). 1.78-1.67 (m, 2H), 1.63-
1.51 (m, 2H), 13C NMR (125 MHz, CDCl3) δ 170.08, 163.76, 161.80, 156.39, 143.89, 137.09, 
134.08, 131.08, 130.13, 128.70, 125.15, 117.82, 117.79, 116.47, 115.76, 114.46, 114.30, 74.71, 
65.36, 40.77, 32.15, 28.59, 27.79, 23.58. HRMS (ESI+), m/z [M+Na+] calculated for 














The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.31 (m, 2H), 7.21-7.19 
(m, 1H), 7.10−7.05 (m, 2H), 7.03-7.00 (m, 1H), 6.97-6.94 (m, 1H), 6.90-6.87 (m, 1H), 6.85-6.84 
(m, 1H), 6.78-6.76 (m, 1H), 5.27 (br, s, 1H), 4.53 (s, 2H), 4.38-4.29 (m, 1H), 3.82 (s, 3H), 3.53-
3.49 (m, 1H), 3.29 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.15-1.87 (m, 4H), 1.88 (s, 3H), 
1.75-1.49 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 169.27, 161.88, 156.87, 155.57, 144.82, 
142.63, 131.10, 131.07, 129.49, 120.72, 117.83, 116.49, 116.32, 115.92, 115.78, 111.13, 64.74, 
55.83, 40.79, 32.16, 27.77, 23.59. HRMS (ESI+), m/z [M+Na+] calculated for C30H33ClFNO4Na 






















The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.56-7.54 (m, 1H), 7.50-7.44 
(m, 1H), 7.41-7.36 (m, 1H), 7.32-7.30 (m, 1H), 7.21-7.19 (m, 1H), 7.09−7.00 (m, 3H), 6.91-6.87 
(m, 1H), 6.78-6.76 (m, 1H), 5.30 (br, s, 1H), 4.55 (s, 2H), 4.38-4.32 (m, 1H), 3.59-3.55 (m, 1H), 
3.29 (q, J = 5 Hz, 2H), 2.74 (t, J = 5 Hz, 2H), 2.15-1.88 (m, 4H), 1.88 (s, 3H), 1.77-1.55 (m, 4H). 
13C NMR (125 MHz, CDCl3) δ 170.09, 163.76, 156.33, 143.91, 142.35, 137.27, 133.86, 132.26, 
132.16, 131.10, 130.16, 129.93, 128.47, 127.90, 125.14, 122.87, 117.81, 116.47, 115.89, 114.48, 
76.44, 69.34, 40.78, 32.16, 28.49, 28.38, 27.75, 27.69, 23.58. HRMS (ESI+), m/z [M+Na+] 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.86-7.80 (m, 4H), 7.51-7.46 
(m, 3H), 7.41−7.37 (m, 1H), 7.21 (d, J = 5 Hz, 1H), 7.09-7.00 (m, 3H), 6.91-6.87 (m, 1H), 6.79-









Hz, 2H), 2.74 (t, J = 5 Hz, 2H), 2.17-1.89 (m, 4H), 1.88 (s, 3H), 1.77-1.55 (m, 4H). 13C NMR 
(125 MHz, CDCl3) δ 170.12, 163.76, 156.37, 142.33, 136.77, 133.57, 133.17, 131.08, 130.15, 
128.41, 128.10, 127.96, 126.34, 126.00, 125.14, 117.83, 116.47, 115.78, 114.30, 74.78, 70.58, 
70.17, 40.78, 32.14, 28.73, 27.78, 27.66, 23.57. HRMS (ESI+), m/z [M+Na+] calculated for 





The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.41-7.36 (m, 1H), 7.31-7.26 
(m, 1H), 7.20−7.18 (m, 1H), 7.10-7.05 (m, 2H), 7.03-7.00 (m, 1H), 6.90-6.87 (m, 1H), 6.79-6.76 
(m, 2H), 6.69-6.68 (m, 1H), 5.28 (br, s, 1H), 4.55 (s, 2H), 4.37-4.28 (m, 1H), 3.83 (s, 3H), 3.54-
3.48 (m, 1H), 3.28 (q, J = 5 Hz, 2H), 2.73 (t, J = 5 Hz, 2H), 2.35 (s, 3H), 2.14-1.89 (m, 4H), 1.88 
(s, 3H), 1.75-1.48 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 170.10, 163.77, 157.19, 156.43, 
143.91, 142.33, 138.79, 131.07, 130.15, 128.94, 128.36, 125.15, 124.57, 121.28, 117.84, 116.48, 
116.31, 115.94, 115.77, 114.46, 114.43, 111.47, 74.96, 65.07, 55.57, 40.77, 32.14, 28.80, 27.78, 



















Phenol 2.9 (0.12 g, 0.298 mmol), triphenylphosphine (0.156 g, 0.597 mmol) and alcohol 2.17 
(0.128g, 0.597mmol) were dissolved in anhydrous THF (2mL) at rt. After 5 minutes DIAD (0.12 
mL, 0.597mmol) was added dropwise to the mixture.  After 3 h, the reaction was concentrated, 
and purified via column chromatography (SiO2, 1:4, EtOAc: hexane) to afford 2.18 as a solid 
(58% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.40 – 7.35 (m, 1H), 7.33 – 7.26 (m, 4H), 
7.20 (d, J = 8.5 Hz, 1H), 7.09 – 7.05 (m, 2H), 7.00 (ddd, J = 9.6, 2.6, 1.6 Hz, 1H), 6.89 (dd, J = 
8.5, 2.8 Hz, 1H), 6.77 (d, J = 2.8 Hz, 1H), 6.00 (td, J = 2.3, 1.1 Hz, 2H), 5.25 (s, 1H), 4.87 – 4.82 
(m, 1H), 4.10 – 4.04 (m, 1H), 3.27 (td, J = 7.2, 5.9 Hz, 2H), 2.73 (t, J = 7.2 Hz, 2H), 2.28 – 2.22 
(m, 1H), 2.22 – 2.14 (m, 1H), 1.87 (s, 3H), 1.80 – 1.65 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 



















OsO4 (0.001g, 0.002mmol) was added at rt to a solution of 2.18 (0.01g, 0.02mmol) and NMO 
(0.006g, 0.05mmol) in THF/H2O (1:1, 0.6 mL).  The resulting solution was stirred at rt on.  After 
12 h the THF was evaporated and the residue was extracted with EtOAc (3 x 5mL).  The organic 
layers were collected, dried, concentrated and purified by column chromatography (SiO2, 1:10, 
MeOH: DCM) to obtain product 2.19 as a white solid (83% yield): 1H-NMR (500 MHz, CDCl3) 
δ 7.41-7.27 (m, 5H), 7.20 (d, J = 5 Hz, 1H), 7.10−7.06 (m, 2H), 7.01-6.99 (m, 1H), 6.92-6.90 (m, 
1H), 6.79 (d, J = 3, 1H), 5.29 (br, s, 1H), 4.62 (dd, J1 = 3Hz, J2 = 7.5Hz, 2H), 4.53-4.50 (m, 1H), 
4.17-4.15 (m, 1H), 4.06-4.04 (m, 1H), 3.72-3.69 (m, 1H), 3.28 (q, J = 3 Hz, 2H), 2.74 (t, J = 3 
Hz, 2H), 2.64 (d, J = 3 Hz, 2H), 1.94-1.72 (m, 4H), 1.88 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
170.13, 161.81, 156.01, 143.65, 142.49, 137.12, 133.77, 130.22, 129.17, 128.92, 125.11, 117.72, 
116.45, 115.75, 114.59, 75.83, 72.12, 71.46, 70.52, 40.76, 23.59, 23.45. HRMS (ESI+), m/z 
















A solution of 2,4-dihydroxybenzaldehyde (0.69 g, 5.0 mmol) and NaBH3CN (1.0 g, 15 mmol) 
in THF (30 mL) was stirred at rt.  Methyl orange was added as an indicator until the reaction was 
a light orange color. I.0 N HCl (15 mL) was added drop wise until the solution turned deep red.  
After 3 h the reaction was quenched with water (40 mL), extracted with Et2O (3 x 40 mL), dried 
(Na2SO4), filtered and concentrated to afford 2.20 a light pink solid (0.69g, 5.56 mmol): 1H NMR 
(500 MHz, Chloroform-d) δ 6.95 (d, J = 8.7 Hz, 1H), 6.33 (dd, J = 4.3, 2.0 Hz, 2H), 4.67 (s, 1H), 
4.62 – 4.56 (m, 1H), 2.17 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 154.90, 154.69, 131.53, 





 Silver triflate (8.66g, 33.85mmol) was added to a dry round bottom flask, which was then 
cooled to -78oC. 4-methylbenzene 1,3-diol (1.40g, 11.28mmol) was dissolved in anhydrous 
DCM (84mL) was added to the round bottom flask drop wise. Dichloromethyl methyl ether 
(3.063mL, 33.85mmol) in DCM (17.1mL) was then added to the mixture.  The reaction was left 
to stir for 3 h. Saturated NaHCO3 (45mL) was added to quench the reaction and after stirring for 
30 minutes the mixture was filtered through a pad of Celite.  The organic layer from the filtrate 
was removed the aqueous layer was washed with EtOAc (3X60mL). The organic layers were 
combined, dried, and concentrated.  Column chromatography (SiO2, 5:1, Hex: EtOAc) was used 







11.03 (s, 1H), 10.09 (s, 1H), 7.24 (m, 1H), 7.19 (d, J = 1.1 Hz, 1H), 6.37 (s, 1H), 2.12 (d, J = 1.1 






A solution of diol 2,4-dihydroxy-5-methylbenzaldehyde (0.025 g, 0.16 mmol), NaHCO3 
(0.018 g, 0.21 mmol), and BnBr (0.02 mL, 0.18 mmol) in anhydrous acetonitrile (1.6mL) were 
stirred and heated at reflux for 16 h.  The reaction was then quenched by the addition of water (3 
mL), extracted with EtOAc (3 x 2mL), dried (Na2SO4), filtered and concentrated.  The residue 
was purified by column chromatography (SiO2, 6:1, Hex: EtOAc) to afford solid phenol 4 (0.015 
g, 0.06 mmol): 1H NMR (500 MHz, Chloroform-d) δ 11.33 (s, 1H), 9.59 (s, 1H), 7.35 – 7.29 (m, 
4H), 7.28 – 7.23 (m, 1H), 7.16 (d, J = 1.1 Hz, 1H), 6.37 (s, 1H), 5.02 (s, 2H), 2.12 (d, J = 1.1 Hz, 




5-(Benzyloxy)-2-formyl-4-methylphenyl trifluoromethanesulfonate (2.22). 
 
A solution of 4-(benzyloxy)-2-hydroxy-5-methylbenzaldehyde (0.29 g, 1.1mmol), N-
bisphenyltriflate (0.59 g, 1.7 mmol), K2CO3 (0.61 g, 4.4 mmol) in anhydrous THF (15.7 mL) was 
stirred in a septum-capped tube.  The reaction was heated to 120 oC for 20 minutes in a 








(10 mL), extracted with EtOAc (3 x 5 mL), dried (Na2SO4), filtered and concentrated.  The 
residue was used without further purification, a yellow oil (0.16 g, 0.41 mmol):  1H NMR (500 
MHz, Chloroform-d) δ 10.30 (s, 1H), 7.59 (s, 1H), 7.33 (t, J = 2.2 Hz, 5H), 6.42 (s, 1H), 5.05 (s, 
2H), 2.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 188.38, 163.02, 161.56, 136.15, 129.98, 
128.75, 128.29, 127.25, 127.06, 120.23, 118.46, 96.98, 70.15, 15.48. 
 
 
5-(Benzyloxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-carbaldehyde (2.23).  
2.22 (0.672g, 2.1 mmol) was dissolved in anhydrous DMF (20mL).  3-fluorophenyl boronic 
acid (0.32g, 2.31mmol), K2CO3 (0.53g, 3.78 mmol), Pd(dppf)Cl2 (0.154g, 0.21mmol) were added 
to the mixture.  The reaction was degassed and then heated to reflux on. Upon completion of the 
reaction, it was cooled to rt.  The reaction was extracted with saturated LiCl and EtOAc (3 x 
50mL). The organic layers were combined, dried, concentrated, and purified via column 
chromatography (SiO2, 6:1, Hex: EtOAc) to afford the purified product as a yellow oil: 1H NMR 
(400 MHz, Chloroform-d) δ 9.83 (s, 1H), 7.89 (s, 1H), 7.51 – 7.31 (m, 5H), 7.12 (ddd, J = 16.5, 
8.6, 2.0 Hz, 3H), 6.86 (s, 1H), 5.19 (s, 2H), 2.36 (d, J = 0.8 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 190.82, 163.49, 161.01, 136.13, 130.12, 129.87, 129.80, 128.70, 128.22, 127.70, 
127.21, 126.71, 125.98, 125.95, 116.98, 114.93, 112.37, 70.19, 16.14. HRMS (ESI+) m/z: [M + 










2.23 (0.11g, 0.327mmol) was dissolved in Nitromethane (0.7mL).  NH4OAc (0.05g, 
0.654mmol) was added, and then the mixture was heated at reflux for 4 h.  After 4 h the reaction 
was cooled to rt.  The product was extracted with EtOAc (3X10mL).  The organic layers were 
combined, dried, concentrated.  The residue was purified by column chromatography (SiO2, 4:1, 
Hex: EtOAc) to afford the purified product as a yellow solid in 90% yield: 1H NMR (500 MHz, 
Chloroform-d) δ 7.89 (s, 1H), 7.86 (s, 1H), 7.44 – 7.41 (m, 2H), 7.40 – 7.26 (m, 6H), 7.08 (tdd, J 
= 8.5, 2.6, 1.0 Hz, 1H), 6.98 – 6.95 (m, 1H), 6.93 (ddd, J = 9.5, 2.6, 1.6 Hz, 1H), 5.08 (s, 2H), 
2.28 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 163.62, 159.68, 137.60, 136.17, 135.74, 130.19, 





A suspension of Lithium Aluminum Hydride (0.11g, 2.75mmol) in anhydrous THF (5.5mL) 
was cooled to 0oC. (E)-5-(Benzyloxy)-3'-fluoro-4-methyl-2-(2-nitrovinyl)-1,1'-biphenyl (0.5g, 
1.377mmol) was dissolved in anhydrous THF (1.96mL) and added drop wise to the reaction.  
The reaction slowly warmed to rt and stirred for 12 h.  Upon completion, 3N NaOH (1mL), 










for one h the mixture was filtered through a pad of Celite.  The solid was washed with warm 
EtOAc (100mL). The filtrate was collected, dried, and concentrated. The oil was purified using 
column chromatography (SiO2, 2:1, DCM: MeOH) and used directly in the next step: 1H NMR 
(500 MHz, Chloroform-d) δ 7.40 – 7.27 (m, 6H), 7.01-6.95 (m, 3H), 6.58 (d, 1H), 5.02 (s, 2H), 
3.01 – 2.89 (m, 2H), 2.87 – 2.74 (m, 2H), 2.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 163.42, 
161.72, 157.77, 143.49, 143.11, 136.84, 129.91, 129.48, 128.06, 127.67, 127.09, 124.79, 116.37, 
114.31, 70.28, 40.64, 29.62, 26.89, 16.76. HRMS (ESI+) m/z: [M + H+] calculated for 




Amine 2.24 (0.10g, 0.29mmol) was dissolved in anhydrous DCM (3mL) and cooled to 0oC.  
Triethylamine (0.03mL, 0.27mmol) was added dropwise.  After 15 minutes acetic anhydride 
(0.02mL, 0.27mmol) was added and the reaction warmed to rt.  The reaction was stirred for 12 h 
and was then quenched by the addition of water.  The mixture was extracted with DCM (2 x 
10mL) and the organic layers were combined, dried, and concentrated.  The mixture was purified 
via column chromatography (SiO2, 2:1, DCM: MeOH) to obtain the product as a white solid in 
72% yield: 1H NMR (500 MHz, Chloroform-d) δ 7.39 – 7.22 (m, 6H), 7.06 – 6.85 (m, 4H), 6.67 
(s, 1H), 4.97 (s, 2H), 3.31 – 3.17 (m, 2H), 2.65 (t, J = 7.2 Hz, 2H), 2.24 (s, 3H), 1.97 (s, 3H), 
1.55 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 169.87, 161.56, 139.23, 137.17, 132.11, 129.87, 







40.68, 31.81, 24.15, 16.12. HRMS (ESI+) m/z: [M + H+] calculated for C24H24FNO2 378.3264; 




Palladium on carbon (10% w/w, 20 mg) was added to a solution of N-(2-(5-(benzyloxy)-3'-
fluoro-4-methyl-[1,1'-biphenyl]-2-yl)ethyl)acetamide (223 mg, 1.0 mmol) in EtOAc (3 ml) 
and the suspension was stirred at rt under a hydrogen atmosphere. After 12 h, the reaction 
mixture was filtrated through Celite and the filtrate was concentrated to get 2.25 as an off-white 
amorphous solid (~100%): 1H NMR (500 MHz, Chloroform-d) δ 7.33 – 7.24 (m, 1H), 6.98 (d, J 
= 1.0 Hz, 3H), 6.87 (s, 1H), 6.57 (s, 1H), 5.20 (s, 1H), 3.20 (td, J = 7.3, 5.9 Hz, 2H), 2.63 (t, J = 
7.3 Hz, 2H), 2.22 (s, 3H), 1.80 (s, 3H), 1.51 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 169.93, 
163.49, 152.19, 132.38, 129.85, 129.79, 128.84, 127.99, 126.34, 124.93, 116.06, 114.10, 113.93, 





yl 2,2,2-trichloroacetimidate (2.26).  


















2.2651-52 (0.023g, 0.150mmol) in anhydrous DCM (0.5mL) was added to a mixture of  2.25 
(0.035g, 0.066mmol) in anhydrous DCM (0.5mL) at rt.  Boron trifluoride diethyl etherate 
(0.07mL) was then added drop wise.  The reaction was monitored via TLC.  Upon completion of 
the reaction (~1 h), triethylamine (0.1mL) was added.  The mixture was concentrated and 
purified via column chromatography (SiO2, 3:1, Hexane: EtOAc- 20:1, DCM:MeOH). The 
product was obtained as a white solid in 30% yield and used directly in the next step. The 
product (0.019g, 0.03mmol) was dissolved in MeOH (12mL) and triethylamine (4mL) was 
added.  The mixture was stirred on.  After 12 h the reaction was concentrated and purified via 
column chromatography (SiO2, 20:1, DCM: MeOH).  The product was obtained in 70% yield to 
produce a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.38 (td, J = 7.9, 6.0 Hz, 
1H), 7.10 – 6.97 (m, 4H), 5.52 – 5.49 (m, 1H), 5.48 (d, J = 2.4 Hz, 1H), 4.20 (dd, J = 9.1, 3.4 Hz, 
1H), 4.13 (dd, J = 3.4, 2.4 Hz, 1H), 3.56 (s, 3H), 3.29 (d, J = 9.1 Hz, 1H), 3.22 (tdd, J = 7.5, 5.8, 
2.0 Hz, 2H), 2.69 (td, J = 7.1, 4.8 Hz, 2H), 2.20 – 2.17 (s, 3H), 1.81 (s, 3H), 1.30 (s, 3H), 1.17 (s, 
3H). 13C NMR (126 MHz, CD2Cl2) δ 170.53, 164.23, 162.27, 154.05, 144.64, 144.58, 140.03, 
132.70, 130.57, 130.50, 129.48, 127.29, 125.97, 125.95, 117.05, 116.88, 115.60, 114.53, 114.36, 
98.49, 85.07, 78.84, 72.14, 69.45, 62.36, 41.37, 32.62, 30.45, 29.54, 23.67, 23.26, 16.61. HRMS 
















A solution of 2,4,6-trihydroxybenzaldehyde (0.025 g, 0.16 mmol), K2CO3 (0.022 g, 0.16 
mmol), and BnBr (0.02 mL, 0.16 mmol) in anhydrous DMF (1.6 mL) was stirred at 0 oC for 6 h 
and then rt for 12 h.  The reaction was quenched by the addition of water, extracted with EtOAc 
(3 x 5 mL), washed with saturated aqueous NaCl solution and a saturated aqueous LiCl solution, 
dried (Na2SO4), filtered and concentrated.  The residue was purified by column chromatography 
(SiO2, 4:1. Hex: EtOAc) to afford solid 2.28 (0.014 g, 0.06 mmol): 1H NMR (500 MHz, 
Chloroform-d) δ 12.36 (s, 1H), 10.09 (s, 1H), 7.38 – 7.26 (m, 5H), 5.93 – 5.87 (m, 2H), 5.03 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 191.95, 166.08, 164.56, 163.41, 135.55, 128.78, 128.46, 




A solution of 2.28 (0.20g, 0.82 mmol) and K2CO3 (0.06 g, 0.41 mmol) in water (0.4 mL) and 
acetone (0.4 mL) was stirred for 30 minutes.  A solution of Me2SO4 (0.08 mL, 0.82 mmol) in 
acetone (0.3 mL) was then added drop wise.  After 2 h the acetone was evaporated using a 
Rotovap, water was added (10mL), extracted with EtOAc (3 x 5 mL), dried (Na2SO4), filtered 
and concentrated.  The residue was purified by column chromatography (SiO2, 4:1, Hex: EtOAc) 
to afford phenol 2.29 as a colorless solid (0.08 g, 0.31 mmol): 1H NMR (400 MHz, Chloroform-










Hz, 1H), 5.09 (s, 2H), 3.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.87, 166.30, 164.41, 




The compound was synthesized following the procedure used for the synthesis of 2.22:  1H 
NMR (400 MHz, Chloroform-d) δ 10.39 (s, 1H), 7.48 – 7.33 (m, 6H), 6.58 (d, J = 2.1 Hz, 1H), 




The compound was synthesized following the procedure used for the synthesis of 2.23: 1H 
NMR (400 MHz, Chloroform-d) δ 10.01 (s, 1H), 7.46 – 7.32 (m, 6H), 7.13 – 6.97 (m, 3H), 6.60 
(d, J = 2.3 Hz, 1H), 6.50 (d, J = 2.3 Hz, 1H), 5.14 (s, 2H), 3.92 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 189.28, 164.17, 162.57, 147.03, 136.22, 129.69, 128.87, 128.25, 127.75, 127.22, 
125.10, 116.31, 114.56, 108.92, 99.32, 70.80, 55.76. HRMS (ESI+) m/z: [M + H+] calculated for 














The compound was synthesized following the procedure used for the synthesis of (E)-5-
(benzyloxy)-3'-fluoro-4-methyl-2-(2-nitrovinyl)-1,1'-biphenyl: 1H NMR (500 MHz, 
Chloroform-d) δ 7.89 – 7.75 (m, 2H), 7.41 – 7.24 (m, 7H), 7.11 – 7.04 (m, 1H), 7.02 – 6.92 (m, 
3H), 6.84 (d, J = 9.0 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 5.17 (s, 2H), 3.78 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 162.58, 160.76, 157.41, 138.14, 137.98, 135.31, 133.50, 130.14, 128.99, 128.61, 




The compound was synthesized following the procedure used for the synthesis of 2.24: 1H 
NMR (500 MHz, Chloroform-d) δ 7.44 – 7.39 (m, 3H), 7.37 – 7.29 (m, 3H), 7.01 (dd, J = 7.8, 
1.8 Hz, 2H), 6.98 – 6.93 (m, 1H), 6.52 (d, J = 2.5 Hz, 1H), 6.34 (d, J = 2.5 Hz, 1H), 5.12 (s, 2H), 
3.75 (s, 3H), 2.91 – 2.85 (m, 2H), 2.83 – 2.79 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 163.48, 
161.52, 158.75, 157.70, 143.39, 143.17, 136.64, 129.95, 129.88, 128.76, 127.97, 127.24, 124.70, 
116.57, 114.30, 106.54, 99.46, 70.28, 55.37, 40.60, 29.72, 27.09. HRMS (ESI+) m/z: [M + H+] 















The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-yl)ethyl)acetamide: 1H NMR (500 MHz, 
Chloroform-d) δ 7.44 – 7.26 (m, 6H), 7.02 – 6.96 (m, 2H), 6.92 (ddd, J = 9.5, 2.5, 1.6 Hz, 1H), 
6.53 (d, J = 2.5 Hz, 1H), 6.32 (d, J = 2.5 Hz, 1H), 5.62 (s, 1H), 5.23 (s, 1H), 5.04 (s, 2H), 3.72 (s, 
3H), 3.24 – 3.18 (m, 2H), 2.68 (t, J = 6.5 Hz, 2H), 1.62 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
169.96, 163.44, 161.48, 158.61, 143.29, 136.46, 129.84, 129.77, 128.83, 128.33, 127.50, 124.87, 
116.05, 114.29, 106.61, 99.31, 70.55, 55.45, 40.68, 25.87, 22.98. HRMS (ESI+), m/z [M+Na+] 




The compound was synthesized following the procedure used for the synthesis of 2.25: 1H 
NMR (500 MHz, Chloroform-d) δ 8.69 (s, 1H), 7.27 (ddd, J = 8.3, 7.5, 6.0 Hz, 1H), 6.96 (dddd, 
J = 12.6, 6.6, 2.6, 1.1 Hz, 2H), 6.88 (ddd, J = 9.7, 2.6, 1.6 Hz, 1H), 6.48 (d, J = 2.6 Hz, 1H), 6.23 
(d, J = 2.6 Hz, 1H), 6.17 (s, 1H), 3.69 (s, 3H), 3.14 (ddd, J = 9.0, 7.6, 5.8 Hz, 2H), 2.63 – 2.56 












141.54, 128.53, 123.67, 114.99, 113.68, 112.99, 106.07, 100.65, 54.26, 39.95, 21.86. HRMS 





The compound was synthesized following the procedure used for the synthesis of 2.27 with 
phenol N-(2-(3'-fluoro-5-hydroxy-3-methoxy-[1,1'-biphenyl]-2-yl)ethyl)acetamide to obtain 
the product as a white solid: 1H NMR (400 MHz, Chloroform-d) δ 7.36 (ddd, J = 8.3, 7.6, 5.9 Hz, 
1H), 7.09 – 6.99 (m, 1H), 6.95 (ddd, J = 9.6, 2.6, 1.5 Hz, 1H), 6.87 (d, J = 2.6 Hz, 1H), 6.37 (d, J 
= 2.5 Hz, 1H), 5.64 (s, 1H), 5.46 (d, J = 6.7 Hz, 1H), 5.30 (s, 1H), 4.38 (t, J = 4.2 Hz, 1H), 4.14 
(dd, J = 6.7, 3.7 Hz, 1H), 3.78 (s, 3H), 3.50 (s, 3H), 3.19 (d, J = 4.6 Hz, 1H), 2.85 – 2.80 (m, 2H), 
2.48 (dd, J = 11.7, 7.0 Hz, 2H), 2.17 (s, 3H), 1.93 (s, 3H), 1.88 – 1.69 (s, 3H). 13C NMR (126 
MHz, CD2Cl2) δ 160.01, 154.63, 144.29, 129.07, 124.22, 115.35, 113.40, 111.65, 105.36, 88.50, 
84.79, 75.27, 70.20, 69.23, 60.33, 54.98, 39.26, 25.66, 25.32, 21.78. HRMS (ESI+), m/z 
[M+Na+] calculated for C25H32FNO7Na 500.2061; found 500.2054. 
 
 















A solution of 2.28 (0.45 g, 1.85 mmol) and DIPA (0.71mL, 0.74 mmol) in anhydrous DCM 
(18mL) was stirred at 0 oC.  Chloromethyl methyl ether (0.84 mL, 11.1 mmol) was added drop 
wise after 10 minutes.  After 16 h the reaction was quenched by the addition of water (5mL), 
extracted with DCM (3 x 10mL), dried (Na2SO4), filtered and concentrated.  The residue was 
purified by column chromatography (SiO2, 8:1, Hex:EtOAc) to afford the product as a white 
solid (0.40 g, 1.38 mmol): 1H NMR (500 MHz, Chloroform-d) δ 12.36 (s, 1H), 10.20 (s, 1H), 
7.44 – 7.40 (m, 5H), 6.97 – 6.94 (m, 2H), 5.18 (s, 2H), 5.10 (s, 2H), 3.48 (s, 3H). 13C NMR (126 





The compound was synthesized following the procedure used for the synthesis of 2.22: 1H 
NMR (500 MHz, Chloroform-d) δ 10.39 (d, J = 1.5 Hz, 1H), 7.43 (dt, J = 4.7, 1.1 Hz, 5H), 6.76 
(s, 1H), 6.57 (d, J = 1.7 Hz, 1H), 5.21 (d, J = 1.7 Hz, 2H), 5.18 (t, J = 1.6 Hz, 3H), 3.49 (d, J = 
1.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 185.73, 163.19, 162.85, 149.39, 134.78, 128.76, 















The compound was synthesized following the procedure used for the synthesis of 2.23: 1H 
NMR (500 MHz, Chloroform-d) δ 10.18 (s, 1H), 7.52 – 7.49 (m, 2H), 7.43 – 7.39 (m, 2H), 7.38 
– 7.32 (m, 2H), 7.10 – 7.04 (m, 2H), 7.02 (ddd, J = 9.5, 2.6, 1.8 Hz, 1H), 6.74 (d, J = 2.2 Hz, 
1H), 6.56 (d, J = 2.3 Hz, 1H), 5.22 (d, 4H), 3.49 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 189.76, 
163.70, 162.55, 161.95, 147.20, 142.27, 136.33, 129.90, 129.08, 128.52, 127.56, 125.35, 118.46, 
116.59, 114.90, 111.27, 101.03, 94.62, 71.11, 56.83. HRMS (ESI+) m/z: [M + H+] calculated for 




The compound was synthesized following the procedure used for the synthesis of 2.24: 1H 
NMR (500 MHz, Chloroform-d) δ 7.46 – 7.41 (m, 2H), 7.41 – 7.36 (m, 2H), 7.33 (td, J = 7.8, 
7.3, 1.7 Hz, 2H), 7.03 (dd, J = 7.8, 1.5 Hz, 2H), 6.97 (ddd, J = 9.6, 2.6, 1.6 Hz, 1H), 6.69 (d, J = 
2.4 Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H), 5.14 (s, 2H), 5.09 (s, 2H), 3.47 (s, 3H), 2.80 – 2.75 (m, 
2H), 2.73 (dd, J = 6.4, 2.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 163.78, 161.82, 158.17, 
156.53, 144.04, 143.50, 137.15, 130.11, 130.04, 129.08, 128.40, 127.73, 125.19, 119.38, 114.51, 
114.34, 109.88, 101.10, 95.01, 70.66, 56.48, 42.01, 30.10. HRMS (ESI+) m/z: [M + H+] 











The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-yl)ethyl)acetamide: 1H NMR (500 MHz, 
Chloroform-d) δ 7.49 – 7.45 (m, 2H), 7.45 – 7.40 (m, 2H), 7.39 – 7.33 (m, 2H), 7.06 (dd, J = 7.8, 
1.6 Hz, 2H), 7.00 – 6.96 (m, 1H), 6.73 (d, J = 2.4 Hz, 1H), 6.55 (d, J = 2.4 Hz, 1H), 5.70 – 5.65 
(m, 1H), 5.16 (s, 2H), 5.11 (s, 2H), 3.49 (s, 3H), 3.33 – 3.24 (m, 2H), 2.76 (t, J = 6.6 Hz, 2H), 
1.68 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.97, 162.38, 160.42, 156.62, 155.25, 142.30, 
135.38, 128.77, 127.77, 127.28, 126.52, 123.86, 118.36, 115.04, 113.08, 108.75, 99.64, 93.58, 
69.52, 55.11, 39.53, 24.89, 21.99. HRMS (ESI+) m/z: [M + H+] calculated for C25H26FNO4 




The compound was synthesized following the procedure used for the synthesis of 2.25: 1H 
NMR (500 MHz, Chloroform-d) δ 7.09 – 6.93 (m, 2H), 6.84 (d, J = 2.5 Hz, 1H), 6.77 (d, J = 2.1 
Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 6.56 (dd, J = 7.5, 2.2 Hz, 1H), 6.52 (d, J = 2.5 Hz, 1H), 5.71 – 
5.67 (m, 1H), 5.17 (d, J = 4.1 Hz, 2H), 3.49 (d, J = 3.2 Hz, 3H), 3.29 (q, J = 6.5 Hz, 2H), 2.75 












142.29, 135.38, 128.36, 123.85, 118.34, 115.20, 113.07, 108.75, 99.63, 93.57, 55.59, 39.52, 






The compound was synthesized following the procedure used for the synthesis of 2.27 using 
phenol N-(2-(3'-fluoro-5-hydroxy-3-(methoxymethoxy)-[1,1'-biphenyl]-2-yl)ethyl)acetamide. 
Addition of a slight excess of boron trifluoride diethyl etherate (~0.02mL) resulted in coupling of 
the activated sugar 2.26 and subsequent removal of the methoxymethyl protecting group64 to 
produce the prodcut as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.40 – 7.31 
(m, 1H), 7.05 (ddddd, J = 9.0, 7.9, 3.7, 2.6, 1.2 Hz, 2H), 6.96 (ddd, J = 9.7, 2.6, 1.6 Hz, 1H), 6.38 
(d, J = 2.5 Hz, 1H), 6.30 (d, J = 2.4 Hz,1H), 5.46 (d, J = 2.5 Hz, 1H), 4.11 (dd, J = 9.0, 3.5 Hz, 
1H), 4.04 (dd, J = 3.5, 2.4 Hz, 1H), 3.54 (s, 3H), 3.35 (p, J = 1.7 Hz, 1H), 3.28 (d, J = 9.0 Hz, 
1H), 2.67 – 2.61 (m, 2H), 1.88 (s, 3H), 1.35 (s, 3H), 1.33 (s, 3H), 13C NMR (126 MHz, CD2Cl2) 
δ 170.94, 162.62, 155.96, 154.95, 143.21, 142.14, 128.92, 124.14, 115.61, 115.08, 112.93, 
108.46, 102.21, 97.09, 77.38, 70.39, 67.66, 60.76, 39.64, 27.69, 22.89, 21.99, 21.77, HRMS 

















 A solution of 2,3,4-trihydroxybenzaldehyde (5g, 32.5mmol) and NaHCO3 (5.45g, 64.9 
mmol) in anhydrous acetonitrile (320mL) was heated at reflux.  BnBr (6.9mL, 58.4 mmol) was 
added over 10 minutes.  After 16 h the reaction was cooled to rt, quenched by the addition of 
water (50ml), extracted with EtOAc (3 x 50mL), washed with saturated aqueous NaCl solution, 
dried (Na2SO4), filtered and concentrated.  The residue was purified by column chromatography 
(SiO2, 10:1, DCM: MeOH) to afford the product as a light brown solid (1.5 g, 6.2 mmol): 1H 
NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.97 (s, 1H), 8.93 (s, 1H), 7.51 – 7.47 (m, 2H), 
7.41 – 7.37 (m, 2H), 7.33 (d, J = 7.3 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 
5.25 (s, 2H). 13C NMR (126 MHz, DMSO) δ 192.45, 152.91, 150.23, 136.60, 133.88, 128.36, 
127.87, 127.59, 122.14, 116.97, 105.46, 69.82. HRMS (ESI+) m/z: [M - H+] calculated for 




 A solution of 4-(benzyloxy)-2,3-dihydroxybenzaldehyde (0.45 g, 1.85 mmol) and DIPEA 
(0.71mL, 0.74 mmol) in anhydrous DCM (18mL) was stirred at 0 oC.  MOMCl (0.84 mL, 11.1 
mmol) was added drop wise after 10 minutes.  After 16 h the reaction was quenched by the 
addition of water (5mL), extracted with DCM (3 x 10mL), dried (Na2SO4), filtered and 










afford 23 as a light yellow solid (0.40 g, 1.38 mmol): 1H NMR (400 MHz, Chloroform-d) δ 
11.29 (s, 1H), 9.77 (s, 1H), 7.52 – 7.48 (m, 1H), 7.42 – 7.28 (m, 5H), 6.79 (d, J = 8.8 Hz, 1H), 




The compound was synthesized following the procedure used for the synthesis of 2.22: 1H 
NMR (500 MHz, Chloroform-d) δ 10.00 (s, 1H), 7.62 (d, J = 8.7 Hz, 1H), 7.37 – 7.24 (m, 5H), 
7.02 (dd, J = 8.9, 0.5 Hz, 1H), 5.18 (s, 2H), 5.13 (s, 2H), 3.48 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 194.93, 157.81, 144.06, 138.45, 134.80, 130.51, 128.89, 128.73, 128.36, 127.63, 




The compound was synthesized following the procedure used for the synthesis of 2.23: 1H 
NMR (500 MHz, Chloroform-d) δ 9.55 (s, 1H), 7.76 (d, J = 8.7 Hz, 1H), 7.39 – 7.27 (m, 6H), 
7.26 – 7.19 (m, 2H), 7.08 – 7.04 (m, 2H), 5.15 (s, 2H), 4.83 (s, 2H), 2.82 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 190.84, 163.26, 156.34, 135.63, 133.76, 129.67, 129.41, 128.79, 128.45, 128.14, 
127.47, 127.03, 125.16, 123.64, 118.16, 114.86, 112.97, 98.61, 70.93, 56.76. HRMS (ESI+) m/z: 














The compound was synthesized following the procedure used for the synthesis of (E)-5-
(benzyloxy)-3'-fluoro-4-methyl-2-(2-nitrovinyl)-1,1'-biphenyl: 1H NMR (400 MHz, 
Chloroform-d) δ 7.84 (d, J = 8.7 Hz, 1H), 7.73 (d, J = 13.6 Hz, 1H), 7.48 – 7.33 (m, 5H), 7.19 – 




The compound was synthesized following the procedure used for the synthesis of 2.24: 1H 
NMR (400 MHz, Chloroform-d) δ 7.43 – 7.29 (m, 6H), 7.06 – 6.96 (m, 4H), 6.93 (d, J = 8.4 Hz, 
1H), 5.07 (s, 4H), 4.86 (s, 2H), 2.85 (s, 3H), 2.79 – 2.63 (m, 4H). HRMS (ESI+) m/z: [M + H+] 




The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-yl)ethyl)acetamide: 1H NMR (500 MHz, 
















4.81 (s, 2H), 3.15 (tdd, J = 7.0, 5.7, 3.7 Hz, 2H), 2.80 (s, 3H), 2.51 (t, J = 7.2 Hz, 2H), 1.80 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 168.85, 160.45, 149.09, 142.85, 138.19, 135.68, 129.01, 
128.51, 128.44, 127.56, 127.00, 126.34, 125.14, 124.16, 116.31, 112.93, 112.50, 97.60, 69.76, 





The compound was synthesized following the procedure used for the synthesis of 2.25: 1H 
NMR (500 MHz, Chloroform-d) δ 7.33 (td, J = 8.0, 6.0 Hz, 1H), 7.03 – 6.79 (m, 5H), 5.27 (s, 
1H), 4.60 (s, 2H), 3.35 (s, 3H), 3.18 – 3.10 (m, 2H), 2.48 (t, J = 7.2 Hz, 2H), 1.81 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 168.93, 160.56, 146.67, 142.23, 137.91, 133.79, 128.86, 127.78, 
125.36, 124.57, 115.90, 115.44, 113.22, 98.69, 56.15, 39.30, 31.28, 22.23. HRMS (ESI+), m/z 





















Addition of a slight excess of boron trifluoride diethyl ethrate (~0.02mL) resulted in coupling of 
the activated sugar 2.26 and subsequent removal of the methoxymethyl protecting group to 
produce the prodcut as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.04 (d, J = 
8.4 Hz, 1H), 7.00 – 6.80 (m, 3H), 6.65 (dd, J = 8.5, 3.6 Hz, 1H), 6.50 (s, 1H), 5.46 – 5.34 (m, 
1H), 4.14 (dd, J = 6.5, 3.5 Hz, 1H), 3.95 (t, J = 4.1 Hz, 1H), 3.42 (s, 3H), 3.14 (dd, J = 6.9, 5.2 
Hz, 1H), 3.09 (q, J = 6.8 Hz, 2H), 2.45 (t, J = 7.3 Hz, 2H), 1.74 (s, 3H), 1.34 (s, 3H), 1.17 (s, 
3H). 13C NMR (126 MHz, CD2Cl2) δ 170.51, 162.04, 144.87, 143.76, 139.28, 132.66, 130.23, 
128.52, 126.40, 120.84, 117.37, 114.31, 100.15, 83.82, 78.74, 70.35, 69.47, 61.05, 40.66, 32.79, 





 2,4-Dihydroxy-3-nitrobenzaldehyde (0.22g, 1.2mmol)57 was dissolved in anhydrous 
acetonitrile (6mL). KI catalyst (0.004g, 0.024mmol) was added and BnBr was added dropwise 
(0.18mL, 1.56 mmol). The reaction was stirred on at reflux.  The reaction was then cool to rt and 
quenched with water.  The mixture was washed with HCl and brine and extracted with EtOAc (3 
x 20mL). The organic layers were combined, dried, and concentrated to obtain 2.37 as a yellow 
solid in 75% yield:  1H NMR (500 MHz, Chloroform-d) δ 11.75 (s, 1H), 9.80 (s, 1H), 7.60 (d, J 
= 8.8 Hz, 1H), 7.42 – 7.35 (m, 5H), 6.70 (d, J = 8.8 Hz, 1H), 5.29 (s, 2H). 13C NMR (126 MHz, 










The compound was synthesized following the procedure used for the synthesis of 2.23: 1H 
NMR (500 MHz, Chloroform-d) δ 12.72 (s, 1H), 7.63 (d, J = 9.1 Hz, 1H), 7.54 – 7.46 (m, 1H), 
7.41 – 7.29 (m, 8H), 6.57 (d, J = 9.1 Hz, 1H), 5.27 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
205.99, 197.26, 162.38, 160.40, 155.63, 154.99, 137.79, 135.02, 133.47, 129.43, 127.86, 127.63, 




The compound was synthesized following the procedure used for the synthesis of (E)-5-
(benzyloxy)-3'-fluoro-4-methyl-2-(2-nitrovinyl)-1,1'-biphenyl: 1H NMR (500 MHz, 
Chloroform-d) δ 7.69 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 13.7 Hz, 1H), 7.42 – 7.34 (m, 7H), 7.31 (d, 
J = 13.6 Hz, 1H), 7.17 (d, J = 8.9 Hz, 1H), 7.03 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 6.98 (ddd, J = 8.9, 
2.6, 1.6 Hz, 1H), 5.30 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 163.50, 161.52, 151.73, 137.67, 




















Lithium Aluminum Hydride (0.22 g, 5.51 mmol) was dissolved in dry THF (10 mL) and 
cooled to 0oC. (E)-3-(benzyloxy)-3'-fluoro-2-nitro-6-(2-nitrovinyl)-1,1'-biphenyl (0.5g, 
1.377mmol) was dissolved in anhydrous THF (2.0 mL) and added drop wise to the reaction.  The 
reaction slowly warmed to rt and stirred for 12 h.  Upon completion, 3N NaOH (1mL), water 
(1mL), and EtOAc (3mL) were added sequentially to quench the reaction.  After stirring for one 
h the mixture was filtered through a pad of Celite.  The solid was washed with warm EtOAc 
(100mL). The filtrate was collected, dried, and concentrated and used directly in the next step: 




The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-4-methyl-[1,1'-biphenyl]-2-yl)ethyl)acetamide: 1H NMR (500 MHz, 
Chloroform-d) δ 7.49 – 7.31 (m, 6H), 7.14 – 6.95 (m, 3H), 6.85 (d, J = 8.3 Hz, 1H), 6.63 (d, J = 
8.3 Hz, 1H), 5.20 (s, 1H), 5.11 (s, 2H), 3.24 – 3.19 (m, 2H), 2.54 – 2.45 (m, 2H), 1.88 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 168.73, 161.24, 146.86, 138.69, 134.41, 133.37, 130.60, 129.31, 
128.32, 127.71, 127.05, 126.58, 126.08, 124.73, 117.08, 115.90, 113.76, 112.68, 110.02, 70.07, 













The compound was synthesized following the procedure used for the synthesis of 2.25: 1H 
NMR (500 MHz, Chloroform-d) δ 7.51 (ddd, J = 8.4, 7.5, 5.9 Hz, 1H), 7.18 (tdd, J = 8.4, 2.6, 1.0 
Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 7.00 (ddd, J = 7.5, 1.6, 1.0 Hz, 1H), 
6.96 – 6.92 (m, 2H), 6.74 (s, 1H), 5.33 (d, J = 6.6 Hz, 1H), 3.22 (qd, J = 7.4, 6.0 Hz, 2H), 2.54 – 
2.46 (m, 2H), 2.25 (d, J = 0.7 Hz, 2H), 1.89 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.05, 
162.27, 138.63, 136.41, 133.89, 131.41, 128.97, 126.46, 125.49, 123.92, 120.32, 116.96, 115.90, 





pyran-2-yl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)acetamide (2.38).  
The compound was synthesized following the procedure used for the synthesis of 2.27 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.45 (tdd, J = 7.7, 5.8, 
1.7 Hz, 1H), 7.14 – 7.05 (m, 1H), 7.04 – 6.91 (m, 2H), 6.63 (d, J = 8.3 Hz, 1H), 5.47 (t, J = 2.5 
Hz, 1H), 5.35 – 5.27 (m, 1H), 4.22 (dd, J = 8.4, 3.2 Hz, 1H), 4.17 (t, J = 3.2 Hz, 1H), 3.58 (s, 
3H), 3.33 (d, J = 8.4 Hz, 1H), 3.22 (dd, J = 8.3, 4.8 Hz, 2H), 2.48 (t, J = 7.1 Hz, 2H), 1.89 (s, 


















130.85, 130.38, 125.68, 118.50, 117.00, 114.76, 114.06, 98.62, 78.16, 70.91, 68.65, 61.50, 39.98, 
32.50, 29.59, 28.40, 23.23. HRMS (ESI+), m/z [M+Na+] calculated for C24H31FN2O6Na 





The compound was synthesized following the procedure used for the synthesis of 2.4 using 
phenol 2.25 to obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.39 – 
7.32 (m, 5H), 7.08 – 7.02 (m, 2H), 6.99 (ddd, J = 9.5, 2.6, 1.5 Hz, 1H), 6.91 – 6.80 (m, 2H), 6.67 
(dd, J = 15.7, 7.1 Hz, 1H), 5.29 – 5.23 (m, 1H), 4.56 (dd, J = 11.6, 1.6 Hz, 2H), 4.36 (dd, J = 6.0, 
3.0 Hz, 1H), 3.53 – 3.44 (m, 1H), 3.30 – 3.24 (m, 2H), 2.70 (dt, J = 9.7, 7.1 Hz, 2H), 2.23 (s, 
3H), 2.10 – 1.99 (m, 2H), 1.87 (s, 3H), 1.79 – 1.71 (m, 2H), 1.68 – 1.54 (m, 4H). 13C NMR (126 
MHz, CDCl3) δ 168.82, 162.45, 155.80, 153.00, 142.86, 142.08, 138.02, 134.06, 131.17, 130.83, 
130.24, 127.43, 124.01, 119.42, 115.31, 113.01, 109.02, 63.52, 54.26, 39.61, 31.31, 30.74, 22.27, 














yl)ethyl)acetamide (2.39b).  
The compound was synthesized following the procedure used for the synthesis of 2.39a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.40 – 7.32 (m, 3H), 
7.13 – 7.03 (m, 5H), 6.86 (ddd, J = 8.0, 2.7, 1.1 Hz, 1H), 6.70 – 6.63 (m, 1H), 5.29 (d, J = 5.6 
Hz, 1H), 4.59 (d, J = 10.5 Hz, 2H), 4.39 – 4.34 (m, 1H), 4.34 – 4.24 (m, 1H, minor 
diasteriomer), 3.83 (d, J = 2.5 Hz, 3H), 3.57 – 3.46 (m, 1H), 3.31 – 3.23 (m, 2H), 2.70 (t, J = 7.3 
Hz, 2H), 2.31 (s, 3H), 2.11 – 1.99 (m, 2H), 1.88 (d, J = 16.7 Hz, 3H), 1.81 – 1.70 (m, 2H), 1.71 – 
1.53 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 168.79, 162.45, 160.49, 152.94, 142.88, 137.95, 
134.38, 134.06, 131.19, 130.83, 130.24, 128.78, 127.33, 126.75, 126.48, 126.40, 124.01, 123.98, 
115.30, 115.14, 112.99, 68.78, 39.60, 30.74, 26.77, 26.38, 22.28, 19.05, 15.14. HRMS (ESI+), 




















yl)ethyl)acetamide (2.39c).  
The compound was synthesized following the procedure used for the synthesis of 2.39a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.29 (dddd, J = 13.5, 
8.2, 6.5, 2.7 Hz, 2H), 7.14 – 7.07 (m, 3H), 6.99 (td, J = 4.2, 3.4, 1.6 Hz, 3H), 6.92 (ddd, J = 9.7, 
2.6, 1.6 Hz, 1H), 6.59 (d, J = 6.4 Hz, 1H), 5.23 (t, J = 5.7 Hz, 1H), 4.46 (d, J = 11.1 Hz, 2H), 
4.30 (dt, J = 6.0, 2.9 Hz, 1H), 4.22 (dt, J = 8.2, 4.8 Hz, 1H), 3.44 (dtt, J = 23.4, 7.9, 3.6 Hz, 1H), 
3.20 (td, J = 7.2, 5.9 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 2.27 (d, J = 9.0 Hz, 3H), 2.17 (dd, J = 
11.8, 0.7 Hz, 3H), 2.06 – 1.92 (m, 2H), 1.79 (s, 3H), 1.74 – 1.66 (m, 2H), 1.64 – 1.54 (m, 
4H).13C NMR (126 MHz, CDCl3) δ 169.86, 163.50, 161.54, 153.99, 144.00, 139.09, 136.73, 
132.24, 130.22, 128.46, 127.69, 125.82, 125.03, 116.35, 114.06, 75.20, 74.49, 72.36, 68.45, 
40.66, 31.79, 27.86, 27.43, 23.32, 18.90, 16.18. HRMS (ESI+), m/z [M+Na+] calculated for 





The compound was synthesized following the procedure used for the synthesis of 2.39a to 











7.41 – 7.30 (m, 2H), 7.23 (dd, J = 12.4, 8.4 Hz, 2H), 7.09 – 7.03 (m, 3H), 6.67 (d, J = 9.5 Hz, 
1H), 5.31 – 5.23 (m, 1H), 4.51 (s, 2H), 4.36 (dt, J = 6.0, 3.0 Hz, 1H), 3.47 (dq, J = 8.0, 4.3, 3.8 
Hz, 1H), 3.27 (td, J = 7.2, 5.8 Hz, 2H), 2.71 (dd, J = 9.6, 7.2 Hz, 2H), 2.26 (s, 3H), 2.02 (td, J = 
11.9, 5.7 Hz, 2H), 1.87 (s, 3H), 1.73 (ddd, J = 13.9, 7.0, 3.8 Hz, 2H), 1.67 – 1.54 (m, 4H). 13C 
NMR (126 MHz, CDCl3) δ 169.95, 161.68, 154.09, 144.04, 139.23, 138.18, 132.39, 131.60, 
129.97, 129.28, 127.91, 127.73, 127.53, 125.18, 121.38, 116.48, 114.63, 114.18, 113.98, 72.42, 
69.52, 56.14, 40.79, 36.05, 31.94, 29.86, 29.48, 28.20, 27.54, 23.46, 16.32. HRMS (ESI+), m/z 




yl)ethyl)acetamide (2.39e).  
The compound was synthesized following the procedure used for the synthesis of 2.39a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.41 – 7.35 (m, 1H), 
7.34 – 7.29 (m, 3H), 7.10 – 7.03 (m, 3H), 6.66 (d, J = 6.3 Hz, 1H), 5.33 – 5.28 (m, 1H), 4.52 (s, 
1H), 4.37 (dt, J = 6.0, 3.0 Hz, 1H), 3.49 – 3.44 (m, 1H), 3.31 – 3.24 (m, 2H), 2.70 (t, J = 7.2 Hz, 
2H), 2.26 (d, J = 0.7 Hz, 3H), 2.12 – 1.99 (m, 2H), 1.87 (s, 3H), 1.77 – 1.70 (m, 4H), 1.68 – 1.58 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.00, 161.66, 154.08, 144.09, 139.23, 137.64, 135.55, 











114.63, 114.17, 113.97, 75.30, 72.40, 69.22, 40.80, 32.49, 31.92, 28.20, 27.93, 27.53, 23.43, 





yl)ethyl)acetamide (2.40a).  
The compound was synthesized following the procedure used for the synthesis of 2.4 using 
phenol N-(2-(3'-fluoro-5-hydroxy-3-methoxy-[1,1'-biphenyl]-2-yl)ethyl)acetamide to obtain 
the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.41 – 7.32 (m, 5H), 7.30 – 
7.27 (m, 1H), 7.08 – 7.04 (m, 1H), 6.99 (ddt, J = 8.1, 3.1, 1.5 Hz, 1H), 6.50 (t, J = 2.9 Hz, 1H), 
6.34 (t, J = 2.8 Hz, 1H), 5.87 (s, 1H), 5.74 (s, 1H), 4.56 (d, J = 1.8 Hz, 2H), 4.42 (dq, J = 6.5, 3.3 
Hz, 1H), 3.79 (d, J = 1.9 Hz, 3H), 3.55 (dt, J = 6.7, 3.5 Hz, 1H), 3.28 (qd, J = 6.0, 5.4, 3.1 Hz, 
2H), 2.75 – 2.64 (m, 2H), 2.21 – 2.15 (m, 2H), 2.11 – 2.01 (m, 2H), 1.94 – 1.88 (m, 2H), 1.85 (d, 
J = 4.9 Hz, 3H), 1.78 (tq, J = 12.6, 4.6, 4.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 169.94, 
163.43, 161.46, 156.41, 143.82, 138.85, 129.79, 128.40, 127.52, 124.85, 118.92, 116.19, 116.02, 
114.23, 114.06, 106.09, 100.02, 73.99, 73.57, 69.90, 55.43, 40.78, 28.33, 27.69, 27.58, 25.81, 














2-yl)ethyl)acetamide (2.40b).  
The compound was synthesized following the procedure used for the synthesis of 2.40a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.45 – 7.41 (m, 1H), 
7.37 (td, J = 8.0, 5.9 Hz, 1H), 7.24 – 7.23 (m, 1H), 7.08 – 7.03 (m, 1H), 7.00 – 6.93 (m, 2H), 
6.87 (ddd, J = 8.2, 3.5, 1.0 Hz, 1H), 6.50 (d, J = 2.5 Hz, 1H), 6.34 (t, J = 2.4 Hz, 1H), 5.84 (t, J = 
4.9 Hz, 1H), 5.69 (q, J = 5.2, 4.5 Hz, 1H), 4.59 (d, J = 3.3 Hz, 2H), 4.41 (tt, J = 8.9, 4.5 Hz, 1H), 
3.81 (d, J = 21.3 Hz, 6H), 3.57 (td, J = 5.9, 4.8, 2.6 Hz, 1H), 3.27 (td, J = 6.6, 4.8 Hz, 2H), 2.70 
(dt, J = 15.2, 6.7 Hz, 2H), 2.19 (ddd, J = 14.7, 6.0, 3.3 Hz, 1H), 2.13 – 2.00 (m, 1H), 1.94 (dt, J = 
11.9, 7.7 Hz, 1H), 1.84 (s, 3H), 1.77 (ddt, J = 18.3, 9.1, 2.6 Hz, 2H), 1.66 – 1.56 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 169.96, 163.56, 161.60, 158.58, 156.59, 143.97, 143.56, 129.90, 
128.61, 127.44, 125.00, 120.61, 119.15, 116.33, 114.18, 110.23, 106.20, 100.16, 73.91, 64.76, 
55.56, 55.44, 40.93, 29.85, 28.52, 27.91, 27.74, 25.93, 23.43. HRMS (ESI+), m/z [M+Na+] 
















The compound was synthesized following the procedure used for the synthesis of 2.40a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 6.43 (d, J = 2.7 Hz, 
1H), 6.26 (t, J = 2.3 Hz, 1H), 5.77 (t, J = 4.9 Hz, 1H), 5.64 (d, J = 5.1 Hz, 1H), 4.46 (s, 2H), 4.38 
– 4.29 (m, 1H), 3.71 (d, J = 1.6 Hz, 3H), 3.48 (dt, J = 7.5, 3.7 Hz, 1H), 3.23 – 3.16 (m, 2H), 2.63 
(q, J = 6.4 Hz, 2H), 2.28 (d, J = 1.6 Hz, 3H), 2.15 – 2.10 (m, 1H), 2.05 – 1.96 (m, 1H), 1.90 – 
1.81 (m, 1H), 1.77 (d, J = 10.1 Hz, 3H), 1.74 – 1.64 (m, 2H), 1.63 – 1.48 (m, 1H). 13C NMR (126 
MHz, CDCl3) δ 168.82, 162.37, 160.41, 157.40, 155.36, 142.36, 135.53, 129.19, 128.73, 127.38, 
126.70, 124.78, 123.81, 117.89, 115.14, 113.16, 105.01, 98.95, 74.30, 73.25, 72.43, 67.46, 54.38, 
39.65, 27.24, 26.63, 26.58, 24.81, 22.22, 17.84, 16.68, 11.25. HRMS (ESI+), m/z [M+Na+] 






















yl)ethyl)acetamide (2.40d).  
The compound was synthesized following the procedure used for the synthesis of 2.40a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.50 – 7.45 (m, 2H), 
7.37 (td, J = 7.9, 6.0 Hz, 1H), 7.23 (dd, J = 8.5, 2.0 Hz, 1H), 7.06 (tdd, J = 7.4, 2.8, 1.9 Hz, 2H), 
7.01 – 6.96 (m, 1H), 6.49 (t, J = 2.9 Hz, 1H), 6.33 (t, J = 2.7 Hz, 1H), 5.74 (s, 1H), 5.62 (s, 1H), 
4.50 (s, 2H), 4.41 (dtd, J = 14.2, 7.7, 7.2, 3.4 Hz, 1H), 3.79 (d, J = 1.8 Hz, 3H), 3.53 (dt, J = 7.2, 
3.7 Hz, 1H), 3.30 – 3.23 (m, 2H), 2.70 (dt, J = 18.8, 6.7 Hz, 2H), 2.21 – 2.14 (m, 2H), 2.05 (ddd, 
J = 14.8, 7.5, 3.4 Hz, 2H), 1.90 – 1.85 (m, 2H), 1.84 (s, 3H), 1.82 – 1.73 (m, 2H), 1.67 – 1.60 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 168.70, 162.39, 160.42, 155.36, 142.73, 142.37, 136.85, 
130.44, 128.68, 128.10, 123.80, 120.26, 117.87, 115.16, 114.99, 113.19, 113.02, 105.01, 98.96, 
68.12, 54.39, 39.60, 28.67, 26.60, 26.53, 24.83, 22.27. HRMS (ESI+), m/z [M+Na+] calculated 





The compound was synthesized following the procedure used for the synthesis of 2.40a to 












7.27 – 7.22 (m, 3H), 7.01 – 6.96 (m, 2H), 6.94 – 6.89 (m, 1H), 6.43 (t, J = 2.8 Hz, 1H), 6.27 (t, J 
= 2.8 Hz, 1H), 5.74 (s, 1H), 5.63 (s, 1H), 4.45 (s, 2H), 4.34 (ddq, J = 14.7, 7.6, 3.7, 3.3 Hz, 1H), 
3.72 (d, J = 1.7 Hz, 3H), 3.46 (dt, J = 7.2, 3.7 Hz, 1H), 3.23 – 3.17 (m, 2H), 2.63 (dt, J = 18.6, 
6.7 Hz, 2H), 2.10 (ddd, J = 10.4, 8.0, 3.9 Hz, 1H), 2.03 – 1.93 (m, 1H), 1.86 – 1.80 (m, 1H), 1.78 
(s, 3H), 1.70 (dddt, J = 15.7, 12.3, 8.4, 3.5 Hz, 2H), 1.61 – 1.47 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 170.01, 163.56, 161.60, 156.53, 143.95, 143.54, 137.50, 133.33, 129.94, 128.95, 
128.92, 128.67, 124.98, 119.00, 116.32, 116.15, 114.37, 114.20, 106.20, 100.15, 73.54, 69.28, 
55.56, 40.82, 28.39, 27.78, 25.99, 23.39. HRMS (ESI+), m/z [M+Na+] calculated for 




yl)ethyl)acetamide (2.41a).  
The compound was synthesized following the procedure used for the synthesis of 2.4 using 
phenol N-(2-(3'-fluoro-5-hydroxy-3-(methoxymethoxy)-[1,1'-biphenyl]-2-yl)ethyl)acetamide 
to obtain the coupled product in 75% yield (0.1mmol), which was then dissolved in MeOH 
(5mL) and PTSA (0.017g, 0.1mmol) was added.  After 12 hr the reaction was quenched via 
addition of sat. NH4Cl (1mL), and then extracted with EtOAc (3 x 7mL).   The organic layers 
were combined, dried, and concentrated.  The product was purified by column chromatography 
(Silica gel, 50% MeOH in DCM) to give 2.41a as a white solid in 55% yield: 1H-NMR (500 











J = 8.5, 2.7, 1.3 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 6.26 (dd, J = 3.8, 2.4 Hz, 1H), 5.88 (d, J = 5.6 
Hz, 1H), 5.83 – 5.79 (m, 1H), 5.74 – 5.69 (m, 1H), 4.56 (d, J = 1.8 Hz, 2H), 4.38 (dtd, J = 19.4, 
8.0, 7.3, 3.3 Hz, 1H), 3.55 (dt, J = 7.4, 3.7 Hz, 1H), 3.29 – 3.20 (m, 2H), 2.67 (dt, J = 17.5, 6.7 
Hz, 2H), 2.17 (dd, J = 11.9, 4.3 Hz, 1H), 2.12 – 1.98 (m, 1H), 1.96 – 1.86 (m, 2H), 1.84 (s, 3H), 
1.76 (qt, J = 9.7, 3.7 Hz, 2H), 1.61 (d, J = 16.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.56, 
163.78, 156.93, 155.23, 143.88, 139.21, 130.10, 130.04, 128.81, 127.92, 125.17, 118.66, 116.48, 
114.56, 114.39, 109.47, 100.60, 74.40, 70.63, 70.29, 41.30, 28.76, 28.07, 27.98, 26.05, 23.66. 




2-yl)ethyl)acetamide (2.41b).  
The compound was synthesized following the procedure used for the synthesis of 2.41a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.44 – 7.40 (m, 1H), 
7.37 – 7.30 (m, 1H), 7.06 – 6.90 (m, 4H), 6.87 (ddd, J = 8.2, 3.9, 1.0 Hz, 1H), 6.47 (d, J = 2.4 
Hz, 1H), 6.28 – 6.23 (m, 1H), 5.90 (s, 1H), 5.73 (s, 1H), 4.59 (s, 2H), 4.38 (ddq, J = 15.2, 7.8, 
3.4 Hz, 1H), 3.83 (d, J = 4.7 Hz, 3H), 3.56 (dd, J = 7.1, 3.5 Hz, 1H), 3.33 – 3.18 (m, 2H), 2.69 (t, 
J = 6.7 Hz, 2H), 2.17 (d, J = 5.6 Hz, 1H), 2.12 – 1.99 (m, 2H), 1.97 – 1.88 (m, 1H), 1.84 (d, J = 
6.3 Hz, 3H), 1.82 – 1.71 (m, 2H), 1.65 – 1.51 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.26, 












118.58, 116.24, 116.07, 114.32, 114.15, 110.24, 109.16, 100.32, 74.31, 73.89, 64.78, 55.44, 
41.05, 28.56, 27.90, 27.75, 25.80, 23.40, 22.50. HRMS (ESI+), m/z [M+Na+] calculated for 




yl)ethyl)acetamide (2.41c).  
The compound was synthesized following the procedure used for the synthesis of 2.41a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.33 (ddd, J = 10.0, 
7.3, 2.2 Hz, 2H), 7.18 (dqt, J = 6.3, 4.0, 1.7 Hz, 3H), 7.06 – 6.95 (m, 2H), 6.91 (ddd, J = 9.5, 2.6, 
1.5 Hz, 1H), 6.47 (d, J = 2.4 Hz, 1H), 6.25 (d, J = 2.4 Hz, 1H), 5.91 (s, 1H), 4.54 (s, 2H), 4.40 
(dt, J = 7.1, 3.6 Hz, 1H), 3.55 (dq, J = 7.2, 3.8, 3.3 Hz, 1H), 3.24 (q, J = 6.2 Hz, 2H), 2.68 (t, J = 
6.6 Hz, 2H), 2.35 (d, J = 2.0 Hz, 3H), 2.09 – 2.00 (m, 1H), 1.95 – 1.86 (m, 1H), 1.84 (s, 2H), 
1.81 – 1.73 (m, 4H), 1.63 (q, J = 10.6 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.34, 163.77, 
156.92, 155.24, 143.87, 136.98, 130.64, 130.12, 128.16, 126.23, 125.20, 118.61, 116.48, 114.39, 
109.47, 100.62, 74.70, 73.88, 68.91, 41.30, 28.03, 26.04, 23.64, 22.75, 19.28. HRMS (ESI+), 














yl)ethyl)acetamide (2.41d).  
The compound was synthesized following the procedure used for the synthesis of 2.41a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.49 – 7.43 (m, 2H), 
7.36 – 7.28 (m, 1H), 7.25 – 7.21 (m, 1H), 7.02 (dddd, J = 11.1, 8.5, 2.6, 0.9 Hz, 1H), 6.96 (ddt, J 
= 7.6, 5.2, 1.2 Hz, 1H), 6.89 (dddd, J = 9.5, 6.3, 2.6, 1.6 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 6.25 
(d, J = 2.4 Hz, 1H), 6.23 (d, J = 14.1 Hz, 1H), 5.86 (t, J = 5.0 Hz, 1H), 5.73 (t, J = 5.1 Hz, 1H), 
4.50 (s, 2H), 4.42 – 4.30 (m, 1H), 3.52 (dt, J = 7.5, 3.8 Hz, 1H), 3.24 (td, J = 6.7, 4.9 Hz, 2H), 
2.66 (dt, J = 16.8, 6.7 Hz, 2H), 2.19 – 2.11 (m, 1H), 2.09 – 1.97 (m, 2H), 1.84 (d, J = 4.4 Hz, 
4H), 1.75 (ddt, J = 15.0, 11.8, 7.4 Hz, 2H), 1.65 – 1.51 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
170.40, 163.52, 156.62, 155.16, 143.57, 137.99, 131.62, 129.84, 129.78, 129.30, 129.27, 124.90, 
121.46, 118.16, 116.21, 116.04, 114.28, 114.12, 109.27, 100.40, 74.44, 73.51, 69.31, 41.05, 
28.43, 27.77, 25.78, 23.39. HRMS (ESI+), m/z [M+Na+] calculated for C29H31BrFNO4Na 
















The compound was synthesized following the procedure used for the synthesis of 2.41a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.35 – 7.27 (m, 4H), 
7.02 (dddd, J = 11.1, 8.5, 2.7, 1.0 Hz, 1H), 6.99 – 6.94 (m, 1H), 6.90 (dddd, J = 9.6, 5.8, 2.6, 1.5 
Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 6.26 (dd, J = 3.8, 2.4 Hz, 1H), 6.03 (d, J = 13.1 Hz, 1H), 5.85 
(t, J = 5.0 Hz, 1H), 5.71 (t, J = 5.2 Hz, 1H), 4.51 (s, 2H), 4.42 – 4.31 (m, 1H), 3.52 (tt, J = 6.9, 
3.1 Hz, 1H), 3.24 (td, J = 6.7, 5.0 Hz, 2H), 2.71 – 2.63 (m, 2H), 2.18 – 2.12 (m, 1H), 2.03 (tdd, J 
= 12.8, 10.5, 7.9 Hz, 2H), 1.91 – 1.85 (m, 1H), 1.84 (s, 3H), 1.81 – 1.69 (m, 2H), 1.61 (s, 2H). 
13C NMR (126 MHz, CDCl3) δ 169.16, 162.34, 155.46, 153.90, 142.41, 136.29, 132.17, 128.67, 
127.78, 127.49, 123.72, 117.07, 115.04, 114.87, 113.12, 112.95, 108.06, 99.19, 73.25, 72.34, 
68.11, 39.83, 26.60, 24.62, 22.22. HRMS (ESI+), m/z [M+Na+] calculated for C29H31ClFNO4Na 






















yl)ethyl)acetamide (2.42a).   
The compound was synthesized following the procedure used for the synthesis of 2.42a using 
phenol N-(2-(3'-fluoro-5-hydroxy-6-(methoxymethoxy)-[1,1'-biphenyl]-2-yl)ethyl)acetamide 
to obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.44 – 7.39 (m, 1H), 
7.36 – 7.33 (m, 4H), 7.30 – 7.26 (m, 1H), 7.10 – 7.03 (m, 2H), 6.99 (ddd, J = 9.5, 2.6, 1.5 Hz, 
1H), 6.86 (d, J = 8.4 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 5.74 (s, 1H), 5.25 (s, 1H), 4.55 (s, 2H), 
4.39 (dq, J = 7.2, 3.6 Hz, 1H), 3.56 (tt, J = 6.7, 3.3 Hz, 1H), 3.24 (q, J = 6.8 Hz, 2H), 2.59 (t, J = 
7.2 Hz, 2H), 2.03 (dtd, J = 12.3, 8.4, 3.7 Hz, 2H), 1.88 (s, 5H), 1.80 (ddt, J = 12.0, 7.7, 3.6 Hz, 
2H), 1.71 (tt, J = 12.6, 3.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 169.93, 163.82, 161.86, 
144.19, 143.06, 139.01, 138.70, 130.09, 130.00, 128.53, 127.58, 125.89, 120.40, 117.12, 114.41, 
112.75, 73.72, 69.97, 40.44, 32.44, 27.78, 27.63, 23.48. HRMS (ESI+), m/z [M+Na+] calculated 




2-yl)ethyl)acetamide (2.42b).  
The compound was synthesized following the procedure used for the synthesis of 2.42a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.45 – 7.38 (m, 2H), 












1H), 5.26 (d, J = 6.4 Hz, 1H), 4.58 (s, 2H), 4.39 (tt, J = 7.3, 3.5 Hz, 1H), 3.82 (s, 3H), 3.58 (dt, J 
= 6.6, 3.3 Hz, 1H), 3.24 (q, J = 6.8 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 2.08 – 1.98 (m, 2H), 1.98 – 
1.89 (m, 2H), 1.88 (s, 3H), 1.80 (ddt, J = 11.6, 7.3, 3.4 Hz, 2H), 1.72 (dtd, J = 12.9, 5.2, 4.4, 2.2 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 168.78, 162.63, 160.68, 155.75, 143.03, 141.93, 137.55, 
137.48, 128.85, 128.81, 127.35, 127.28, 126.29, 124.71, 119.45, 119.20, 116.11, 115.94, 113.38, 
111.57, 109.01, 72.76, 63.55, 54.26, 39.26, 31.25, 26.69, 26.48, 22.30.  HRMS (ESI+), m/z 




yl)ethyl)acetamide (2.42c).  
The compound was synthesized following the procedure used for the synthesis of 2.42a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.38 – 7.32 (m, 1H), 
7.31 – 7.25 (m, 2H), 7.15 – 7.06 (m, 5H), 7.04 – 6.97 (m, 2H), 6.96 – 6.90 (m, 1H), 6.79 (dd, J = 
8.4, 4.8 Hz, 1H), 6.70 (dd, J = 8.4, 3.6 Hz, 1H), 5.67 (s, 1H), 5.62 (s, 1H), 5.19 (d, J = 6.4 Hz, 
1H), 5.05 (s, 1H), 4.49 – 4.41 (m, 2H), 4.31 (ddt, J = 19.9, 8.4, 4.2 Hz, 1H), 3.69 (dt, J = 7.8, 3.9 
Hz, 1H), 3.49 (dt, J = 6.8, 3.4 Hz, 1H, minor diast.), 3.44 (tt, J = 6.3, 3.1 Hz, 1H), 3.17 (q, J = 6.8 
Hz, 2H), 2.52 (t, J = 7.2 Hz, 2H), 2.28 (d, J = 3.6 Hz, 3H), 2.16 – 2.08 (m, 1H), 2.02 (dd, J = 
12.0, 4.9 Hz, 1H), 1.98 – 1.91 (m, 1H), 1.88 – 1.83 (m, 2H), 1.81 (s, 3H), 1.74 (dd, J = 8.7, 4.0 











143.05, 138.65, 136.67, 130.27, 130.06, 128.40, 127.70, 125.94, 120.40, 117.28, 114.41, 112.74, 
7574.05, 69.00, 68.44, 40.44, 32.45, 30.76, 29.85, 28.66, 27.80, 23.48, 19.02. HRMS (ESI+), 




yl)ethyl)acetamide (2.42d).  
The compound was synthesized following the procedure used for the synthesis of 2.42a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.45 (s, 1H), 7.42 
(ddd, J = 8.4, 7.6, 6.0 Hz, 1H), 7.24 – 7.20 (m, 2H), 7.11 – 7.04 (m, 3H), 6.99 (ddd, J = 9.6, 2.7, 
1.4 Hz, 1H), 6.86 (dd, J = 8.4, 4.3 Hz, 1H), 6.77 (dd, J = 8.4, 3.2 Hz, 1H), 5.73 (s, 1H), 5.25 (d, J 
= 6.8 Hz, 1H), 4.49 (s, 2H), 4.39 (dq, J = 6.9, 3.5 Hz, 1H), 3.53 (dq, J = 6.7, 3.3 Hz, 1H), 3.49 
(dq, J = 5.9, 3.2 Hz, 2H), 2.59 (td, J = 7.2, 1.6 Hz, 2H), 2.20 – 2.14 (m, 1H), 2.02 (dtd, J = 20.5, 
8.0, 7.4, 4.6 Hz, 3H), 1.88 (s, 3H), 1.79 (ddt, J = 12.0, 7.7, 3.5 Hz, 2H), 1.75 – 1.66 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 169.96, 163.82, 161.86, 144.18, 143.01, 138.67, 138.03, 131.61, 
130.14, 129.20, 127.49, 125.88, 121.41, 120.42, 117.28, 117.11, 114.59, 114.43, 112.78, 74.00, 
69.26, 40.45, 32.44, 29.85, 27.74, 27.60, 23.47. HRMS (ESI+), m/z [M+Na+] calculated for 















yl)ethyl)acetamide (2.42e).  
 The compound was synthesized following the procedure used for the synthesis of 2.42a to 
obtain the product as a white solid: 1H-NMR (500 MHz, Chloroform-d) δ 7.45 – 7.39 (m, 1H), 
7.33 – 7.27 (m, 4H), 7.10 – 7.03 (m, 2H), 6.99 (ddd, J = 9.6, 2.7, 1.4 Hz, 1H), 6.86 (dd, J = 8.4, 
4.3 Hz, 1H), 6.77 (dd, J = 8.4, 3.2 Hz, 1H), 5.73 (s, 1H), 5.26 (s, 1H), 4.50 (s, 2H), 4.42 – 4.34 
(m, 1H), 3.54 (dt, J = 6.8, 3.4 Hz, 1H), 3.28 – 3.19 (m, 2H), 2.59 (td, J = 7.2, 1.6 Hz, 2H), 2.19 – 
2.14 (m, 2H), 2.09 – 1.96 (m, 2H), 1.88 (s, 3H), 1.79 (ddt, J = 12.0, 7.7, 3.6 Hz, 2H), 1.75 – 1.66 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 169.81, 163.68, 161.72, 144.04, 142.87, 138.53, 137.37, 
133.16, 130.00, 128.73, 128.52, 127.35, 125.74, 120.28, 117.14, 116.97, 114.45, 114.29, 112.64, 
73.85, 69.10, 40.31, 32.30, 28.45, 27.60, 27.47, 23.34. HRMS (ESI+), m/z [M+H+] calculated for 






















A solution of 2.9 (0.025g, 0.06mmol) and 4-(dibenzylamino)cyclohexanol (0.014mL, 
0.12mmol) in anhydrous benzene (0.6 mL) was cooled to 0oC.  Tributylphosphine (0.03mL, 
012mmol) and TMAD (0.021g, 0.12mmol) were added to the mixture. The reaction mixture was 
stirred at reflux for 12 h.  After 12 h the reaction was cooled to rt and purified via column 
chromatography (SiO2, 1:20 MeOH:DCM) to afford 2.46 as white amorphous solid (30%): 1H 
NMR (500 MHz, Chloroform-d) δ 7.40 – 7.36 (m, 4H), 7.30 – 7.26 (m, 5H), 7.23 – 7.16 (m, 
3H), 7.10 – 7.04 (m, 2H), 7.00 (ddd, J = 9.7, 2.6, 1.6 Hz, 1H), 6.87 (dd, J = 8.5, 2.7 Hz, 1H), 
6.76 (d, J = 2.7 Hz, 1H), 5.25 (s, 1H), 4.46 (t, J = 2.9 Hz, 1H), 3.67 (s, 4H), 3.27 (td, J = 7.2, 5.9 
Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.58 (ddd, J = 11.8, 8.3, 3.5 Hz, 1H), 2.11 (dt, J = 14.9, 3.0 Hz, 
2H), 1.90 – 1.78 (m, 2H), 1.70 (dd, J = 12.9, 3.4 Hz, 2H), 1.56 (s, 3H), 1.45 – 1.33 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 169.95, 163.62, 156.02, 142.17, 141.17, 131.47, 130.92, 129.93, 
129.42, 128.54, 128.24, 128.07, 126.70, 125.00, 117.84, 116.18, 115.66, 114.14, 71.26, 56.92, 
53.98, 40.64, 32.00, 29.46, 23.47, 22.49. HRMS (ESI+), m/z [M+H+] calculated for C36H39FN2O2 
551.3089; found 551.3077.  
 
 
N-(2-(5-((4-Aminocyclohexyl)oxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)acetamide (2.47).  
Pd/C (10%wt., 0.05 g) was added to a sealed tube containing a mixture of 2.46  (0.10 g, 
0.182mmol) and cyclohexene (3mL).  The tube was sealed and heated at 120oC on.  After 12 h 
the mixture was cooled to rt and the mixture was filtered through a pad of Celite.  The filtrate 
was collected, concentrated and purified by column chromatography (Silica gel, 30% EtOAc in 









(td, J = 8.1, 6.0 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H), 7.04 (dt, J = 7.7, 1.2 Hz, 2H), 6.96 (ddd, J = 
9.5, 2.6, 1.5 Hz, 1H), 6.84 (dd, J = 8.5, 2.6 Hz, 1H), 6.73 (d, J = 2.7 Hz, 1H), 5.70 (q, J = 10.8, 
8.3 Hz, 1H), 4.46 – 4.40 (m, 1H), 3.79 – 3.61 (br m, 1H), 3.26 – 3.19 (m, 2H), 2.86 – 2.78 (m, 
1H), 2.69 (t, J = 7.2 Hz, 2H), 2.06 – 1.99 (m, 2H), 1.83 (s, 3H), 1.74 – 1.67 (m, 2H), 1.67 – 1.48 
(m, 4H). 13C NMR (126 MHz, CDCl3) δ 169.77, 163.22, 155.51, 141.77, 130.57, 129.56, 127.93, 
124.66, 117.28, 115.94, 115.37, 113.90, 70.55, 49.15, 40.32, 31.65, 29.33, 28.01, 22.99. HRMS 





Benzyl Bromide (0.006mL, 0.05mmol) was added to a solution of K2CO3 (0.011g, 0.08mmol) 
and 2.47 (0.04g, 0.1mmol) in MeCN (1mL).  The mixture was heated at reflux and monitored by 
TLC.  After 12 h the reaction mixture was determined to be complete and cooled to rt.  The 
reaction was quenched with water (3mL) and extracted with EtOAc (3x 5mL).  The organic 
layers were combined, dried, concentrated, and purified by column chromatography (Silica gel, 
30% EtOAc in Hexane) to give 2.48 as a white solid in 40% yield: 1H NMR (500 MHz, 
Chloroform-d) δ 7.39 – 7.35 (m, 3H), 7.35 – 7.30 (m, 3H), 7.18 (d, J = 8.5 Hz, 1H), 7.06 (dd, J = 
7.9, 1.3 Hz, 2H), 6.99 (ddd, J = 9.7, 2.6, 1.6 Hz, 1H), 6.88 (dd, J = 8.5, 2.7 Hz, 1H), 6.76 (d, J = 
2.7 Hz, 1H), 5.32 (t, J = 5.9 Hz, 1H), 4.46 (dt, J = 4.6, 1.9 Hz, 1H), 3.86 (s, 2H), 3.26 (td, J = 
7.2, 5.8 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.66 (dt, J = 9.6, 4.0 Hz, 1H), 2.09 – 2.02 (m, 2H), 










163.60, 155.95, 142.13, 130.92, 129.99, 128.64, 128.56, 128.12, 127.33, 125.00, 117.63, 116.32, 
115.81, 114.29, 71.64, 54.74, 50.62, 40.64, 31.99, 28.25, 23.43. HRMS (ESI+), m/z [M+H+] 
calculated for C29H33FN2O2 461.2523; found 461.2544. 
 
 
N-(7-Hydroxy-8-methyl-2-oxo-2H-chromen-3-yl)acetamide (2.55).  
This compound was synthesized following a previously reported procedure.13, 41, 48, 65 
 
 
N-(7-((4-(Benzyloxy)cyclohexyl)oxy)-2-oxo-2H-chromen-3-yl)acetamide (2.56a).  
The compound was synthesized following the procedure used for the synthesis of 2.4 to 
obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 8.00 (s, 1H), 
7.38−7.35 (m, 2H), 7.30-7.27 (m, 2H), 7.23-7.17 (m, 2H), 6.89-6.86 (m, 1H), 4.56 (s, 2H), 4.51-
4.48 (m, 1H), 3.54-3.51 (m, 1H), 2.37 (s, 3H), 2.33 (s, 3H), 2.24 (s, 3H), 2.12-2.03 (m, 2H), 
1.95-1.87 (m, 2H), 1.82-1.63 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 169.46, 159.57, 157.39, 
149.73, 136.91, 130.50, 128.71, 128.00, 126.10, 125.66, 124.81, 121.41, 115.50, 113.27, 110.62, 
75.37, 73.68, 28.02, 27.67, 25.00, 19.16, 8.59. HRMS (ESI+), m/z [M+Na+] calculated for 
















yl)acetamide (2.56e).  
The compound was synthesized following the procedure used for the synthesis of 2.4, using 
phenol 2.55, to obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 
7.99 (s, 1H), 7.58−7.52 (m, 2H), 7.36-7.28 (m, 2H), 7.18-7.13 (m, 1H), 6.90-6.87 (m, 1H), 4.62 
(s, 2H), 4.52-4.46 (m, 1H), 3.61-3.56 (m, 1H), 2.35 (s, 3H), 2.24 (s, 3H), 2.18-2.05 (m, 2H), 
1.97-1.91 (m, 2H), 1.85-1.62 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 169.45, 159.58, 157.40, 
149.74, 138.48, 132.76, 129.27, 129.05, 127.70, 125.68, 124.81, 122.82, 121.43, 115.50, 113.31, 
110.65, 75.63, 69.67, 28.01, 27.74, 25.02, 8.63. HRMS (ESI+), m/z [M+H+] calculated for 






















The compound was synthesized following the procedure used for the synthesis of 2.4, using 
phenol 2.55, to obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 
7.99 (s, 1H), 7.58−7.52 (m, 2H), 7.36-7.28 (m, 2H), 7.18-7.13 (m, 1H), 6.90-6.87 (m, 1H), 4.62 
(s, 2H), 4.52-4.46 (m, 1H), 3.61-3.56 (m, 1H), 2.35 (s, 3H), 2.24 (s, 3H), 2.18-2.05 (m, 2H), 
1.97-1.91 (m, 2H), 1.85-1.62 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 169.45, 159.58, 157.40, 
149.74, 138.48, 132.76, 129.27, 129.05, 127.70, 125.68, 124.81, 122.82, 121.43, 115.50, 113.31, 
110.65, 75.63, 69.67, 28.01, 27.74, 25.02, 8.63. HRMS (ESI+), m/z [M+Na+] calculated for 




yl)acetamide (2.56c).  
The compound was synthesized following the procedure used for the synthesis of 2.4, using 
phenol 2.55, to obtain the product as a white solid: 1H-NMR (500 MHz, CDCl3) δ 8.62 (s, 1H), 
8.00 (s, 1H), 7.38−7.35 (m, 2H), 7.30-7.27 (m, 2H), 7.23-7.17 (m, 1H), 6.89-6.86 (m, 1H), 4.56 
(s, 2H), 4.51-4.48 (m, 1H), 3.54-3.51 (m, 1H), 2.37 (s, 3H), 2.33 (s, 3H), 2.24 (s, 3H), 2.12-2.03 
(m, 2H), 1.95-1.87 (m, 2H), 1.82-1.63 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 169.46, 159.57, 
157.39, 149.73, 136.91, 130.50, 128.71, 128.00, 126.10, 125.66, 124.81, 121.41, 115.50, 113.27, 
110.62, 75.37, 73.68, 28.02, 27.67, 25.00, 19.16, 8.59. HRMS (ESI+), m/z [M+Na+] calculated 
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3. Modified Biphenyl Hsp90 C-terminal Inhibitors for the Treatment of 
Cancer 
Introduction  
Heat Shock Protein 90 (Hsp90) is a molecular chaperone that is responsible for the 
maturation of more than 300 nascent polypeptides.1-5 Hsp90-dependent client proteins are 
associated with all 10 hallmarks of cancer, making it an excellent therapeutic target for the 
treatment of cancer.6-8 As a result, 17 Hsp90 inhibitors have been investigated in clinical trials for 
the treatment of cancer.9-13 Hsp90 exists as a homodimer and contains a C-terminus, a middle 
domain, and an N-terminal ATP-binding site.3 In stressed cells, Hsp90 exists as a heteroprotein 
complex bound to various co-chaperones and partner proteins, and Hsp90 inhibitors exhibit 200-
fold higher affinity for the heteroprotein complex versus the homodimer that resides in non-
stressed cells.14-20 Inhibition of Hsp90 by traditional inhibitors that bind the N-terminal ATP-
binding site results in induction of the heat shock response (HSR) and the overexpression of 
Hsp27, Hsp40, Hsp70, and Hsp90.21-23 Since N-terminal inhibitors induce this HSR, challenges 
associated with dosing and scheduling have arisen in the clinic.9, 13, 24-25 As a result, new inhibitors 
that do not induce the heat shock response are actively sought.26-27 
The natural product, novobiocin, was the first Hsp90 C-terminal inhibitor identified, 28-29 
and preliminary SAR studies resulted in the identification of KU-32, a C-terminal inhibitor that 
contains an acetamide in lieu of the benzamide side chain present in novobiocin.23, 30 
Interestingly, KU-32 induces the HSR, but at significantly lower concentrations than that needed 
to induce the degradation of client proteins.31-32 Since KU-32 was able to induce the pro-survival 
HSR, it was investigated for the treatment of neurodegenerative diseases. Studies in mice 




clinical endpoints of diabetic peripheral neuropathy.33 A second generation of noviosylated 
analogs contained a biphenyl scaffold in lieu of the coumarin ring, and allowed the preparation 
of additional analogs. KU-596, the lead compound resulting from this latter generation, was 
found to exhibit comparable biological activity to KU-32.34-35 Since the biphenyl scaffold 
resulted in improved neuroprotection, compounds containing this new core were investigated for 
the treatment of cancer.  An initial study found that the biphenyl scaffold in KU-596 could be 
modified to append a biaryl side chain in lieu of the acetamide and replace the noviose sugar 
with N-methyl piperidine, produced compounds which manifested anti-cancer activity, did not 
induce the pro-survival HSR, and were similarly active to known cytotoxic C-terminal inhibitor 
KU-174.35 Figure 3.1 illustrates this parallel approach taken during the discovery of Hsp90 C-
terminal inhibitors for either the treatment of cancer or neurodegeneration.  Furthermore, 
modifications on the central biaryl ring have not been investigated, therefore analogs were 
prepared to determine whether such modifications could improve the anti-cancer activity of this 





Design   
Molecular modeling studies were performed with a homology model of the C-terminal 
binding site to identify potential interactions with the biaryl core. Two hydrogen-bonding 
interactions appeared attainable by inclusion of a phenol onto the central biphenyl ring as 
suggested in Figure 3.2. Molecular modeling studies suggested that compounds containing 
substituents pointing toward amino acids Glu537 and Thr540 could also form hydrogen-bonding 
interactions, and consequently may be more efficacious.  In silico studies suggested that the 
attachment of a methyl group onto the biphenyl core could produce hydrophobic interactions 
within the binding site and increase affinity. These interactions might be similar to previously 
studied Hsp90 C-terminal inhibitors that contain a coumarin core.  Additionally, incorporation of 
 




a methyl group may reinstate interactions lost upon transitioning from the coumarin core to the 




Derivatives of the central ring were selected for initial investigation, as illustrated in 
Scheme 3.1A.  Synthesis of each derivative began via a different core. Synthesis of the derivative 
containing a methyl substituent (3.19) began by reduction of 2,4-dihydroxybenzaldehyde, 3.12, 
with sodium cyanoborohydride in acidic THF to yield 3.13 (Scheme 3.1B).39 Silver triflate and 
dichloro-methyl methyl ether were then used to formylate 3.13, which produced aldehyde 3.14.40 
The resultant methylbenzaldehyde, 3.14, was then benzylated to give 3.15, which was then 
 
Figure 3.2. Molecular modeling of compounds 3.9 and 3.10 docked into the C-





transformed unto the trifluoromethanesulfonate derivative under microwave conditions.41 
Subsequent Suzuki coupling with 3-fluorophenyl boronic acid generated the biaryl core of 3.17. 
Henry olefination conditions were used to homologate the aldehyde into the α,β-unsaturated 
nitro compound 3.18, which was subsequently reduced to provide amine 3.19. 
 
The remaining analogs required alternative routes for their preparation, however 
installment of the triflate and subsequent steps to yield the free amine were identical to the 
conditions described for 3.19, as outlined in Scheme 3.1B.  Synthesis of the methoxy and phenol 
derivatives began by formylation of phloroglucinol, followed by selective benzyl ether formation 
to give 3.20 (Scheme 3.2A and B). Aldehyde 3.20 was then treated with dimethyl sulfate in 
water and acetone to yield 3.21 (Scheme 3.2A).42 Intermediate 3.21 was subjected to conditions 
 
Scheme 3.1. A. Proposed analogs with substitutions off of the central ring. 
B. Synthesis of free amine, 3.19. Reagents and Conditions a). NaBH3CN, 
HCl, THF, 90%; b). AgOTf, Cl2CHOMe, DCM, 40%; c). NaHCO3, BnBr, 
MeCN, 70%; d). N-PhTf2, K2CO3, THF, 120 oC, microwave, 95%; e). 
FC6H4B(OH)2, Pd(dppf)Cl2, K2CO3, DMF, 75%; f). NH4OAc, CH3NO2, 





previously outlined in Scheme 1B to produce amine 3.22. In order to obtain the phenol, 
derivative 3.20 was treated with chloromethyl methyl ether to produce 3.23 (Scheme 3.2B),43-44 
which was then subjected to conditions described in Scheme 3.1B to attain amine 3.24.  
Synthesis of amine 3.27 began by selective benzylation of 2,3,4-trihydroxybenzaldehyde, which 
was subsequently reacted with chloromethyl methyl ether and diisopropylamine to yield 
aldehyde 3.26 (Scheme 3.2C).  Compound 3.26 was then subjected to the conditions described in 
scheme 1B to afford amine 3.27.  Amine 3.30, was attained via treatment with chloromethyl 
methyl ether to yield ether 3.29 (Scheme 3.2D), which was subjected to previously described 
methods to produce amine 3.30. Analogue 3.33 was synthesized by subjecting 2-nitrobenzene-
1,3-diphenol to Duff reaction conditions to yield 3.31 (Scheme 3.2E).  Aldehyde 3.31 then 
underwent selective benzylation to produce the key intermediate, 3.32, which was subsequently 





Two different amide side chains were investigated with these analogs, the original 
prenylated side chain present in novobiocin and the optimized biaryl side chain found in 3.4.  
Additionally, compounds were made to contain either the noviose sugar or the noviose surrogate, 
N-methyl piperidine.45   Installation of the biaryl side chain began by an acid chloride coupling of 
previously synthesized 3.35 with the free amine of each central ring derivative (Scheme 3.3A 
and 3.3B).  Once the coupled product was obtained, hydrogenolysis was employed to produce 
the free phenols, 3.36-3.41 (Scheme 3.3A).  Phenol 3.42 was obtained via removal of the 
methoxymethyl protecting group in the presence of p-Toluenesulfonic acid (Scheme 3.3B). The 
 
Scheme 3.2. Synthesis of free amines 3.22, 3.24, 3.27, 
3.30, and 3.33.  Reagents and Conditions: a). Me2SO4, 
K2CO3, H2O/Acetone (1/1), 55%; b). MOMCl, DIPA, 
DCM, 65%; c). NaHCO3, BnBr, MeCN, 45-60%; d). 
MOMCl, DIPEA, DCM, 65-70%; e). NaHCO3, BnBr, 




free phenols 3.36-3.40 and 3.42 were then coupled with the activated noviose sugar (3.43), using 
Schmidt conditions.46 The carbonate was then removed under solvolysis conditions to procure 
the corresponding noviose products, 3.5-3.10 (Scheme 3.3C).  Simultaneously, free phenols 
3.37-3.42 were subjected to Mitsunobu conditions with 1-methylpiperidin-4-ol (3.44) to yield the 






Scheme 3.3.  A. Synthesis of phenols 3.36-3.41. B. Synthesis of phenol 
3.42. C. Synthesis of final products 3.5-3.10 and 3.6a-3.11a. D. 
Synthesis of final products 3.5a and 3.6b-3.9b.  Reagents and 
Conditions:  a). DMAP, Pyridine, DCM, 50-60%; b). H2 (g), Pd/C, 
EtOAc, 70-80%; c). PTSA, MeOH, 65-70%; d). BF3 OEt, DCM, 35-
40%; e). Et3N, MeOH, 85-90%; f). PBu3, TMAD, Benzene, 30-35%; 
g).DMAP, Et3N, DCM, 35-40%; h). Pd(OAc)2, Et3Si, Et3N, DCM, 80-





Analogs that contained the prenylated side chain were synthesized by an acid chloride 
coupling reaction between 3.47 and the free amine of each analogue (Scheme 3.3D).  Coupled 
products 3.48-3.52 were subjected to Pd(OAc)Cl2, Et3SiH, Et3N, to give the silyl protected 
phenols.  Upon cleavage of the silyl ether with TBAF at 0oC, 3.53-3.57 were obtained in good 
yields (Scheme 3.3D).  The resulting phenols, 3.53-3.57, were then subjected to a Mitsunobu 
reaction with 3.44, to give the amino products, 3.6b-3.9b, respectively.  Additionally phenol 3.53 
was coupled with activated noviose sugar 3.43, followed directly by solvolysis conditions 
yielded final product 3.5a.   
 
Biological Evaluation 
Upon preparation of these new analogs, an MTS anti-proliferation assay was conducted 
against two breast cancer cell lines, MCF-7 (estrogen receptor positive cells) and SkBr3 
(estrogen receptor negative HER2 overexpressing), and two prostrate cancer cell lines, LNCap-
LN3 (androgen receptor sensitive prostate cancer cells) and PC3-MM2 (androgen receptor 
insensitive prostate cancer cells).  These cell lines were selected due to their dependency upon 
Hsp90 client proteins. All new analogs exhibited anti-proliferative activity against the 4 cancer 
cell lines as detailed in Table 3.1. Compounds containing an N-methyl piperidine exhibited 
greater inhibitory activity than those containing noviose.  Additionally, compounds with a 
prenylated amide side chain were found to be more efficacious than compounds that contain the 







Table 3.1. Anti-proliferative values of new analogs  
 
Compound    X Y    Z    
R 












3.3    H H   H   A - >500 >500 >500 >500 
3.5    H H   H   A    A >50 >50 >50 >50 
3.5a    H H   H   A    B 15.4±1.75 23.7±0.04 22.5 5.49 
3.6 CH3 H   H   A    A >50 43.9 ±4.4 >100 >100 
3.6a CH3 H   H   A    B 9.14 ± 2.72 7.81 ±1.1 20.8 13.9 
3.6b CH3 H   H   B    B 35.6 ± 3.03 15.2 ±1.67 >100 >100 
3.7    H OCH3   H   A    A 44.7 ±4.15 49.4±2.03 8.09 10.6 
3.7a    H OCH3   H   A    B 8.71 ±1.20 5.72±0.89 >100 32.1 
3.7b    H OCH3   H   B    B 7.86 ±0.20 8.16±0.29 >100 1.84 
3.8    H OH   H   A    A 23.8±0.47 23.5±0.44 >50 >50 
3.8a    H OH   H   A    B 12.2 ±0.89 15.7 ±1.5 44.8 >50 
3.8b    H OH   H   B    B 5.89 ±0.67 7.59 ±0.58 22.8 1.32 
3.9    H H OH   A    A 13.6 ±2.01 16.7 ±0.93 >100 9.37 
3.9a    H H OH   A    B 11.3 ± 1.62 9.29±1.07 22.4 8.61 
3.9b    H H OH   B    B 1.45 ±0.87 3.25 ±1.2 23.1 42.3 
3.10    H H CH3   A    A 8.99±0.28 43.5±1.03 25.1 >50 
3.10a    H H CH3   B    A 17.8±1.48 21.3±2.82 >50 >50 
3.10b    H H CH3   C    A 7.97±0.46 9.34±0.68 44.8 1.32 
3.11a H H NH2   A    B 11.3±1.3 15.3±2.3 22.4 18.9 
aValues represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
 
 Interestingly, the synthesized analogs followed the same trend in activity independent of 
the sugar surrogate or amide side chain.  The methyl derivatives were more active than the parent 
compound; the methoxy derivatives were more active than the methyl derivatives, and the phenol 
derivatives more active than both the methoxy and the methyl derivatives.  Analogs that 
contained the sugar surrogate, N-methyl piperidine, were more active than the analogs containing 

























active than analogs containing the biaryl side chain.  Analogue 3.6 was similarly active to the 
parent compound, 3.5.  However analogs 3.6a and 3.6b, which contained N-methyl piperidine in 
lieu of noviose, were more active than 3.6.  In addition, analogs containing moieties that could 
participate in hydrogen bonding interactions manifested improved inhibitory activity as 
compared to 3.5.  More specifically, it appears that a hydrogen bond donor is more beneficial as 
analogs 3.8, 3.8a, and 3.8b exhibited similar or improved activity as compared to analogs 3.7, 
3.7a, and 3.7b.  
 After determination of IC50 values, compounds 3.6a, 3.7b, 3.8b, 3.9. 3.9b, and 3.10 were 
further evaluated by western blot analysis of MCF7 cell lysates.  Compound 3.10 exhibited 
significant Hsp90-dependent client protein degradation at concentrations that mirrored its anti-
proliferative activity, clearly linking Hsp90 inhibition to cell viability, as illustrated in Figure 
3.3.  In fact, Hsp90 dependent clients Her-2, Cyclin D1, and c-Raf were degraded upon treatment 
with 3.10 for 24 hours. 3.6a, 3.8b, and 3.9 also demonstrated client protein degradation, but to a 
lesser extent.  Compounds 7b and 9b did not demonstrate client protein degradation. 
Importantly, no increase in Hsp90 levels was observed with these C-terminal inhibitors, which is 







In summary, a series of Hsp90 C-terminal inhibitors with modifications to the central ring 
of the biphenyl scaffold were designed, synthesized, and biologically evaluated.  Modifications 
to the central ring produced compounds that exhibited increased biological activity.  Structure-
activity relationship studies revealed that modifications, which include a hydrogen bond donor, 
resulted in the most potent anti-proliferative activity. Finally, western blot analysis confirmed 
that compounds 3.8b, 3.9 and 3.10 manifest their anti-proliferative activity via Hsp90 inhibition, 
 
Figure 3.3. Western Blot analysis from MCF-7 cells.  The high concentration is five times 
the IC50 value, and the low concentration is half the IC50 value.  Concentrations for each 
analog tested were as follows: 3.6a (high: 45.7 μM, low: 4.57 μM), 3.7b (high: 39.3 μM, 
low: 3.93μM), 3.8b (high: 29.45 μM, low: 2.95 μM), 3.9 (high: 68 μM, low: 6.8 μM), 3.9b 
(high: 7.25 μM, low: 0.725 μM), 3.10 (high: 45 μM, low: 4.49 μM).  The positive control 





as client protein degradation was observed at concentrations that mirrored anti-proliferative 
activity.    
 
Future Directions 
Recently we began testing select Hsp90 C-terminal inhibitors in a TR-FRET Assay kit 
that evaluates possible isoform selectivity by measuring %activity against both Hsp90α and 
Hsp90β.  Compounds 3.5 and 3.10 were evaluated for activity against both isoforms using this 
assay.  Compound 3.5 did not exhibit selectivity for either isoform as is had 72.2% activity for 
Hsp90α and 100% activity for Hsp90β at 100μM.  Interestingly compound 3.10 was found to be 
selective for Hsp90α as it exhibited 45% activity at 100μM and 100% activity for Hsp90β. The 
cellular activity of these compounds supports this assay data because the IC50 value of 3.10 is 
single digit micromolar and only Hsp90β knockout is known to be lethal, so targeting the alpha 
isoform could result in a compound that is not very cytotoxic.47 This initial assay result provides 
an excellent starting point for the exploration of potential isoform selective inhibitors with these 
compounds and similar analogs, as Hsp90α selectivity occurred from the addition of a methyl 
group.  Identification of different structural motifs that result in isoform selectivity would be 
extremely beneficial for the development of future C-terminal inhibitors. Identifying isoform 
selective inhibitors would lead to new and interesting studies that would investigate the 
biological effects of targeting one isoform over the other with a C-terminal inhibitor.        
 
Materials and Methods 
 




Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with 
non-essential amino acids, L-glutamine (2 mM), streptomycin (500 μg/mL), penicillin (100 
units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C, 
5% CO2), seeded (2000/well, 100 μL) in 96-well plates, and allowed to attach overnight. 
Compound or GDA at varying concentrations in DMSO (1% DMSO final concentration) was 
added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells was 
determined using an MTT/PMS cell proliferation kit (Promega) per the manufacturer’s 
instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were 
adjusted accordingly. IC50 values were calculated from separate experiments performed in 
triplicate using GraphPad Prism. 
 
Western blot Analyses.  
MCF-7 cells were cultured as described above and treated with various concentrations of drug, 
GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were 
harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium 
orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min 
at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the 
manufacturer’s instructions. Equal amounts of protein (20 μg) were electrophoresed under 
reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 






Chemistry General.  
1H NMR were recorded at 500 MHz (Avance AVIII 500 MHz spectrometer with a dual 
carbon/proton cryoprobe) or 400 (Bruker AVIIIHD 400 MHz NMR with a broadband X-channel 
detect gradient probe) and 13C NMR were recorded at 125 MHz (Bruker AVIII spectrometer 
equipped with a cryogenically cooled carbon observe probe).   Chemical shifts are reported in δ 
(ppm) relative to the internal standard (CDCl3, 7.26 ppm, or as stated). HRMS spectra were 
recorded with a LCT Premier with ESI ionization. 1H and 13C NMR was used to verify that all 
tested compounds were >95% pure. TLC analysis was performed on glass backed silica gel 
plates and visualized by UV light. All solvents were reagent grade and used without further 
purification. 
 
Synthesis and Compound Characterization 
 
 
2-(5-(Benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethanamine (3.34).  


















Thionyl chloride (0.13 ml, 0.75 mmol) was added to a solution of biaryl acid (97 mg, 0.38 
mmol) in anhydrous tetrahydrofuran (2 ml) and the solution was refluxed for 3h. The solution 
was then concentrated under vacuum to get acid chloride 3.35 (105 mg) as brown semi-solid that 
was used directly in the next step.  Triethylamine (0.13 ml, 0.75 mmol) was added to an ice-
cooled solution of acid chloride in anhydrous DCM (1 ml), followed by a dropwise addition of 
amine 2-(5-(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethanamine  (50 mg, 0.25 mmol).  The 
solution was then allowed to stir at rt for 12h. The reaction mixture was concentrated and the 
residue was purified by column chromatography (SiO2, 1:25, Acetone: DCM) to afford the 
product as a white amorphous solid (65%): 1H NMR (500 MHz, Chloroform-d) δ 8.00 – 7.86 (m, 
6H), 7.23 (td, J = 7.9, 1.9 Hz, 3H), 7.06 – 6.98 (m, 5H), 6.94 – 6.87 (m, 3H), 6.80 (ddt, J = 8.3, 
2.6, 1.1 Hz, 2H), 5.19 (s, 1H), 4.23 (s, 2H), 3.76 (s, 3H), 3.73 (s, 3H), 3.56 (t, J = 6.3 Hz, 2H), 
2.90 – 2.69 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 169.38, 160.42, 160.09, 156.59, 138.85, 
138.76, 132.74, 132.17, 131.31, 130.78, 130.29, 128.99, 128.52, 127.42, 122.78, 122.77, 122.26, 
121.93, 115.28, 112.78, 112.70, 110.56, 70.59, 55.72, 55.20, 44.56, 26.44. HRMS (ESI+) m/z: 
















3-carboxamide (0.05g) at rt was dissolved in EtOAc  (20mL).  Pd/C (10% w/w, 20 mg) was 
added, the mixture was degassed and flushed with argon, then degassed and flushed with 
hydrogen using a balloon.  After 12 h the reaction was filtered through a pad of Celite, washed 
with EtOAc.  The filtrate was concentrated and purified via column chromatography (20-
50%EtOAc/Hex). Compound was isolated as an oil in 70% yield: 1H NMR (500 MHz, 
Chloroform-d) δ 7.92 – 7.80 (m, 2H), 7.23 (td, J = 6.6, 3.9 Hz, 4H), 7.09 – 7.02 (m, 3H), 6.90 – 
6.79 (m, 3H), 6.64 (d, 2H), 5.09 (s, 1H), 3.76 (s, 3H), 3.73 (s, 3H), 3.61 (t, J = 5.7 Hz, 2H), 2.90 
– 2.69 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 169.65, 160.87, 160.11, 159.36, 156.75, 138.43, 
132.14, 130.66, 130.43, 128.91, 128.82, 127.43, 122.73, 122.55, 122.26, 121.03, 115.67, 112.14, 
112.07, 110.98, 55.66, 55.31, 44.31, 26.48.  HRMS (ESI+) m/z: [M - H+] calculated for 
C29H26FNO4 470.1768; found 470.1771. 
 
(3aR,7R,7aR)-7-Methoxy-6,6-dimethyl-2-oxotetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-
yl 2,2,2-trichloroacetimidate (3.43).  
















Activated noviose sugar 3.4736, 48 in anhydrous dichloromethane (0.5mL) was added to a 
mixture of 3.36 (0.042g, 0.066mmol) in anhydrous dichloromethane (0.5mL) at rt.  Boron 
trifluoride diethyl etherate (0.07mL) was then added drop wise.  The reaction was monitored via 
TLC.  Upon completion of the reaction (~1 hour), triethylamine (0.1mL) was added.  The 
mixture was concentrated and purified via column chromatography (SiO2, 3:1, Hexane: EtOAc- 
20:1, DCM:MeOH). The product was obtained as a white solid in 30% yield and used directly in 
the next step. The product (0.023g, 0.03mmol) was dissolved in MeOH (12mL) and 
triethylamine (4mL) was added.  The mixture was stirred over night.  After 12 hours the reaction 
was concentrated and purified via column chromatography (SiO2, 20:1, DCM: MeOH) to afford 
3.5 as white amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 7.67 (dd, J = 8.6, 2.4 
Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.35 – 7.29 (m, 2H), 7.24 (d, J = 8.5 Hz, 1H), 7.09 – 6.96 (m, 
6H), 6.95 (s, 1H), 6.91 – 6.85 (m, 2H), 5.96 (t, J = 5.6 Hz, 1H), 5.53 (d, J = 2.3 Hz, 1H), 4.19 
(dd, J = 9.1, 3.4 Hz, 1H), 4.14 (dd, J = 3.4, 2.3 Hz, 1H), 3.84 (d, J = 1.9 Hz, 6H), 3.58 (s, 3H), 
3.50 – 3.43 (m, 2H), 3.32 (d, J = 9.1 Hz, 1H), 2.85 (t, J = 7.2 Hz, 2H), 1.34 (s, 3H), 1.19 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.99, 161.62, 159.37, 159.05, 155.28, 143.47, 139.06, 131.06, 















114.18, 112.95, 110.91, 94.46, 78.33, 71.39, 68.66, 61.98, 55.89, 55.45, 41.07, 32.12, 29.83, 




en-1-yl)phenyl acetate (3.48). 
Oxalyl chloride (0.10 ml, 0.75 mmol) was added to a solution of prenylated acid (97 mg, 0.38 
mmol) in anhydrous tetrahydrofuran (2 ml) and the solution was refluxed for 9h. The solution 
was then concentrated under vacuum to get acid chloride 3.47 (105 mg) as brown semi-solid that 
was used directly in the next step.  Pyridine (0.10 ml, 0.75 mmol) was added to an ice-cooled 
solution of acid chloride in anhydrous DCM (1 ml), followed by a dropwise addition of amine 2-
(5-(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethanamine  (50 mg, 0.25 mmol).  The solution 
was then allowed to stir at rt for 12h. The reaction mixture was concentrated and the residue was 
purified by column chromatography (SiO2, 1:25, Acetone: DCM) to afford the product as a white 
amorphous solid (40%): 1H NMR (500 MHz, Chloroform-d) δ 7.58 (d, J = 2.2 Hz, 1H), 7.44 (dt, 
J = 8.4, 2.2 Hz, 3H), 7.41 – 7.37 (m, 3H), 7.36 – 7.32 (m, 2H), 7.09 – 7.06 (m, 1H), 7.05 – 7.00 
(m, 3H), 6.97 (dd, J = 8.5, 2.8 Hz, 1H), 6.87 (d, J = 2.7 Hz, 1H), 6.05 (t, J = 5.8 Hz, 1H), 5.19 
(dddd, J = 7.2, 5.8, 2.9, 1.4 Hz, 1H), 5.06 (s, 2H), 3.46 (td, J = 7.1, 5.8 Hz, 2H), 3.25 (d, J = 7.3 
Hz, 2H), 2.86 (t, J = 7.1 Hz, 2H), 2.32 (s, 3H), 1.73 (d, J = 1.3 Hz, 3H), 1.70 (d, J = 1.3 Hz, 3H). 









132.54, 131.05, 129.95, 129.27, 128.68, 128.48, 128.12, 127.63, 125.46, 124.97, 122.46, 121.03, 
116.55, 116.27, 114.58, 114.32, 70.16, 40.99, 31.97, 28.95, 25.84, 20.96, 17.99. HRMS (ESI+) 




yl)phenyl acetate (3.53). 
A catalytic amount of Pd(OAc)2 was added to a solution of Triethylamine (0.15mL, 1.1mmol) 
and triethylsilane (0.19 mL, 1.2mmol) in anhydrous dichloromethane (3mL). The reaction was 
stirred at rt for 15 min and then 4-((2-(5-(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-
yl)ethyl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate ( 0.551 g, 1.0mmol) in 
anhydrous dichloromethane (2mL) was added dropwise. After 12 h the reaction was quenched 
with sat. NH4OAc and worked up with EtOAc (3 x 20mL). The organic layers were dried, 
concentrated, and purified via column chromatography (SiO2, 1:4, EtOAc: Hex).  The silyl-
protected product was obtained as a clear oil in 80% yield.  The silyl ether (0.8mmol) was 
dissolved in anhydrous tetrahydrofuran (2mL) and cooled to 0oC.  TBAF, 1.0M in THF (0.1mL, 
0.35mmol) was added dropwise and the reaction was stirred at 0oC for 15 minutes.  After 15 
minutes the reaction progress was monitored by TLC, as soon as the reaction was complete it 
was quenched via the addition of sat. NH4Cl.  The reaction was worked-up with EtOAc (3 x 5 









chromatography (SiO2, 1:2, EtOAc: Hex).  4-((2-(3'-Fluoro-5-hydroxy-[1,1'-biphenyl]-2-
yl)ethyl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate was obtained in 60% yield as a 
white solid:  1H NMR (500 MHz, Chloroform-d) δ 7.44 (d, J = 2.3 Hz, 1H), 7.36 – 7.30 (m, 2H), 
7.06 – 7.02 (m, 3H), 7.02 – 6.96 (m, 2H), 6.94 (d, J = 2.5 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 6.08 
(t, J = 5.8 Hz, 1H), 5.27 (dddd, J = 7.2, 5.7, 2.8, 1.4 Hz, 1H), 3.50 – 3.44 (m, 2H), 3.33 (d, J = 
7.2 Hz, 2H), 2.88 (t, J = 7.1 Hz, 2H), 2.29 (s, 3H), 1.73 (dd, J = 3.8, 1.4 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 169.61, 167.64, 163.34, 161.38, 157.67, 148.74, 142.43, 141.96, 134.49, 133.82, 
130.75, 129.86, 128.80, 127.35, 126.20, 125.76, 124.75, 122.95, 121.25, 121.00, 115.90, 115.24, 
114.16, 40.68, 32.11, 29.12, 25.68, 21.00, 17.77. HRMS (ESI+) m/z: [M + Na+] calculated for 





Compound 3.5a was synthesized following the procedure used for the synthesis of 3.5 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.42 (d, J = 2.4 Hz, 
1H), 7.38 (dd, J = 8.5, 2.3 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.13 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.6 
Hz, 1H), 7.03 – 7.00 (m, 2H), 6.93 (ddd, J = 9.6, 2.6, 1.6 Hz, 1H), 6.81 (dd, J = 8.3, 2.7 Hz, 1H), 
6.71 (d, J = 2.7 Hz, 1H), 6.01 (t, J = 5.7 Hz, 1H), 5.45 (d, J = 2.3 Hz, 1H), 5.13 (tdd, J = 5.6, 2.8, 














3.40 (m, 2H), 3.34 (d, J = 9.1 Hz, 1H), 3.26 – 3.13 (m, 2H), 2.80 (t, J = 7.2 Hz, 2H), 1.68 (d, J = 
1.3 Hz, 6H), 1.65 (d, J = 1.2 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 167.96, 163.57, 161.61, 
157.31, 133.09, 131.09, 130.53, 129.96, 128.67, 127.54, 127.25, 126.18, 124.98, 122.09, 117.26, 
116.27, 116.10, 115.36, 114.23, 114.06, 113.30, 97.76, 78.59, 71.27, 68.74, 62.00, 41.20, 31.96, 










The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.62 














2H), 7.29 – 7.23 (m, 3H), 7.10 – 7.06 (m, 1H), 7.01 – 6.96 (m, 3H), 6.96 – 6.88 (m, 3H), 6.83 
(ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.67 (s, 1H), 5.85 (d, J = 5.7 Hz, 1H), 4.97 (s, 2H), 3.77 (d, J = 
8.5 Hz, 6H), 3.44 – 3.38 (m, 2H), 2.77 (t, J = 7.1 Hz, 2H), 2.22 (d, J = 0.7 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 166.80, 161.54, 159.27, 158.90, 155.28, 139.26, 138.98, 137.19, 132.30, 
130.38, 129.88, 129.81, 129.31, 129.08, 128.51, 128.03, 127.91, 127.84, 127.20, 126.99, 126.90, 
125.04, 121.95, 116.19, 115.28, 113.88, 113.10, 112.83, 110.79, 69.98, 55.78, 55.31, 41.11, 






Compound 3.37 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.67 (dd, J = 8.6, 2.4 
Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.10 – 7.05 (m, 2H), 7.04 – 6.88 (m, 
6H), 6.65 (s, 1H), 5.94 (t, J = 5.2 Hz, 1H), 3.84 (d, J = 1.1 Hz, 6H), 3.48 – 3.38 (m, 2H), 2.81 (t, 
J = 7.2 Hz, 2H), 2.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 167.18, 161.61, 159.35, 159.09, 
152.70, 139.70, 139.07, 132.64, 130.47, 129.94, 129.87, 129.42, 129.21, 128.25, 127.76, 125.07, 
125.05, 122.16, 116.34, 115.49, 114.10, 113.94, 112.89, 110.96, 55.90, 55.48, 41.28, 31.85, 















carboxamide (3.6).  
Compound 3.6 was synthesized following the procedure used for the synthesis of 3.5 to obtain 
the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.61 (ddd, J = 8.6, 4.9, 2.4 
Hz, 2H), 7.49 (d, J = 2.4 Hz, 1H), 7.44 (d, J = 2.4 Hz, 1H), 7.30 – 7.20 (m, 4H), 7.05 – 7.03 (m, 
2H), 7.03 – 6.89 (m, 1H), 6.84 (dtd, J = 8.2, 2.5, 1.0 Hz, 2H), 6.58 (s, 1H), 5.82 (dd, J = 12.2, 5.9 
Hz, 1H), 4.17 (dd, J = 9.2, 3.3 Hz, 1H), 4.12 (dd, J = 3.3, 2.3 Hz, 1H), 3.78 (d, 6H), 3.77 (s, 3H), 
3.69 (dt, J = 6.8, 3.4 Hz, 1H), 3.43 – 3.35 (m, 2H), 2.76 (t, J = 7.2 Hz, 2H), 2.18 (s, 3H), 1.34 (s, 
3H), 1.18 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.99, 161.65, 159.40, 159.06, 153.42, 
139.12, 132.72, 132.35, 130.53, 129.94, 129.39, 129.22, 128.90, 128.17, 127.02, 126.70, 125.06, 
123.98, 122.19, 116.72, 115.44, 114.05, 112.86, 110.97, 97.71, 73.78, 71.50, 68.83, 62.04, 55.92, 
55.47, 41.18, 32.04, 22.79, 15.61. HRMS (ESI+) m/z: [M + Na+] calculated for C38H42FNO8 


















dimethoxy-[1,1'-biphenyl]-3-carboxamide (3.6a).   
A solution of 3.41 (0.025g, 0.06mmol) and N-Methyl-4-piperidinol (0.014mL, 0.12mmol) in 
anhydrous benzene (0.6 mL) was cooled to 0oC.  Tributylphosphine (0.03mL, 012mmol) and 
TMAD (0.021g, 0.12mmol) were added to the mixture. The reaction mixture was stirred at reflux 
for 12 h.  After 12 h the reaction was cooled to rt and purified via column chromatography (SiO2, 
1:20 MeOH:DCM) to afford 3.6a as white amorphous solid (30%):  1H NMR (500 MHz, 
Chloroform-d) δ 7.70 (dd, J = 8.6, 2.3 Hz, 1H), 7.40 (s, 1H), 7.35 (d, J = 2.3 Hz, 1H), 7.30 (s, 
1H), 7.28 (d, J = 2.3 Hz, 1H), 7.24 – 7.22 (m, 1H), 7.11 (d, J = 4.3 Hz, 1H), 7.00 – 6.93 (m, 2H), 
6.92 (d, J = 8.7 Hz, 1H), 6.81 (dd, J = 8.8, 3.1 Hz, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.54 (s, 1H), 
5.81 (d, J = 19.5 Hz, 1H), 4.60 (s, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.70 (d, J = 4.1 Hz, 2H), 3.45 – 
3.39 (m, 4H), 3.28 (m, 2H), 3.06 (s, 3H), 2.74 (d, J = 7.6 Hz, 2H), 2.57 (d, J = 27.2 Hz, 2H), 2.21 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.99, 161.65, 159.40, 159.06, 153.42, 139.12, 132.72, 
132.35, 130.53, 129.94, 129.39, 129.22, 128.90, 128.17, 127.02, 126.70, 125.06, 123.98, 122.19, 
116.72, 115.44, 114.05, 112.86, 110.97, 97.71, 73.78, 71.50, 68.83, 62.04, 55.92, 55.47, 41.18, 















methylbut-2-en-1-yl)phenyl acetate (3.49). 
Compound 3.49 was synthesized following the procedure used for the synthesis of 3.34 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.50 (d, J = 3.0 Hz, 
1H), 7.42 (dt, J = 7.6, 2.8 Hz, 3H), 7.36 – 7.30 (m, 3H), 7.22-7.19 (m, 1H), 7.10 (d, J = 8.0, 5.9, 
2.1 Hz, 1H), 7.03 (d, J = 11.9 Hz, 1H), 6.99 – 6.92 (m, 2H), 6.91 – 6.86 (m, 1H), 6.58 (d, J = 2.0 
Hz, 1H), 5.85 (d, J = 6.3 Hz, 1H), 5.28 – 5.21 (m, 1H), 5.14 – 5.07 (m, 2H), 3.38 (dq, J = 13.4, 
7.0 Hz, 2H), 3.17 (d, J = 7.3 Hz, 2H), 2.75 (q, J = 8.1, 7.2 Hz, 2H), 2.22 (s, 6H), 2.09 (s, 3H), 
1.63 (d, J = 18.5 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 168.98, 166.86, 161.38, 152.29, 
151.10, 139.51, 134.01, 133.61, 132.37, 129.74, 129.04, 127.58, 125.22, 124.82, 123.71, 122.29, 
120.80, 116.40, 116.09, 115.92, 113.93, 113.76, 71.09, 41.01, 31.61, 28.76, 25.61, 20.77, 17.77, 


















Compound 3.54 was synthesized following the procedure used for the synthesis of 3.53 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.53 (d, 1H), 7.37 – 
7.32 (m, 1H), 7.24-7.21 (m, 1H), 7.18 (d, J = 7.7, 6.1, 2.3 Hz, 1H), 7.08 (d, J = 11.6 Hz, 1H), 
6.91 – 6.88 (m, 2H), 6.78 – 6.73 (m, 1H), 6.62 (d, J = 2.4 Hz, 1H), 5.88 (d, J = 6.5 Hz, 1H), 5.10 
– 5.05 (m, 1H), 3.40 (dq, J = 13.1, 7.3 Hz, 2H), 3.21 (d, J = 7.6 Hz, 2H), 2.78 (q, J = 8.3, 7.5 Hz, 
2H), 2.32 – 2.26 (m, 6H), 1.66 (d, J = 18.1 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 168.07, 
165.95, 162.43, 151.38, 150.19, 138.59, 133.09, 131.45, 128.82, 128.13, 126.66, 124.30, 123.91, 
122.80, 121.37, 119.88, 115.49, 115.01, 113.01, 110.33, 40.09, 30.70, 27.84, 24.70, 19.85, 16.86, 





Compound 3.6b was synthesized following the procedure used for the synthesis of 3.6a, 
which was utilized to obtain the acetate-protected product.  The acetate group was removed by 
dissolving the Mitsunobu coupled product (0.02mg) in anhydrous methanol (1mL) and K2CO3 
(0.02mg).  The mixture was stirred at rt.  After 8 h the reaction was concentrated and purified via 
column chromatography (SiO2, 1:10, MeOH: DCM) to obtain the product as a white solid (35%): 
1H NMR (500 MHz, Chloroform-d) δ 7.53 – 7.51 (m, 1H), 7.43 (dd, J = 8.5, 2.4 Hz, 1H), 7.34 










6.88 (s, 1H), 6.78 (d, J = 8.6 Hz, 1H), 5.91 (t, J = 5.7 Hz, 1H), 5.22 (dddd, J = 6.9, 5.5, 2.8, 1.4 
Hz, 1H), 4.75 (s, 1H), 3.52 – 3.46 (m, 2H), 3.32 (d, J = 6.7 Hz, 2H), 3.07 (s, 2H), 2.88 (t, J = 7.2 
Hz, 2H), 2.74 (s, 4H), 2.61 (s, 2H), 2.32 (s, 3H), 2.19 (s, 3H), 1.74 (d, J = 1.4 Hz, 3H), 1.71 (d, J 
= 1.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.34, 163.50, 161.54, 156.89, 139.65, 133.94, 
133.11, 132.61, 129.90, 129.39, 127.41, 126.09, 125.07, 123.40, 122.10, 116.33, 116.16, 114.28, 
114.11, 111.28, 78.04, 53.51, 44.03, 40.88, 32.11, 30.98, 28.99, 25.86, 18.08, 15.96. HRMS 


























carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.57 
(dd, J = 8.5, 2.4 Hz, 2H), 7.51 (d, J = 2.3 Hz, 2H), 7.34 (s, 2H), 7.10 – 6.96 (m, 5H), 6.89 (d, J = 
8.6 Hz, 3H), 6.57 (d, J = 2.5 Hz, 3H), 6.37 (d, J = 2.4 Hz, 1H), 6.32 (t, J = 5.0 Hz, 1H), 5.05 (s, 
2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.77 (s, 3H), 3.51 – 3.44 (m, 2H), 2.89 (t, J = 6.5 Hz, 2H). 13C 
NMR (126 MHz, CDCl3) δ 167.22, 161.84, 159.68, 159.04, 158.97, 158.16, 139.55, 136.83, 
130.57, 130.23, 130.16, 129.74, 129.43, 129.07, 128.49, 128.36, 127.70, 127.53, 118.71, 116.62, 
116.45, 115.69, 114.64, 114.47, 113.22, 111.05, 107.32, 99.99, 71.15, 56.13, 55.71 (2Cs), 40.37, 





Compound 3.38 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.64 (dd, J = 6.6, 2.1 
Hz, 2H), 7.56 (d, J = 3.1 Hz, 2H), 7.22 (s, 2H), 7.16 – 7.02 (m, 2H), 6.91 (d, J = 7.9 Hz, 2H), 
6.61 (d, J = 2.7 Hz, 2H), 6.39 (d, J = 3.1 Hz, 1H), 6.30 (t, J = 4.8 Hz, 1H), 3.79 (s, 3H), 3.78 (s, 
3H), 3.70 (s, 3H), 3.49 – 3.40 (m, 2H), 2.90 (t, J = 6.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
167.43, 161.64, 159.23, 159.16, 158.96, 158.36, 139.87, 136.33, 130.42, 130.32, 130.06, 129.84, 












113.52, 111.35, 107.35, 100.01, 56.33, 55.34 (2Cs), 41.07, 28.05. HRMS (ESI+) m/z: [M - H+] 





carboxamide (3.7).  
Compound 3.7 was synthesized following the procedure used for the synthesis of 3.5 to obtain 
the product as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.64 (dd, J = 8.6, 
2.4 Hz, 1H), 7.53 (d, J = 2.4 Hz, 1H), 7.33 – 7.27 (m, 1H), 7.27 – 7.21 (m, 1H), 7.02 – 6.97 (m, 
3H), 6.97 – 6.91 (m, 2H), 6.81 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.77 (d, J = 2.6 Hz, 1H), 6.32 (d, J 
= 2.5 Hz, 1H), 6.24 (dd, J = 8.3, 5.0 Hz, 1H), 5.37 (d, J = 6.6 Hz, 1H), 5.26 – 5.22 (m, 1H), 4.28 
(dd, J = 4.7, 3.7 Hz, 1H), 3.99 (dd, J = 6.6, 3.6 Hz, 1H), 3.77 (s, 3H), 3.74 (s, 3H), 3.70 (s, 3H), 
3.41 (s, 3H), 3.10 (d, J = 4.7 Hz, 1H), 2.82 (td, J = 11.9, 4.3 Hz, 2H), 2.51 (td, J = 12.1, 5.7 Hz, 
2H), 1.31 (s, 3H), 1.19 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 166.33, 160.69, 158.57, 158.37, 
156.57, 141.93, 138.30, 129.65, 129.02, 128.61, 128.20, 127.24, 125.67, 124.19, 121.10, 116.25, 
115.30, 114.53, 113.18, 113.01, 111.86, 110.06, 107.36, 82.14, 76.69, 69.44, 67.68, 59.02, 54.96, 





















Compound 3.7a was synthesized following the procedure used for the synthesis of 3.6a to 
obtain the product as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.72 – 7.68 
(m, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.40 – 7.31 (m, 2H), 7.10 – 6.98 (m, 5H), 6.97 – 6.86 (m, 2H), 
6.50 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 6.33 – 6.28 (m, 1H), 4.59 (s, 1H), 3.84 (s, 3H), 
3.82 (s, 3H), 3.77 (s, 3H), 3.44 – 3.34 (m, 2H), 2.87 – 2.78 (m, 2H), 2.75 – 2.65 (m, 2H), 2.36 – 
2.26 (m, 2H), 2.23 (s, 3H), 2.10 – 1.98 (m, 2H), 1.61 – 1.54 (m, 2H). 13C NMR (126 MHz, 
CD2Cl2) δ 166.45, 163.53, 161.57, 159.47, 159.01, 156.18, 143.96, 139.29, 136.76, 130.35, 
129.96, 129.89, 129.29, 129.12, 128.71, 128.09, 127.56, 127.06, 126.29, 125.04, 121.96, 116.18, 
116.01, 115.48, 112.64, 110.92, 107.74, 106.87, 77.53, 55.01, 54.22 (2Cs), 53.15(2Cs), 47.10, 





















methylbut-2-en-1-yl)phenyl acetate (3.50).  
Compound 3.50 was synthesized following the procedure used for the synthesis of 3.48 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.36 – 7.19 (m, 8H), 
7.01 – 6.84 (m, 3H), 6.49 (d, J = 2.5 Hz, 1H), 6.31 – 6.25 (m, 1H), 5.08 – 5.02 (m, 2H), 4.99 (s, 
1H), 3.69 – 3.62 (s, 3H), 3.12 (d, J = 7.4 Hz, 2H), 2.80 (d, J = 6.5 Hz, 2H), 2.20 (d, J = 2.5 Hz, 
2H), 1.93 (s, 3H), 1.64 – 1.54 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 167.92, 165.77, 162.33, 
160.37, 157.54, 156.70, 142.20, 135.40, 132.33, 128.78, 128.72, 128.25, 127.69, 127.12, 126.29, 
126.18, 124.08, 123.87, 121.14, 120.11, 117.11, 115.13, 113.15, 112.99, 105.84, 69.67, 54.30, 
39.96, 28.64, 27.87, 24.67, 19.80, 16.83. HRMS (ESI+) m/z: [M + Na+] calculated for 




methylbut-2-en-1-yl)phenyl acetate (3.55). 
Compound 3.55 was synthesized following the procedure used for the synthesis of 3.53 to 
obtain the product as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 8.89 (s, 1H), 
7.66 (d, J = 2.2 Hz, 1H), 7.58 (dd, J = 8.3, 2.3 Hz, 1H), 7.38 (ddd, J = 8.6, 7.6, 6.0 Hz, 1H), 7.08 
(ddd, J = 9.1, 8.2, 2.5 Hz, 2H), 7.03 – 6.96 (m, 1H), 6.81 (t, J = 5.7 Hz, 1H), 6.55 (d, J = 2.7 Hz, 









2H), 3.27 (d, J = 7.6 Hz, 2H), 2.76 – 2.69 (m, 2H), 2.30 (s, 3H), 1.72 (dd, J = 18.9, 1.3 Hz, 6H). 
13C NMR (126 MHz, CD2Cl2) δ 169.53, 169.03, 163.90, 161.95, 157.95, 152.35, 135.01, 134.51, 
131.71, 130.23, 130.16, 129.53, 126.16, 125.40, 123.21, 121.30, 116.32, 114.43, 114.26, 107.58, 
102.12, 55.80, 41.87, 29.25, 26.99, 25.99, 21.22, 18.13. HRMS (ESI+) m/z: [M + H+] calculated 




hydroxy-3-(3-methylbut-2-en-1-yl)benzamide (3.7b).  
Compound 3.7b was synthesized following the procedure used for the synthesis of 3.6b to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.41 (ddd, J = 10.8, 
5.4, 2.5 Hz, 2H), 7.11 (dddd, J = 9.5, 8.5, 2.6, 1.0 Hz, 1H), 7.01 (ddd, J = 9.3, 2.6, 1.5 Hz, 1H), 
6.84 (d, J = 8.3 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2.4 Hz, 1H), 6.04 (dt, J = 29.0, 9.6 
Hz, 2H), 5.28 – 5.21 (m, 1H), 4.83 (q, J = 6.3 Hz, 1H), 4.75 (s, 1H), 3.88 (d, J = 6.6 Hz, 2H), 
3.79 (s, 3H), 3.73 – 3.60 (m, 2H), 3.37 – 3.32 (m, 2H), 3.29 (d, J = 9.8 Hz, 2H), 3.01 (dd, J = 
12.6, 5.1 Hz, 2H), 2.80 – 2.73 (m, 2H), 2.66 (t, J = 14.9 Hz, 2H), 2.21 – 2.17 (s, 3H), 1.81 – 1.72 
(m, 6H). 13C NMR (126 MHz, CDCl3) δ 166.85, 158.63, 157.49, 155.59, 143.66, 136.94, 136.16, 
135.43, 129.83, 128.73, 127.10, 126.21, 124.54, 120.89, 117.21, 115.94, 115.55, 106.39, 98.91, 
66.08, 55.37, 48.88, 43.00, 39.74, 29.56, 27.08, 25.73, 21.73, 17.84. HRMS (ESI+) m/z: [M + 



















The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.57 
(dd, J = 8.5, 2.4 Hz, 1H), 7.51 (d, J = 2.4 Hz, 1H), 7.43 – 7.37 (m, 4H), 7.36 – 7.28 (m, 5H), 7.09 
– 7.01 (m, 3H), 7.01 – 6.96 (m, 1H), 6.93 – 6.90 (m, 1H), 6.66 (d, J = 2.4 Hz, 1H), 6.48 (d, J = 
2.5 Hz, 1H), 6.31 (t, J = 5.0 Hz, 1H), 5.03 (s, 2H), 5.01 (s, 2H), 3.83 (d, J = 2.4 Hz, 6H), 3.63 (s, 
3H), 3.52 – 3.44 (m, 2H), 2.89 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 166.84, 
161.45, 159.29, 158.66, 157.82, 139.15, 136.63, 136.40, 130.19, 129.85, 129.78, 129.34, 129.05, 
















115.30, 114.27, 114.10, 112.82, 110.66, 107.93, 100.29, 95.40, 70.23, 55.74, 55.32, 40.98, 





Compound 3.39 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.58 – 7.47 (m, 2H), 
7.19 – 7.06 (m, 2H), 6.92 – 6.87 (m, 3H), 6.85 – 6.75 (m, 2H), 6.78 – 6.66 (m, 3H), 6.46 (d, J = 
2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H), 5.03 (s, 2H), 3.66 (d, J = 1.2 Hz, 6H), 3.63 (s, 3H), 3.32 – 
3.27 (m, 2H), 2.66 – 2.58 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.44, 167.60, 162.19, 
160.23, 158.14, 158.03, 155.26, 154.06, 142.73, 141.97, 137.69, 129.26, 128.54, 128.00, 127.09, 
124.64, 123.69, 120.96, 114.26, 113.73, 111.70, 109.85, 108.09, 102.11, 59.50, 54.61, 54.21, 




























carboxamide (3.8).  
Compound 3.8 was synthesized following the procedure used for the synthesis of 3.5 to obtain 
the product as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.80 – 7.74 (m, 1H), 
7.70 (dd, J = 3.9, 2.3 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.08 – 7.00 (m, 4H), 6.97 (dtd, J = 7.5, 
2.6, 1.2 Hz, 1H), 6.89 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.72 (s, 1H), 6.67 (d, J = 2.5 Hz, 1H), 6.48 
(d, J = 2.5 Hz, 1H), 6.42 (d, J = 2.5 Hz, 1H), 6.24 (d, J = 2.5 Hz, 1H), 5.50 (d, J = 2.4 Hz, 1H), 
4.16 (dd, J = 9.0, 3.4 Hz, 1H), 4.08 (dd, J = 3.4, 2.3 Hz, 1H), 3.86 (d, J = 0.8 Hz, 6H), 3.82 (s, 
3H), 3.55 (d, J = 1.0 Hz, 1H), 3.40 – 3.33 (m, 2H), 2.73 (ddd, J = 10.6, 7.8, 5.5 Hz, 2H), 1.30 (s, 
3H), 1.22 (s, 3H). 13C NMR (126 MHz, CD2Cl2) δ 169.21, 161.95, 160.05, 159.90, 156.48, 
155.50, 143.35, 139.43, 131.08, 130.07, 129.56, 128.61, 125.96, 125.31, 122.40, 122.39, 116.43, 
116.26, 115.77, 114.43, 114.27, 113.30, 111.51, 109.48, 98.15, 78.57, 71.80, 69.08, 62.14, 56.31, 

















Compound 3.8a was synthesized following the procedure used for the synthesis of 3.6a, to 
obtain the coupled product, which was then dissolved in methanol (3mL).  p-TSA (0.1mg, 
0.63mmol) was added and the mixture was stirred at rt.  After 12 h the reaction mixture was 
concentrated; the residue was diluted with saturated ammonium chloride and extracted with 
EtOAc (3x30mL).  The organic layers were combined, dried, concentrated, and purified via 
column chromatography (SiO2, 1:20, MeOH: DCM) to give 3.8a as a white solid (60% yield): 1H 
NMR (500 MHz, Chloroform-d) δ 7.62 (dd, J = 8.6, 2.4 Hz, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.32 – 
7.22 (m, 2H), 7.01 (dt, J = 7.8, 1.1 Hz, 1H), 6.98 – 6.93 (m, 5H), 6.91 (d, J = 8.7 Hz, 1H), 6.88 – 
6.83 (m, 1H), 6.45 – 6.42 (m, 1H), 6.27 (d, J = 2.2 Hz, 1H), 4.31 (s, 1H), 3.78 (d, J = 1.2 Hz, 
6H), 3.40 – 3.24 (m, 2H), 2.72 (t, J = 7.4 Hz, 2H), 2.61 – 2.45 (m, 2H), 2.28 – 2.10 (m, 2H), 1.86 
(s, 3H), 1.61 – 1.49 (m, 2H), 1.39 – 1.28 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 165.99, 
162.35, 160.39, 158.20, 155.22, 154.84, 142.56, 137.92, 129.27, 128.78, 128.71, 128.27, 128.15, 
127.09, 123.70, 121.02, 114.85, 114.60, 113.18, 111.57, 109.86, 108.93, 78.21, 54.77 (2Cs), 
54.39 (2Cs), 48.23, 40.90, 28.68, 28.30, 21.67. HRMS (ESI+) m/z: [M + H+] calculated for 
C35H37FN2O5 585.2765; found 585.2793. 
 
4-((2-(5-(Benzyloxy)-3'-fluoro-3-(methoxymethoxy)-[1,1'-biphenyl]-2-
yl)ethyl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate (3.51). 
Compound 3.51 was synthesized following the procedure used for the synthesis of 3.48 to 









Hz, 1H), 7.46 – 7.29 (m, 8H), 7.11 – 6.92 (m, 4H), 6.68 (d, J = 2.5 Hz, 1H), 6.49 (d, J = 2.5 Hz, 
1H), 6.35 – 6.24 (m, 1H), 5.13 – 5.05 (m, 2H), 5.05 – 4.97 (m, 2H), 4.46 – 4.24 (m, 2H), 3.52 – 
3.36 (m, 3H), 2.96 – 2.82 (m, 4H), 2.16 (s, 3H), 1.95 (dq, J = 5.5, 2.9 Hz, 3H), 1.74 – 1.69 (m, 
3H). 13C NMR (126 MHz, CDCl3) δ 167.97, 165.81, 162.38, 160.42, 156.80, 154.95, 152.51, 
135.58, 135.36, 132.89, 132.41, 131.69, 128.75, 128.31, 127.59, 127.08, 126.33, 124.05, 123.87, 
121.15, 120.10, 117.45, 115.18, 115.01, 113.05, 106.87, 99.27, 95.34, 69.75, 59.37, 43.59, 32.35, 
28.67, 28.22, 27.91, 24.71, 20.04, 16.87. HRMS (ESI+) m/z: [M + H+] calculated for 




(3-methylbut-2-en-1-yl)phenyl acetate (3.56). 
Compound 3.56 was synthesized following the procedure used for the synthesis of 3.53 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 8.84 (s, 1H), 7.95 (d, J 
= 2.2 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.53 (dd, J = 8.4, 2.3 Hz, 1H), 7.32 (td, J = 8.0, 6.0 Hz, 
1H), 7.07 – 6.90 (m, 4H), 6.69 (d, J = 2.5 Hz, 1H), 6.44 (d, J = 2.5 Hz, 1H), 5.20 – 5.11 (m, 2H), 
3.45 (s, 3H), 3.44 – 3.37 (m, 2H), 3.23 (d, J = 7.3 Hz, 2H), 2.77 (dt, J = 8.7, 3.6 Hz, 2H), 2.31 (s, 
3H), 1.71 (d, J = 1.5 Hz, 3H), 1.67 (d, J = 1.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.19, 
168.28, 163.35, 161.39, 156.25, 151.52, 142.80, 134.22, 133.78, 131.49, 129.62, 129.37, 127.82, 









28.89, 26.17, 25.75, 20.89, 17.89. HRMS (ESI+) m/z: [M + H+] calculated for C30H32FNO6 





Compound 3.8b was synthesized following the procedure used for the synthesis of 3.6b, to 
obtain the acetate deprotected product, which was then dissolved in methanol (3mL).  p-TSA 
(0.1mg, 0.63mmol) was added and the mixture was stirred at rt.  After 12 h the reaction mixture 
was concentrated; the residue was diluted with saturated ammonium chloride and extracted with 
EtOAc (3x30mL).  The organic layers were combined, dried, concentrated, and purified via 
column chromatography (SiO2, 1:20, MeOH: DCM) to give 3.8b as a white solid (60% yield): 1H 
NMR (500 MHz, Chloroform-d) δ 7.21 – 7.01 (m, 2H), 6.83 – 6.70 (m, 2H), 6.59 (t, J = 7.2 Hz, 
2H), 6.48 – 6.33 (m, 2H), 6.15 (dd, J = 15.4, 7.9 Hz, 1H), 5.82 (d, J = 7.2 Hz, 1H), 5.70 (d, J = 
7.8 Hz, 1H), 4.71 – 4.59 (m, 1H), 3.33 (dd, J = 20.5, 8.7 Hz, 2H), 3.06 – 2.93 (m, 4H), 2.85 – 
2.63 (m, 4H), 2.39 (dt, J = 9.5, 4.0 Hz, 2H), 2.33 – 2.25 (m, 2H), 2.14 (s, 3H), 1.82 – 1.69 (d, 
6H). 13C NMR (126 MHz, CDCl3) δ 168.24, 163.64, 161.69, 143.81, 140.96, 133.24, 129.99, 
129.20, 128.68, 126.31, 125.01, 122.19, 116.27, 114.77, 114.08, 109.86, 85.97, 53.21, 53.18, 
43.62, 40.10, 32.10, 29.92, 28.58, 27.46, 25.90, 17.91. HRMS (ESI+) m/z: [M + H+] calculated 



















The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 8.06 
(d, J = 2.3 Hz, 1H), 7.69 – 7.60 (m, 3H), 7.37 – 7.21 (m, 7H), 6.98 (s, 1H), 6.93 (dd, J = 11.5, 
8.6 Hz, 2H), 6.88 – 6.74 (m, 4H), 6.29 (t, J = 5.5 Hz, 1H), 5.00 (s, 2H), 4.93 (s, 2H), 3.81 (s, 
3H), 3.74 (s, 3H), 3.73 (s, 3H), 3.63 – 3.58 (m, 2H), 2.83 – 2.75 (m, 2H). 13C NMR (126 MHz, 
CDCl3) δ 167.43, 161.35, 159.66, 159.61, 151.56, 144.02, 139.43, 139.11, 138.87, 136.98, 
133.43, 132.14, 131.20, 130.57, 130.18, 129.53, 129.36, 128.95, 128.43, 127.22, 125.61, 125.19, 






















Compound 3.40 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.68 (dd, J = 8.6, 2.4 
Hz, 1H), 7.60 (d, J = 2.4 Hz, 1H), 7.37 – 7.29 (m, 3H), 7.10 – 6.92 (m, 7H), 6.89 (ddd, J = 8.3, 
2.6, 1.0 Hz, 1H), 6.08 (t, J = 5.8 Hz, 1H), 4.66 (s, 2H), 3.83 (d, J = 4.1 Hz, 6H), 3.43 – 3.39 (m, 
2H), 3.38 (s, 3H), 2.66 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 165.80, 162.49, 
158.20, 157.87, 146.70, 142.22, 137.90, 129.29, 128.85, 128.36, 128.02, 127.86, 126.96, 125.76, 
125.47, 124.60, 120.92, 115.91, 115.44, 114.21, 113.33, 111.78, 109.76, 98.62, 56.08, 54.71, 





























carboxamide (3.9).  
Compound 3.9 was synthesized following the procedure used for the synthesis of 3.5 to obtain 
the product as a white solid: 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.65 (dd, J = 8.5, 
2.4 Hz, 1H), 7.58 (d, J = 2.4 Hz, 1H), 7.42 – 7.34 (m, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 
8.4 Hz, 1H), 7.07 – 6.94 (m, 6H), 6.88 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 
6.10 (t, J = 5.9 Hz, 1H), 5.30 (d, J = 4.6 Hz, 1H), 4.19 (dd, J = 6.9, 3.5 Hz, 1H), 4.05 – 4.01 (m, 
1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.80 – 3.79 (m, 1H), 3.56 – 3.50 (m, 1H), 3.49 (s, 3H), 3.21 (d, J 
= 6.9 Hz, 2H), 2.66 (t, J = 7.2 Hz, 2H), 1.39 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CD2Cl2) 
δ 167.13, 162.05, 159.71, 159.37, 156.24, 155.31, 144.92, 143.71, 139.47, 132.75, 130.70, 
130.19, 129.74, 129.37, 128.57, 128.25, 127.10, 126.42, 122.26, 121.67, 121.02, 117.55, 115.67, 
115.12, 114.51, 114.34, 113.02, 111.19, 100.31, 78.81, 70.52, 69.36, 61.15, 56.09, 55.64, 41.07, 





Compound 3.9a was synthesized following the procedure used for the synthesis of 3.8a to 












1H), 7.56 (d, J = 2.1 Hz, 1H), 7.41 (q, J = 7.4 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.11 – 6.96 (m, 
5H), 6.95 – 6.89 (m, 2H), 6.86 (d, J = 4.9 Hz, 1H), 5.92 (s, 1H), 5.51 (s, 1H), 4.68 (s, 1H), 3.85 
(d, J = 1.1 Hz, 6H), 3.43 (d, J = 6.6 Hz, 2H), 3.27 (s, 2H), 2.75 (s, 2H), 2.68 (t, J = 7.0 Hz, 2H), 
2.61 (s, 3H), 2.20 – 2.14 (m, 2H), 1.35 – 1.16 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 167.14, 
162.15, 159.70, 159.38, 144.22, 142.52, 139.33, 138.77, 131.86, 130.98, 130.73, 129.58, 129.52, 
128.52, 127.13, 126.21, 122.34, 121.71, 117.65, 117.48, 115.87, 114.60, 113.04, 111.27, 78.30, 
56.20, 55.79, 49.83, 44.17, 40.89, 30.10, 27.34 (2Cs). HRMS (ESI+) m/z: [M + H+] calculated 




yl)ethyl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate (3.52). 
Compound 3.52 was synthesized following the procedure used for the synthesis of 3.48 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.59 (d, J = 2.2 Hz, 
1H), 7.46 – 7.41 (m, 4H), 7.38 (td, J = 8.0, 1.5 Hz, 4H), 7.35 – 7.32 (m, 1H), 7.11 – 7.01 (m, 
4H), 6.98 (d, J = 8.5 Hz, 1H), 5.92 – 5.87 (m, 1H), 5.12 (s, 2H), 4.89 (d, J = 2.4 Hz, 2H), 3.46 – 
3.37 (m, 2H), 3.25 (d, J = 7.3 Hz, 2H), 2.87 (s, 3H), 2.70 (t, J = 7.0 Hz, 2H), 2.31 (d, J = 1.5 Hz, 
3H), 1.71 (dd, J = 19.8, 1.3 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 169.43, 167.17, 163.85, 
161.89, 151.60, 150.59, 144.36, 139.56, 137.09, 134.51, 132.89, 130.38, 129.98, 129.91, 129.61, 










71.20, 56.96, 41.00, 32.85, 29.27, 26.14, 21.27, 18.30. HRMS (ESI+) m/z: [M + H+] calculated 




(3-methylbut-2-en-1-yl)phenyl acetate (3.57). 
Compound 3.57 was synthesized following the procedure used for the synthesis of 3.53 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.57 (d, J = 2.2 Hz, 
1H), 7.44 (dd, J = 8.3, 2.2 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.08 – 6.91 (m, 5H), 6.13 (t, J = 5.8 Hz, 
1H), 5.16 (dddd, J = 7.1, 5.7, 2.8, 1.4 Hz, 1H), 4.66 (s, 2H), 3.42 – 3.33 (m, 2H), 3.23 (d, J = 7.4 
Hz, 2H), 3.01 (s, 3H), 2.65 (t, J = 7.1 Hz, 2H), 2.30 (d, J = 6.1 Hz, 3H), 1.71 (d, J = 1.6 Hz, 3H), 
1.67 (d, J = 1.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 168.92, 166.78, 163.34, 151.05, 147.60, 
143.07, 138.68, 134.74, 133.56, 132.18, 129.72, 129.65, 128.98, 128.56, 126.26, 125.49, 125.23, 
122.23, 120.71, 116.59, 114.20, 114.03, 99.43, 56.94, 40.56, 32.13, 28.66, 25.54, 20.68, 17.69. 




















hydroxy-3-(3-methylbut-2-en-1-yl)benzamide (3.9b).  
Compound 3.9b was synthesized following the procedure used for the synthesis of 3.8b to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.53 (d, J = 2.3 Hz, 
1H), 7.43 (d, J = 2.3 Hz, 1H), 7.38 (ddd, J = 8.2, 5.9, 2.4 Hz, 2H), 7.31 (dddd, J = 11.0, 8.2, 5.9, 
3.0 Hz, 2H), 7.07 (d, J = 8.3 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 8.6 Hz, 1H), 6.47 (s, 
1H), 5.11 (tdd, J = 5.7, 2.9, 1.5 Hz, 1H), 4.40 (s, 1H), 3.35 (qd, J = 7.3, 5.9 Hz, 2H), 3.18 (d, J = 
7.3 Hz, 2H), 2.63 (t, J = 7.0 Hz, 2H), 2.38 (d, J = 5.4 Hz, 2H), 2.29 (d, J = 4.1 Hz, 2H), 2.25 (d, J 
= 5.5 Hz, 2H), 2.07 – 1.94 (s, 3H), 1.89 – 1.80 (m, 2H), 1.67 – 1.61 (m, 6H). 13C NMR (126 
MHz, CDCl3) δ 167.01, 163.66, 161.73, 143.54, 140.33, 133.74, 129.84, 129.26, 128.53, 126.05, 
125.74, 122.34, 116.41, 114.53, 114.11, 109.46, 85.72, 53.44, 53.20, 43.02, 40.11, 33.01, 29.22, 





A solution of 2,4-dihydroxy-3-methylbenzaldehyde (0.45 g, 1.85 mmol) and DIPEA (0.71mL, 
0.74 mmol) in anhydrous DCM (18mL) was stirred at 0 oC.  Chloromethyl methyl ether (0.84 
mL, 11.1 mmol) was added drop wise after 10 minutes.  After 16 h the reaction was quenched by 
the addition of water (5mL), extracted with DCM (3 x 10mL), dried (Na2SO4), filtered and 
concentrated.  The residue was purified by column chromatography (SiO2, 8:1, Hex:EtOAc) to 






9.73 (d, J = 0.6 Hz, 1H), 7.39 – 7.29 (m, 1H), 6.75 (d, J = 8.6 Hz, 1H), 5.28 (s, 2H), 3.49 (s, 3H), 
2.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 195.12, 162.04, 161.45, 132.99, 115.92, 114.49, 




A solution of 3.29 (0.29 g, 1.1mmol), N-bisphenyltriflate (0.59 g, 1.7 mmol), K2CO3 (0.61 g, 
4.4 mmol) in anhydrous tetrahydrofuran (15.7 mL) was stirred in a septum-capped tube.  The 
reaction was heated to 120 oC for 20 minutes in a microwave synthesizer.  Upon completion the 
reaction was cooled to rt and quenched with water (10 mL), extracted with EtOAc (3 x 5 mL), 
dried (Na2SO4), filtered and concentrated.  The residue was used without further purification, a 
yellow oil (99%). 
 
3'-Fluoro-5-(methoxymethoxy)-6-methyl-[1,1'-biphenyl]-2-carbaldehyde. 
6-Formyl-3-(methoxymethoxy)-2-methylphenyl trifluoromethanesulfonate (5.10 mmol) was 
dissolved in Dioxane (25mL).  3-fluorophenyl boronic acid (1.06 g, 7.65 mmol), K3PO4 (3.24 g, 
15.3 mmol), Pd(dba)3 (0.117, 0.127 mmol), and S-Phos (0.21g, 0.51mmol) were added to the 
mixture.  The reaction was degassed and then heated to reflux on. Upon completion of the 
reaction, it was cooled to rt.  The reaction was extracted with saturated LiCl and EtOAc (3 x 









chromatography (SiO2, 6:1, Hex: EtOAc) to afford the purified product as a yellow oil (70%): 1H 
NMR (500 MHz, Chloroform-d) δ 9.55 (d, J = 0.8 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.47 – 7.35 
(m, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.13 (tdd, J = 8.5, 2.6, 0.9 Hz, 1H), 7.01 (dt, J = 7.5, 1.2 Hz, 
1H), 6.97 (ddd, J = 9.2, 2.6, 1.5 Hz, 1H), 5.33 (s, 2H), 3.52 (s, 3H), 1.99 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 191.27, 163.51, 161.53, 145.71, 138.97, 129.99, 128.46, 126.99, 123.61, 117.08, 
114.92, 114.75, 112.82, 94.18, 56.43, 13.00. HRMS (ESI+) m/z: [M + Na+] calculated for 




3'-Fluoro-5-(methoxymethoxy)-6-methyl-[1,1'-biphenyl]-2-carbaldehyde (0.11g, 0.327mmol) 
was dissolved in Nitromethane (0.7mL).  NH4OAc (0.05g, 0.654mmol) was added, and then the 
mixture was heated at reflux for 4 h.  After 4 h the reaction was cooled to rt.  The product was 
extracted with EtOAc (3 x 10mL).  The organic layers were combined, dried, concentrated.  The 
residue was purified by column chromatography (SiO2, 4:1, Hex: EtOAc) to afford the purified 
product as a yellow solid in 90% yield: 1H NMR (400 MHz, Chloroform-d) δ 7.58 (d, J = 13.6 
Hz, 1H), 7.45 (d, J = 8.8 Hz, 1H), 7.42 – 7.36 (m, 1H), 7.24 – 7.21 (m, 1H), 7.13 – 7.06 (m, 2H), 











Lithium Aluminum Hydride (0.11g, 2.75mmol) was dissolved in anhydrous tetrahydrofuran 
(5.5mL) and cooled to 0oC. (E)-3'-Fluoro-3-(methoxymethoxy)-2-methyl-6-(2-nitrovinyl)-1,1'-
biphenyl (0.5g, 1.377mmol) was dissolved in anhydrous tetrahydrofuran (1.96mL) and added 
drop wise to the reaction.  The reaction slowly warmed to rt and stirred for 12 h.  Upon 
completion, 3N NaOH (1mL), water (1mL), and EtOAc (3mL) were added sequentially to 
quench the reaction.  After stirring for one h the mixture was filtered through a pad of Celite.  
The solid was washed with warm EtOAc (100mL). The filtrate was collected, dried, and 
concentrated. The oil was purified using column chromatography (SiO2, 2:1, DCM: MeOH) and 
used directly in the next step: 1H NMR (500 MHz, Chloroform-d) δ 7.38 (td, J = 8.0, 6.0 Hz, 
1H), 7.06 – 7.02 (m, 3H), 6.91 (dt, J = 7.6, 1.2 Hz, 1H), 6.85 (ddd, J = 9.5, 2.6, 1.4 Hz, 1H), 5.22 
(s, 2H), 3.51 (s, 3H), 2.69 (t, J = 7.3 Hz, 2H), 2.46 (t, J = 7.3 Hz, 2H), 2.27 (s, 5H), 1.90 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 163.72, 153.78, 137.9, 137.1, 130.25, 129.17, 127.27, 125.15, 
123.81, 116.26, 113.80, 113.37, 94.67, 56.06, 42.92, 36.75, 13.73. HRMS (ESI+) m/z: [M + H+] 


















The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.72 
(dd, J = 8.6, 2.4 Hz, 1H), 7.63 (d, J = 2.4 Hz, 1H), 7.40 – 7.29 (m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 
7.09 – 7.01 (m, 4H), 6.99 – 6.85 (m, 4H), 6.09 (t, J = 5.7 Hz, 1H), 5.22 (s, 2H), 3.84 (s, 3H), 3.83 
(s, 3H), 3.51 (s, 3H), 3.43 (tdd, J = 7.2, 5.7, 2.0 Hz, 2H), 2.62 (t, J = 7.2 Hz, 2H), 1.92 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.84, 161.85, 159.32, 158.93, 154.00, 141.89, 139.06, 130.37, 
130.13, 129.90, 129.47, 129.13, 128.12, 127.48, 127.01, 126.08, 125.21, 122.03, 116.44, 116.28, 
115.35, 114.02, 113.44, 112.85, 110.86, 94.68, 56.01, 55.92, 55.89, 40.81, 32.97, 13.84. HRMS 





Compound 3.42 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.62 (dd, J = 8.6, 2.4 
Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.15 (s, 1H), 7.02 – 6.97 (m, 1H), 6.96 – 6.88 (m, 3H), 6.86 (d, 











3.0 Hz, 6H), 3.35 – 3.28 (m, 2H), 2.49 (t, J = 7.1 Hz, 2H), 1.79 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 167.55, 162.14, 159.56, 159.39, 153.45, 143.04, 142.14, 139.28, 130.45, 129.74, 
129.45, 128.71, 128.58, 128.29, 127.88, 126.99, 125.55, 123.35, 122.48, 116.77, 116.61, 115.86, 
115.00, 114.43, 114.26, 113.05, 111.28, 56.14, 55.75, 41.26, 33.20, 13.79. HRMS (ESI+) m/z: 





carboxamide (3.10).  
Compound 3.10 was synthesized following the procedure used for the synthesis of 3.5 to 
obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.69 (dd, J = 8.6, 2.4 
Hz, 1H), 7.59 (t, J = 2.5 Hz, 1H), 7.33 (t, J = 8.0 Hz, 2H), 7.17 (dd, J = 8.6, 1.1 Hz, 1H), 7.12 (s, 
1H), 7.08 – 7.00 (m, 3H), 6.97 (d, J = 8.6 Hz, 1H), 6.95 – 6.86 (m, 2H), 5.94 (td, J = 5.7, 2.0 Hz, 
1H), 5.53 (d, J = 2.2 Hz, 1H), 4.23 (dd, J = 9.3, 3.2 Hz, 1H), 4.19 (t, J = 2.8 Hz, 1H), 3.84 (d, J = 
3.0 Hz, 6H), 3.60 (s, 3H), 3.53 (d, J = 1.3 Hz, 1H), 3.49 – 3.38 (m, 2H), 3.39 – 3.31 (m, 1H), 
2.81 – 2.77 (m, 1H), 2.64 (d, J = 25.0 Hz, 2H), 1.82 (s, 3H), 1.39 (s, 3H), 1.21 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 166.83, 163.76, 159.25, 158.91, 153.55, 142.44, 141.67, 138.96, 130.38, 















112.93, 112.84, 110.81, 97.83, 71.45, 68.75, 61.92, 55.78, 55.34, 40.73, 32.90, 29.25, 22.61, 





Compound 3.10a was synthesized following the procedure used for the synthesis of 3.6a to 
obtain the product as a white solid: 1H NMR (500 MHz, DMSO-d6) δ 7.65 (t, J = 5.6 Hz, 1H), 
7.12 (dd, J = 8.6, 2.3 Hz, 1H), 7.05 (d, J = 2.4 Hz, 1H), 6.80 (ddd, J = 8.1, 7.0, 5.3 Hz, 1H), 6.65 
(t, J = 7.9 Hz, 1H), 6.56 – 6.48 (m, 1H), 6.44 (dd, J = 23.1, 8.7 Hz, 2H), 6.37 – 6.19 (m, 6H), 
3.70 (s, 1H), 3.59 (s, 2H), 3.13 (s, 3H), 3.10 (s, 3H), 2.68 (s, 2H), 2.60 – 2.52 (m, 2H), 2.49 (s, 
2H), 2.12 (s, 3H), 1.96 (d, J = 20.2 Hz, 4H), 1.92 (s, 3H). 13C NMR (126 MHz, DMSO) δ 
167.03, 162.11, 159.72, 159.30, 158.43, 152.71, 142.12, 142.09, 140.96, 138.50, 129.95, 128.84, 
128.57, 127.99, 127.57, 126.78, 126.32, 125.03, 124.17, 121.23, 115.61, 114.70, 113.44, 112.06, 
111.92, 110.72, 77.62, 55.28, 54.61, 51.54 (2Cs), 48.14, 45.00, 35.35, 32.10 (2Cs), 13.11. 














dimethoxy-[1,1'-biphenyl]-3-carboxamide (3.10b).  
Compound 3.10b was synthesized following the procedure used for the synthesis of 3.6a to 
obtain the product as a white solid: 1H NMR (500 MHz, DMSO-d6) δ 8.02 (t, J = 5.6 Hz, 1H), 
7.50 (dd, J = 8.6, 2.3 Hz, 1H), 7.43 (d, J = 2.4 Hz, 1H), 7.21 – 7.15 (m, 1H), 7.03 (t, J = 7.9 Hz, 
1H), 6.90 (td, J = 8.6, 2.5 Hz, 1H), 6.82 (dd, J = 17.9, 8.6 Hz, 2H), 6.76 – 6.66 (m, 4H), 6.65 – 
6.60 (m, 2H), 3.68 (t, J = 6.2 Hz, 2H), 3.51 (s, 3H), 3.48 (s, 3H), 2.95 – 2.88 (m, 2H), 2.20 (s, 
3H), 2.19 – 2.15 (m, 2H), 2.09 (t, J = 7.1 Hz, 2H), 1.85 (s, 6H), 1.58 – 1.53 (m, 2H). 13C NMR 
(126 MHz, DMSO) δ 165.36, 161.12, 158.92, 158.68, 158.21, 154.86, 141.16, 138.99, 130.43, 
129.33, 129.06, 128.78, 128.48, 127.34, 126.82, 125.42, 123.66, 121.72, 116.11, 115.19, 113.76, 
112.41, 111.22, 110.70, 65.88, 55.77, 55.09, 48.63, 45.16, 35.80, 32.59, 26.98, 13.43. HRMS 























The compound was synthesized following the procedure used for the synthesis of N-(2-(5-
(benzyloxy)-3'-fluoro-[1,1'-biphenyl]-2-yl)ethyl)-3',6-dimethoxy-[1,1'-biphenyl]-3-
carboxamide to obtain the product as a white solid: 1H NMR (500 MHz, Chloroform-d) δ 7.70 
(t, J = 5.5 Hz, 1H), 7.18 (dd, J = 8.5, 2.2 Hz, 1H), 7.09 (d, J = 2.5 Hz, 1H), 6.85 – 6.79 (m, 5H), 
6.60 (t, J = 8.1 Hz, 1H), 6.51 (td, J = 8.5, 2.6 Hz, 1H), 6.42 (dd, J = 18.1, 8.5 Hz, 2H), 6.37 – 
6.29 (m, 5H), 6.26 – 6.21 (m, 3H), 5.58 (s, 1H), 5.09 (s, 2H), 3.68 (s, 3H), 3.63 (s, 3H), 3.40 (d, J 
= 6.7 Hz, 2H), 2.58 (t, J = 6.8 Hz, 2H). 13C NMR (126 MHz, DMSO) δ 167.04, 161.35, 159.25, 
159.00, 144.32, 139.53, 138.07, 131.77, 130.45, 130.02, 129.82, 129.54, 128.62, 127.43, 126.71, 
122.34, 121.60, 120.19, 117.67, 117.45, 115.72, 114.65, 113.77, 111.07, 110.43, 70.11, 56.45, 

























Compound 3.41 was synthesized following the procedure used for the synthesis of 3.36 to 
obtain the product as a white solid which was verified using HRMS and used immediately due to 





dimethoxy-[1,1'-biphenyl]-3-carboxamide (3.11a).  
Compound 3.11a was synthesized following the procedure used for the synthesis of 3.6a to 
obtain the product as a white solid:1H NMR (500 MHz, DMSO-d6) δ 7.65 (t, J = 5.6 Hz, 1H), 
7.13 (dd, J = 8.6, 2.3 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 6.84 – 6.78 (m, 1H), 6.66 (t, J = 7.9 Hz, 
1H), 6.53 (td, J = 8.6, 2.5 Hz, 1H), 6.45 (dd, J = 17.9, 8.6 Hz, 2H), 6.39 – 6.29 (m, 5H), 6.28 – 
6.22 (m, 2H), 5.58 (s, 1H), 3.75 (s, 1H), 3.65 (s, 3H), 3.62 (s, 3H), 3.46 (d, J = 6.6 Hz, 2H), 2.68 
(t, J = 7.0 Hz, 2H), 2.53 – 2.48 (m, 2H), 2.38-2.30 (m, 2H), 2.19 (s, 3H), 1.92 – 1.86 (m, 2H). 
13C NMR (126 MHz, DMSO) δ 167.34, 162.05, 159.65, 159.08, 142.12, 139.03, 138.77, 131.89, 
130.90, 130.62, 129.55, 129.32, 128.72, 127.43, 126.44, 122.14, 121.61, 120.09, 117.63, 117.08, 
115.55, 114.45, 113.72, 111.67, 110.01, 78.90, 56.00, 55.39, 48.43, 40.79, 30.16, 27.74. HRMS 
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4. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of 
Hsp90 C-terminal Inhibitors 
Introduction 
Heat shock protein 90 (Hsp90) is an evolutionarily conserved molecular chaperone that 
plays a critical role in the maintenance of protein homeostasis as well as an adaptive response to 
cell stress.1 Hsp90 is a core component of the protein folding machinery that regulates the 
folding, stability, function, and proteolytic turnover of more than 300 client proteins, including 
protein kinases, transcription factors, and signal transducers.2 These client proteins control a 
wide range of cellular functions, such as cell signaling, protein trafficking, chromatin 
remodeling, cell proliferation and survival.2-4 However, in cancer, these clients are frequently 
mutated and/or over-expressed to drive oncogenic processes, such as dysregulated proliferation, 
metastasis, and angiogenesis. In fact, ~25% of the Hsp90-dependent clients (eg. Her-2, CDK6, 
Raf1, Akt, survivin, telomerase) represent oncoproteins that are directly associated with all ten 
hallmarks of cancer.3, 5-7 Moreover, Hsp90 is overexpressed in cancer cells to stabilize these 
oncoproteins against proteotoxic stresses and to fold mutants that enable the growth and/or 
survival of tumorigenic cells.8-9 Consequently, Hsp90 inhibition provides an opportunity to 
simultaneously disrupt multiple oncogenic pathways that are required for cancer cell survival. As 
a result, Hsp90 has emerged as a promising therapeutic target for the development of cancer 
chemotherapeutics.10-11 17 Small molecules that target the Hsp90 N-terminus have entered 
clinical trials for the treatment of cancer, demonstrating proof-of-concept for Hsp90 inhibitors as 
potential anticancer agents.12 Although these molecules have shown some promising clinical 
responses, several concerns have arisen such as concomitant induction of the pro-survival heat 




additional risks that must be overcome during the development of new inhibitors.4 Therefore, 
small molecules that modulate Hsp90 via alternative mechanisms represent a novel approach 
towards the evolution of Hsp90 inhibitors.4, 13 
In 2000, Neckers and co-workers discovered that novobiocin, a clinically used antibiotic 
and DNA gyrase inhibitor, binds the Hsp90 C-terminus, and allosterically inhibits Hsp90 
function.14-15 Importantly, novobiocin and related natural products do not induce the HSR and 
therefore, can avoid the clinical limitations associated with Hsp90 N-terminal inhibitors. 
Unfortunately, novobiocin exhibits low cellular activity (SkBr3 IC50 ~ 700 μM) and thus, has 
limited therapeutic potential. Preliminary studies with novobiocin identified key structural 
features required for Hsp90 inhibitory activity, which led to analogues with improved inhibitory 
activity.16-17 Subsequent studies revealed that the benzamide side chain of novobiocin is 
important for anti-proliferative activity and modification of this side chain produced several 
promising compounds, such as KU-174 (Figure 4.1).18 Additional studies demonstrated that the 
stereochemically complex sugar moiety could be replaced with ionizable amines, which 
produced analogues that manifest mid-nanomolar to low micromolar activity against multiple 
cancer cell lines.19-22 In contrast to these side chains, limited structural investigations have been 
performed on the coumarin core of novobiocin.  
Recent investigation of the novobiocin scaffold demonstrated that an aromatic or 
heteroaromatic ring system could be used in lieu of the coumarin core without compromising 
activity, suggesting that the central core may serve as a backbone to orient both the benzamide 
and sugar/side chains within the binding pocket.23-24 Consequently, it was proposed that the 
coumarin core could be replaced with other scaffolds to identify compounds upon which more 




compounds is necessary to better understand the mechanism by which the C-terminal domain 
regulates the Hsp90 chaperone cycle. Towards this objective, we discovered the coumarin core 
of novobiocin could be replaced with a biphenyl scaffold, which led to analogues that exhibit 
potent anti-proliferative activity, like 4.3 (Figure 4.1).25-26 More recently, we demonstrated that a 
stilbene core (4.4) could be used in lieu of the coumarin core as well.27 In continuation of these 
studies, the current work identifies a novel core, which has led to the development of more 




Prior SAR studies on novobiocin revealed the benzamide side chain and sugar are critical 
for Hsp90 inhibitory activity and that modification to these moieties has produced several 
promising compounds, such as 4.5 (Figure 4.2), which manifests improved activity against 
several cancer cell lines.18-22, 28 Recently, it was demonstrated that a biphenyl scaffold could be 
used in lieu of the coumarin core, which also led to potent inhibitors, such as KU-820 (Figure 
4.2), presumably due to the favorable conformation adopted by the relatively flexible biphenyl 
core within the binding pocket.25, 29 In addition, it was determined that the planarity and 
 




flexibility of the central core are important for Hsp90 inhibitory activity.27 Therefore, it was 
hypothesized that the central core could be modified to optimize orientation of the side chains for 
increased inhibitory activity. Since biphenyl analogues manifest superior activity, this scaffold 
was chosen as the starting point for the discovery of more efficacious Hsp90 inhibitors.  
 
Increasing evidence suggests that molecules with aromatic scaffolds offer limited spatial 
diversity, while the incorporation of a saturated ring system can improve drug-like properties, 
such as ligand/receptor interactions as well as solubility.30-31 As a flexible structure, the saturated 
ring system has the ability to adopt multiple conformations and to project substituents into 
optimal orientations within the binding pocket. Therefore, optimization of the core began by 
replacement of the A- and/or B-ring of the biphenyl core with a saturated ring system (Figure 
 






4.3). The previously optimized biaryl amide side chain and N-methylpiperidine present in 4.3 
were appended to these new cores for evaluation of preliminary structure-activity relationships.  
A 3D overlay was used to verify that the general three-dimensional structure would be similar 
with the proposed analogs when compared to 4.3 (Figure 4.3).    
  
Chemistry 
As shown in Scheme 4.1, the preparation of analogues that contain a saturated B-ring 
(4.8a and 4.8b) commenced via benzyl-protection of phenol 4.9 to afford ketone 4.10, which was 
then stereoselectively reduced with either L-selectride or sodium borohydride to give the syn 
(4.11a) or anti (4.11b) diastereomers in >90% de, respectively. Inversion of stereochemistry was 
made possible by mesylation of the alcohols (4.11a, 4.11b), followed by SN2 substitution with 
sodium azide to yield 4.13a and 4.13b. Reduction of the azides with palladium on carbon under a 
hydrogen atmosphere gave amines 4.14a and 4.14b, which were then coupled with biaryl acid 
4.15 using standard coupling conditions to afford the corresponding amides, 4.16a and 4.16b. 
Mitsunobu etherification of the resulting amides with 1-methyl-4-hydroxypiperidine (4.17a) 
gave the desired products, 4.8a and 4.8b, in moderate yields. 
 
Figure 4.3. A). Proposed Analogs for the exploration of a new core. B). 3D overlay 
of 4.3 (blue) and proposed phenyl cyclohexyl analog, 4.8, (pink).  The overlay was 
created using energy minimized conformations and the Forge Modeling Program, no 





In addition, an analogue that contains a piperidine ring (4.23) was designed to determine 
whether orientation of the cyclohexyl ring is important for activity. Synthesis of 4.23 was 
achieved via a Buchwald coupling between aryl bromide 4.18 and piperidine 4.19 to produce 
4.20, which then underwent hydrogenolysis with palladium hydroxide under a hydrogen 
atmosphere to give the free phenol, 4.21 (Scheme 4.2). Mitsunobu etherification of 4.21 with 1-
methyl-4-hydroxypiperdine (4.17a) yielded the N-Boc-protected amine 4.22, which was then 
treated with trifluoroacetic acid to remove the Boc- protecting group before the resulting amine 
was coupled with biaryl acid 4.15 to afford the desired product, 4.23.  
 
 
Scheme 4.1: Synthesis of phenylcyclohexyl carboxamides. Reagents and 
conditions: a BnBr, K2CO3, acetone, 0 oC to rt, 12 h, 95%; b L-selectride, THF,  -
40 oC to rt, 12 h, 92% or NaBH4, MeOH, 0 oC to rt, 12 h, 90%; c MsCl, Et3N, 
DCM, 0 oC to rt, 4 h, 92 − 94%; d NaN3, DMF, 100 oC, 12 h, 80 − 85%; e 10% 
Pd(OH)2, H2, MeOH/THF, rt, 12 h, ~100%; f . EDCI•HCl, Et3N, DCM, 0 oC to rt, 
12 h, 45 − 50%; g 1-Methylpiperdin-4-ol (4.17a), DIAD, PPh3, THF, 0 oC to rt, 12 






In parallel, an analogue containing a saturated A-ring (4.6) was prepared as illustrated in 
Scheme 4.3. Synthesis of compound 4.6 was initiated by selective mono-benzylation of 
cyclohexane-1,4-diol to give 4.25,32 which was then oxidized with pyridinium chlorochromate to 
yield ketone 4.26.33 The ketone was then converted to the vinyl triflate (4.27), before Suzuki 
coupling with boronic acid 4.28 to give the cyclohexyl phenyl core, 4.29. Acid-catalyzed 
hydrolysis of the Boc-protecting group on 4.30 yielded aniline 4.29, which underwent an amide 
coupling reaction with acid chloride 4.15 to afford 4.31. Hydrogenolysis of 4.31 with palladium 
on carbon under a hydrogen atmosphere gave the free alcohol, 4.32, which underwent an SN2 
substitution reaction with 4.17b to afford 4.6 in moderate yield. Following a similar protocol as 
standardized for 4.8a and 4.8b, compound 4.7 was prepared to contain two cyclohexyl rings as 
shown in Scheme 4.4. 
 
Scheme 4.2: Synthesis of phenylpiperdin-4-yl carboxamide, 4.23. Reagents and 
conditions: a Pd2(dba)3, X-Phos, tBuONa, toluene, 130 oC, 2 h, m.w., 37%; b 10% 
Pd(OH)2, H2, MeOH/THF, rt, 12 h, ~100%; c 4.17a, DIAD, PPh3, THF, 0 oC to rt, 
12 h, 30%; d i. 30% TFA/DCM, 0 oC to rt, 4 h, ~100%; ii. EDCI•HCl, Et3N, 






 Upon construction, analogues containing saturated A- and/or B-rings were evaluated for 
their anti-proliferative activity against two cancer cell lines, SkBr3 (estrogen receptor negative, 
Her-2 overexpressing breast cancer cells) and MCF-7 (estrogen receptor positive breast cancer 
cells).  
 
Scheme 4.3: Synthesis of a cyclohexylphenylamide, 4.6. Reagents and conditions: a 
BnBr, NaH, DMF, 0 oC to rt, 12 h, 70%; b PCC, DCM, rt, 12 h, 50%; c N-Ph2Tf, LDA, 
THF, 55%; d Pd(dppf)Cl2, Cs2CO3, DMF, 100 oC, 12 h,30% ; e 30% TFA, DCM, rt, 12 
h, ~100%; f 12, EDCI•HCl, Et3N, DCM, 0 oC to rt, 12 h, 80%; g Pd(OH)2, H2, MeOH, 






 As shown in Table 4.1, compound 4.8a (anti) exhibited 4-fold greater anti-proliferative 
activity than the lead compound 4.3, and 10-15 fold better activity than 4.8b and 4.23, indicating 
the anti-stereochemistry is important for anti-proliferative activity.  Incorporation of a saturated 
ring into the A-position was detrimental, as compounds 4.6 and 4.7 were both inactive up to 
50μM, suggesting that planarity of the A-ring is important for anti-proliferative activity. 
 











  SKBr3 
    (IC50, µM)a 
        MCF-7 
(IC50, µM)a 
4.3 - 0.47 ± 0.06 0.71 ± 0.02 
4.8a 
 









Scheme 4.4: Synthesis of a cyclohexyl derivative. Reagents and conditions: a 
MsCl,Et3N, DCM, 0 oC to rt, 12 h, 90%; b NaN3, DMF, 100 oC, 12 h, 30%; c Pd/C, 
H2, MeOH, 12 h, ~100%; d 4.12a, DIPEA, DCM, 0 oC to rt, 12 h, 60%; e K2CO3, 






aValues represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
 
Preliminary SARs indicate that the phenyl A-ring is necessary for maintaining anti-
proliferative activity, while modifications to the B-ring could improve activity. Since no co-
crystal structure of Hsp90 bound to C-terminal inhibitors has been solved, there is limited 
knowledge about the size and nature of this binding pocket. Therefore, a library of analogues 
containing the phenyl A-ring attached to various appendages in lieu of the cyclohexyl B-ring was 
pursued to identify an optimal scaffold that could orient both side chains and maximize 
interactions for increased inhibitory activity. Recent studies have suggested that an optimal 
distance between 7.7 and 12.1 Å from the amine to the amide is important for Hsp90 inhibitory 
activity.27 Therefore, analogues containing five-, six- and seven-membered rings with varying 
distance and orientation of both the amine and amide were pursued.  Additionally all compounds 
were synthesized with either the open or closed chain amine, as the dimethyl-propylamine has 
been identified as a noviose surrogate.34 A three-dimensional overlay of the proposed analogs 
4.8b 
 
2.57 ± 0.08 2.43 ± 0.05 
4.23 
 
2.87 ± 0.13 
 







































compared to the phenyl cyclohexyl was performed in order to better understand how the 
geometry would change with the various saturated B rings (Figure 4.4).  The 3-D overlay study 
was carried out using the Forge Modeling Program, no bias was applied and 4.3 was used as the 
reference compound.  Compounds 4.38 and 4.44 overlaid most similarly to 4.3 and 4.8a and 
might be expected to bind similarly within the binding pocket and exhibit similar biological 
activity.  Interestingly, the amide moiety in 4.40 doesn’t overlay with 4.3 and 4.8a, and from 
previous analog development we know that amide positioning is critical for inhibitor activity.35-36 
This shift in the amide positioning may lead to decreased biological activity when compared to 





Lastly, analog 4.42 does not overly well with 4.3 and 4.8a and therefore might not be 
expected to exhibit similar biological activity as the cyclopentane ring is contorted out.  Once the 
modeling studies were complete, analogues containing five-, six- and seven-membered rings 
with varying distances and orientations of both the amine and amide were synthesized.  
Preparation of analogues (4.38 and 4.39) that contain a five-membered saturated ring is 
illustrated in Scheme 4.5. Synthesis began by a Heck coupling between aryl bromide 4.45 and 
cyclopent-2-enone to yield 4.46, which was subsequently reduced via palladium on carbon and 
hydrogen gas to afford cyclopentanone 4.47.37 Reduction of 4.47 with sodium borohydride gave 
 
Figure 4.4. Three-dimensional overlay of 4.3 (blue), 4.8a (red), and proposed 
analogs. A). Overlay with proposed analog 4.38 (green). B). Overlay with proposed 
analog 4.40 (green). C). Overlay with proposed analog 4.42 (pink). D). Overlay with 





an inseparable mixture of anti and syn diastereomers, 4.48, in a 7:3 ratio, respectively. The 
mixture of 4.48 was converted to the methanesulfonate ester, 4.49, before nucleophilic 
substitution with sodium azide to produce 4.50. Following reduction of the azide, the resulting 
amine was coupled with biaryl acid 4.15 to form the corresponding amide 4.52. Removal of the 
methoxymethyl-protecting group present in 4.52 provided the free phenol, 4.53. Mixture of 
diastereomers 4.53 was submitted to the KU Specialized Chemistry Center for separation.  
Unfortunately even with a chiral HPLC column the syn and anti were inseparable.  Mitsunobu 
etherification of the resulting phenol, 4.53, with 1-methyl-4-hdroxypiperdine (4.17a) finally 
furnished the desired product 4.38 and 4.39 in moderate yield.  
 
As shown in Scheme 4.6, synthesis of analogues that contain a seven-membered ring 
began via a Grignard coupling reaction of commercially available ester 4.54 with allyl 
 
Scheme 4.5: Synthesis of phenylcyclopentyl carboxamides. Reagents 
and conditions: a Cyclopent-2-en-1-one, Pd(OAc)2, triethanolamine; b 
Pd/C, H2, EtOAc, rt, 12 h, ~100%; c NaBH4, MeOH, 0 oC to rt, 12 h, 
90%; d MsCl, pyridine, DCM, 0 oC to rt, 12 h, 90%; e.  NaN3, DMF, 100 
oC, 12 h, 65%; f. 10% Pd/C, H2, EtOAc, rt, 12 h, ~100%; g Ar-COCl, 
DIPEA, DCM, 0 oC to rt, 12 h, 68%; h 6N HCl, MeOH, 0 oC to rt, 12 h, 





magnesium bromide to yield 4.55.38 Ring-closing metastasis using Grubbs first-generation 
catalyst, followed by removal of the hydroxyl group using triethylsilane provided the desired 
phenylcycloheptyl core, 4.57. Oxidation of alkene 4.57 with meta-chloroperoxybenzoic acid 
resulted in an inseparable mixture of epoxides 4.58a and 4.58b, in a 1:1 ratio.  Reduction of 
these epoxides with lithium aluminum hydride resulted in alcohol 4.59, which upon acid-
catalyzed cleavage of the methyl ether, provided 4.60. Next, 4.60 was converted to 
methanesulfonate ester 4.61 before nucleophilic substitution with sodium azide and then 
subsequently reduced to afford amine 4.62. Amide coupling of 4.62 with acid chloride 4.15 
produced 4.63, which after base-catalyzed deprotection of the methanesulfonate group gave the 
free phenol, 4.64. Again phenol 4.64 was submitted to the KU Specialized Chemistry Center for 
hopeful separation and again separation of syn and anti was unattainable.  Finally, Mitsunobu 
etherification of the resulting phenol with 1-methyl-4-hdroxypiperdine (4.17a and 4.17b) 







Compounds (4.42 and 4.44) that contain a methylene linker were envisioned to impart 
additional flexibility and explore potential binding interactions as a consequence of the flexible 
benzamide side chain. As shown in Scheme 4.7, construction of the phenylcyclopentyl methyl 
derivative (4.42 and 4.43) was accomplished by employing the methanesulfonate ester 4.49 as a 
key intermediate. Briefly, 4.49 was first converted to cyanide 4.65 via a nucleophilic substitution 
 
Scheme 4.6: Synthesis of phenylcycloheptyl carboxamides. Reagents and 
conditions: a AllylMgBr, THF, 70 oC, 12 h; b Grubbs I, DCM, rt, 12 h; c 
Et3SiH, TFA, DCM, 48 h, 60%; d mCPBA, NaHCO3, DCM,  0 oC, 12 h; e 
LAH, AlCl3, THF,  0 oC, 12 h; f BBr3, DCM,  0 oC, 12 h, 60%; g MsCl, 
pyridine, DCM, 0 oC to rt, 12 h, 90%; h i. NaN3, DMF, 100 oC, 12 h, 65%; ii. 
Pd/C, H2, EtOAc, rt, 12 h, 90%; i Ar-COCl, DIPEA, DCM, 0 oC to rt, 12 h, 
68%; j 6N HCl, MeOH, 0 oC to rt, 12 h, 90%; k amino alcohol, TMAD, PBu3, 





reaction with tetra-butylammonium cyanide and then reduced with lithium aluminum hydride to 
afford the free amine, 4.66.39-41 Amide coupling of the resulting amine with acid chloride 4.15 
gave the corresponding amide 4.67.  Acid-catalyzed deprotection of the methoxymethyl-
protecting group generated the free phenol, 4.68, which underwent Mitsunobu etherification to 
yield an inseparable mixture of anti and syn diastereomers of 4.42 and 4.43 in a 6:4 ratio 
respectively. 
 
As outlined in Scheme 4.8, the phenylcyclohexyl methyl derivatives (4.44a/b and 
4.45a/b) were assembled following the general strategy described earlier.  
 
Scheme 4.7: Synthesis of phenylcyclopentyl methyl carboxamide. Reagents 
and conditions: a (CH3CH2CH2CH2)4N(CN), DMF,  50 oC, 12 h, 60%; b Pd/C, 
H2, EtOAc, rt, 12 h, 90%; c Ar-COCl, DIPEA, DCM, 0 oC to rt, 12 h, 68%; d 
6N HCl, MeOH, 0 oC to rt, 12 h, 90%; e amino alcohol, TMAD, PBu3, 






Upon construction of the modified B-ring analogues, the compounds were evaluated for 
their anti-proliferative activity against both breast cancer cell lines as summarized in Table 4.2. 
In general, compounds containing other ring systems were less active than the lead compound 
4.8a, suggesting the 1,4-anti-cyclohexyl core is optimal. Incorporation of either a five- or seven-
membered ring system resulted in less potent analogues as evidenced by 4.38/4.39 and 4.40/4.41, 
which were 25-40 fold less active than 4.8a, highlighting the importance of orientation of the 
side chains for increased anti-proliferative activity. Inclusion of a methylene linker (4.42, 4.43, 
4.44a/b, and 4.45a/b, vs. 4.8a) did not improve activity, suggesting that flexibility is not 
necessary for maximal activity. Surprisingly, the stereochemistry of analogues 4.44a/b and 
 
Scheme 4.8: Synthesis of phenylcyclohexyl methyl carboxamides. Reagents 
and conditions: a MOMCl, DIPEA, DCM, 0 oC to rt, 12 h, 95%; b L-
selectride, THF,  -40 oC to rt, 12 h, 90%; c MsCl, pyridine, DCM, 0 oC to rt, 
12 h, 90%; d (CH3CH2CH2CH2)4N(CN), DMF,  50 oC, 12 h, 60%; e Pd/C, 
H2, EtOAc, rt, 12 h, 90%; f Ar-COCl, DIPEA, DCM, 0 oC to rt, 12 h, 68%; g 
6N HCl, MeOH, 0 oC to rt, 12 h, 90%; h amino alcohol, TMAD, PBu3, 





4.45a/b was not important for anti-proliferative activity, as both the syn and anti-diastereomers 
manifested similar activities.  Additionally, compounds with noviose replacement N,N-
dimethylaminopropoyl did not improve activity when compared to those analogs with N-
methylpiperidine.  
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aValues represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
 
Validation of Hsp90 inhibition via Western Blot Analysis. 
Western blot analyses were performed on MCF-7 cell lysates treated with six 
representative compounds (4.8a, 4.46, 4.38, 4.39, 4.40 and 4.41) to confirm these analogues 
manifest anti-proliferative activity via Hsp90 inhibition. As shown in Figure 4.5A, incubation 




treatment with compound 4.46 led to the degradation of Her-2, EGFR, ERα, and Akt, clearly 
linking cell viability to Hsp90 inhibition. In addition, treatment of MCF-7 cells with 4.38 and 
4.39 induced the degradation of the Hsp90-dependent client substrates c-Raf, and Akt (Figure 
4.5B). Unfortunately, compounds 4.40 and 4.41 did not result in any client protein degradation 
(Figure 4.5C).  The Hsp90-independent protein, actin remained unchanged, suggesting selective 
degradation of Hsp90-dependent client proteins.  In addition, Hsp90 levels remained constant, 
which is a hallmark shared by Hsp90 C-terminal inhibitors.  The 3-D overlay (Figure 4.4) 
supports the western blot data as compound 4.38 overlaid well with the parent compound 4.3, 
however 4.40 did not overlay well as the position of the amide moiety was different from the 
parent compound.  Clearly the size and geometry of the 7-membered ring affected the interaction 
of the compound with the C-terminal binding site, and resulted in 4.40 and 4.41 not targeting 











Figure 4.5. Western blot analyses of compounds after incubation with MCF-7 
breast cancer cells for 24 h. A). Western blot analyses of Hsp90-dependent client 
proteins (Her2, EGFR, ERα and Akt) degradation after treatment with 4.8a and 
4.46. B). Western blot analyses of Hsp90-dependent client proteins (CDK4, Akt, c-
Raf, and ERα) degradation after treatment with 4.38 and 4.39. C). Western blot 
analyses of Hsp90-dependent client proteins (CDK4 and Akt) degradation after 
treatment with 4.40 and 4.41. L represents a concentration 1/2 of the anti-
proliferative IC50 value, while H represents a concentration 5-fold of the anti-
proliferative IC50 value. Geldanamycin (G, 0.5 µM) and dimethylsulfoxide (D, 
100%) were employed as positive and negative controls, respectively.  Protein levels 






In summary, the biphenyl core was explored to identify an optimized scaffold for Hsp90 
C-terminal inhibition. These studies led to the development of phenyl cyclohexyl carboxamides 
that manifest sub-micromolar to mid-nanomolar anti-proliferative activity against breast cancer 
cell lines. Structural investigations suggest that the central core is important for projection of the 
amine and amide side chains as evidenced by increased anti-proliferative activity. Furthermore, 
SAR studies on these side chains indicate the phenyl cyclohexyl derivatives exhibit a different 
binding mode as compared to other scaffolds. Discovery of the phenyl cyclohexyl core provides 
a new platform on which the development of more efficacious Hsp90 C-terminal inhibitors can 
be explored.  
 
Materials and Methods 
Anti-proliferation assays.  
Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with 
non-essential amino acids, L-glutamine (2 mM), streptomycin (500 μg/mL), penicillin (100 
units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C, 
5% CO2), seeded (2000/well, 100 μL) in 96-well plates, and allowed to attach overnight. 
Compound or GDA at varying concentrations in DMSO (1% DMSO final concentration) was 
added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells was 
determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer’s 
instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were 
adjusted accordingly. IC50 values were calculated from separate experiments performed in 




Western Blot Analyses.  
MCF-7 cells were cultured as described above and treated with various concentrations of drug, 
GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were 
harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium 
orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min 
at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the 
manufacturer’s instructions. Equal amounts of protein (20 μg) were electrophoresed under 
reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 
peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and 
visualized. 
 
Chemistry General.  
1H NMR were recorded at 500 MHz (Avance AVIII 500 MHz spectrometer with a dual 
carbon/proton cryoprobe) or 400 (Bruker AVIIIHD 400 MHz NMR with a broadband X-channel 
detect gradient probe) and 13C NMR were recorded at 125 MHz (Bruker AVIII spectrometer 
equipped with a cryogenically cooled carbon observe probe).   Chemical shifts are reported in δ 
(ppm) relative to the internal standard (CDCl3, 7.26 ppm, or as stated). HRMS spectra were 
recorded with a LCT Premier with ESI ionization. 1H and 13C NMR was used to verify that all 
tested compounds were >95% pure. TLC analysis was performed on glass backed silica gel 






Synthesis and Compound Characterization 
 
4-(4-(Benzyloxy)phenyl)cyclohexan-1-one (4.10). 
A solution of phenol 4.9 (1.0 g, 5.26 mmol) in anhydrous acetone was cooled to 0 OC and 
potassium carbonate (1.46 g, 11.5 mmol) was added, followed by a dropwise addition of benzyl 
bromide (0.94 ml, 7.89 mmol). The reaction mixture was then allowed to stir at rt. After 12 h, the 
reaction mixture was concentrated and the residue purified by column chromatography (SiO2, 
1:5, EtOAc: hexane) to afford 4.10 as a white amorphous solid (1.4 g, 95%): 1H NMR (400 
MHz, Chloroform-d) δ 7.46 – 7.35 (m, 4H), 7.35 – 7.30 (m, 1H), 7.19 – 7.14 (m, 2H), 6.96 – 
6.91 (m, 2H), 5.05 (s, 2H), 3.03 – 2.90 (m, 1H), 2.53 – 2.45 (m, 4H), 2.25 – 2.13 (m, 2H), 1.99 – 
1.82 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 211.48, 157.58, 137.31, 137.19, 128.74, 128.11, 




4-(4-(Benzyloxy)phenyl)cyclohexan-1-one 4.10 (1g, 3.57 mmol) was dissolved in anhydrous 
tetrahydrofuran (10 ml) and the solution was cooled to -40 OC. L-selectride (1.0 M in THF, 4.29 
ml) was added dropwise to the solution and the reaction mixture was allowed to stir at rt for 12 h. 
The reaction mixture was concentrated and the residue was diluted with water. The suspension 
was acidified with 1N HCl and extracted with ethyl acetate. The organic layers were combined, 








hexane) to afford 4.11a as a white amorphous solid (920 mg, 92%): 1H NMR (400 MHz, 
Chloroform-d) δ 7.49 – 7.37 (m, 4H), 7.37 – 7.32 (m, 1H), 7.22 – 7.17 (m, 2H), 6.98 – 6.92 (m, 
2H), 5.06 (s, 2H), 4.14 (m, 1H), 2.52 (tt, J = 11.4, 2.9 Hz, 1H), 1.96 – 1.86 (m, 4H), 1.69 (tdd, J 
= 12.2, 5.4, 2.3 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 157.08, 139.96, 137.30, 128.63, 127.96, 




Sodium borohydride (202.4 mg, 5.35 mmol) was added to an ice-cooled solution of 4-(4-
(benzyloxy)phenyl)cyclohexan-1-one 4.10 (1g, 3.57 mmol) in methanol (10 ml) and the reaction 
mixture was allowed to stir at rt for 12 h. The reaction mixture was concentrated and the residue 
was diluted with water. The suspension was acidified with 1N HCl and extracted with ethyl 
acetate. The organic layers were combined, dried (over Na2SO4), concentrated and purified by 
column chromatography (SiO2, 1:4, EtOAc: hexane) to afford 4.11b as a white amorphous solid 
(900 mg, 90%): 1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.35 (m, 4H), 7.35 – 7.29 (m, 1H), 
7.14 – 7.08 (m, 2H), 6.93 – 6.87 (m, 2H), 5.04 (s, 2H), 3.67 (dd, J = 9.4, 5.5 Hz, 1H), 2.45 (td, J 
= 11.8, 3.5 Hz, 1H), 2.08 (d, J = 11.4 Hz, 2H), 1.91 (d, J = 12.7 Hz, 2H), 1.56 – 1.39 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 157.26, 139.13, 137.32, 128.71, 128.05, 127.78, 127.63, 114.80, 










(1s,4s)-4-(4-(Benzyloxy)phenyl)cyclohexyl methanesulfonate (4.12a). 
Triethylamine (0.28 ml, 2 mmol) was added to an ice-cooled solution of alcohol 4.11a (282.4 
mg, 1 mmol) in anhydrous THF (3 ml), followed by a dropwise addition of methanesulfonyl 
chloride (0.12 ml, 1.5 mmol). The reaction mixture was then allowed to stir at rt for 4 h. The 
reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were 
combined, dried (over Na2SO4), concentrated to yield 4.12a as a white amorphous solid (339 mg, 
94%) that was used in the next step without further purification. 
 
 
(1r,4r)-4-(4-(Benzyloxy)phenyl)cyclohexyl methanesulfonate (4.12b). 
Compound 4.12b was obtained following the procedure used for the synthesis of 4.12a, as a 
white amorphous solid (92%): 1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.35 (m, 4H), 7.35 – 
7.29 (m, 1H), 7.12 – 7.07 (m, 2H), 6.94 – 6.89 (m, 2H), 5.04 (s, 2H), 4.69 (td, J = 11.2, 5.5 Hz, 
1H), 3.03 (s, 3H), 2.53 – 2.42 (m, 1H), 2.27 (d, J = 11.9 Hz, 2H), 1.98 (d, J = 13.7 Hz, 2H), 1.72 
(qd, J = 12.4, 11.8, 3.5 Hz, 2H), 1.55 (qd, J = 13.4, 3.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 






A mixture of  methanesulfonate ester 4.12a (361 mg, 1.0 mmol) and sodium azide (195 mg, 








concentrated. The residue was diluted with water and extracted with ethyl acetate. The organic 
layers were combined, concentrated and purified by column chromatography (SiO2, 1:20, EtOAc 
: hexane) to afford 4.13a as a white amorphous solid (246 mg, 80%): 1H NMR (400 MHz, 
Chloroform-d) δ 7.53 – 7.30 (m, 5H), 7.21 – 7.08 (m, 2H), 6.97 (tt, J = 5.7, 3.1 Hz, 2H), 5.07 (s, 
2H), 3.36 (qt, J = 7.6, 3.4 Hz, 1H), 2.51 (ddd, J = 12.1, 7.7, 3.8 Hz, 1H), 2.23 – 2.07 (m, 2H), 
2.00 (d, J = 8.4 Hz, 2H), 1.93-1.85 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 157.29, 138.59, 





Compound 4.13b was obtained following the procedure used for the synthesis of 4.13a, as a 
white amorphous solid (85%): 1H NMR (400 MHz, Chloroform-d) δ 7.46 – 7.35 (m, 4H), 7.35 – 
7.30 (m, 1H), 7.17 – 7.12 (m, 2H), 6.95 – 6.90 (m, 2H), 5.03 (s, 2H), 3.95 (t, J = 3.1 Hz, 1H), 
2.54 – 2.43 (m, 1H), 2.01 – 1.94 (m, 2H), 1.82 – 1.62 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 





Palladium hydroxide (20% w/w, 20 mg) was added to a solution of 4.13a (225 mg, 0.73 
mmol) in MeOH/THF (3:1, 4 ml) and the resulting mixture was stirred under a hydrogen 








concentrated to get 4.14a as a white amorphous solid (140 mg, ~100%): 1H NMR (400 MHz, 
Chloroform-d) δ 6.98 (t, J = 8.0 Hz, 2H), 6.74 – 6.63 (m, 2H), 2.67 (tt, J = 11.2, 4.0 Hz, 1H), 
2.34 (tt, J = 12.1, 3.4 Hz, 1H), 1.97 – 1.58 (m, 4H), 1.48 – 1.10 (m, 4H). 13C NMR (126 MHz, 
CDCl3 + CD3OD) δ 154.79, 137.94, 127.60, 115.10, 50.04, 42.60, 34.75, 33.19. HRMS (ESI+) 




Compound 4.14b was obtained following the procedure used for the synthesis of 4.14a, as a 
white amorphous solid (~100%): 1H NMR (400 MHz, Chloroform-d) δ 7.06 (dd, J = 27.1, 8.2 
Hz, 2H), 6.73 (dd, J = 8.7, 2.4 Hz, 2H), 3.44 – 3.34 (m, 1H), 2.43 (d, J = 32.2 Hz, 1H), 2.18 (d, J 
= 17.1 Hz, 5H), 1.90 (d, J = 11.6 Hz, 1H), 1.86 – 1.60 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
154.80, 137.33, 127.97, 115.32, 46.69, 43.77, 29.50, 27.05. HRMS (ESI+) m/z: [M + H+] 





Triethylamine (0.11 ml, 0.79 mmol) was added to a solution of amine 4.14a (50mg, 0.26 
mmol) and acid 4.15 (81 mg, 0.32 mmol) in anhydrous dichloromethane (0.5 ml) and the 












the reaction mixture and the resulting solution was then allowed to stir at rt. After 12 h, the 
reaction mixture was concentrated; the residue was diluted with water, and extracted with ethyl 
acetate. The organic layers were combined, concentrated and purified by column 
chromatography (SiO2, 1:25, Acetone: DCM) to afford 4.16a as a white amorphous solid (56 mg, 
50%): 1H NMR (500 MHz, Chloroform-d) δ 7.82 (dd, J = 8.5, 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz, 
1H), 7.35 (t, J = 7.9 Hz, 1H), 7.10 (dt, J = 7.6, 1.2 Hz, 1H), 7.09 – 7.05 (m, 3H), 7.01 (d, J = 8.6 
Hz, 1H), 6.92 (ddd, J = 8.4, 2.7, 1.0 Hz, 1H), 6.83 – 6.79 (m, 2H), 5.94 (d, J = 8.1 Hz, 1H, NH), 
5.48 (s, 1H, OH), 4.03 (dtt, J = 12.7, 8.8, 4.4 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 2.45 (tt, J = 
12.1, 3.5 Hz, 1H), 2.19 (dd, J = 13.9, 3.4 Hz, 2H), 1.96 – 1.88 (m, 2H), 1.63 – 1.50 (m, 2H), 1.36 
(qd, J = 12.7, 3.4 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 166.52, 159.43, 159.10, 154.24, 
139.16, 138.73, 130.57, 129.41, 129.25, 128.36, 127.87, 127.19, 122.14, 115.50, 115.42, 112.94, 
111.02, 55.95, 55.48, 48.97, 42.73, 33.75, 33.34. HRMS (ESI+) m/z: [M + H+] calculated for 





Compound 4.16b was obtained following the procedure used for the synthesis of 4.16a, as an 
off-white amorphous solid (45%): 1H NMR (400 MHz, Chloroform-d) δ 8.30 (s, 1H, OH), 7.80 
(dd, J = 8.5, 2.4 Hz, 1H), 7.74 (d, J = 2.5 Hz, 1H), 7.33 (dd, J = 4.4, 2.9 Hz, 1H), 7.13 – 7.05 (m, 
4H), 7.01 (d, J = 8.6 Hz, 1H), 6.90 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 6.87 – 6.82 (m, 2H), 6.37 (d, J 










– 1.93 (m, 2H), 1.88 – 1.71 (m, 4H), 1.64 (qd, J = 14.4, 13.3, 4.8 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 166.49, 159.40, 159.01, 155.42, 139.13, 139.10, 130.60, 129.48, 129.22, 128.07, 
127.86, 127.56, 122.10, 116.06, 115.54, 112.94, 110.96, 55.92, 55.43, 45.64, 41.89, 30.28, 29.11. 






Diisopropylazodicarboxylate (23 µL, 0.12 mmol) was added to an ice-cooled solution of 
phenol 4.13a (25 mg, 0.06 mmol), N-methyl-4-hydroxy-piperidine (10.4 mg, 0.09 mmol) and 
triphenylphosphine (24 mg, 0.09 mmol) in anhydrous THF (0.25 mL) and resulting solution was 
then allowed to stir at room temperature for 12 hours. The reaction mixture was concentrated 
under reduced pressure and the residue was purified by column chromatography (SiO2, 
Methanol: CH2Cl2, 1:25) to afford a white amorphous solid (12 mg, 40%): 1H NMR (500 MHz, 
Chloroform-d) δ 7.81 (dd, J = 8.6, 2.3 Hz, 1H), 7.68 (d, J = 2.4 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 
7.15 – 7.08 (m, 3H), 7.07 (dd, J = 2.7, 1.6 Hz, 1H), 7.01 (d, J = 8.7 Hz, 1H), 6.91 (ddd, J = 8.3, 
2.6, 0.9 Hz, 1H), 6.87 – 6.81 (m, 2H), 5.93 (d, J = 8.1 Hz, NH), 4.45 – 4.35 (m, 1H), 4.03 (dtt, J 
= 16.4, 8.5, 4.3 Hz, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 2.94 – 2.80 (m, 2H), 2.75 – 2.56 (m, 2H), 
2.53 – 2.41 (m, 4H), 2.20 (ddd, J = 11.2, 7.8, 3.8 Hz, 4H), 1.95 (ddd, J = 14.6, 10.6, 5.9 Hz, 4H), 
1.62 (qd, J = 13.2, 3.3 Hz, 2H), 1.36 (qd, J = 12.6, 3.4 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 
166.33, 159.42, 159.02, 155.35, 139.54, 139.19, 130.52, 129.39, 129.23, 128.31, 127.93, 127.33, 

















Compound 4.8b was obtained following the procedure utilized for the synthesis of 4.8a, as a 
white amorphous solid (36%):1H NMR (400 MHz, Chloroform-d) δ 7.80 (dd, J = 8.5, 2.4 Hz, 
1H), 7.72 (d, J = 2.4 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.18 – 7.06 (m, 4H), 7.02 (d, J = 8.6 Hz, 
1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.87 – 6.81 (m, 2H), 6.27 (d, J = 7.2 Hz, NH), 4.43 – 
4.31 (m, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 2.81 (d, J = 9.3 Hz, 2H), 2.66 – 2.55 (m, 1H), 2.55 – 
2.35 (m, 5H), 2.11 (d, J = 10.1 Hz, 2H), 2.01 (dd, J = 13.2, 3.3 Hz, 2H), 1.96 – 1.73 (m, 4H), 
1.72 – 1.58 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 166.60, 159.51, 159.12, 155.53, 139.23, 
139.22, 130.71, 129.59, 129.32, 128.18, 127.97, 127.67, 122.21, 116.17, 115.56, 113.05, 111.07, 
77.48, 56.03, 55.54, 52.09, 45.75, 45.05, 42.00, 30.39, 29.92, 29.22. HRMS (ESI+) m/z: [M + 
H+] calculated for C33H41N2O4 529.3066; found 529.3066. 
 
 
















A mixture of  iodide 4.18 (200 mg, 0.65 mmol), tert-butyl piperidin-4-ylcarbamate  (194 mg, 
0.97 mmol), sodium tert-butoxide (93 mg, 0.97 mmol), 2-dicyclohexylphosphino-2′,4′,6′-
triisopropylbiphenyl (15.4 mg, 0.03 mmol) and tris(dibenzylideneacetone)dipalladium(29.3 mg, 
0.03 mmol) was suspended in toluene (2 mL) and the resulting mixture was purged with argon 
for 20 min before being heated at 130 OC for 1 h under microwave conditions. The reaction 
mixture was concentrated and the residue was purified by column chromatography (SiO2, 1:9, 
EtOAc : hexane) to afford 4.20 as a yellow amorphous solid (90 mg, 37%): 1H NMR (400 MHz, 
Chloroform-d) δ 7.44 – 7.34 (m, 4H), 7.32 (d, J = 7.1 Hz, 1H), 6.89 (s, 4H), 5.01 (s, 2H), 4.51 – 
4.42 (m, 1H), 3.58 (s, 1H), 3.44 (d, J = 12.3 Hz, 2H), 2.75 (t, J = 11.3 Hz, 2H), 2.04 (d, J = 12.6 
Hz, 2H), 1.55 (qd, J = 11.7, 3.8 Hz, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 156.68, 
146.20, 135.87, 130.26, 128.67, 127.99, 127.62, 118.89, 115.69, 77.36, 70.65, 50.32, 50.26, 




tert-Butyl (1-(4-hydroxyphenyl)piperidin-4-yl)carbamate (4.21). 
Palladium hydroxide (20% w/w, 20 mg) was added to a solution of 4.20 (85 mg, 0.22 mmol) 
in MeOH/THF (2:1, 3 ml) and the resulting mixture was stirred under a hydrogen atmosphere for 
12 h. The reaction mixture was filtrated through Celite and the filtrate was concentrated to get 
4.21 as a white amorphous solid (65 mg, ~100%): 1H NMR (400 MHz, Chloroform-d) δ 6.85 (d, 
J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 4.63 – 4.41 (m, 1H), 4.48 (s, 1H), 3.56 (s, 1H), 3.40 (d, 









2H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 151.47, 119.24, 115.95, 77.36, 50.52, 50.50, 




tert-Butyl (1-(4-((1-Methylpiperidin-4-yl)oxy)phenyl)piperidin-4-yl)carbamate (4.22). 
Diisopropylazodicarboxylate (85 µL, 0.43 mmol) was added to an ice-cooled solution of 
phenol 4.21 (63 mg, 0.21 mmol), N-methyl-4-hydroxy-piperidine (37 mg, 0.32 mmol) and 
triphenylphosphine (87 mg, 0.43 mmol) in anhydrous THF (0.20 mL) and the resulting solution 
was then allowed to stir at rt for 12 h. The reaction mixture was concentrated under reduced 
pressure and the residue was purified by column chromatography (SiO2, Methanol: CH2Cl2, 
1:25) to afford 4.22 as a brownish amorphous solid (42 mg, 50%): 1H NMR (400 MHz, 
Chloroform-d) δ 6.89 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 4.61 – 4.52 (m, 1H), 4.51 – 
4.41 (m, 1H), 3.58 (s, 1H, NH), 3.46 (d, J = 12.4 Hz, 2H), 3.39 – 3.16 (m, 4H), 2.76 (d, J = 4.8 
Hz, 5H), 2.67 – 2.50 (m, 2H), 2.19 (d, J = 15.2 Hz, 2H), 2.09 – 1.99 (m, 2H), 1.55 (qd, J = 11.7, 
3.8 Hz, 2H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 155.33, 149.87, 147.09, 118.84, 
117.17, 77.48, 77.36, 51.63, 50.05, 49.93, 44.00, 32.70, 28.57, 27.02. HRMS (ESI+) m/z: [M + 






















Trifluoroacetic acid (30% v/v in DCM, 0.27 mmol) was added to a solution of 4.22 (40 mg, 
0.11 mmol) in dichloromethane (0.5 ml) and the resulting solution was stirred at rt for 4 h. The 
reaction mixture was then neutralized with 7N-ammoniated methanol and concentrated to get 
amine, which was used in the next step without further purification.  
Triethylamine (0.05 ml, 0.33 mmol) was added to a solution of amine (0.11 mmol) and 
biaryl acid 4.15 (43 mg, 0.17 mmol) in dry dichloromethane (0.5 ml) and the solution was cooled 
to 0 OC.  At this temperature, EDCIHCl (33 mg, 0.17 mmol) was added to the reaction mixture 
and the resulting solution was then allowed to stir at rt for 16 h. The reaction mixture was 
concentrated and the residue was purified by column chromatography (SiO2, methanol:DCM, 
1:25) to afford 4.23 as  a white amorphous solid (29%); 1H NMR (400 MHz, Chloroform-d) δ 
7.80 (d, J = 8.7 Hz, 1H), 7.67 (d, J = 2.2 Hz, 1H), 7.35 (t, J = 8.1 Hz, 1H), 7.13 – 7.03 (m, 2H), 
7.01 (d, J = 8.7 Hz, 1H), 6.91 (d, J = 8.7 Hz, 3H), 6.83 (d, J = 8.7 Hz, 1H), 5.95 (d, J = 7.9 Hz, 
1H), 4.49 – 4.41 (m, 1H), 4.18 – 4.05 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 3.56 – 3.48 (m, 2H), 
3.12 – 2.91 (m, 4H), 2.86 (t, J = 11.7 Hz, 2H), 2.62 (s, 3H), 2.48 – 2.30 (m, 3H), 2.19 – 2.02 (m, 
4H), 1.67 (q, J = 11.6, 11.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 166.49, 159.48, 159.20, 
146.76, 141.72, 139.14, 130.69, 129.44, 129.26, 128.29, 127.09, 122.13, 118.83, 117.30, 115.57, 
112.94, 111.06, 77.36, 55.96, 55.49, 53.56, 50.08, 47.10, 44.68, 32.50, 28.29. HRMS (ESI+) 









Sodium hydride (0.480g, 20mmol) was added to an ice-cooled solution of cyclohexane-1,4-
diol (1.16g, 10mmol) in anhydrous DMF (25mL), followed by a dropwise addition of benzyl 
bromide (1.43mL,  12.5mmol).  The reaction mixture was allowed to stir at rt for 12 h. The 
reaction mixture was quenched with brine and 1M HCl, and extracted with EtOAc. The organic 
layers were combined, dried, concentrated and purified via column chromatography (SiO2, 1:1 
EtOAc:Hex) to afford 4.25 as a white amorphous solid (70% yield): 1H NMR (500 MHz, 
Chloroform-d) δ 7.27 (d, J = 4.4 Hz, 3H), 7.19 (s, 2H), 4.47 (s, 2H), 3.64 (tt, J = 9.5, 4.1 Hz, 
1H), 3.32 (tt, J = 9.7, 4.0 Hz, 1H), 2.04 – 1.96 (m, 2H), 1.92 (dddt, J = 10.3, 6.1, 2.8, 1.5 Hz, 
2H), 1.51 – 1.42 (m, 3H), 1.41 – 1.18 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 138.94, 128.37 
(2Cs), 127.49 (2Cs), 127.45, 86.21, 70.17, 69.70, 32.71 (2Cs), 29.32 (2Cs). HRMS (ESI+) m/z: 




Pyridinium chlorochromate (1.4g, 6.49mmol) and 4A molecular sieves (1.4g) were added to a 
solution of 4.25 (0.89g, 4.32mmol) in anhydrous DCM (40mL) and the reaction mixture was 
stirred at rt for 12 h.  The reaction was concentrated and the residue was purified via column 
chromatography (SiO2, 1:1 EtOH:Hex) to yield 4.26 as a white amorphous solid product (50% 
yield): 1H NMR (500 MHz, Chloroform-d) δ 7.32 – 7.29 (m, 4H), 4.54 (s, 2H), 3.76 (tt, J = 5.7, 
2.9 Hz, 1H), 2.56 (dddd, J = 15.2, 10.7, 5.2, 1.2 Hz, 2H), 2.24 – 2.18 (m, 2H), 2.09 (dtdd, J = 
11.7, 5.9, 4.4, 1.2 Hz, 2H), 1.96 – 1.84 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 211.30, 138.49, 








4-(Benzyloxy)cyclohex-1-en-1-yl trifluoromethanesulfonate (4.27). 
Freshly prepared LDA (1.18 mmol) was taken in a 25 ml 2-neck round flask and cooled to -
78oC. A solution of ketone 4.26 (0.20 g, 0.98 mmol) in anhydrous THF (2 ml) was added 
dropwise to the flask and the reaction mixture was stirred for 15 min at the same temperature. A 
solution of N-bisphenyltriflate (385 mg, 1.08 mmol) in THF (1 mL) was added and the reaction 
mixture was then allowed to stir at rt for 90 minutes. The reaction was quenched with saturated 
NH4Cl, diluted with water, and extracted with EtOAc (3x 15mL). The organic layers were 
combined, dried, and concentrated to obtain 4.27 as white amorphous solid (185 mg, 55%) that 
was used in the next step without further purification. 
 
 
tert-Butyl (4'-(benzyloxy)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-4-yl)carbamate (4.29). 
A mixture of  triflate 4.27 (160 mg, 0.48 mmol), 4-boc-aminophenyl boronic acid 4.28 (170 
mg, 0.71 mmol), cesium carbonate (310 mg, 0.95 mmol) and 
tetrakis(triphenylphosphine)palladium (10 mg, 0.14 mmol) was suspended in anhydrous DMF (4 
mL) was purged with argon for 20 min before heating at 100 OC for 12 h. The reaction mixture 
was cooled to rt; diluted with saturated LiCl and extracted with EtOAc (3x 15mL). The organic 
layers were combined, dried, concentrated and the residue purified by column chromatography 
(SiO2, 1:3, EtOAc : hexane) to afford 4.29 as a solid (30%): 1H NMR (400 MHz, Chloroform-d) 
δ 7.45 – 7.34 (m, 4H), 7.32 – 7.25 (m, 5H), 6.48 (s, 1H), 5.97 (dt, J = 5.0, 1.6 Hz, 1H), 4.65 (d, J 








2.35 – 2.24 (m, 1H), 2.13 (dtd, J = 9.8, 4.7, 2.4 Hz, 1H), 1.86 (dtd, J = 12.6, 9.5, 5.5 Hz, 1H), 
1.53 (d, J = 4.7 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 172.18, 138.80, 136.84, 135.74, 134.31, 
129.65 (2C), 128.51, 127.80, 127.67, 127.31, 125.61, 123.50 (2C), 118.66, 80.95, 73.63, 70.13, 
32.25, 29.82, 28.71, 28.42, 28.18, 26.07. HRMS (ESI+) m/z: [M + Na+] calculated for 




4.29 (0.1g, 0.36 mmol) was dissolved in anhydrous DCM (1 mL) and the solution was cooled 
to 0oC. Trifluoroacetic Acid (30% wt./vol, 0.5 mL) was added to the solution and the reaction 
mixture was allowed stir at rt for 3 h.  The reaction was concentrated and the crude product 
(~100%) was used directly in the next step without further purification: HRMS (ESI+) m/z: [M + 





Thionyl chloride (0.13 ml, 0.75 mmol) was added to a solution of biaryl acid 4.15 (97 mg, 
0.38 mmol) in anhydrous tetrahydrofuran (2 ml) and the solution was refluxed for 3h. The 
solution was then concentrated under vacuum to get acid chloride 4.15a (105 mg) as brown 












DIPEA (0.13 ml, 0.75 mmol) was added to an ice-cooled solution of acid chloride in 
anhydrous DCM (1 ml), followed by a dropwise addition of amine 4.30 (50 mg, 0.25 mmol).  
The solution was then allowed to stir at rt for 12h. The reaction mixture was concentrated and the 
residue was purified by column chromatography (SiO2, 1:25, Acetone: DCM) to afford 4.31 as a 
white amorphous solid (80%): 1H NMR (400 MHz, Chloroform-d) δ 7.87 (s, 1H), 7.82 (dd, J = 
8.6, 2.4 Hz, 1H), 7.74 (d, J = 2.4 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 7.37 – 7.21 (m, 8H), 7.07 – 
6.95 (m, 2H), 6.85 – 6.77 (m, 1H), 5.92 (td, J = 3.6, 1.9 Hz, 1H), 4.56 – 4.51 (m, 2H), 3.78 (d, J 
= 12.4 Hz, 6H), 3.73 – 3.64 (m, 1H), 2.56 – 2.46 (m, 2H), 2.43 – 2.33 (m, 1H), 2.26 – 2.17 (m, 
1H), 2.08 – 1.98 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 169.56, 158.32 (2Cs), 143.69, 139.09, 
137.23 (2Cs), 133.03, 130.41, 129.62, 128.74(2Cs), 128.36 (2Cs), 127.93 (2Cs), 127.69 (2Cs), 
127.55, 124.68, 121.09 (2Cs), 119.08, 118.75, 115.84 (2Cs), 114.07, 79.86, 68.98, 55.25(2Cs), 






Palladium on carbon (10% w/w, 20 mg) was added to a solution of 4.31 (223 mg, 1.0 mmol) 
in MeOH (3 ml) and the suspension was stirred at rt under a hydrogen atmosphere. After 12 h, 
the reaction mixture was filtrated through Celite and the filtrate was concentrated to get 4.32 as 
an off-white amorphous solid (~100%): 1H NMR (500 MHz, Chloroform-d) δ 7.85 (d, J = 8.0 










7.9, 4.3, 3.4 Hz, 1H), 7.21 – 7.16 (m, 2H), 7.12 (d, J = 8.5 Hz, 1H), 7.03 – 6.98 (m, 1H), 6.93 (d, 
J = 8.7 Hz, 1H), 6.83 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.07 – 4.04 (m, 1H), 3.78 (d, J = 1.1 Hz, 
3H), 3.75 (s, 3H), 2.48 – 2.35 (m, 1H), 2.03 – 1.98 (m, 2H), 1.83 – 1.73 (m, 3H), 1.63 – 1.53 (m, 
3H). 13C NMR (126 MHz, CDCl3) δ 165.38, 159.16 (2Cs), 143.55, 138.68, 135.60, 130.49, 
129.45, 129.33, 128.99, 128.27, 127.20, 126.95, 123.33, 121.84, 120.44, 115.16, 112.81, 110.91, 
65.65, 55.68, 55.18, 43.04, 32.76 (2Cs), 27.61 (2Cs). HRMS (ESI+) m/z: [M + H+] calculated for 





Compound 4.6 was obtained following the procedure utilized for the synthesis of 4.8a, as a 
white amorphous solid (25%): 1H NMR (500 MHz, Chloroform-d) δ 7.96 (dd, J = 8.6, 2.4 Hz, 
1H), 7.71 – 7.65 (m, 2H), 7.58 – 7.51 (m, 2H), 7.36 (dd, J = 8.5, 0.6 Hz, 4H), 7.24 (d, J = 8.5 Hz, 
1H), 7.05 (s, 1H), 6.92 – 6.82 (m, 1H), 4.14 (q, J = 3.3 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.06 – 
2.99 (m, 1H), 2.56 – 2.50 (m, 2H), 1.94 – 1.85 (m, 2H), 1.68 (d, J = 5.8 Hz, 3H), 1.56 (d, J = 
14.6 Hz, 4H), 1.25 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 158.54, 157.04, 142.56, 136.40, 
134.80, 128.99, 128.54, 128.11, 126.37, 124.26, 119.25, 115.67, 113.83, 109.88, 64.61, 54.92, 
54.56, 42.24, 31.97, 28.68, 26.73. HRMS (ESI+) m/z: [M + H+] calculated for C33H40N2O4 













4'-Hydroxy-[1,1'-bi(cyclohexan)]-4-yl methanesulfonate (4.34). 
Triethylamine (0.140 mL, 1.009 mmol) was added to a solution of [1,1'-bi(cyclohexane)]-4,4'-
diol (0.1g, 0.505mmol) in anhydrous DCM (2.5mL) and the solution was cooled to 0 oC. 
Methanesulfonyl chloride (0.07mL, 0.909 mmol) was added dropwise and the reaction mixture 
was then allowed to stir at rt.  After 12 h, water was added to quench the reaction and the 
suspension was extracted using EtOAc (3 x 20mL). The organic layers was combined, dried and 
concentrated to yield 4.34 as an amorphous solid (90%) that was used directly in the next step: 




Compound 4.35 was obtained as a white amorphous solid (30%) by following the general 
procedure D: 1H NMR (500 MHz, Chloroform-d) δ 5.69 – 5.63 (m, 1H), 4.03 – 3.97 (m, 1H), 
3.82 (t, J = 3.6 Hz, 1H), 2.06 – 1.97 (m, 1H), 1.88 – 1.79 (m, 4H), 1.78 – 1.70 (m, 2H), 1.58 – 
1.45 (m, 4H), 1.47 – 0.97 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 71.14, 57.82, 41.59 (2Cs), 
35.77 (2Cs), 32.67, 31.89, 29.69, 28.07, 24.55, 23.81. HRMS (ESI+) m/z: [M + Na+] calculated 













Palladium on carbon (10% w/w, 20 mg) was added to a solution of 4.35 (223 mg, 1.0 mmol) 
in MeOH (3 ml) and the resulting mixture was stirred at rt under a hydrogen atmosphere. After 
12 h, the reaction mixture was filtrated through Celite and the filtrate was concentrated to get 
4.36 as a white amorphous solid (~100%): 1H NMR (500 MHz, Chloroform-d) δ 5.67 – 5.64 (m, 
2H), 3.99 (q, J = 3.6 Hz, 1H), 3.53 (tt, J = 10.9, 4.2 Hz, 1H), 3.09 – 3.00 (m, 1H), 2.07 – 1.94 
(m, 2H), 1.85 – 1.69 (m, 2H), 1.65 – 1.38 (m, 10H), 1.30 – 1.15 (m, 4H), 1.15 – 0.94 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 70.18, 52.54, 42.34 (2Cs), 35.98 (2Cs), 32.82 (2Cs), 28.55 (2Cs), 





Compound 4.37 was obtained following the procedure used for the synthesis of 4.31, as an 
off-white amorphous solid (60%): 1H NMR (500 MHz, Chloroform-d) δ 7.78 (dd, J = 8.6, 2.4 
Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.16 – 7.06 (m, 2H), 7.01 (d, J = 8.6 
Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.11 (d, J = 7.5 Hz, 1H), 4.24 (dt, J = 8.1, 4.2 Hz, 
1H), 3.85 (d, J = 5.2 Hz, 6H), 3.54 (ddd, J = 11.0, 6.6, 4.3 Hz, 1H), 2.03 – 1.95 (m, 1H), 1.87 – 
1.75 (m, 4H), 1.63 (dt, J = 12.2, 3.5 Hz, 3H), 1.60 – 1.47 (m, 1H), 1.34 – 1.11 (m, 6H), 1.08 – 
0.94 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 165.19, 158.24, 157.81, 138.00, 129.39, 128.24, 










(2Cs), 28.77 (2Cs), 27.29 (2Cs), 24.35 (2Cs). HRMS (ESI+) m/z: [M + Na+] calculated for 





Compound 4.7 was obtained following the procedure utilized for the synthesis of 4.8a, as a 
white amorphous solid (25%): 1H NMR (500 MHz, Chloroform-d) δ 7.78 (dd, J = 8.6, 2.4 Hz, 
1H), 7.67 (d, J = 2.4 Hz, 2H), 7.35 (t, J = 7.9 Hz, 2H), 7.16 – 7.06 (m, 4H), 7.01 (d, J = 8.6 Hz, 
1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.11 (d, J = 7.5 Hz, 1H), 4.24 (dt, J = 8.1, 4.2 Hz, 1H), 
3.85 (d, J = 5.2 Hz, 6H), 3.54 (ddd, J = 11.0, 6.6, 4.3 Hz, 1H), 2.03 – 1.95 (m, 1H), 1.87 – 1.75 
(m, 8H), 1.63 (dt, J = 12.2, 3.5 Hz, 3H), 1.60 – 1.47 (m, 2H), 1.34 – 1.11 (m, 12H), 1.08 – 0.94 
(m, 4H). 13C NMR (126 MHz, CDCl3) δ 165.19, 158.24, 157.81, 138.00, 129.39, 128.24, 128.06, 
126.96, 120.97, 114.34, 111.73, 109.80, 76.24, 70.03, 54.76, 54.29, 34.67, 28.77, 27.29, 24.35. 




DIPEA (30mL, 173.4mmol) was added to a solution of 4-bromophenol (10g, 57.8mmol) in 
anhydrous DCM (289mL) and the solution was cooled to 0 oC.  Chloromethyl methyl ether 













h.  The reaction mixture was quenched with water; extracted with DCM (3x 80mL). The organic 
layers was combined, dried, concentrated, and purified via column chromatography (SiO2, 1:4, 
EtOAc: Hex). The product was isolated as oil in 48% yield: 1H NMR (500 MHz, Chloroform-d) 
δ 7.38 (d, J = 9.0 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 5.14 (s, 2H), 3.47 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 156.44, 132.44 (2Cs), 118.19 (2Cs), 114.32, 94.60, 56.18. HRMS (ESI+) m/z: 




1-bromo-4-(methoxymethoxy)benzene 4.45 (1.2g, 5.53mmol), 2-Cyclopenten-1-one (0.23mL, 
2.76mmol), and Pd(OAc)2 (0.06g, 0.276mmol) were suspended in anhydrous toluene (10 ml)  
and the suspension was stirred at rt for 15 minutes.  Triethanolamine (11mL) was added and the 
mixture was heated at 110oC. After 12 h, the reaction mixture was cooled to rt and extracted with 
ether (3 x 50mL).  The organic layers were combined, dried, concentrated and purified via 
column chromatography (SiO2, 1:3, EtOAc: Hex). Compound was isolated was a yellow oil, 
75%yield: 1H NMR (500 MHz, Chloroform-d) δ 7.51 (d, J = 8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 
2H), 6.38 (t, J = 1.7 Hz, 1H), 5.13 (s, 2H), 3.39 (s, 3H), 2.93 – 2.87 (m, 2H), 2.48 – 2.42 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 209.65, 159.85, 153.92, 130.22, 128.74, 127.81, 125.89, 
116.49 (2Cs), 94.27, 56.39, 35.41, 28.79. HRMS (ESI+) m/z: [M + H+] calculated for C13H14O3 








± 3-(4-(Methoxymethoxy)phenyl)cyclopentanone (4.47). 
10% Pd/C (0.015g) was added to the solution of 4.46 (0.05g) in EtOAc  (2 mL) and the 
suspension was stirred under a hydrogen atmosphere. After 12 h, the reaction mixture was 
filtered through a pad of Celite; the residue was washed with EtOAc.  The filtrate was 
concentrated and purified by column chromatography (SiO2, 1:3, EtOAc: Hex) to yield 4.47 as 
an oil (60% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.14 (d, J = 8.7 Hz, 2H), 6.99 (d, J = 
8.7 Hz, 2H), 5.12 (s, 2H), 3.43 (s, 3H), 3.36 – 3.26 (m, 1H), 2.63 – 2.53 (m, 1H), 2.43 – 2.32 (m, 
2H), 2.29 – 2.18 (m, 2H), 1.94 – 1.85 (m, 1H).13C NMR (126 MHz, CDCl3) δ 210.05, 155.94, 




NaBH4 (0.001 g, 0,227mmol) was added to an ice-cooled solution of 4.47 (0.05g, 0.227mmol) 
in MeOH (0.5mL) and the reaction mixture was then allowed to stir at rt. After 1 h, the reaction 
mixture was concentrated; the residue was diluted with water and extracted with ethyl acetate (3 
x10 mL). The combined organic layers were dried, concentrated, and purified via column 
chromatography (SiO2, 1:3, EtOAc: Hex) to yield a mixture of diastereomers.  The product was 
isolated as a clear oil, 90% yield: 1H NMR (500 MHz, Chloroform-d) δ 7.12 (d, J = 8.6 Hz, 2H), 
6.97 (d, J = 8.7 Hz, 2H), 5.15 (s, 2H), 3.68 (tt, J = 10.5, 4.3 Hz, 1H), 3.48 (s, 3H), 2.45 (tt, J = 








– 1.48 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 155.36, 139.91, 127.55 (2Cs), 116.04 (2Cs), 
94.45, 70.54, 55.85,  51.53, 42.47, 35.84, 32.50, 27.80. 
 
 
3-(4-(Methoxymethoxy)phenyl)cyclopentyl methanesulfonate (4.49). 
Triethylamine (0.1 mL, 0.68 mmol) was added to a solution of 4.48 (75 mg, 0.34 mmol) in 
anhydrous THF (0.5 mL) and the solution was cooled to 0oC.  Methanesulfonyl chloride (0.039 
mL, 0.51 mmol) was added dropwise and the reaction mixture was allowed to stir at rt for 1 h.  
The mixture was quenched by the addition of water, and extracted with EtOAc (3 x 15mL).  The 
combined organic layers were dried, and concentrated to get 4.49 (90%) was used as such 




Sodium Azide (0.026g, 0.41 mmol) was added to a solution of 4.49 (60 mg, 0.21 mmol) in 
anhydrous DMF (0.84 mL) and the reaction mixture was heated at 100 OC. After 12 h, the 
reaction mixture was cooled to rt and diluted with water. The mixture was worked up with 
saturated LiCl and EtOAc (3 x 30mL).  The combined organic layers were dried and purified via 
column chromatography, (SiO2, 1:4, EtOAc: Hex).    The product was isolated in 85% yield: 1H 
NMR (500 MHz, Chloroform-d) δ 7.21 – 7.07 (m, 2H), 6.98 (dd, J = 8.8, 2.6 Hz, 2H), 5.16 (d, J 








Hz, 3H), 3.24 (tt, J = 10.4, 7.4 Hz, 1H), 3.03 (tt, J = 10.3, 7.7 Hz, 1H), 2.48 – 2.39 (m, 1H), 2.27 
– 2.11 (m, 2H), 2.10 – 1.93 (m, 1H), 1.93 – 1.74 (m, 1H), 1.73 – 1.57 (m, 2H). 13C NMR (126 





Compound 4.51 was obtained as a mixture of diastereomers (71%) by following the 
procedure for 4.32. 1H NMR (500 MHz, Chloroform-d) δ 7.19 – 7.11 (m, 4H), 6.96 (ddd, J = 
8.6, 2.0, 0.9 Hz, 4H), 5.15 (d, J = 1.1 Hz, 4H), 3.47 (d, J = 1.0 Hz, 6H), 3.43 – 3.37 (m, 1H), 
3.34 – 3.27 (m, 1H), 3.22 (t, J = 8.4 Hz, 1H), 2.98 (ddd, J = 11.3, 5.4, 2.8 Hz, 1H), 2.41 – 2.33 
(m, 2H), 2.21 – 2.10 (m, 2H), 2.04 (td, J = 5.0, 3.2 Hz, 1H), 1.99 – 1.84 (m, 2H), 1.82 – 1.54 (m, 
4H), 1.52 – 1.38 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 155.40, 138.85, 127.94 (2Cs), 116.16 
(2Cs), 94.53, 55.90, 52.29, 43.04, 42.56, 34.48, 32.63. HRMS (ESI+) m/z: [M + H+] calculated 














DIPEA (0.35 mL, 2.0 mmol) was added to a solution of 3-(4-(methoxymethoxy) 
phenyl)cyclopentanamine 4.51 (0.3g, 1.0 mmol), biaryl acid 4.15 (0.31g, 1.2mmol), and HOBt-
H2O (0.382g, 2.0mmol) in anhydrous DCM (10 mL) and the solution was cooled to 0 OC. 
EDCIHCl (0.382 g, 2.0 mmol) was added to the reaction mixture and the resulting solution was 
then allowed to stir at rt. After 12 h, the reaction mixture was concentrated; the residue was 
diluted with water, and extracted with DCM (3x 40mL). The organic layers were combined, 
concentrated and purified by column chromatography (SiO2, 1:4 EtOAc:Hex) to afford 4.52 as a 
white amorphous solid (80%): 1H NMR (500 MHz, Chloroform-d) δ 7.89 – 7.76 (m, 2H), 7.31 
(td, J = 7.9, 2.0 Hz, 1H), 7.15 – 7.05 (m, 4H), 6.99 – 6.92 (m, 3H), 6.91 – 6.87 (m, 1H), 6.82 – 
6.74 (m, 1H), 5.13 (d, J = 6.2 Hz, 2H), 4.54 (dt, J = 7.5, 2.0 Hz, 1H), 3.85 – 3.75 (m, 6H), 3.46 
(d, J = 4.1 Hz, 3H), 2.26 – 2.18 (m, 1H), 2.18 – 2.13 (m, 1H), 2.09 – 2.02 (m, 3H), 1.75 – 1.55 
(m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.15, 159.18, 158.75, 155.40, 139.01, 138.50, 130.18, 
129.51, 128.98, 128.25, 127.84, 127.78, 125.06, 121.95, 116.14 (2Cs), 115.28, 112.66, 110.70, 
94.45, 55.85, 55.65, 55.18, 51.04, 42.94, 41.65, 33.64, 32.22. HRMS (ESI+) m/z: [M + H+] 





6N HCl (1mL/1g starting material, 0.2mL) was added to a solution of 4.52 (158 mg, 0.34 








the reaction mixture was stirred at rt for 12 h. The reaction mixture was concentrated under 
reduced pressure to get 4.53 as a mixture of diastereomers, white solid (60%): 1H NMR (500 
MHz, Chloroform-d) δ 7.83 (dd, J = 8.6, 2.4 Hz, 1H), 7.79 (dd, J = 8.6, 2.4 Hz, 1H), 7.70 (d, J = 
2.4 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H), 7.33 (td, J = 7.9, 2.6 Hz, 2H), 7.11 – 7.01 (m, 7H), 6.98 
(dd, J = 8.7, 7.6 Hz, 2H), 6.90 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 6.81 (dd, J = 8.5, 6.1 Hz, 6H), 6.34 
(d, J = 7.2 Hz, 1H), 6.31 (d, J = 7.5 Hz, 1H), 4.66 – 4.58 (m, 1H), 4.53 (q, J = 7.7, 7.1 Hz, 1H), 
3.84 (s, 6H), 3.83 (s, 6H), 3.17 (p, J = 8.8 Hz, 1H), 3.11 – 2.99 (m, 1H), 2.53 (dt, J = 13.1, 6.8 
Hz, 1H), 2.40 – 2.33 (m, 2H), 2.30 – 2.22 (m, 1H), 2.19 – 1.96 (m, 4H), 1.82 – 1.66 (m, 2H), 
1.66 – 1.52 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 167.11, 167.00, 159.29, 159.09, 154.64, 
154.55, 138.96 (2Cs), 136.53, 136.29, 130.48, 130.40, 129.34, 129.32, 129.12, 129.09, 128.35, 
128.32, 127.88, 127.84, 126.71, 126.66, 122.12, 122.02, 115.41(2Cs), 115.37 (2Cs), 112.86 
(2Cs), 112.75 (2Cs), 110.99 (2Cs), 55.81 (2Cs), 55.79 (2Cs), 55.34 (2Cs), 42.04 (2Cs), 41.40 
(2Cs), 33.84, 33.60, 32.74, 31.93. HRMS (ESI+) m/z: [M + Na+] calculated for C26H27NO4Na 





A solution of 4.53 (0.025g, 0.06mmol) and N-Methyl-4-piperidinol (0.014mL, 0.12mmol) in 
anhydrous benzene (0.6 mL) was cooled to 0oC.  Tributylphosphine (0.03mL, 012mmol) and 









for 12 h.  After 12 h the reaction was cooled to rt and purified via column chromatography (SiO2, 
1:20 MeOH:DCM) to afford 4.38 as white amorphous solid (27%): 1H NMR (500 MHz, 
Chloroform-d) δ 7.82 (dd, J = 8.6, 2.4 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.35 (td, J = 7.9, 2.9 
Hz, 1H), 7.15 (dd, J = 8.3, 5.9 Hz, 2H), 7.11 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.07 (dd, J = 2.6, 1.5 
Hz, 1H), 7.01 (dd, J = 8.6, 5.4 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.84 (d, J = 8.6 Hz, 
2H), 6.08 (d, J = 7.1 Hz, 1H), 4.64 (td, J = 7.1, 4.5 Hz, 1H), 4.56 (q, J = 8.0 Hz, 1H), 4.35 (s, 
2H), 3.86 (d, J = 1.8 Hz, 3H), 3.85 (d, J = 1.8 Hz, 3H), 3.25 – 3.15 (m, 1H), 3.14 – 3.06 (m, 2H), 
2.79 (s, 3H), 2.40 (td, J = 6.3, 4.9, 2.7 Hz, 4H), 2.26 – 2.16 (m, 1H), 2.15 – 1.99 (m, 2H), 1.91 (s, 
2H), 1.80 – 1.51 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 166.89, 159.68, 159.31, 155.84, 
139.43, 137.96, 130.80, 129.62, 129.51, 129.51, 128.60, 128.39, 128.30, 127.43, 122.39, 116.42 
(2Cs), 115.77, 113.17, 111.26, 56.19 (2Cs), 55.74, 51.49, 43.32, 41.84, 34.34, 33.96, 32.58 






A solution of 4.53 (0.025g, 0.06mmol) and 3-dimethylamino-1-propanol (0.014mL, 
0.12mmol) in anhydrous benzene (0.6 mL) was cooled to 0oC.  Tributylphosphine (0.03mL, 
012mmol) and TMAD (0.021g, 0.12mmol) were added to the mixture. The reaction mixture was 









chromatography (SiO2, 1:20 MeOH:DCM) to afford 4.39 as white amorphous solid (29%):1H 
NMR (500 MHz, Chloroform-d) δ 7.82 (dd, J = 8.6, 2.4 Hz, 1H), 7.67 (d, J = 2.4 Hz, 1H), 7.35 
(t, J = 7.9 Hz, 1H), 7.16 – 7.04 (m, 4H), 7.01 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 8.2, 2.6, 1.0 Hz, 
1H), 6.83 (d, J = 8.7 Hz, 2H), 6.08 (d, J = 7.2 Hz, 1H), 4.64 (td, J = 7.1, 4.4 Hz, 1H), 4.00 (t, J = 
6.3 Hz, 2H), 3.86 (d, J = 5.9 Hz, 6H), 3.20 (t, J = 8.2 Hz, 1H), 2.56 (m, 2H), 2.34 (s, 6H), 2.23 – 
2.16 (m, 1H), 2.12 (ddd, J = 13.7, 9.7, 8.0 Hz, 1H), 2.08 – 1.97 (m, 4H), 1.78 – 1.51 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.63, 159.43, 159.04, 157.34, 139.18, 137.28, 130.54, 129.38, 
129.25, 128.34, 128.00, 127.20, 122.14, 115.51 (2Cs), 114.53, 112.93, 111.00, 66.14, 56.49, 
55.94, 55.48, 51.26, 45.26 (2Cs), 43.08, 41.60, 34.11, 33.76, 29.85. HRMS (ESI+) m/z: [M + H+] 




Magnesium turnings (1.46 g, 60.2 mmol) were suspended in anhydrous THF (12 mL) in a 3-
neck flask. 4-Bromo-1-butene (1.02 mL of total 3.08 mL, 9.84 mmol) in anhydrous THF (7.5 
mL) was added dropwise and the mixture was heated at reflux while the remaining bromide 
(2.06 mL, 20.29 mmol) was added. The reaction mixture was refluxed until all of the magnesium 
had reacted, approximately 2h. The mixture was then cooled to rt and methyl 4-methoxybenzoate 
(1.0 g, 6.02 mmol) in anhydrous THF (12 mL) was added dropwise over 30min. The reaction 
was stirred overnight at rt. After 12 h the reaction was quenched with saturated NH4Cl (15mL), 
and the emulsion was stirred for 2h.  The mixture was then extracted with ether (3 x 50 mL), 






was isolated as a colorless oil, 84% yield: 1H NMR (500 MHz, Chloroform-d) δ 7.29 – 7.27 (m, 
2H), 6.88 (d, J = 8.8 Hz, 2H), 5.84 – 5.73 (m, 2H), 4.97 (d, J = 1.7 Hz, 1H), 4.94 – 4.87 (m, 3H), 
3.81 (s, 3H), 2.08 – 1.99 (m, 2H), 1.97 – 1.80 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 158.23, 





Grubbs 1st generation catalyst (0.2g, 0.04mol%) was added to a solution of 4.55 (1.5 g, 6.09 
mmol) and  the reaction mixture was heated at 40oC for 12 h.  The reaction mixture was 
concentrated and purified by column chromatography (SiO2, 1:10 EtOAc:Hex) to yield 4.56 as a 
white solid (54%): 1H NMR (500 MHz, Chloroform-d) δ 7.13 – 7.07 (m, 2H), 6.83 (d, J = 8.7 
Hz, 2H), 5.91 – 5.85 (m, 2H), 3.79 (s, 3H), 2.69 (tt, J = 11.2, 3.2 Hz, 1H), 2.34 – 2.24 (m, 1H), 
2.22 – 2.13 (m, 2H), 1.86 (dddd, J = 11.8, 5.2, 2.8, 1.2 Hz, 1H), 1.56 (s, 1H), 1.48 (dtd, J = 13.5, 
11.4, 2.2 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 157.97, 141.89, 132.87 (2Cs), 127.93 (2Cs), 




Et3SiH (0.257 mL, 1.61 mmol) was added to a solution of 1-(4-methoxyphenyl)cyclohept-4-







acid (1.12 mL, 14.7 mmol) and  the solution was stirred at rt for 48h.  The reaction mixture was 
concentrated and purified via column chromatography (SiO2, 1:20 EtOAc:Hex) to yield 4.57 as a 
clear oil (50% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.14 – 7.07 (m, 2H), 6.83 (d, J = 8.7 
Hz, 2H), 5.91 – 5.86 (m, 2H), 3.79 (s, 3H), 2.69 (tt, J = 11.2, 3.2 Hz, 1H), 2.34 – 2.24 (m, 2H), 
2.17 (ddt, J = 14.4, 11.5, 1.9 Hz, 2H), 1.86 (dddd, J = 11.7, 5.1, 3.3, 1.8 Hz, 1H), 1.48 (dtd, J = 
13.5, 11.4, 2.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 157.72, 141.63, 132.62 (2Cs), 127.68 
(2Cs), 113.81(2Cs), 55.38, 49.57, 35.05 (2Cs), 28.04 (2Cs). HRMS (ESI+) m/z: [M + Na+] 




A solution of 4.57 (0.25g, 1.24mmol) in anhydrous DCM (8.5mL) was added dropwise to an 
ice-cooled solution of m-CPBA (0.36g, 2.10mmol) in anhydrous DCM (5mL). NaHCO3 (0.26g, 
3.1mmol) was added and the reaction was stirred at rt for 12 h. The reaction mixture was 
extracted with DCM (3 x 30mL) and saturated NaHCO3. The organic layers were collected, 
dried, concentrated, and purified via column chromatography (SiO2, 1:5 EtOAc:Hex) to yield a 
mixture of diastereomers 4.58 (89% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.13 – 7.03 
(m, 4H), 6.87 – 6.77 (m, 4H), 3.79 (s, 3H), 3.78 (s, 3H), 3.20 – 3.15 (m, 1H), 3.13 – 3.06 (m, 
1H), 2.55 (tt, J = 11.5, 3.3 Hz, 4H), 2.41 – 2.29 (m, 2H), 2.16 – 2.10 (m, 2H), 1.92 – 1.56 (m, 
10H), 1.50 – 1.39 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 158.19, 157.98, 141.64, 140.27, 
127.94 (2Cs), 127.64 (2Cs), 114.18 (2 Cs), 114.09 (2Cs), 56.49 (4 Cs), 55.64, 55.48, 49.61, 








Lithium aluminum hydride (0.12 g, 2.97 mmol) was added to a solution of (1R,7S)-4-(4-
methoxyphenyl)-8-oxabicyclo[5.1.0]octane 4.58 (0.20 g, 0.99 mmol) was dissolved in anhydrous 
THF (20 mL), followed by addition of AlCl3 (0.05 mL, 0.99 mmol) and the mixture was stirred at 
rt.  After 12 h, 30 drops of water were added, followed by 6mL of 3M NaOH and 20mL of water.  
The reaction mixture was stirred for one hour and then filtered through a pad of Celite.  The 
filtrate was concentrated and purified via column chromatography (SiO2, 1:3 EtOAc:Hex) to 
yield 4.59 as mixture of diastereomers, white solid (60% yield): 1H NMR (500 MHz, 
Chloroform-d) δ 7.10 (dd, J = 10.0, 7.9 Hz, 4H), 6.83 (dt, J = 8.7, 1.5 Hz, 4H), 4.07 – 4.00 (m, 
1H), 3.98 – 3.91 (m, 1H), 3.78 (d, J = 0.8 Hz, 6H), 2.67 (tdd, J = 7.2, 4.8, 1.6 Hz, 1H), 2.60 (ddd, 
J = 8.6, 6.9, 4.3 Hz, 1H), 2.10 (dddt, J = 9.8, 7.3, 4.1, 1.5 Hz, 2H), 2.00 – 1.87 (m, 4H), 1.86 – 
1.78 (m, 4H), 1.80 – 1.65 (m, 4H), 1.65 – 1.45 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 157.70 
(2Cs), 141.61, 141.47, 127.63 (2Cs), 113.84 (2Cs), 72.90, 71.76, 55.39 (2Cs), 46.35, 46.09, 




4.59 (0.75g, 3.41 mmol) was dissolved in anhydrous DCM (340mL) and the solution was 








the solution was stirred at same temperature for ~30minutes before warming to rt over 2 h. The 
mixture was quenched with water and extracted with DCM (3 x 70mL). The combined organic 
layers were dried and concentrated to yield a mixture of diastereomers 4.60 as white solid (46% 
yield): 1H NMR (500 MHz, Chloroform-d) δ 7.08 – 7.05 (m, 2H), 7.04 – 7.01 (m, 2H), 6.81 – 
6.70 (m, 4H), 4.78 – 4.68 (m, 2H), 4.52 (dtd, J = 9.5, 5.3, 4.4 Hz, 1H), 4.38 (ddt, J = 10.6, 7.2, 
4.8 Hz, 1H), 2.72 (tdd, J = 10.5, 5.1, 3.5 Hz, 1H), 2.68 – 2.61 (m, 1H), 2.53 – 2.45 (m, 2H), 2.45 
– 2.38 (m, 2H), 2.38 – 2.28 (m, 2H), 2.16 – 2.07 (m, 2H), 2.03 – 1.91 (m, 2H), 1.90 – 1.68 (m, 
8H), 1.68 – 1.53 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 153.94, 153.93, 141.45, 141.32, 128.10 
(2Cs), 115.56 (2Cs), 70.90, 56.36, 56.00, 46.15, 45.71, 39.79, 39.59, 38.17, 37.95, 36.75, 34.60, 
31.65, 25.61, 23.91, 21.49. HRMS (ESI+) m/z: [M + H+] calculated for C13H18O2 207.1385; 
found 207. 1410. 
 
 
4-(4-((Methylsulfonyl)oxy)cycloheptyl)phenyl methanesulfonate (4.61). 
Compound 4.61 was obtained as a brown amorphous solid (90% yield) by following the 
procedure used for the synthesis of 4.12a: 1H NMR (400 MHz, Chloroform-d) δ 7.20 (s, 3H), 
7.16 (s, 1H), 7.14 (s, 1H), 7.13 (d, J = 0.6 Hz, 3H), 4.47 (dq, J = 9.6, 4.9 Hz, 1H), 4.36 – 4.28 
(m, 1H), 3.08 (s, 6H), 3.06 (d, J = 1.4 Hz, 6H), 2.79 – 2.71 (m, 1H), 2.65 (dq, J = 10.0, 5.1, 4.3 
Hz, 1H), 2.48 – 2.41 (m, 2H), 2.38 – 2.10 (m, 4H), 2.10 – 1.98 (m, 4H), 1.97 – 1.88 (m, 2H), 
1.87 – 1.63 (m, 4H), 1.62 – 1.47 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 149.78, 147.87, 139.12 
(2Cs), 128.16 (4Cs), 121.95 (4Cs), 55.52, 55.09, 45.91 (2Cs), 39.73 (2Cs), 37.27, 36.10, 33.89, 







4-(4-Azidocycloheptyl)phenyl methanesulfonate (4.62a). 
Compound 4.62a was obtained as a white amorphous solid (40% yield) by following the 
procedure used for the synthesis of 4.13a: 1H NMR (500 MHz, Chloroform-d) δ 6.99 (dd, J = 
8.7, 6.6 Hz, 4H), 6.76 – 6.69 (m, 4H), 3.66 (s, 6H), 3.65 – 3.60 (m, 1H), 3.51 (ddt, J = 10.1, 7.4, 
4.7 Hz, 1H), 2.60 – 2.47 (m, 2H), 2.06 – 1.96 (m, 2H), 1.90 – 1.67 (m, 9H), 1.64 – 1.42 (m, 9H). 
13C NMR (126 MHz, CDCl3) δ 157.70 (2Cs), 140.93, 140.81, 127.46 (4Cs), 113.76 (4Cs), 62.45, 




4-(4-Aminocycloheptyl)phenyl methanesulfonate (4.62). 
Compound 4.62 was obtained as a white amorphous solid (85% yield) by following the 
procedure used for the synthesis of 4.32. The amine was used immediately after synthesis: 1H 
NMR (400 MHz, Methanol-d4) δ 6.84 (q, J = 8.8 Hz, 4H), 3.74 (q, J = 7.1 Hz, 1H), 3.08 – 2.94 
(m, 2H), 2.78 (d, J = 2.3 Hz, 3H), 2.33 (ddd, J = 12.2, 8.0, 3.3 Hz, 1H), 2.28 – 2.13 (m, 2H), 1.89 
– 1.78 (m, 2H), 1.66 – 1.05 (m, 6H). HRMS (ESI+) m/z: [M + H+] calculated for C14H21NO3S 












Compound 4.63 was obtained as a white amorphous solid (90% yield) by following the 
procedure used for the synthesis of 4.16a: 1H NMR (500 MHz, Chloroform-d) δ 7.82 (ddd, J = 
8.6, 3.6, 2.3 Hz, 2H), 7.74 (t, J = 2.6 Hz, 2H), 7.35 – 7.28 (m, 2H), 7.20 – 7.12 (m, 8H), 7.12 – 
7.04 (m, 4H), 6.97 (d, J = 8.7 Hz, 2H), 6.88 (ddt, J = 8.3, 2.4, 1.1 Hz, 2H), 6.46 (d, J = 7.8 Hz, 
1H), 6.40 (d, J = 7.9 Hz, 1H), 4.31 – 4.26 (m, 1H), 4.21 (ddt, J = 8.9, 4.5, 2.5 Hz, 1H), 3.83 – 
3.82 (m, 6H), 3.81 (d, J = 1.7 Hz, 6H), 3.08 (s, 3H), 3.07 (s, 3H), 2.72 (ddd, J = 14.6, 7.2, 3.6 
Hz, 1H), 2.69 – 2.64 (m, 1H), 2.16 (dt, J = 7.2, 4.0 Hz, 2H), 2.09 – 1.95 (m, 4H), 1.92 – 1.79 (m, 
4H), 1.79 – 1.47 (m, 7H). 13C NMR (126 MHz, CDCl3) δ 171.19 (2Cs), 159.25 (2Cs), 158.84 
(2Cs), 148.38, 148.24, 139.05 (2Cs), 130.26 (2Cs), 129.43 (2Cs), 129.07 (2Cs), 128.25, 128.13 
(2Cs), 127.19 (2Cs), 122.00 (2Cs), 121.85 (2Cs), 115.39 (2Cs), 115.37 (2Cs), 112.71 (2Cs), 
112.68 (2Cs), 55.77 (2Cs), 55.29 (2Cs), 50.91, 49.98, 46.67, 45.74, 37.91, 37.12, 36.08, 35.44, 
34.78, 34.34, 33.13, 32.83, 30.93, 24.95, 22.67, 21.06. HRMS (ESI+) m/z: [M + Na+] calculated 




















3.2N NaOH (0.05 mL, 1.15 mmol) was added to a solution of 4.63 (0.20 g, 0.38 mmol) in 
ethanol (3 mL) and the solution was refluxed for 3 h. The reaction mixture was cooled to rt and 
concentrated under vacuum. The residue was neutralized with 1N HCl and extracted with EtOAc 
(3 x 10mL). The organic layers were collected, dried and concentrated to get 4.64 as a white 
solid (60% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.81 (dd, J = 8.6, 2.4 Hz, 1H), 7.67 (d, J 
= 2.3 Hz, 1H), 7.35 (t, J = 7.9 Hz, 2H), 7.12 – 6.99 (m, 7H), 6.91 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 
6.77 (dd, J = 8.4, 6.1 Hz, 2H), 6.03 (dd, J = 13.2, 7.9 Hz, 1H), 4.31 (s, 1H), 4.25 (dt, J = 10.9, 
4.4 Hz, 1H), 3.86 (d, J = 4.8 Hz, 8H), 2.73 – 2.59 (m, 1H), 2.25 – 2.16 (m, 1H), 2.15 – 1.96 (m, 
1H), 1.96 – 1.76 (m, 3H), 1.76 – 1.62 (m, 2H), 1.55 (qd, J = 11.4, 3.5 Hz, 1H). 13C NMR (126 
MHz, CDCl3) δ 165.81 (2Cs), 159.71 (2Cs), 159.31 (2Cs), 154.13 (2Cs), 139.45 (2Cs), 130.85 
(2Cs), 129.62 (2Cs), 129.50 (2Cs), 128.58 (2Cs), 128.07 (2Cs), 128.05 (2Cs), 122.42 (2Cs), 
122.41 (2Cs), 115.79, 115.77, 115.60, 115.58, 113.22 (2Cs), 113.20 (2Cs), 111.31 (2Cs), 51.42, 
50.40, 46.92, 45.79, 38.49, 36.70, 35.35, 35.01, 33.93, 33.38, 31.71, 30.11, 25.32, 23.17. HRMS 















 Compound 4.40 was obtained following the procedure utilized for the synthesis of 4.38, as a 
white amorphous solid (32%): 1H NMR (500 MHz Chloroform-d) δ 7.81 (ddd, J = 8.6, 2.4, 1.3 
Hz, 2H), 7.67 (d, J = 2.4 Hz, 2H), 7.34 (t, J = 7.9 Hz, 2H), 7.14 – 7.04 (m, 8H), 7.00 (d, J = 8.6 
Hz, 2H), 6.91 (ddd, J = 8.3, 2.6, 0.9 Hz, 2H), 6.81 (dd, J = 8.7, 2.5 Hz, 4H), 6.09 (dd, J = 15.4, 
8.0 Hz, 2H), 4.43 – 4.38 (m, 2H), 4.33 – 4.27 (m, 1H), 4.27 – 4.20 (m, 1H), 3.85 (s, 6H), 3.84 (s, 
6H), 2.94 – 2.85 (m, 5H), 2.75 – 2.61 (m, 6H), 2.53 – 2.48 (m, 4H), 2.22 – 2.15 (m, 7H), 2.08 
(qd, J = 11.2, 9.8, 6.2 Hz, 1H), 2.04 – 1.92 (m, 5H), 1.92 – 1.85 (m, 2H), 1.82 – 1.76 (m, 1H), 
1.75 – 1.62 (m, 4H), 1.54 (dddd, J = 13.7, 10.9, 8.9, 2.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
165.96, 159.38, 158.96, 155.00, 141.94, 139.15, 130.46, 129.36, 129.20, 128.26 (2Cs), 127.82, 
127.35, 122.10, 116.03 (2Cs), 115.46, 112.87, 110.95, 55.90, 55.44, 51.04, 50.08, 46.60, 45.56, 
45.32, 38.22, 36.44, 34.65, 33.48, 33.06, 25.02, 22.84. HRMS (ESI+) m/z: [M + H+] calculated 





Compound 4.41 was obtained following the procedure utilized for the synthesis of 4.39, as a 
yellow amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 7.80 (ddd, J = 8.5, 2.4, 1.2 
Hz, 2H), 7.70 (d, J = 2.3 Hz, 2H), 7.32 (t, J = 7.9 Hz, 2H), 7.11 – 7.03 (m, 8H), 6.98 (d, J = 8.6 
Hz, 2H), 6.89 (ddd, J = 8.3, 2.6, 1.0 Hz, 2H), 6.79 (dd, J = 8.7, 2.6 Hz, 4H), 6.22 (dd, J = 15.2, 











3.83 (d, J = 4.8 Hz, 12H), 2.94 (d, J = 3.7 Hz, 2H), 2.73 (td, J = 7.7, 3.6 Hz, 4H), 2.69 – 2.58 (m, 
4H), 2.46 (d, J = 2.5 Hz, 12H), 2.22 – 2.13 (m, 1H), 2.12 – 2.04 (m, 6H), 2.01 – 1.96 (m, 1H), 
1.93 – 1.73 (m, 4H), 1.73 – 1.61 (m, 4H), 1.57 – 1.47 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
165.88, 159.27, 158.83, 156.70, 141.51, 139.06, 130.31, 129.35, 129.09, 128.17 (2Cs), 127.55, 
127.29, 122.01, 115.34 (2Cs), 114.31, 112.78, 110.83, 65.55, 56.24, 55.79, 55.33, 50.96, 46.48, 
45.48, 44.56, 38.18, 36.41, 35.63, 34.91, 34.53, 33.40, 31.24, 26.44, 24.91, 22.75. HRMS (ESI+) 




Tetrabutylammonium cyanide was added to a solution of mesylate 4.49 (0.10g, 0.33 mmol) in 
anhydrous DMF (0.6 mL) and the solution was heated at 85oC. After 12 h, the reaction was 
cooled to rt; diluted with water and extracted with EtOAc (3 x 10mL).  The organic layers were 
combined, dried, concentrated, and purified via column chromatography (SiO2, 1:4, EtOAc: 
Hex) to afford 4.65 as an oil (55% yield): 1H NMR (500 MHz, Chloroform-d) δ 7.16 – 7.09 (m, 
2H), 7.00 – 6.95 (m, 2H), 5.14 (d, J = 1.5 Hz, 2H), 3.46 (d, J = 1.0 Hz, 3H), 3.30 – 3.21 (m, 2H), 
3.04 – 2.97 (m, 1H), 2.39 – 2.32 (m, 1H), 2.30 – 2.20 (m, 1H), 2.14 (ddt, J = 6.9, 5.0, 1.8 Hz, 
1H), 2.08 – 1.87 (m, 1H), 1.70 – 1.59 (m, 1H), 1.42 (q, J = 7.4 Hz, 1H). 13C NMR (126 MHz, 










A solution of 4.65 (0.60g, 2.45mmol) in anhydrous THF (4mL) was added to an ice-cooled 
suspension of Lithium Aluminum Hydride (0.48 g, 12.24 mmol) in anhydrous THF (4 mL) and 
the reaction mixture was allowed to stir at rt for 3 h. The reaction was quenched by sequential 
addition of 3M NaOH, water, and EtOAc.  The emulsion was stirred for one hour and then 
filtered through Celite. The filtrate was concentrated and purified via column chromatography 
(SiO2, 1:20, MeOH: DCM) to yield 4.66 as a white solid (88% yield): 1H NMR (500 MHz, 
Chloroform-d) δ 7.15 – 7.07 (m, 2H), 6.99 – 6.92 (m, 2H), 5.22 – 5.08 (m, 2H), 3.47 (d, J = 1.3 
Hz, 2H), 3.46 (d, J = 0.7 Hz, 3H), 3.12 – 2.96 (m, 1H), 2.89 – 2.76 (m, 1H), 2.12 – 2.01 (m, 1H), 
1.82 (ddd, J = 8.9, 6.8, 3.5 Hz, 1H), 1.71 – 1.56 (m, 1H), 1.46 – 1.20 (m, 3H). 13C NMR (126 
MHz, CDCl3) δ 154.43, 138.05, 127.02, 126.80, 115.13, 115.09, 93.52, 54.89, 44.02, 41.17, 





DIPEA (0.11mL, 0.596mmol) was added to a mixture of 4.66 (0.07g, 0.298mmol), biaryl acid 
4.15 (0.09g, 0.357mmol), and HOBt (0.114g, 0.596mmol) in anhydrous DCM (3 mL) and the 
suspension was cooled to 0 OC. EDCI (0.114g, 0.6 mmol) was added and the reaction mixture 











(3 x 15mL).  The organic layers were combined, dried, concentrated, and purified by column 
chromatography (SiO2, 1:4, EtOAc: Hex) to yield 4.67 as a white foam (80% yield): 1H NMR 
(500 MHz, Chloroform-d) δ 7.83 (ddd, J = 11.2, 8.5, 2.4 Hz, 1H), 7.76 (t, J = 2.4 Hz, 1H), 7.32 
(td, J = 7.9, 2.2 Hz, 1H), 7.16 – 7.05 (m, 4H), 6.96 (ddd, J = 8.6, 3.6, 2.4 Hz, 3H), 6.89 (dtd, J = 
8.2, 2.4, 0.9 Hz, 1H), 6.59 (d, J = 7.3 Hz, 1H), 5.15 (s, 1H), 5.14 (s, 1H), 4.62 (q, J = 6.3 Hz, 
1H), 4.54 (qd, J = 8.7, 7.9, 2.0 Hz, 1H, minor), 3.83 (d, J = 1.1 Hz, 3H), 3.82 (d, J = 1.7 Hz, 3H), 
3.47 (s, 2H), 3.46 (s, 1H minor), 3.11-3.00 (m, 1H), 2.53 (dt, J = 12.9, 6.7 Hz, 1H minor), 2.41 – 
2.29 (m, 1H), 2.26 – 2.11 (m, 1H), 2.09 – 2.04 (m, 1H), 1.81 – 1.69 (m, 1H), 1.68 – 1.53 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 166.65, 159.27, 158.85, 155.50, 139.08, 138.54, 130.30, 
129.50, 128.30, 128.24, 127.86, 127.13, 125.07, 122.03, 116.23 (2 Cs), 115.37, 112.76, 110.80, 
94.55, 55.95, 55.76, 55.30, 43.21, 41.34, 33.81, 33.70, 32.68, 32.28, 21.08. HRMS (ESI+) m/z: 





PTSA (360 mg, 1.89 mmol) was added to a solution 4.67 (300 mg, 0.63 mmol) was dissolved 
in MeOH (3 mL) and the reaction mixture was stirred at rt for 12 h.  The reaction mixture was 
concentrated; the residue was diluted with saturated ammonium chloride and extracted with 
EtOAc (3x30mL).  The organic layers were combined, dried, concentrated, and purified via 
column chromatography (SiO2, 1:20, MeOH: DCM) to give 4.68 as a white solid (60% yield): 1H 









7.33 (t, J = 7.9 Hz, 1H), 7.11 – 7.01 (m, 4H), 6.99 (dd, J = 8.6, 0.9 Hz, 1H), 6.90 (ddd, J = 8.2, 
2.6, 0.9 Hz, 1H), 6.80 – 6.75 (m, 2H), 6.26 (q, J = 6.0 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.54 – 
3.45 (m, 1H), 3.40 (ddd, J = 13.1, 7.2, 5.6 Hz, 1H), 3.12 – 3.02 (m, 1H), 2.97 (td, J = 10.8, 5.4 
Hz, 1H), 2.47 – 2.38 (m, 1H), 2.37 – 2.28 (m, 1H), 2.26 – 2.15 (m, 1H), 2.13 – 1.97 (m, 1H), 
1.94 – 1.73 (m, 2H), 1.72 – 1.47 (m, 1H), 1.42 – 1.36 (m, 1H), 1.34 – 1.22 (m, 1H). 13C NMR 
(126 MHz, CDCl3) δ 167.41, 159.28, 159.05, 154.23, 138.95, 137.37, 130.52, 129.36, 129.10, 
128.18, 127.96, 127.91, 126.83, 122.00, 115.32, 115.22, 115.20, 112.89, 110.95, 55.80, 55.33, 
45.39, 43.55, 39.86, 34.76, 33.29, 30.69, 29.47. HRMS (ESI+) m/z: [M + H+] calculated for 




Compound 4.42 was obtained following the procedure utilized for the synthesis of 4.38, as a 
white amorphous solid (33%): 1H NMR (500 MHz, Chloroform-d) δ 7.79 (ddd, J = 8.5, 3.8, 2.4 
Hz, 1H), 7.69 (d, J = 2.3 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.17 – 7.04 (m, 4H), 7.00 (dd, J = 8.7, 0.9 
Hz, 1H), 6.90 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.79 (dd, J = 8.8, 1.0 Hz, 2H), 6.18 – 6.11 (m, 1H), 
4.02 (t, J = 5.9 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.48 – 3.40 (m, 1H), 3.15 – 3.05 (m, 1H), 2.91 
(d, J = 8.0 Hz, 2H), 2.61 (s, 3H), 2.48 – 2.36 (m, 1H), 2.24 – 2.15 (m, 4H), 2.15 – 2.01 (m, 2H), 
1.94 – 1.76 (m, 2H), 1.72 – 1.49 (m, 2H), 1.47 – 1.23 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
167.03, 159.28, 158.92, 156.63, 139.00, 130.44, 129.33, 129.11, 127.99, 127.08, 121.99, 115.32, 









34.77, 33.32, 30.75, 29.52, 25.76. HRMS (ESI+) m/z: [M + H+] calculated for C33H40N2O4 





Compound 4.43 was obtained following the procedure utilized for the synthesis of 4.39, as a 
yellow amorphous solid (27%): 1H NMR (500 MHz, Chloroform-d) δ 7.79 (ddd, J = 8.5, 3.8, 2.4 
Hz, 1H), 7.69 (d, J = 2.3 Hz, 1H), 7.36 – 7.31 (m, 1H), 7.17 – 7.04 (m, 4H), 7.00 (dd, J = 8.7, 0.9 
Hz, 1H), 6.90 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.79 (dd, J = 8.8, 1.0 Hz, 2H), 6.18 – 6.11 (m, 1H), 
4.02 (t, J = 5.9 Hz, 2H), 3.85 (s, 3H), 3.84 (s, 3H), 3.48 – 3.40 (m, 1H), 3.15 – 3.05 (m, 1H), 2.91 
(d, J = 8.0 Hz, 2H), 2.61 (s, 6H), 2.48 – 2.36 (m, 1H), 2.24 – 2.15 (m, 2H), 2.15 – 2.01 (m, 1H), 
1.94 – 1.76 (m, 1H), 1.72 – 1.49 (m, 1H), 1.47 – 1.23 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
167.03, 159.28, 158.92, 156.63, 139.00, 130.44, 129.33, 129.11, 127.99, 127.08, 121.99, 115.32, 
114.22, 112.82, 110.85, 65.22, 56.16, 55.80, 55.34, 45.26, 44.02, 43.59, 39.72, 39.01, 38.25, 
34.77, 33.32, 30.75, 29.52, 25.76. HRMS (ESI+) m/z: [M + H+] calculated for C32H40N2O4 















DIPEA (13.7 mL, 78.95 mmol) was added to a solution of 4-(4-
hydroxyphenyl)cyclohexanone (10 g, 52.63 mmol) in anhydrous DCM (500 mL), and the 
mixture was cooled to 0oC.  MOMCl was added dropwise (11.2mL, 157.89 mmol) and the 
solution was allowed to stir at rt. After 12 h, the reaction mixture was quenched by water and 
extracted with DCM.  The organic layers were combined, dried, concentrated, and purified via 
column chromatography (SiO2, 1:4, EtOAc: Hex) to afford 4.69 as a white solid (65% yield): 1H 
NMR (500 MHz, Chloroform-d) δ 7.16 (d, J = 8.6 Hz, 2H), 7.00 – 6.96 (m, 2H), 5.15 (d, J = 1.9 
Hz, 2H), 3.48 (d, J = 1.6 Hz, 3H), 2.56 – 2.42 (m, 1H), 2.11 – 2.05 (m, 2H), 1.94 – 1.83 (m, 2H), 
1.71 – 1.61 (m, 2H), 1.54 – 1.31 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 211.13, 158.94, 




Compound 4.70a was obtained as an oil (70% yield) by following the procedure used for the 
synthesis of 4.11a: 1H NMR (500 MHz, Chloroform-d) δ 7.15 – 7.09 (m, 2H), 6.97 (d, J = 8.7 
Hz, 2H), 5.15 (s, 2H), 3.73 – 3.62 (m, 1H), 3.48 (s, 3H), 2.45 (tt, J = 11.9, 3.4 Hz, 1H), 2.13 – 
2.06 (m, 2H), 1.94 – 1.84 (m, 2H), 1.52 – 1.35 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 155.49, 











Compound 4.70b was obtained as an oil (85% yield) by following the procedure used for the 
synthesis of 4.11b: 1H NMR (500 MHz, Chloroform-d) δ 7.12 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 
8.7 Hz, 2H), 5.15 (s, 2H), 3.68 (tt, J = 10.5, 4.3 Hz, 1H), 3.48 (d, J = 1.6 Hz, 3H), 2.45 (tt, J = 
12.0, 3.6 Hz, 1H), 2.13 – 2.05 (m, 2H), 1.94 – 1.87 (m, 2H), 1.56 – 1.47 (m, 2H), 1.47 – 1.35 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 155.87, 140.42, 128.05 (2Cs), 116.55 (2Cs), 94.95, 71.05, 
56.35, 42.98, 36.35 (2Cs), 33.44 (2Cs).  
 
 
(1s,4s)-4-(4-(Methoxymethoxy)phenyl)cyclohexyl methanesulfonate (4.71a). 
Compound 4.71a was obtained as an oil (85 % yield) by following the procedure used for the 
synthesis of 4.12a and used directly in the next step. 
 
 
(1r,4r)-4-(4-(Methoxymethoxy)phenyl)cyclohexyl methanesulfonate (4.71b). 
Compound 4.71b was obtained as a white solid (85 % yield) by following the procedure used 













Compound 4.72a was obtained as a light yellow oil (45%) by following the procedure used 
for the synthesis of 4.65: 1H NMR (500 MHz, Chloroform-d) δ 7.15 (d, J = 8.6 Hz, 2H), 7.01 – 
6.96 (m, 2H), 5.16 (s, 2H), 3.48 (s, 3H), 3.06 – 2.97 (m, 1H), 2.48 (tt, J = 11.5, 4.0 Hz, 1H), 2.15 
– 2.07 (m, 2H), 1.93 – 1.76 (m, 4H), 1.75 – 1.64 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 155.69, 




Compound 4.72b was obtained as a light yellow solid (49%) by following the procedure used 
for the synthesis of 4.65: 1H NMR (500 MHz, Chloroform-d) δ 7.18 – 7.12 (m, 2H), 7.01 – 6.97 
(m, 2H), 5.16 (s, 2H), 3.47 (s, 3H), 3.00 (td, J = 3.9, 1.4 Hz, 1H), 2.48 (tt, J = 11.5, 4.0 Hz, 1H), 
2.12 – 2.07 (m, 2H), 1.89 – 1.77 (m, 4H), 1.72 – 1.64 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 





Compound 4.73a was obtained as a light yellow solid (75%) by following the procedure used 
for the synthesis of 4.66:  1H NMR (500 MHz, Chloroform-d) δ 7.18 (m, 2H), 6.99 (qd, J = 5.9, 
2.9 Hz, 2H), 5.10 (d, 2H), 3.41 (s, 3H), 3.41 – 3.27 (m, 1H), 3.08 – 3.00 (m, 1H), 2.56 – 2.47 (m, 








1.62 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 156.33, 136.43, 127.59 (2Cs), 115.67 (2Cs), 95.04, 




Compound 4.73b was obtained as a light yellow solid (65%) by following the procedure used 
for the synthesis of 4.66:  1H NMR (500 MHz, Chloroform-d) δ 7.20 – 7.13 (m, 2H), 6.99 (qd, J 
= 5.6, 3.1 Hz, 2H), 5.16 (d, J = 1.2 Hz, 2H), 3.48 (s, 3H), 3.41 – 3.27 (m, 1H), 3.08 – 3.00 (m, 
1H), 2.56 – 2.47 (m, 1H), 2.44 – 2.31 (m, 1H), 2.29 – 2.17 (m, 1H), 2.16 – 1.98 (m, 1H), 1.90 – 
1.76 (m, 1H), 1.71 – 1.62 (m, 1H).13C NMR (126 MHz, CDCl3) δ 155.52, 138.40, 128.16 (2Cs), 





Compound 4.74a was obtained as a light yellow solid (80%) by following the procedure used 
for the synthesis of 4.31: 1H NMR (500 MHz, Chloroform-d) δ 7.82 (ddd, J = 8.6, 3.7, 2.4 Hz, 
1H), 7.73 (t, J = 2.3 Hz, 1H), 7.37 – 7.32 (m, 1H), 7.17 – 7.13 (m, 3H), 7.13 – 7.05 (m, 2H), 7.02 
– 6.93 (m, 2H), 6.93 – 6.87 (m, 1H). 6.27 (t, J = 5.8 Hz, 1H), 5.15 (d, J = 0.8 Hz, 2H), 3.84 (dd, 
J = 6.7, 1.1 Hz, 6H), 3.48 (d, J = 3.1 Hz, 3H), 3.34 (t, J = 6.5 Hz, 2H), 2.56 (dt, J = 9.7, 5.1 Hz, 












(126 MHz, CDCl3) δ 165.62, 161.02, 159.95, 155.07, 140.89, 139.61, 130.06, 129.19, 129.08, 
127.94, 127.73, 127.44, 124.91, 122.14, 116.21 (2Cs) 114.69, 112.63, 111.31, 96.05, 56.45, 
55.05, 55.01, 43.56, 42.59, 37.84, 31.23 (2Cs), 28.07 (2Cs). HRMS (ESI+) m/z: [M + H+] 





Compound 4.74b was obtained as a light yellow solid (70%) by following the procedure used 
for the synthesis of 4.31: 1H NMR (400 MHz, Chloroform-d) δ 7.84 (d, J = 1.0 Hz, 1H), 7.32 – 
7.23 (m, 1H), 7.13 – 7.01 (m, 5H), 6.97 – 6.89 (m, 4H), 6.86 (ddd, J = 8.3, 2.4, 1.2 Hz, 1H), 5.11 
(s, 2H), 3.78 (d, J = 4.2 Hz, 6H), 3.50 (dd, J = 7.7, 5.8 Hz, 2H), 3.44 (s, 3H), 2.55 – 2.47 (m, 
1H), 1.99 (dd, J=7.8, 4.1hZ, 1H), 1.76 – 1.54 (m, 8H). 13C NMR (126 MHz, CDCl3) δ 167.14, 
159.34, 158.95, 155.46, 140.54, 139.10, 130.46, 129.45, 128.20, 127.91, 127.81, 127.74, 127.17, 
122.07, 116.18 (2Cs), 115.39, 112.87, 110.91, 94.65, 56.02, 55.85, 55.38, 43.11, 41.93, 36.01, 





















Compound 4.75a was obtained as a white solid (66%) by following the procedure used for the 
synthesis of 4.53:  1H NMR (400 MHz, Chloroform-d) δ 7.86 – 7.80 (m, 1H), 7.70 (dd, J = 5.4, 
2.4 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.12 – 7.05 (m, 3H), 7.01 (t, J = 7.5 Hz, 1H), 6.91 (dd, J = 
8.1, 2.6 Hz, 1H), 6.85 – 6.75 (m, 1H), 6.21 (t, J = 6.1 Hz, 1H), 3.88 – 3.80 (d, 6H), 3.58 (t, J = 
6.9 Hz, 2H), 2.56 – 2.44 (m, 1H), 2.15 (dd, 1H), 1.75 – 1.59 (m, 8 H). 13C NMR (126 MHz, 
CDCl3) δ 166.19, 159.75 (2Cs), 154.09, 139.67, 131.04, 129.83, 129.64, 128.39 (2Cs), 128.17, 






Compound 4.75b was obtained as a white solid (72%) by following the procedure used for the 
synthesis of 4.53: 1H NMR (500 MHz, Chloroform-d) δ 7.74 (dd, J = 8.6, 2.4 Hz, 1H), 7.61 (d, J 
= 2.4 Hz, 1H), 7.27 (t, J = 7.9 Hz, 1H), 7.05 – 7.02 (m, 3H), 7.00 (dd, J = 2.6, 1.5 Hz, 1H), 6.94 
(d, J = 8.6 Hz, 1H), 6.84 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.71 (d, J = 8.5 Hz, 2H), 6.02 (t, J = 6.1 
Hz, 1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.50 (dd, J = 7.7, 5.6 Hz, 2H), 2.47 (dt, J = 9.7, 5.9 Hz, 1H), 
1.91 (dt, J = 7.5, 3.9 Hz, 1H), 1.64 (ddq, J = 11.0, 7.3, 3.5 Hz, 7H). 13C NMR (126 MHz, CDCl3) 










122.17, 115.51, 115.26 (2Cs), 112.99, 111.10, 55.95, 55.49, 42.57, 42.06, 39.26, 33.89, 29.27, 





Compound 4.44a was obtained following the procedure utilized for the synthesis of 4.38, as a 
white amorphous solid (39%): 1H NMR (500 MHz, Chloroform-d) δ 7.81 (dd, J = 8.6, 2.4 Hz, 
1H), 7.69 (d, J = 2.4 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.17 – 7.13 (m, 2H), 7.10 (dt, J = 7.6, 1.3 
Hz, 1H), 7.07 (dd, J = 2.7, 1.6 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 0.9 Hz, 
1H), 6.83 (d, J = 8.6 Hz, 2H), 6.07 (t, J = 5.9 Hz, 1H), 4.88 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 
3.54 (dd, J = 7.3, 5.8 Hz, 2H), 3.35-3.24 (m, 2H), 3.14 (d, 2H), 2.84 (s, 3H), 2.40 (d, 2H), 2.35 
(s, 4H), 3.15-2.05 (m, 2H), 1.99 (m, 1H), 1.80 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 167.03, 
159.31, 158.96, 142.66, 140.47, 139.76, 139.01, 130.48, 129.28, 129.09, 128.73, 128.21, 128.09, 
127.05, 125.92, 121.98, 115.71, 115.38, 112.78, 110.90, 55.82 (2Cs), 55.35 (2Cs), 44.31, 41.78, 
329.03, 27.93, 23.80, 23.67, 23.12, 22.65, 21.32. HRMS (ESI+) m/z: [M + H+] calculated for 






















Compound 4.44b was obtained following the procedure utilized for the synthesis of 4.39, as a 
yellow amorphous solid (27%): 1H NMR (500 MHz, Chloroform-d) δ 7.83 (dd, J = 8.8, 2.2 Hz, 
1H), 7.70 (d, J = 2.6 Hz, 1H), 7.36 (t, 1H), 7.18 – 7.14 (m, 2H), 7.11 (dt, J = 7.7, 1.5 Hz, 1H), 
7.08 (dd, J = 2.8, 1.4 Hz, 1H), 7.03 (d, 1H), 6.90 (ddd, J = 8.1, 2.6, 0.8 Hz, 1H), 6.82 (d, J = 8.8 
Hz, 2H), 6.05 (t, J = 5.8 Hz, 1H), 4.00 (t, J = 6.6 Hz, 2H), 3.86 (s, 3H), 3.84 (s, 3H), 3.55 (dd, J 
= 7.5, 5.6 Hz, 2H), 2.60 (m, 3H), 2.31 (s, 6H), 1.99 (t, J = 7.2 Hz, 3H), 1.70 (dd, J = 10.3, 4.4 
Hz, 8H). ).  13C NMR (126 MHz, CDCl3) δ 167.05, 159.35, 158.72, 157.34, 139.44, 139.11, 
130.67, 129.75, 129.18, 128.58, 127.45, 127.12, 125.34, 121.79, 115.04, 114.20, 112.55 (2Cs), 
110.44, 66.56, 56.64, 55.59, 55.30, 44.07, 41.37, 32.67, 29.60, 28.19. HRMS (ESI+) m/z: [M + 





Compound 4.45a was obtained following the procedure utilized for the synthesis of 4.38, as a 
white amorphous solid (31%): 1H NMR (500 MHz, Chloroform-d) δ 7.81 (dd, J = 8.6, 2.4 Hz, 
1H), 7.78 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 2.3 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.17 (dd, J = 8.3, 
3.0 Hz, 2H), 7.11 – 7.05 (m, 2H), 7.01 (d, J = 8.7 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 
6.81 (d, J = 8.7 Hz, 1H), 6.08 (t, J = 5.9 Hz, 1H), 4.96 (s, 1H), 4.59 (s, 1H), 3.86 (s, 3H), 3.84 (s, 











2.59 – 2.52 (m, 1H), 2.39 (d, J = 11.9 Hz, 2H), 2.35 (s, 4H), 2.18 – 2.07 (m, 2H), 1.70 (dtt, J = 
12.8, 8.1, 3.4 Hz, 5H). 13C NMR (126 MHz, CDCl3) δ 13C NMR (126 MHz, CDCl3) δ 167.03, 
159.31, 158.96, 142.66, 140.47, 139.76, 139.01, 130.48, 129.28, 129.09, 128.73, 128.21, 128.09, 
127.05, 125.92, 121.98, 115.71, 115.38, 112.78 (2Cs), 110.90, 55.80 (2Cs), 55.33 (2Cs), 44.34, 
42.40, 33.84 (2Cs), 29.03 (2Cs), 27.93 (2Cs). HRMS (ESI+) m/z: [M + H+] calculated for 





Compound 4.45b was obtained following the procedure utilized for the synthesis of 4.39, as a 
yellow amorphous solid (30%): 1H NMR (500 MHz, Chloroform-d) δ 7.81 (dd, J = 8.6, 2.4 Hz, 
1H), 7.69 (d, J = 2.4 Hz, 1H), 7.34 (t, J = 7.9 Hz, 1H), 7.17 – 7.13 (m, 2H), 7.10 (dt, J = 7.6, 1.3 
Hz, 1H), 7.07 (dd, J = 2.7, 1.6 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.91 (ddd, J = 8.3, 2.6, 0.9 Hz, 
1H), 6.83 (d, J = 8.6 Hz, 2H), 6.07 (t, J = 5.9 Hz, 1H), 4.00 (t, J = 6.3 Hz, 2H), 3.86 (s, 3H), 3.84 
(s, 3H), 3.55 (dd, J = 7.7, 5.8 Hz, 2H), 2.53 (m, 3H), 2.31 (s, 6H), 2.05 (t, J = 7.0 Hz, 3H), 1.65 
(m, 8H).  13C NMR (126 MHz, CDCl3) δ 167.00, 159.30, 158.92, 157.04, 139.13, 139.03, 
130.47, 129.30, 129.08, 128.08, 127.77, 127.13, 121.99, 115.34, 114.28, 112.83 (2Cs), 110.88, 
66.06, 56.44, 55.79, 55.33, 45.27, 41.87, 33.66, 29.10, 28.02. HRMS (ESI+) m/z: [M + H+] 

















Compound 4.46a was obtained following the procedure utilized for the synthesis of 4.39, as a 
yellow amorphous solid (27%): 1H NMR (400 MHz, Chloroform-d) δ 7.82 (dd, J = 8.6, 2.5 Hz, 
1H), 7.68 (t, J = 2.4 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.12 (dt, J = 7.8, 3.1 Hz, 3H), 7.07 (q, J = 
3.6, 2.9 Hz, 1H), 7.01 (dd, J = 9.0, 3.7 Hz, 1H), 6.92 (dd, J = 8.2, 2.7 Hz, 1H), 6.84 (dd, J = 9.5, 
2.9 Hz, 2H), 5.92 (d, J = 8.0 Hz, 1H), 4.10 – 3.95 (m, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 2.53 – 2.41 
(m, 3H), 2.27 (s, 6H), 2.24 – 2.16 (m, 2H), 1.96 (dq, J = 10.9, 5.3, 4.0 Hz, 4H), 1.62 (qd, J = 
13.2, 3.0 Hz, 2H), 1.38 (td, J = 12.3, 3.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 166.32, 159.42, 
159.00, 157.41, 139.19, 138.83, 130.52, 129.40, 129.23, 128.30, 127.70, 127.37, 122.13, 115.48, 
114.49, 112.92, 110.97, 66.27, 56.59, 55.93, 55.47, 48.84, 45.55, 42.86, 33.79, 33.35, 27.62. 
HRMS (ESI+) m/z: [M + H+] calculated for C32H41N2O4 517.3066; found 517.3069. 
 
Reference 
1. Taipale, M.; Jarosz, D. F.; Lindquist, S., HSP90 at the hub of protein homeostasis: 
emerging mechanistic insights. Nature Reviews Molecular Cell Biology 2010, 11 (7), 515-528. 
2. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, Kenneth D.; Karras, 
Georgios I.; Lindquist, S., Quantitative Analysis of Hsp90-Client Interactions Reveals Principles 











3. Garg, G.; Khandelwal, A.; Blagg, B. S., Anticancer Inhibitors of Hsp90 Function: 
Beyond the Usual Suspects. Advances in Cancer Research 2016, 129, 51-88. 
4. Whitesell, L.; Lindquist, S. L., HSP90 and the chaperoning of cancer. Nature Reviews 
Cancer 2005, 5 (10), 761-772. 
5. Hanahan, D.; Weinberg, R. A., The Hallmarks of Cancer. Cell 2000, 100 (1), 57-70. 
6. Hanahan, D.; Weinberg, Robert A., Hallmarks of Cancer: The Next Generation. Cell 
2011, 144 (5), 646-674. 
7. Powers, M. V.; Workman, P., Targeting of multiple signalling pathways by heat shock 
protein 90 molecular chaperone inhibitors. Endocrine-Related Cancer 2006, 13, S125-S135. 
8. Dai, C.; Dai, S.; Cao, J., Proteotoxic stress of cancer: Implication of the heat-shock 
response in oncogenesis. Journal of Cellular Physiology 2012, 227 (8), 2982-2987. 
9. Stephanie, C. B.; Joseph, A. B.; Brian, S. J. B., Hsp90: A Novel Target for the Disruption 
of Multiple Signaling Cascades. Current Cancer Drug Targets 2007, 7 (4), 369-388. 
10. Chaudhury, S.; Welch, T. R.; Blagg, B. S. J., Hsp90 as a Target for Drug Development. 
ChemMedChem 2006, 1 (12), 1331-1340. 
11. Bishop, S. C.; Burlison, J. A.; Blagg, B. S., Hsp90: a novel target for the disruption of 
multiple signaling cascades. Current Cancer Drug Targets 2007, 7 (4), 369-88. 
12. Neckers, L.; Workman, P., Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? 
Clinical Cancer Research 2012, 18 (1), 64-76. 
13. Brandt, G. E.; Blagg, B. S., Alternate strategies of Hsp90 modulation for the treatment of 




14. Marcu, M. G.; Schulte, T. W.; Neckers, L., Novobiocin and Related Coumarins and 
Depletion of Heat Shock Protein 90-Dependent Signaling Proteins. Journal of the National 
Cancer Institute 2000, 92 (3), 242-248. 
15. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M., The Heat Shock 
Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding 
Domain in the Carboxyl Terminus of the Chaperone. Journal of Biological Chemistry 2000, 275 
(47), 37181-37186. 
16. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J., 
Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues. Journal of the American 
Chemical Society 2005, 127 (37), 12778-12779. 
17. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J., Novobiocin:  
Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90. Journal of the American 
Chemical Society 2006, 128 (48), 15529-15536. 
18. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J., 
Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against 
Several Cancer Cell Lines. The Journal of Organic Chemistry 2008, 73 (6), 2130-2137. 
19. Zhao, H.; Reddy Kusuma, B.; Blagg, B. S. J., Synthesis and Evaluation of Noviose 
Replacements on Novobiocin That Manifest Antiproliferative Activity. ACS Medicinal 
Chemistry Letters 2010, 1 (7), 311-315. 
20. Zhao, H.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E. L.; Brown, D.; Rajewski, R. A.; 
Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. J., Engineering an Antibiotic to Fight 
Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents. Journal 




21. Sadikot, T.; Swink, M.; Eskew, J. D.; Brown, D.; Zhao, H.; Kusuma, B. R.; Rajewski, R. 
A.; Blagg, B. S. J.; Matts, R. L.; Holzbeierlein, J. M.; Vielhauer, G. A., Development of a High-
Throughput Screening Cancer Cell-Based Luciferase Refolding Assay for Identifying Hsp90 
Inhibitors Assay and Drug Development Technologies 2013, 11 (8), 478-488. 
22. Garg, G.; Zhao, H.; Blagg, B. S. J., Design, Synthesis, and Biological Evaluation of 
Ring-Constrained Novobiocin Analogues as Hsp90 C-Terminal Inhibitors. ACS Medicinal 
Chemistry Letters 2014. 
23. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, 
J.; Blagg, B. S. J., The Design, Synthesis, and Evaluation of Coumarin Ring Derivatives of the 
Novobiocin Scaffold that Exhibit Antiproliferative Activity. The Journal of Organic Chemistry 
2008, 73 (22), 8901-8920. 
24. Kusuma, B. R.; Khandelwal, A.; Gu, W.; Brown, D.; Liu, W.; Vielhauer, G.; 
Holzbeierlein, J.; Blagg, B. S. J., Synthesis and biological evaluation of coumarin replacements 
of novobiocin as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry 2014, 22 (4), 1441-1449. 
25. Zhao, H.; Garg, G.; Zhao, J.; Moroni, E.; Girgis, A.; Franco, L. S.; Singh, S.; Colombo, 
G.; Blagg, B. S. J., Design, synthesis and biological evaluation of biphenylamide derivatives as 
Hsp90 C-terminal inhibitors. European Journal of Medicinal Chemistry 2015, 89 (0), 442-466. 
26. Zhao, H.; Moroni, E.; Colombo, G.; Blagg, B. S. J., Identification of a New Scaffold for 
Hsp90 C-Terminal Inhibition. ACS Medicinal Chemistry Letters 2013, 5 (1), 84-88. 
27. Byrd, K. M.; Subramanian, C.; Sanchez, J.; Motiwala, H. F.; Liu, W.; Cohen, M. S.; 
Holzbeierlein, J.; Blagg, B. S. J., Synthesis and Biological Evaluation of Novobiocin Core 




28. Zhao, J.; Zhao, H.; Hall, J. A.; Brown, D.; Brandes, E.; Bazzill, J.; Grogan, P. T.; 
Subramanian, C.; Vielhauer, G.; Cohen, M. S.; Blagg, B. S. J., Triazole containing novobiocin 
and biphenyl amides as Hsp90 C-terminal inhibitors. MedChemComm 2014, 5 (9), 1317-1323. 
29. Garg, G.; Zhao, H.; Blagg, B. S., Design, synthesis and biological evaluation of 
alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Bioorganic & Medicinal Chemistry 
2017, 25 (2), 451-457. 
30. Lovering, F.; Bikker, J.; Humblet, C., Escape from Flatland: Increasing Saturation as an 
Approach to Improving Clinical Success. Journal of Medicinal Chemistry 2009, 52 (21), 6752-
6756. 
31. Aldeghi, M.; Malhotra, S.; Selwood, D. L.; Chan, A. W. E., Two- and Three-dimensional 
Rings in Drugs. Chemical Biology & Drug Design 2014, 83 (4), 450-461. 
32. Uyanik, M.; Akakura, M.; Ishihara, K., 2-Iodoxybenzenesulfonic Acid as an Extremely 
Active Catalyst for the Selective Oxidation of Alcohols to Aldehydes, Ketones, Carboxylic 
Acids, and Enones with Oxone. Journal of the American Chemical Society 2009, 131 (1), 251-
262. 
33. Allen, J. R.; Bourbeau, M. P.; Chen, N.; Hu, E.; Kunz, R.; Rumfelt, S., Pyrazine 
compounds as phosphodiesterase 10 inhibitors. WO2010057121 A1, 2010.  
34. Zhao, H.; Blagg, B. S. J., Novobiocin Analogues with Second-Generation Noviose 
Surrogates. Bioorganic & Medicinal Chemistry Letters 2013, 23 (2), 552-7. 
35. Huang, Y.-T.; Blagg, B. S. J., A Library of Noviosylated Coumarin Analogues. Journal 




36. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J., 
Development of Novobiocin Analogues that Manifest Anti-Proliferative Activity Against 
Several Cancer Cell Lines. Journal of Organic Chemistry 2008, 73, 2130-2137. 
37. Lu, Z.; Chen, Y. H.; Smith, C.; Li, H.; Thompson, C. F.; Sweis, R.; Sinclair, P.; Kallashi, 
F.; Hunt, J.; Adamson, S. E., Cyclic amine substituted oxazolidinone cetp inhibitor. 
WO2012058187 A1, 2012. 
38. Donaldson, W. A.; Sem, D. S.; Neumann, T. S., Substituted (4'-
hydroxyphenyl)cycloaklkane compounds and uses thereof as selective agonists of the estrogen 
receptor beta isoform. US20160340279 A1, 2016. 
39. Trah, S.; Lamberth, C., Pyridazine derivatives, processes for their preparation and their 
use as fungicides. WO2011095459 A1, 2011. 
40. Lewis, H. D.; Harrison, T.; Shearman, M. S., Cyclohexyl sulphones for treatment of 
cancer. WO2006123182 A3, 2006. 
41. Nolte, B.; Schröder, W.; Linz, K.; Englberger, W.; Schick, H.; Graubaum, H.; Roloff, B.; 
Ozegowski, S.; Bálint, J.; Sonnenschein, H., Substituted 4-aminocyclohexane derivatives. 





5. Probing the Hsp90 C-terminal Binding Pocket with Cytotoxic Noviose 
Replacements 
Introduction 
Molecular chaperones maintain cellular protein homeostasis via the proper folding, 
maturation, and degradation of proteins.  The 90-kDa heat shock protein, Hsp90, is a molecular 
chaperone that is responsible for the maturation and folding of more than 300 client protein 
substrates.1-2 Hsp90-dependent client proteins are associated with a variety of disease states, 
including neurodegenerative disorders, infectious diseases, and cancer.3-4    Hsp90 exists as a 
homodimer with an N-terminal ATP-binding site that hydrolyzes ATP to provide the requisite 
energy for the protein folding cycle, a middle domain that maintains co-chaperone and substrate 
interactions, and a C-terminal dimerization domain that contains an EEVD motif that is critical 
for the interactions with various co-chaperone.  There are four Hsp90 isoforms: Hsp90α and 
Hsp90β reside in the cytoplasm, TRAP1 is localized to the mitochondria, and Grp94 is found in 
the endoplasmic reticulum.5-6  
Client proteins of Hsp90 are associated with all 10 Hallmarks of cancer, making it 
an ideal drug target for the development of cancer therapeutics.7-11 Due to the cellular stressful 
nature of tumor cells, Hsp90 exists in a heteroprotein complex that exhibits 200-fold greater 
affinity for ATP as compared to the Hsp90 complex in non-stressed cells.10-12 The higher affinity 
manifested by the heteroprotein complex produces an inherent selectivity for cancer cells versus 
normal cells. Consequently, inhibitors of the N-terminal ATP-binding site have been pursued 
clinically for the treatment of cancer, and 17 small molecules have been evaluated in clinical 
trials.9, 13 Unfortunately toxicity, dosing and scheduling issues have been observed for most of 




approved. As a consequence of these issues, C-terminal inhibitors or isoform selective inhibitors 
are sought to overcome these clinical detriments. Hsp90 C-terminal inhibitors are sought because 
they are able to segregate client protein degradation from induction of the pro-survival heat 
shock response, which could overcome the dosing issues observed in the clinic.  The second 
approach is the development of isoform selective inhibitors as certain toxicities are associated 
with specific Hsp90 isoforms. 14-15 
The first Hsp90 C-terminal inhibitor identified was the natural product, 
novobiocin, which is also a clinically used DNA gyrase inhibitor.16-17 In contrast to N-terminal 
inhibitors, treatment of cancer cells with novobiocin did not induce of the heat shock response at 
concentrations that led to client protein degradation.  Initial structure activity relationship studies 
demonstrated that modifications to novobiocin could result in compounds that were either 
cytotoxic or neuroprotective.18-19 The Hsp90 C-terminal inhibitor, KU-32, replaced the 
benzamide side chain with an acetamide, which induced the pro-survival HSR without 
concomitant client protein degradation and upon further evaluation manifested efficacious 
neuroprotective activity in Alzheimer’s disease,  animal models of Diabetic Peripheral 
Neuropathy, and chemo-brain.20  
Synthetic complexity of the noviose sugar resulted in discovery efforts focused on 
simplified groups with similar or improved biological activity.21 Initial exploration of simplified 
functional groups and sugars, yielded a new series of non-noviosylated compounds 
“Noviomimetics”, that maintained desired neuroprotective activity.22 Exploration of cytotoxic 
replacements for the noviose sugar identified piperidines that include KU-248 and KU-258 
(Figure 5.1).23-24 Exploration of replacements for the noviose sugar replacement in both 




donor/acceptor at specific positions on the noviose sugar and sugar replacements.25-26 Improved 
C-terminal inhibitors are constantly pursued, thus potential anti-cancer therapeutics that 
maintains those important interactions were designed.  These compounds contained simple alkyl 
rings with either an alcohol or an amine and were coupled to a previously optimized coumarin 
core that yields anti-cancer activity (Figure 5.1).23-24 The four initial compounds were designed to 
explore possible electronic interactions when the hydrogen bond donor/acceptor was removed 
from the ring.  Additionally the simplified replacements were selected because similar biological 
results were obtained when the noviose sugar was replaced with a cyclohexanol ring.22 Synthesis 
of these compounds commenced.  
 
 
Results and Discussion 
Synthesis of coumarin core 5.36 began by coupling Cbz-protected glycine 5.28 with 
Bredreck’s Reagent in Toluene (Scheme 5.1A).  Resulting enamine 5.29 was coupled with 2-4-
dihydroxytoluene 5.30 in Acetic Acid for 72 hours to produce the Cbz-protected coumarin core 
5.31.  Treatment of 5.31 with acetic acid and pyridine in dichloromethane resulted 5.32. 
Hydrogenolysis gave free amine 5.33, which was subsequently coupled with acid chloride 5.34 
 






to yield coumarin 5.35.  Removal of the acetate resulted in phenol 5.36 (Scheme 5.1A).   
Mitsunobu conditions were utilized to obtain coupled products 5.1, 5.39, 5.2, 5.9a, and 5.9b 
(Scheme 5.1B and 5.1C).  Subsequent removal of the Boc protecting group produced final 





Scheme 5.1:A). Synthesis of phenol 5.36. B). Synthesis of final products 5.1 
and 5.3. C). Synthesis of final products 5.2, 5.4a and 5.4b. Reagents and 
Conditions: a). Bredereck's Reagent, Toluene, 100oC, 75%; b). AcOH, 
130oC, 60%; c). Ac2O, Pyridine, DCM, 75%; d). Pd/C, H2 (g) EtOAc, 90%; 
e). Et3N, THF, 65%; f). K2CO3, MeOH, 70%. g). tBuP, TMAD, Benzene, 





Upon synthetic completion the anti-proliferative activity was determined by an MTS assay.  
Analogs were evaluated in two breast cancer cell lines MCF-7 (estrogen receptor positive cells) 
and SkBr3 (estrogen receptor negative HER2 overexpressing).  
 
Table 5.1. Anti-proliferative activity of cyclohexylamine and cyclohexanol analogs. 
 













































All analogs displayed anti-proliferative activity against the breast cancer cell lines 
illustrated in Table 5.1. Analogs 5.1, 5.2, and 5.3, diastereomeric mixtures, exhibited similar 
activity in both cell lines. Interestingly the 4-syn-amine (5.4b) produced the best anti-
proliferative activity of all of the new analogs.  This data suggests that extending the hydrogen 
bond donor/acceptor from the ring is equally beneficial as the biological activity is similar to the 
parent compounds KU-248 and KU-258 (Figure 5.1).  Due to these promising initial results, new 
analogs were designed that extended a variety of functional groups off of both the syn- and anti-
amine at the 4-position.  The functional groups selected continued to explore electrostatic 
interactions and investigate if a bulky substituent could be tolerated within the binding pocket at 
the 4- position.  Noviomimetic exploration highlighted that groups as large as a benzyl could be 
tolerated at the 4 position of a cyclohexane ring, so both a benzyl and benzamide functional 
group will be utilized in this study.22 These new analogs were synthesized in the following 






Each mono-substituted product was synthesized in the manner described in Scheme 5.2.  
Analogs 5.6a and 5.6b were obtained via treatment of 5.4a/b with Pt/C, acetonitrile, and 
hydrogen gas.  These conditions ensured mono addition to the amine.  5.4a or 5.4b was subjected 
to acetic acid, formaldehyde, and sodium cyanoborohydride to obtain di-methylated amine 5.7a 
or 5.7b.  Acetate 5.8a or 5.8b was obtained by subjecting 5.4a/b to acetic anhydride in 
 
Scheme 5.2. Synthesis of final products 5.6a/b, 5.7a/b, 5.8a/b. 5.9a/b, 5.10a/b, 
5.11a/b, 5.12a/b/c/d, 5.13a/b/c/d, 5.14a/b/c/d, and 5.15a/b/c/d.  Reagents and 
Conditions: a). Pt/C, H2 (g), MeCN, MeOH, 60%; b). Acetic Acid, Formaldehyde, 
NaBH3CN, MeOH, 40%; c). Acetic Anhydride, TEA, DCM, rt, on, 70%; d). 
Benzoyl Chloride, TEA, THF, rt, on, 70%; e). BnBr, K2CO3, MeCN, 40%; f). RBr, 





dichloromethane.   Similarly, the benzamide analogs 5.10a and 5.10b were obtained via addition 
of triethylamine and benzoyl chloride at 0 oC to 5.4a/b.  Benzyl substituted amines 5.11a and 
5.11b were obtained via refluxing 5.4a/b with benzyl bromide and K2CO3 in acetonitrile 
overnight.    
   
 
 
Mono-methyl derivates 5.5a and 5.5b were obtained by selective reduction of tert-butyl 
methyl(4-oxocyclohexyl)carbamate to either the syn or anti alcohol (5.47a and 5.47b) using 
NaBH4 or L-selectride.  Mitsunobu conditions were used to couple alcohols 5.47a/b with phenol 
5.36.  Subsequent Boc-deprotection of 5.48a/b yielded methylamine 5.5a/b.  
Methylcyclohexamine analogs 5.17a/b were obtained via coupling 5.49a/b with phenol 5.36 
using Mitsunobu conditions.  Removal of the Boc-protecting group provided final products 
5.17a/b.   
 
Scheme 5.3. Synthesis of final products 5.5a/b and 5.17a/b. Reagents and Conditions: a). 






Analog 5.16 was synthesized via coupling mesylate 5.52 with phenol 5.36. The coupled 
mesylate was subsequently subjected to NaN3, to obtain azide 5.54.  Osmium tetroxide was 
added to obtain cis-diol 5.55.  Hydrogenolysis was used to acquire amine 5.16. Upon completion 
of synthesis the analogs were evaluated in the MTS anti-proliferation assay in MCF-7 and SkBr3 
cells.     
 
Table 5.2. Anti-proliferative activity of cyclohexylamine derivatives  
 





















Scheme 5.4. Synthesis of 5.16. Reagents and Conditions: a). TEA, MsCl, THF, 
94%; b). Cs2CO3, DMF, 55%; c). NaN3, DMF, 60%; d). OsO4, NMO, THF/H2O, 

























































































































































































aValues represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
 
The modified amines did not exhibit improved biological activity when compared to 
























corresponding syn analog.  The larger mono-substituted amines had improved activity when 
compared to the corresponding di-substituted amine (5.13a versus 5.13c).  It is possible that the 
bulk of the di-substituted amines decreased the binding affinity of the compound, resulting in the 
loss of biological activity.  In contrast, the smaller di-methyl analogs 5.7a/b exhibited improved 
activity compared to the mono-methyl, 5.5a/b. Interesting anti analogs 5.8a and 5.11a exhibited 
anti-proliferative activity while the corresponding syn derivatives were not active even at high 
concentrations.  To determine what causes this dramatic difference in activity, more analogs will 
need to be synthesized and additional biological studies should be carried on these compounds.  
Since analogs did not improve anti-proliferative activity as compared to 5.4a/b, new cores were 
selected to replace the coumarin core in order to see what effect increasing core flexibility and 
length would have on the biological activity of these compounds.  The phenyl cyclohexyl and 





 The synthesis of analogs with a phenyl cyclohexyl and biphenyl core was carried out as 
illustrated in Scheme 5.5. Upon completion of synthesis the analogs were evaluated in the MTS 







Scheme 5.5. Synthesis of known Hsp90 C-terminal cores with optimized 
noviose replacements. Reagents and conditions: a). DIPEA, MOMCl, DCM, 65-
80%; b). L-selectride, THF, 80%; c). Et3N, MsCl, THF, 90%; d). NaN3, DMF, 
70%; e). Pd/C, H2(g), EtOAc, 65%; f). Et3N, DMAP, THF, 45%; g). PTSA, 
MeOH, 50%; h). tBuP, TMAD, Benzene, 75oC, 45%;  i). Pd(dppf)Cl2, Na2CO3, 















X 4.7±1.21 3.43±0.14 
5.18b B 
 
X 2.33±1.02 1.58±0.32 
5.19a A 
 
Y 3.21±0.35 3.56±0.11 
5.19b B 
 
Y 3.62±0.1 3.52±0.05 
aValues represent mean ± standard deviation for at least two separate experiments performed in 
triplicate. 
 
The anti-proliferative activity of these compounds is relatively flat. Even with the increased 
length and flexibility of the phenyl cyclohexyl and biphenyl cores compared to the coumarin, the 
anti-proliferative activity of all analogs is very similar.  Additionally, the stereochemistry of the 
cyclohexylamine does not appear to have any impact on anti-proliferative activity.   
 
Validation of Hsp90 inhibition via Western Blot Analysis 
After determination of the IC50 values, a few compounds were selected for western blot 
analysis in MCF-7 cells.  Analogs 5.4a, 5.4b, and 5.7a were selected to explore the effect of 



























Compound 5.4b caused the degradation of many Hsp90 client proteins.  5.7a resulted in 
slight degradation of ER-α, however 5.4a did not result in degradation of any of the client 
proteins.  No compounds resulted in induction of the heat shock proteins, which is a hallmark of 
 
Figure 5.2. Western blot analyses of 5.4a, 5.4b, and 5.7a after 
incubation with MCF-7 breast cancer cells for 24 h.  The high 
concentration is five times the IC50 value, and the low 
concentration is half the IC50 value.  Concentrations for each 
analog tested were as follows: 5.4a (high: 8.25 μM, low: 0.83 
μM), 5.4b (high: 4.50 μM, low: 0.45 μM), and 5.7a (high: 6.15 
μM, low: 3.08 μM). GDA (500nM) was the positive control and 





C-terminal inhibitors. Additionally Actin, a Hsp90 independent protein, levels did not change in 
response to compound treatment. This data strongly suggests that for cyclohexylamine analogs 
syn stereochemistry is important for Hsp90 activity.  
The current study was then expanded upon to include noviomimetic side chains that were 
utilized in neuroprotective compounds (KU-1202, Figure 5.3).  These noviomimetic side chains 
were coupled with anti-cancer scaffolds (coumarin and biaryl KU-1242 and KU-111, Figure 5.3) 
to investigate potential anti-cancer activity (Figure 5.3). Noviomimetic side chains were able to 
produce similar and often improved neuroprotective activity as compared to the noviose sugar 
for a variety of scaffolds.22    
 
These compounds were selected to verify whether the noviomimetic side chains were 
non-toxic in cells and to explore how different side chains may impact anti-cancer activity.     
 
Figure 5.3. Overview of the proposed analogs that include 






Biaryl containing analogs were synthesized beginning with selective benzyl protection of 
2, 4-dihydroxybenzaldehye, 5.73 (Scheme 5.6).  Microwave conditions were used to convert 
benzyl ether 5.74 to the corresponding trifluoromethanesulfonate, which was then coupled with 
3-fluorophenyl boronic acid using Suzuki coupling conditions to generate the biaryl ring system 
found in 5.76. Henry reaction conditions were utilized to obtain the α-β unsaturated nitro 5.77. 
Treatment with lithium aluminum hydride reduced both the nitro and olefin to amine 5.78.  Acid 
chloride 5.34 was coupled with amine 5.78 in the presence of triethylamine and DMAP, to 
generate 5.79. Hydrogenolysis conditions were then utilized to cleave the benzyl ether and obtain 
phenol 5.80. 
The toluenesulfonates of the noviomimetic side chains were synthesized (Scheme 5.6b) 
and coupled with phenol 5.80 via SN2 substitution reaction to obtain compounds 5.20-5.23. 






Coumarin core phenol 5.36 was synthesized as described in Scheme 1.  SN2 substitution 
reaction conditions were then utilized to couple toluenesuolfonate noviomimetics to yield 
compounds 5.24-5.27 (Scheme 5.6c).  
 
Scheme 5.6. Synthesis of final products 5.20-5.27. Reagents and Conditions: a). 
BnBr, NaHCO3, CH3CN, 75%; b). (CF3CO)2O, K2CO3, THF, 60%; c). 3-fluoro-
phenylboronic acid, Pd(PPh3)4, K2CO3, DMF, 90%; d).CH3NO2, NH4OAc, 98%; e). 
LiAlH4, THF, 30 min; f). Et3N, THF, 72% over 2 steps; g).H2, Pd/C, EtOAc, 90%; h).  
K2CO3, DMF, 80oC, 2d, 55-80%; i). TsCl, Pyr., 0 oC-rt,on, CHCl3, 45%; i). ACN, 





Upon completion of the synthesis, the analogs were evaluated in a MTS anti-proliferation 
assay in MCF-7 (estrogen receptor positive cells), SkBr3 (estrogen receptor negative HER-2 
overexpressing), and MDA-MB-231 (triple negative) breast cancer cell lines, and non-cancerous 
HEK-293 cells (human embryonic kidney). 
 
Table 5.4. Anti-proliferative activity of Compounds 5.20-5.27.  
 
Compound   Side 
Chain 





   (IC50, µM)a  
  HEK293 
(IC50, µM)a 
5.20 A X >50 >50 >50 >10 
5.21 B X >50 >50 >50 >10 
5.22 C X >50 >50 >50 >10 
5.23 D X >50 >50 >50 >10 
5.24 A Y >50 >50 >50 >10 
5.25 B Y >50 >50 >50 >10 
5.26 C Y >50 >50 >50 >10 
5.27 D Y >50 >50 >50 >10 
































The analogs did not exhibit cytotoxic activity against any of the breast cancer cell lines nor 
did they exhibit cytotoxicity in the non-cancerous cell line HEK-293, Table 5.4.  The absence of 
cytotoxicity is significant because these side chains were originally designed to replace the 
noviose sugar for the treatment of neurodegenerative diseases.  Development of compounds that 
replace the noviose sugar with a surrogate have lead to new studies which investigate the 
biological importance of the noviose sugar.    
Recently, the Hsp90 C-terminal inhibitor KU-174, which contains the biaryl side chain, 
was able to prevent cancer cell migration.27 Due to these promising results, analogs of KU-174 
were evaluated to determine the importance of the noviose sugar with regards to the desired anti-
migratory activity.  Two analogs, KU-177 and KU-308, were selected for initial studies due to 
their lack of cytotoxicity in a variety of immortalized cancer cell lines.  These two analogs were 
void of any cytotoxic moiety in lieu of the noviose sugar.  It is possible that the lack of 
cytotoxicity is because these two analogs are unable to interact with several amino acids within 
the binding pocket known to form important binding interactions with noviose sugar (Thr540, 
Gln682, and Asn686). Unpublished co-immunoprecipitation results show that the three analogs 





  Highly metastatic PC3-MM2 prostate cancer cells were utilized to verify anti-migratory 
activity via a wound healing scratch assay (WHSA) of the compounds due to disruption of the 
 
Figure 5.4. Noviose sugar is not essential for the anti-migratory activities of Hsp90 C-
terminal inhibitors. A). Cell migration assay was performed with PC3-MM2 cells in 
the presence of DMSO (0.1%), KU-308 (5 µM, and 10 µM), KU-177 (5 µM, and 10 
µM) or KU-174 (5 µM, and 10 µM) for 24 h. Bright field photomicrographs were 
taken at 0 and 24 h time points of the cell migration/scratch assay. B). PC3-MM2 cells 
were treated with DMSO (0.1%), KU-308 (100 µM), KU-177 (100 µM), and KU-174 
(10 µM) for 24 h. Aha1 was immunoprecipitated and Hsp90α and Aha1 were 
analyzed by western blotting. Aha1 bound Hsp90α was quantified using Image J 






Hsp90α/Aha1 complex. Both KU-308 and KU-177 inhibit cancer cell migration at ~10 µM 
concentration (Figure 5.4b). KU-177, which contains the acetyl ester, was more effective than 
the non-acetylated derivative KU-308 at inhibition of cell motility.  Because KU-177 and KU-
308 are non-toxic, the therapeutic window is very large since the IC50 value exhibited by these 
compounds is >100 µM and anti-migratory activity were observed at low micro-molar 
concentrations (Figure 5.4b).  
These preliminary results highlight that the noviose sugar is not essential for anti-
migratory activity, and verification that there were no unintended cytotoxic effects upon 
treatment with 5.20-5.27.  A WHSA was carried out with MDA-MB-231 cells to evaluate 






Compounds 5.20, 5.24, and 5.25 resulted in promising anti-metastatic activity (Figure 
5.5).  The increased length of C-terminal inhibitors that contain the biaryl core appear too long to 
fit within the binding pocket, whereas the coumarin core is shorter in length, and produced two 
analogs that manifest the most promising activity and are also the shortest.   
 After a promising initial screen (Figure 5.5), compound 5.20 was selected for further 
evaluation.  A dose response WHSA in MDA-MB-231 breast cancer cells was carried out using 
1μM, 5μM, 10μM, and 25μM concentrations (Figure 5.6).  
 
 
Figure 5.5. Anti-Metastatic Activity of compounds 5.20-5.27 in MDA-MB-231 cells. 
MDA-MB-231 cells were treated for 24 hours with DMSO (0.1%), and 25uM of 5.20-
5.27. Bright field photomicrographs were taken at 0 and 24 h time points of the cell 
migration/scratch assay. Image j was used to quantify the area of each scratch and 
obtain a % closed after 24 hours for each scratch. 5.20 28% close, 5.21 58% closed, 
5.22 55% closed, 5.23 50% closed, 5.24 42% closed, 5.25 37% closed, 5.26 77% 






Compound 5.20 exhibits excellent anti-metastatic activity with only 50% of the wound 
being closed after 24 hours at 10μM (Figure 5.6).  Because 5.20 does not exhibit any cytotoxicity 
the therapeutic window is quite large, making it an interesting biological probe with therapeutic 
potential.  Therefore investigation of the mechanism of action for compounds 5.20 and 5.25 
began. Compound 5.25 was also selected for further evaluation because it exhibited promising 
anti-metastatic activity.  These compounds were first evaluated for potential Grp94 activity 
because there is a well-established connection between Grp94 selective inhibitors and prevention 
of cell migration. 
Recent studies have shown that Hsp90 isoform Grp94, is responsible for the maturation 
of toll-like receptors, immunoglobulins, and integrins.28 Integrins are important for cell adhesion 
and metastasis; therefore inhibition of Grp94 would prevent metastasis.  Also, inhibition of 
 
Figure 5.6. Anti-Metastatic Activity of 5.20 in MDA-MB-231 cells. MDA-MB-231 
cells were treated for 24 hours with DMSO (0.1%), and 25μM, 10, 5, and 1μM of 
5.20. Bright field photomicrographs were taken at 0 and 24 h time points of the cell 
migration/scratch assay. Image j was used to quantify the area of each scratch and 
obtain a % closed after 24 hours for each scratch.  25μM, 25% closed, 10μM, 48% 





Grp94 prevents the Grp94-mediated toll-like receptor trafficking to the cell surface, which is also 
important for cancer cell migration.14 Collectively these studies have shown that Grp94-selective 
inhibitors are promising anti-metastatic agents.   
As a result of these findings and the anti-metastatic properties, the analogs were assessed 
for Grp94, e Hsp90 (extracellular Hsp90), and general Hsp90 activity. Immunoblot analysis of 
MDA-MB-231 cells was performed and client proteins involved in cellular metastasis pathways, 
such as pERK1/2 and pAKT, and client proteins associated with the Hsp90 isoform Grp94 (Int 
α2 and Rab10) were visualized.  Additionally levels of select extracellular proteins were selected 
to determine if 5.20 and 5.25 have an effect on extracellular heat shock protein 90. 29 MMP-2, 
metalloproteinase-2, is a protein that plays a pivotal role in wound healing and relies upon Hsp90 
for cleavage into its active form.  Levels of both pro- and active MMP-2 were analyzed in 
response to treatment with different concentrations of 5.20 and 5.25.  Unfortunately there was no 
clear down regulation of the active form of MMP-2, meaning compounds were not acting via 




Immunoblot analysis of 5.20 (Figure 5.7), did not clarify a possible mechanism of action.  
There was no observed degradation of extracellular proteins, specifically no change in 
extracellular MMP-2 pro to active levels.  Importantly, no extracellular actin was found, thus 
verifying that cellular contents were not in the extracellular space due to cell lysis from stress. 
Therefore, we were able to conclude that we only isolated the extracellular proteins. Due to an 
absence of change in eHsp90α and MMP-2 levels, compound 5.20 is likely not targeting 
 
Figure 5.7. Western Blot analysis of 5.20 after incubation with MDA-MB-231 breast 
cancer cells for 24 h. cells.  The extracellular proteins that were analyzed: MMP-2, 
Hsp90 α, and actin were analyzed.  The intracellular proteins that were analyzed: 
Hsp90, Hsp70, Hsp90 clients, and Grp94 clients were analyzed.  Compound 5.20 was 
tested at 2.5μM, 10μM, 25μM, and 50μM concentrations.  GDA (500nM) was the 





extracellular Hsp90. Additionally, there were no changes in intracellular p-AKT and pErk1/2 
levels, indicating that the compounds are not preventing metastasis by targeting intracellular 
pathways.  There was no decrease in Grp94-dependent clients Int α2 and Rab10 indicating that 
the compounds are not causing anti-metastatic activity through a Grp94-isoform-dependent effect.  
There is slight client protein degradation of Her2, C-Raf, and Cyclin D1 at the highest 
concentration tested, however it is unlikely that this client protein degradation is related to the 
anti-metastatic activity.  The degradation of these client proteins confirms that at 50μM these 
compounds are exhibiting characteristics associated with C-terminal inhibition (lack of heat 
 
Figure 5.8. Western Blot analysis of 5.25 after incubation with MDA-MB-231 
breast cancer cells for 24 h. cells.  The extracellular proteins that were analyzed: Int 
α2, Hsp90α, and actin were analyzed.  The intracellular proteins that were analyzed: 
Hsp90, Hsp90 client proteins, and Grp94 clients were analyzed.  Compound 5.25 
was tested at 2.5μM, 10μM, 25μM, and 50μM concentrations.  GDA (500nM) was 
the positive control and DMSO was used as the negative control.     




shock protein induction at concentrations where there is client protein degradation).   
Simultaneously immunoblot analysis of 5.25 was carried out in MDA-MB-231 cells (Figure 5.8).  
 Similar to compound 5.20, immunoblot analysis of 5.25 did not confirm a possible 
mechanism of action for these compounds.  The difference between these compounds was that 
5.25 exhibited significant degradation at the highest concentrations of C-Raf. Again, degradation 
of C-Raf is likely unrelated to the anti-metastatic activity, but is indicative of Hp90 C-terminal 
inhibition. Interestingly there appears to be slight degradation of Rab10 at the highest 
concentration of 5.25.  It is possible that at very high concentrations of inhibitor some Grp94-
dependent clients could be affected.  However without observed degradation of Grp94-dependent 
client Integrin α2, it is difficult to say compound 5.25 targets Grp94.     
Conclusion 
Two series of compounds were synthesized in attempt to probe the C-terminal binding site.  
One series of compounds were either coumarin or biaryl containing compounds with 
noviomimetic side chains that were synthesized and found to exhibit anti-metastatic activity. 
These compounds were non-toxic and exhibited good anti-migratory activity in a wound healing 
scratch assay. An initial study to determine the mechanism of action for these compounds was 
inconclusive.  Moving forward, co-IP studies between Hsp90 isoforms and co-chaperones are 
necessary to continue to probe mechanism of action.  Once the mechanism of action can be 
determined this series of compounds could be expanded to evaluate all noviomimetic side chains 
explored for KU-596 derivatives.  This series of compounds represent a promising new scaffold 
of non-toxic compounds with a large therapeutic window that exhibit anti-metastatic activity. 
The second series of compounds were designed and synthesized to project hydrogen bond 




derivatives of the cyclohexylamine compounds were similarly cytotoxic, however western blot 
analysis highlighted that syn stereochemistry is important for Hsp90 inhibition.  
Cyclohexylamine derivative development should continue and more cyclohexylamines should be 
coupled with the phenyl cyclohexyl core to further explore anti-cancer activity due to inhibition 
of the Hsp90 C-terminus.   
 
Materials and Methods 
Anti-proliferation assays.  
Cells were maintained in a 1:1 mixture of Advanced DMEM/F12 (Gibco) supplemented with 
non-essential amino acids, L-glutamine (2 mM), streptomycin (500 μg/mL), penicillin (100 
units/mL), and 10% FBS. Cells were grown to confluence in a humidified atmosphere (37° C, 
5% CO2), seeded (2000/well, 100 μL) in 96-well plates, and allowed to attach overnight. 
Compound or GDA at varying concentrations in DMSO (1% DMSO final concentration) was 
added, and cells were returned to the incubator for 72 h. At 72 h, the number of viable cells was 
determined using an MTT/PMS cell proliferation kit (Promega) per the manufacturer’s 
instructions. Cells incubated in 1% DMSO were used at 100% proliferation, and values were 
adjusted accordingly. IC50 values were calculated from separate experiments performed in 
triplicate using GraphPad Prism. 
 
Wound Healing Scratch Assay. 
Trypan blue exclusion was utilized to count MDA-MB-231 cells and seed 12-well plates at 
200,000 cells/mL/well, which were then placed in an incubator for 24 h. After 12 h, two 




then fresh media was added to each well. The compound or DMSO control was then added 
(0.25% DMSO final concentration) and pictures taken were taken (0h) with a camera-mounted 
Olympus IX-71 microscope (10X objective). Plates were then returned to the incubator until 24 
h, at which point pictures were taken again. Images were processed and % migration determined 
via ImageJ. All experiments were performed in at least duplicate.  
 
Western blot Analysis.  
MCF-7 cells were cultured as described above and treated with various concentrations of drug, 
GDA in DMSO (1% DMSO final concentration), or vehicle (DMSO) for 24 h. Cells were 
harvested in cold PBS and lysed in RIPA lysis buffer containing 1 mM PMSF, 2 mM sodium 
orthovanadate, and protease inhibitors on ice for 1 h. Lysates were clarified at 14000g for 10 min 
at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the 
manufacturer’s instructions. Equal amounts of protein (20 μg) were electrophoresed under 
reducing conditions, transferred to a nitrocellulose membrane, and immunoblotted with the 
corresponding specific antibodies. Membranes were incubated with an appropriate horseradish 




1H NMR were recorded at 500 MHz (Avance AVIII 500 MHz spectrometer with a dual 
carbon/proton cryoprobe) or 400 (Bruker AVIIIHD 400 MHz NMR with a broadband X-channel 
detect gradient probe) and 13C NMR were recorded at 125 MHz (Bruker AVIII spectrometer 




(ppm) relative to the internal standard (CDCl3, 7.26 ppm, or as stated). HRMS spectra were 
recorded with a LCT Premier with ESI ionization. 1H and 13C NMR was used to verify that all 
tested compounds were >95% pure. TLC analysis was performed on glass backed silica gel 
plates and visualized by UV light. All solvents were reagent grade and used without further 
purification. 
 









Phenol 5.36 (0.12 g, 0.298 mmol), and cyclohexane-1,3-diol (0.128g, 0.597mmol) were 
dissolved in anhydrous Benzene (2mL).  Tri-butylphosphine (0.147mL, 0.597 mmol) was added 
dropwise and the reaction was stirred at 0oC.  After 5 minutes the mixture was covered and 


















heated to reflux.  The reaction was stirred at reflux for 12 h, cooled to rt, concentrated, and 
purified via column chromatography (SiO2, 1:4, EtOAc: hexane) to afford 5.1 as a white 
amorphous solid (35% yield): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (d, J = 2.8 
Hz, 1H), 7.93 – 7.88 (m, 3H), 7.35 (dt, J = 15.6, 8.3 Hz, 3H), 7.12 (dt, J = 7.6, 1.2 Hz, 2H), 7.10 
– 7.04 (m, 4H), 6.95 – 6.87 (m, 3H), 4.81 (dt, J = 6.0, 3.2 Hz, 1H), 4.39 (tt, J = 8.9, 3.8 Hz, 1H), 
4.14 (ddd, J = 14.5, 9.9, 5.8 Hz, 1H), 3.90 (s, 4H), 3.86 (s, 4H), 3.83 – 3.77 (m, 1H), 2.33 (s, 
3H), 2.13 (dt, J = 12.6, 4.6 Hz, 1H), 2.04 – 1.98 (m, 1H), 1.94 – 1.86 (m, 2H), 1.70 (ddt, J = 
21.7, 12.5, 7.0 Hz, 3H), 1.60 – 1.33 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 165.67, 159.92, 
159.64, 159.47, 157.23, 149.56, 138.75, 131.19, 130.10, 129.31, 128.29, 125.67, 124.43, 122.15, 
121.85, 115.39, 113.30, 111.15, 110.90, 75.58, 73.70, 68.47, 67.04, 40.49, 39.11, 34.41, 30.89, 





Compound 5.2 was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (d, J = 1.0 Hz, 2H), 8.70 (d, 
J = 2.6 Hz, 2H), 7.95 – 7.87 (m, 5H), 7.39 – 7.31 (m, 4H), 7.12 (dt, J = 7.6, 1.2 Hz, 2H), 7.10 – 
7.05 (m, 5H), 6.95 – 6.88 (m, 4H), 4.53 (dt, J = 5.4, 2.7 Hz, 1H), 4.40 (dt, J = 8.6, 4.6 Hz, 1H), 
3.90 (s, 6H), 3.86 (s, 7H), 2.36 (d, J = 2.7 Hz, 3H), 2.32 (s, 3H), 2.14 (ddd, J = 12.5, 5.0, 2.5 Hz, 












2H), 1.49 (dq, J = 8.6, 2.8, 2.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 165.51, 159.76, 159.56, 
159.33, 157.30, 138.61, 131.04, 129.95, 129.17, 128.15, 126.13, 125.53, 124.41, 122.01, 115.24, 
113.16, 111.01, 110.66, 75.24, 68.59, 31.54, 28.17, 28.15, 8.32, 1.03. HRMS (ESI+), m/z 





Compound 5.3 was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%).  The boc- protected amine was then subjected to the conditions utilized 
to obtain 5.4a to obtain compound 5.3 in (70%) yield as a white solid: 1H NMR (500 MHz, 
Methanol-d4) δ 8.73 (s, 1H), 7.87 (dd, J = 8.6, 2.4 Hz, 1H), 7.84 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 
8.2 Hz, 2H), 7.10 – 7.01 (m, 4H), 6.89 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.83 (d, J = 8.7 Hz, 1H), 
4.82 (t, J = 3.1 Hz, 1H), 3.85 (s, 3H), 3.81 (s, 3H), 3.50 – 3.43 (m, 1H), 2.37 – 2.32 (m, 2H), 2.28 
(s, 3H), 2.07 (d, J = 12.6 Hz, 2H), 2.03 – 1.96 (m, 2H), 1.76 – 1.64 (m, 2H). 13C NMR (126 
MHz, MeOD) δ 166.59, 160.67, 160.10, 157.13, 150.21, 139.40, 131.83, 130.74, 129.98, 129.01, 
126.59, 125.44, 122.82, 122.37, 116.05, 114.37, 113.93, 111.89, 110.92, 72.74, 56.66, 56.11, 
49.98, 47.22, 30.49, 28.76, 19.65, 8.95. HRMS (ESI+), m/z [M+H+] calculated for C31H32N2O6 
















Compound 5.9a was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 8.79 (d, J = 4.0 Hz, 1H), 8.70 (d, 
J = 6.6 Hz, 1H), 7.94 – 7.87 (m, 2H), 7.39 – 7.29 (m, 1H), 7.14 – 7.03 (m, 3H), 6.93 (dt, J = 8.3, 
4.5 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 4.58 (d, J = 18.7 Hz, 1H), 3.88 (d, J = 20.6 Hz, 6H), 3.62 – 
3.51 (m, 1H), 2.34 (s, 3H), 2.05 (dt, J = 10.3, 4.5 Hz, 2H), 1.88 – 1.81 (m, 1H), 1.76 – 1.54 (m, 
4H), 1.46 (s, 7H), 1.38 (s, 1H), 1.30 – 1.21 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 165.96, 
160.14, 159.96, 159.68, 157.22, 156.56, 149.99, 149.83, 138.96, 131.38, 130.33, 129.56, 128.54, 
126.42, 126.00, 124.90, 122.38, 121.86, 115.61, 113.51, 111.37, 110.56, 79.80, 77.16, 71.95, 
48.79, 30.09, 28.94, 28.82, 8.74, 8.37. HRMS (ESI+), m/z [M+H+] calculated for C36H40N2O8   





Compound 5.9a (0.05mg, 0.0795mmol) was dissolved in anhydrous dichloromethane (1mL).  





















warmed to rt and after 12 h the reaction was concentrated and purified via column 
chromatography (SiO2, 1:10, MeOH: DCM) to afford 5.4a as a white amorphous solid (70% 
yield): 1H NMR (500 MHz, Chloroform-d) δ 8.77 (d, J = 4.0 Hz, 1H), 8.71 (d, J = 6.8 Hz, 1H), 
7.90 – 7.82 (m, 2H), 7.38 – 7.30 (m, 1H), 7.10 – 7.02 (m, 3H), 6.90 (dt, J = 8.1, 4.6 Hz, 1H), 
6.84 (d, J = 8.5 Hz, 1H), 4.53 (d, J = 18.5 Hz, 1H), 3.88 (d, 6H), 3.60 – 3.54 (m, 1H), 2.24 (s, 
3H), 2.09 (m, 2H), 1.88 – 1.81 (m, 2H), 1.76 – 1.54 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 
165.99, 160.44, 159.91, 159.58, 157.02, 155.06, 149.00, 148.83, 138.16, 131.28, 130.53, 129.86, 
128.52, 126.22, 126.01, 124.40, 122.88, 121.83, 115.63, 113.52, 111.57, 110.50, 79.00, 77.36, 
71.05, 48.29, 30.39, 28.12, 8.17.HRMS (ESI+), m/z [M+H+] calculated for C31H32N2O6 





Compound 5.9b was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) 8.78 (s, 1H), 8.69 (s, 1H), 7.92 (m, 
1H), 7.87 (m, 2H), 7.37 (m, 1H), 7.29 (m, 2H), 7.12 (dt, J = 7.6, 1.2 Hz, 1H), 7.09 (dd, J = 2.7, 
1.6 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.85 (d, J = 8.7 Hz, 
1H), 4.62 (s, 1H) 4.53 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.52 (m, 1H), 2.33 (s, 3H), 1.98 (m, 
2H),  1.77 (m, 2H), 1.70 (tt, J = 14.2, 2.8 Hz, 2H), 1.54 (m, 2H), 1.45 (s, 9H). 13C NMR (126 













129.26, 128.25, 126.14, 125.69, 124.54, 122.09, 121.58, 117.42, 115.31, 113.27, 113.21, 111.07, 
110.27, 79.41, 71.68, 48.49, 28.64, 28.52, 27.98. HRMS (ESI+), m/z [M+H+] calculated for 





Compound 5.4b was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid 70%):  1H NMR (500 MHz, Methanol-d4) δ 8.47 (d, J = 1.3 Hz, 1H), 7.61 (dt, J 
= 8.6, 1.9 Hz, 1H), 7.57 (d, J = 2.4 Hz, 1H), 7.08 – 7.03 (m, 2H), 6.82 (dt, J = 7.6, 1.2 Hz, 1H), 
6.80 – 6.76 (m, 2H), 6.63 (ddd, J = 8.2, 2.7, 1.0 Hz, 1H), 6.57 (d, J = 8.7 Hz, 1H), 4.39 (t, J = 3.1 
Hz, 1H), 3.60 (d, J = 1.3 Hz, 3H), 3.55 (d, J = 1.3 Hz, 3H), 2.84 (ddt, J = 11.2, 7.9, 3.9 Hz, 1H), 
2.06 (s, 3H), 1.92 – 1.83 (m, 2H), 1.65 – 1.58 (m, 2H), 1.55 – 1.45 (m, 2H), 1.39 (tt, J = 13.6, 3.3 
Hz, 2H). 13C NMR (126 MHz, MeOD) δ 165.81, 159.77, 159.54, 159.17, 156.47, 149.36, 
138.51, 130.90, 129.84, 129.11, 128.16, 125.70, 124.81, 121.93, 121.33, 115.14, 113.01, 111.00, 
109.98, 70.03, 55.78, 55.22, 27.85, 25.39, 7.93. HRMS (ESI+), m/z [M+H+] calculated for 
















tert-Butyl ((1s,4s)-4-hydroxycyclohexyl)(methyl)carbamate (5.47a). 
tert-Butyl (4-oxocyclohexyl)carbamate (0.10 g, 0.44 mmol) was dissolved in anhydrous 
tetrahydrofuran (4 mL) and the solution was cooled to -40 OC. L-selectride (1.0 M in THF, 0.12 
ml) was added dropwise to the solution and the reaction mixture was allowed to stir at rt for 12 h. 
The reaction mixture was concentrated and the residue was diluted with water. The suspension 
was acidified with 1N HCl and extracted with ethyl acetate. The organic layers were combined, 
dried (over Na2SO4), concentrated and purified by column chromatography (SiO2, 1:2, EtOAc : 
hexane) to afford 5.47a as a white amorphous solid (30%): 1H NMR (500 MHz, Chloroform-d) δ 
3.87 (tt, J = 10.0, 4.5 Hz, 1H), 2.80 (s, 1H), 2.58 (s, 1H), 2.20 – 2.12 (m, 2H), 2.04 – 1.90 (m, 
2H), 1.86 – 1.79 (m, 2H), 1.69 – 1.58 (m, 2H), 1.38 (d, J = 2.4 Hz, 9H). 13C NMR (126 MHz, 





Compound 5.48a was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Methanol-d4) δ 8.00 (s, 1H), 7.20 (dd, J = 8.9, 2.3 
Hz, 1H), 7.10 (d, J = 2.5 Hz, 1H), 6.60 – 6.52 (m, 3H), 6.40 – 6.32 (m, 4H), 6.24 – 6.18 (m, 2H), 
4.02 (t, J = 3.1 Hz, 1H), 3.14 (s, 3H), 3.10 (s, 3H), 2.60 (p, J = 1.8 Hz, 1H), 2.30 (tt, J = 11.9, 4.3 
Hz, 1H), 1.96 (s, 3H), 1.87 (s, 3H), 1.65-1.55 (m, 2H), 1.45 (m, 4H), 1.32 – 1.25 (m, 2H), 1.11 – 










138.07, 130.35, 129.06, 128.71, 127.28, 125.17, 124.37, 121.09, 121.00, 114.89, 112.75, 110.09, 
109.14, 69.74, 56.54, 55.49, 54.00, 29.52, 28.02, 27.09, 22.38, 7.58. HRMS (ESI+), m/z 





Compound 5.5a was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid 70%): 1H NMR (500 MHz, Methanol-d4) δ 8.02 (s, 1H), 7.18 (dd, J = 8.6, 2.5 
Hz, 1H), 7.14 (d, J = 2.4 Hz, 1H), 6.67 – 6.58 (m, 3H), 6.41 – 6.34 (m, 4H), 6.22 – 6.13 (m, 2H), 
3.99 (t, J = 2.9 Hz, 1H), 3.17 (s, 3H), 3.12 (s, 3H), 2.62 (p, J = 1.6 Hz, 1H), 2.34 (tt, J = 11.7, 4.1 
Hz, 1H), 1.94 (d, J = 2.6 Hz, 3H), 1.62 (s, 3H), 1.50 (dt, J = 16.0, 2.9 Hz, 2H), 1.26 (dd, J = 13.0, 
3.8 Hz, 2H), 1.18 – 1.07 (m, 2H), 1.04 – 0.92 (m, 2H). 13C NMR (126 MHz, MeOD) δ 165.63, 
159.55, 159.25, 158.92, 156.15, 149.11, 138.27, 130.65, 129.56, 128.81, 127.88, 125.47, 124.67, 
121.65, 121.07, 114.89, 112.71, 110.79, 109.74, 69.73, 56.58, 55.46, 54.90, 29.22, 27.49, 22.88, 
7.57. HRMS (ESI+), m/z [M+H+] calculated for C32H34N2O6 543.2495; found 543.2462. 
 
 















Sodium borohydride (0.02g, 0.53 mmol) was added to an ice-cooled solution of tert-butyl (4-
oxocyclohexyl)carbamate (0.1g, 0.44 mmol) in methanol (4.5 ml) and the reaction mixture was 
allowed to stir at rt for 12 h. The reaction mixture was concentrated and the residue was diluted 
with water. The suspension was acidified with 1N HCl and extracted with ethyl acetate. The 
organic layers were combined, dried (over Na2SO4), concentrated and purified by column 
chromatography (SiO2, 1:2, EtOAc: hexane) to afford 5.47b as a white amorphous solid 
(60%):1H NMR (500 MHz, Chloroform-d) δ 3.50 (tt, J = 10.7, 4.3 Hz, 1H), 2.71 (s, 1H), 2.66 (s, 
1H), 2.17 – 2.08 (m, 2H), 2.01 – 1.93 (m, 2H), 1.85 – 1.78 (m, 2H), 1.67 – 1.56 (m, 2H), 1.42 (d, 





Compound 5.48b was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 9.35 (d, J = 9.7 Hz, 2H), 9.02 (s, 
1H), 8.67 (d, J = 10.2 Hz, 1H), 8.60 (s, 1H), 7.90 – 7.82 (m, 2H), 7.35 (dt, J = 21.7, 8.3 Hz, 2H), 
7.16 – 7.08 (m, 3H), 6.90 (dd, J = 8.1, 2.5 Hz, 1H), 6.82(dd, J = 12.0, 8.5 Hz, 1H), 4.55 (d, J = 
3.9 Hz, 1H), 3.95 (s, 3H), 3.91(s, 3H), 2.67 (d, J = 5.1 Hz, 1H), 2.32 (m, 2H), 2.29 (s, 3H), 
2.20(d, J = 15.5 Hz, 2H), 2.04 – 1.92 (m, 4H), 1.52 (s, 3H), 1.29 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 165.04, 159.66, 159.25, 149.02, 138.99, 130.93, 129.56, 129.25, 128.03, 126.54, 










29.62, 29.17, 27.45, 26.03, 23.60, 7.93. HRMS (ESI+), m/z [M+Na+] calculated for 





Compound 5.5b was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid 70%): 1H NMR (500 MHz, Chloroform-d) δ 9.39 (d, J = 9.9 Hz, 2H), 9.22 (s, 
1H), 8.77 (d, J = 10.0 Hz, 1H), 8.67 (s, 1H), 7.92 – 7.85 (m, 2H), 7.33 (dt, J = 21.9, 8.1 Hz, 2H), 
7.14 – 7.03 (m, 3H), 6.92 (dd, J = 7.9, 2.5 Hz, 1H), 6.83 (dd, J = 12.0, 8.7 Hz, 1H), 4.68 (d, J = 
3.7 Hz, 1H), 4.30 (d, J = 9.6 Hz, 1H), 3.89 (d, J = 6.3 Hz, 3H), 3.85 (s, 3H), 3.06 – 2.93 (m, 2H), 
2.67 (d, J = 5.1 Hz, 5H), 2.32 (s, 2H), 2.29 (s, 1H), 2.22 (d, J = 15.8 Hz, 3H), 2.04 – 1.92 (m, 
5H), 1.70 – 1.52 (m, 3H), 1.29 (d, J = 33.7 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 165.34, 
159.65, 159.21, 149.32, 138.49, 130.91, 129.86, 129.05, 128.00, 126.94, 125.91, 125.42, 124.07, 
122.21, 121.89, 115.13, 113.03, 110.89, 109.74, 55.75, 55.21, 30.28, 29.60, 29.07, 27.85, 26.00, 



























Compound 5.4a (0.04g, 0.06mmol) was dissolved in methanol (0.6mL). 10% Pt/C (0.002, 
0.008mmol) and acetonitrile (0.01mL) were added to the mixture and the suspension was stirred 
under a hydrogen atmosphere. After 25 h, the reaction mixture was filtered through a pad of 
Celite; the residue was washed with ethyl acetate.  The filtrate was concentrated and purified by 
column chromatography (SiO2, 1:10, MeOH: DCM) to yield 5.6a as a white solid (60% yield): 
1H NMR (500 MHz, Methanol-d4) δ 8.02 (s, 1H), 7.18 (dd, J = 8.6, 2.5 Hz, 1H), 7.14 (d, J = 2.4 
Hz, 1H), 6.67 – 6.58 (m, 3H), 6.41 – 6.34 (m, 4H), 6.22 – 6.13 (m, 2H), 3.99 (t, J = 2.9 Hz, 1H), 
3.17 (s, 3H), 3.12 (s, 3H), 2.62 (p, J = 1.6 Hz, 2H), 2.34 (tt, J = 11.7, 4.1 Hz, 1H), 2.20-2.15 (m, 
4H), 1.94 (d, J = 2.6 Hz, 3H), 1.88 (t, 4H), 1.62 (s, 3H). 13C NMR (126 MHz, MeOD) δ 165.63, 
159.55, 159.25, 158.92, 156.15, 149.11, 138.27, 130.65, 129.56, 128.81, 127.88, 125.47, 124.67, 
121.65, 121.07, 114.89, 112.71, 110.79, 109.74, 69.73, 56.58, 55.46, 54.90, 29.22, 27.49, 22.88, 





Compound 5.6b was obtained following the procedure for the synthesis of 5.6a as a white 
amorphous solid (60%): 1H NMR (500 MHz, Chloroform-d) δ 9.39 (d, J = 9.9 Hz, 2H), 9.22 (s, 













7.14 – 7.03 (m, 3H), 6.92 (dd, J = 7.9, 2.5 Hz, 1H), 6.83 (dd, J = 12.0, 8.7 Hz, 1H), 4.68 (d, J = 
3.7 Hz, 1H), 4.30 (d, J = 9.6 Hz, 1H), 3.89 (d, J = 6.3 Hz, 3H), 3.85 (s, 3H), 3.06 – 2.93 (m, 2H), 
2.67 (d, J = 5.1 Hz, 2H), 2.22 (d, J = 15.8 Hz, 1H), 2.11 (s, 3H), 2.04 – 1.92 (m, 4H), 1.70 – 1.64 
(m, 2H), 1.61 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.34, 159.65, 159.21, 149.32, 138.49, 
130.91, 129.86, 129.05, 128.00, 126.94, 125.91, 125.42, 124.07, 122.21, 121.89, 115.13, 113.03, 
110.89, 109.74, 55.75, 55.21, 30.28, 29.60, 29.07, 27.85, 26.00, 23.10, 8.22, 7.93. HRMS 





Acetic Acid (0.5mg, 8.5mmol) was added to a solution of 5.4a (0.20g, 1.7mmol) in methanol 
(20mL).  Formaldehyde (0.10g, 3.4mmol) and NaBH3CN (0.23g, 3.7mmol) were added and the 
mixture was stirred at rt.  After 12h the reaction was diluted with 40mL of H2O and then 
extracted with DCM ( 3 x 30mL).  The organic layers were combined, dried, and concentrated.  
The crude mixture was purified by column chromatography (SiO2, 1:10, MeOH: DCM) to yield 
5.7a as a white solid (40% yield):1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 
1H), 7.94 – 7.87 (m, 2H), 7.39 – 7.32 (m, 2H), 7.12 (dt, J = 7.6, 1.2 Hz, 1H), 7.10 – 7.08 (m, 
2H), 7.06 (s, 1H), 6.93 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 4.70 (t, J = 2.9 
Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.18 – 3.03 (m, 1H), 2.69 (s, 6H), 2.35 (s, 3H), 2.31 – 2.21 












159.92, 159.56, 159.45, 156.33, 149.56, 138.71, 131.15, 130.07, 129.32, 128.31, 126.15, 125.87, 
124.31, 122.13, 115.37, 113.26, 111.13, 110.18, 70.33, 63.46, 39.57, 28.61, 21.12, 8.54. HRMS 





Compound 5.7b was obtained following the procedure for the synthesis of 5.7a as a white 
amorphous solid (60%):1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.94 – 
7.87 (m, 2H), 7.40 – 7.30 (m, 2H), 7.13 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.09 (dd, J = 2.6, 1.6 Hz, 
1H), 7.07 (d, J = 8.6 Hz, 1H), 6.93 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 4.65 
(t, J = 3.0 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 2.51 (t, J = 11.4 Hz, 1H), 2.43 (s, 7H), 2.36 (s, 
3H), 2.23 – 2.14 (m, 2H), 1.81 – 1.72 (m, 5H), 1.63 (ddt, J = 14.0, 11.1, 2.7 Hz, 2H). 13C NMR 
(126 MHz, CDCl3) δ 165.64, 159.88, 159.68, 159.45, 156.86, 149.60, 138.73, 131.13, 130.08, 
129.32, 128.29, 126.23, 125.71, 124.52, 122.14, 115.35, 113.28, 111.11, 110.29, 71.46, 62.92, 


























Compound 5.4a (0.03g, 0.08mmol) was dissolved in anhydrous dichloromethane (0.8mL).  
Triethylamine (0.013mL, 0.08mmol) was added and the mixture was cooled to 0oC.  After 10 
minutes, acetic anhydride (0.008mL, 0.08mmol) was added dropwise.  The reaction was 
quenched after 12 h, via the addition of water.  The mixture was worked-up with 
dichloromethane (3 x 5mL), dried, concentrated, and purified via column chromatography (SiO2, 
1:10, MeOH: DCM) to afford 5.8a as a white amorphous solid (70% yield): 1H NMR (500 MHz, 
Chloroform-d) δ 8.79 (d, J = 1.3 Hz, 1H), 8.70 (s, 1H), 7.94 – 7.86 (m, 2H), 7.40 – 7.34 (m, 1H), 
7.31 (d, J = 8.6 Hz, 1H), 7.12 (dd, J = 7.6, 1.4 Hz, 1H), 7.10 – 7.05 (m, 2H), 6.96 – 6.90 (m, 1H), 
6.87 (d, J = 8.6 Hz, 1H), 5.34 (d, J = 7.8 Hz, 1H), 4.31 – 4.22 (m, 1H), 3.88 (dd, J = 20.0, 1.4 
Hz, 6H), 2.31 (d, J = 1.4 Hz, 3H), 2.19 – 2.05 (m, 4H), 1.98 (d, J = 1.4 Hz, 3H), 1.71 – 1.57 (m, 
4H). 13C NMR (126 MHz, CDCl3) δ 169.42, 165.52, 159.77, 159.51, 159.33, 157.25, 138.61, 
131.04, 129.96, 129.17, 128.13, 126.10, 125.44, 124.30, 122.00, 121.64, 115.25, 113.15, 111.01, 
110.77, 55.89, 55.33, 47.44, 30.42, 30.30, 23.57, 8.37. HRMS (ESI+), m/z [M+Na+] calculated 

















Compound 5.8b was obtained following the procedure for the synthesis of 5.8a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.81 (s, 1H), 8.70 (s, 1H), 7.92 
(dd, J = 8.6, 2.4 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.36 – 7.32 (m, 1H), 
7.13 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.09 (dd, J = 2.6, 1.6 Hz, 1H), 7.07 (d, J = 8.7 Hz, 1H), 6.93 
(ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 5.40 (d, J = 8.1 Hz, 1H), 4.63 (t, J = 3.3 
Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 2.36 (s, 3H), 2.11 – 2.03 (m, 2H), 2.00 (s, 3H), 1.86 – 1.81 
(m, 2H), 1.78 – 1.69 (m, 2H), 1.65 – 1.57 (m, 7H). 13C NMR (126 MHz, CDCl3) δ 169.41, 
165.64, 159.90, 159.70, 159.45, 156.91, 149.58, 138.74, 131.15, 130.07, 129.33, 128.32, 126.21, 
125.80, 124.54, 122.14, 121.70, 115.37, 114.98, 113.39, 113.28, 111.13, 110.28, 71.51, 47.44, 






Compound 5.4a (0.03g, 0.08mmol) was dissolved in anhydrous tetrahydrofuran (0.8mL).  
Triethylamine (0.013mL, 0.08mmol) was added and the mixture was cooled to 0oC.  After 10 
minutes, benzyl chloride (0.013mL, 0.08mmol) was added dropwise.  The reaction was 
quenched after 12 hours, via the addition of water.  The mixture was worked-up with ethyl 
acetate (3 x 5mL), dried, concentrated, and purified via column chromatography (SiO2, 1:10, 
MeOH: DCM) to afford 5.10a as a white amorphous solid (70% yield): 1H NMR (500 MHz, 














(d, J = 7.1 Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 
7.12 (d, J = 7.7 Hz, 1H), 7.09 (t, J = 2.0 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.93 (dd, J = 8.2, 2.5 
Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 6.10 (d, J = 7.8 Hz, 1H), 4.30 (tt, J = 9.8, 3.5 Hz, 1H), 4.09 
(dq, J = 10.5, 3.6 Hz, 1H), 3.87 (d, J = 18.7 Hz, 6H), 2.32 (s, 3H), 2.21 (td, J = 11.5, 10.1, 5.1 
Hz, 5H), 1.71 (tdd, J = 13.1, 9.9, 4.0 Hz, 2H), 1.49 – 1.38 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 167.34, 165.86, 160.13, 159.86, 159.69, 157.62, 149.80, 138.97, 135.06, 131.84, 130.32, 
129.54, 128.94, 128.49, 127.22, 125.82, 124.66, 122.36, 115.62, 113.50, 111.38, 111.11, 76.44, 
56.25, 55.69, 48.25, 30.77, 30.70, 8.74. HRMS (ESI+), m/z [M+Na+] calculated for 





Compound 5.10b was obtained following the procedure for the synthesis of 5.10a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 8.10 
(dd, J = 8.3, 1.3 Hz, 1H), 7.93 – 7.87 (m, 2H), 7.81 – 7.76 (m, 2H), 7.52 – 7.40 (m, 3H), 7.40 – 
7.30 (m, 2H), 7.14 – 7.03 (m, 3H), 6.93 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 
6.16 (d, J = 8.0 Hz, 1H), 4.66 (dd, J = 4.7, 2.5 Hz, 1H), 4.17 – 4.08 (m, 1H), 3.99 – 3.90 (m, 1H), 
3.89 (s, 3H), 3.85 (s, 3H), 2.37 (s, 2H), 2.18 – 2.07 (m, 2H), 1.99 – 1.92 (m, 2H), 1.83 – 1.67 (m, 
4H). 13C NMR (126 MHz, CDCl3) δ 170.23, 167.04, 165.63, 159.86, 159.66, 159.41, 156.93, 














127.00, 126.16, 125.77, 124.55, 122.11, 121.63, 115.34, 114.96, 113.23, 111.10, 110.27, 71.57, 
70.90, 48.54, 47.94, 28.81, 28.57, 27.71, 26.92, 8.56. HRMS (ESI+), m/z [M+Na+] calculated for 





Benzyl Bromide (0.12mL,1.0mmol), was added to a solution of 5.4a ( 1.32g, 2.5mmol), 
K2CO3 ( 0.15g, 1.1mmol), in MeCN (30mL) and heated at reflux.  After 24 h. the reaction was 
cooled to rt, quenched with water, and worked-up with EtOAc (3 x 50mL).  The organic layers 
were combined, dried, concentrated and purified via column chromatography (SiO2, 1:10, 
MeOH: DCM) to afford 5.10a as a white amorphous solid (50% yield): 1H NMR (500 MHz, 
Chloroform-d) δ 8.79 (s, 1H), 8.69 (s, 1H), 7.92 – 7.87 (m, 2H), 7.53 (d, J = 7.4 Hz, 2H), 7.41 – 
7.30 (m, 6H), 7.12 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.09 (dd, J = 2.6, 1.6 Hz, 1H), 7.06 (d, J = 8.7 
Hz, 1H), 6.93 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 4.32 (ddt, J = 9.5, 6.7, 3.4 
Hz, 1H), 3.96 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 2.82 (dd, J = 12.3, 8.8 Hz, 1H), 2.27 (s, 3H), 
2.21 (d, J = 11.3 Hz, 5H), 1.71 – 1.62 (m, 2H), 1.49 (td, J = 11.2, 9.9, 2.6 Hz, 2H).13C NMR (126 
MHz, CDCl3) δ 165.62, 159.87, 159.64, 159.44, 157.10, 149.53, 138.73, 131.12, 130.07, 129.31, 
129.11, 128.31, 126.22, 125.69, 124.43, 122.14, 121.81, 115.34, 113.64, 113.28, 111.11, 110.85, 
75.48, 54.42, 49.13, 29.76, 27.59, 8.48. HRMS (ESI+), m/z [M+H+] calculated for C38H38N2O6 

















Compound 5.11b was obtained following the procedure for the synthesis of 5.11a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.79 (d, J = 2.0 Hz, 1H), 8.70 (d, 
J = 2.9 Hz, 1H), 7.94 – 7.88 (m, 3H), 7.41 – 7.36 (m, 3H), 7.35 – 7.27 (m, 5H), 7.23 – 7.19 (m, 
1H), 7.13 (dt, J = 7.6, 1.2 Hz, 2H), 7.10 – 7.04 (m, 3H), 6.93 (dd, J = 8.3, 2.5 Hz, 1H), 6.86 (dd, 
J = 11.6, 8.7 Hz, 1H), 4.66 (s, 1H), 4.60 (dd, J = 7.4, 4.3 Hz, 1H), 3.90 (s, 4H), 3.86 (d, J = 5.3 
Hz, 5H), 3.69 (s, 2H), 2.64 (dt, J = 11.5, 3.7 Hz, 1H), 2.36 (d, J = 1.2 Hz, 3H), 2.18 – 2.02 (m, 
2H), 1.79 (ddd, J = 26.3, 13.3, 6.6 Hz, 2H), 1.69 – 1.55 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 
165.90, 160.15, 159.73, 149.83, 141.33, 139.02, 131.44, 130.36, 129.57, 128.82, 128.57, 128.49, 
127.05, 126.56, 125.89, 124.88, 122.43, 115.64, 113.56, 111.41, 110.62, 72.12, 57.15, 56.29, 
55.73, 54.24, 51.40, 29.82, 28.83, 28.43, 22.85, 8.83. HRMS (ESI+), m/z [M+H+] calculated for 

























Cyclopropylmethyl methanesulfonate (0.18g, 1.2mmol) was added to a solution of DIPEA ( 
0.32 mL, 1.8mmol), 5.4b ( 0.528g, 1.0mmol), and anhydrous MeCN (10mL).  The mixture was 
placed in a sealed microwave safe septum-capped tube, and heated to 120 oC in a microwave 
synthesizer.  After 1h the reaction was complete and the vial was cooled to rt and quenched with 
water.  The reaction was worked-up with EtOAc (3 x 20mL).  The organic layers were 
combined, dried, concentrated, and purified via column chromatography  (SiO2, 1:10, MeOH: 
DCM) to afford 5.12a as a white amorphous solid (30% yield):  1H NMR (500 MHz, Methanol-
d4) δ 8.69 (d, J = 3.4 Hz, 1H), 7.86 (dd, J = 8.8, 2.3 Hz, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.35 (d, J 
= 2.2 Hz, 1H), 7.33 – 7.28 (m, 2H), 7.10 – 7.05 (m, 3H), 6.85 – 6.82 (m, 2H), 4.32 – 4.30 (m, 
1H), 3.85 (d, J = 25.3 Hz, 6H), 2.80 (m, 1H), 2.25 (s, 3H), 2.20 (m, 4H), 2.07 (d, J = 12.9 Hz, 
3H), 1.90 – 1.85 (m, 2H), 1.80 (td, J = 11.5, 3.1 Hz, 1H), 1.69 (d, J = 12.3 Hz, 2H). -0.10 – -0.15 
(m, 2H), -0.69 (m, 4H), -0.79 – -0.95 (m, 4H). 13C NMR (126 MHz, MeOD) δ 166.39, 160.42, 
160.02, 157.76, 150.42, 139.12, 131.81, 130.23, 129.76, 129.21, 126.86, 125.52, 122.27, 122.11, 
116.31, 115.96, 114.34, 113.75, 113.04, 111.62, 110.72, 70.44, 56.51, 55.93, 54.34, 30.41, 28.22, 

















Compound 5.12b was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.75 (d, J = 3.6 Hz, 1H), 7.82 (dd, 
J = 8.7, 2.4 Hz, 1H), 7.79 (d, J = 2.6 Hz, 1H), 7.35 (d, J = 2.7 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.07 
– 7.02 (m, 3H), 6.88 – 6.82 (m, 2H), 4.66 – 4.63 (m, 1H), 3.84 (d, J = 24.6 Hz, 6H), 3.13 – 3.09 
(m, 1H), 2.32 (s, 3H), 2.27 (m, 4H), 2.18 (d, J = 13.4 Hz, 3H), 1.93 – 1.88 (m, 2H), 1.81 (td, J = 
12.1, 3.3 Hz, 1H), 1.68 (d, J = 12.4 Hz, 2H). -0.04 – -0.14 (m, 2H), -0.65 (m, 4H), -0.83 – -1.00 
(m, 4H). 13C NMR (126 MHz, MeOD) δ 166.20, 160.15, 160.46, 157.42, 150.45, 139.48, 
131.38, 130.69, 129.95, 129.00, 126.64, 125.75, 122.74, 122.34, 116.02, 115.36, 114.51, 113.13, 
113.00, 111.52, 110.11, 70.49, 56.66, 55.75, 54.81, 30.32, 28.75, 25.91, 13.11, 8.07, 3.55. 





Compound 5.12c was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.68 (d, J = 3.3 Hz, 1H), 7.85 (dd, 
J = 8.7, 2.6 Hz, 1H), 7.80 (d, J = 2.6 Hz, 1H), 7.33 (d, J = 2.4 Hz, 1H), 7.32 – 7.29 (m, 2H), 7.06 
– 7.04 (m, 3H), 6.87 – 6.82 (m, 2H), 4.52 (s, 1H), 4.35 – 4.30 (m, 1H), 3.81 (d, J = 24.9 Hz, 6H), 
2.83 (m, 1H), 2.29 (s, 3H), 2.24 (t, J = 5.5 Hz, 2H), 2.10 (d, J = 13.0 Hz, 3H), 1.94 – 1.89 (m, 
2H), 1.81 (td, J = 11.7, 3.4 Hz, 1H), 1.68 (d, J = 12.2 Hz, 2H) -0.08 – -0.16 (m, 1H), -0.66 (dt, J 













160.11, 157.39, 150.36, 139.43, 131.66, 130.08, 129.42, 129.30, 126.45, 125.77, 122.32, 122.06, 
116.31, 115.83, 114.33, 113.11, 113.00, 111.67, 110.22, 70.84, 56.59, 55.97, 54.33, 30.53, 28.05, 






Compound 5.12d was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.70 (d, J = 3.4 Hz, 1H), 7.86 (dd, 
J = 8.5, 2.5 Hz, 1H), 7.81 (d, J = 2.7 Hz, 1H), 7.36 (d, J = 2.6 Hz, 1H), 7.34 – 7.27 (m, 2H), 7.08 
– 7.01 (m, 3H), 6.89 – 6.83 (m, 2H), 4.69 – 4.62 (m, 1H), 4.49 (s, 1H), 3.82 (d, J = 24.7 Hz, 6H), 
3.15 – 3.06 (m, 1H), 2.30 (s, 3H), 2.25 (t, J = 5.7 Hz, 2H), 2.14 (d, J = 13.3 Hz, 3H), 1.92 – 1.83 
(m, 2H), 1.79 (td, J = 11.9, 3.2 Hz, 1H), 1.66 (d, J = 12.3 Hz, 2H). -0.04 – -0.15 (m, 1H), -0.64 
(dt, J = 7.9, 2.9 Hz, 2H), -0.85 – -1.03 (m, 2H). 13C NMR (126 MHz, MeOD) δ 166.82, 160.71, 
160.06, 157.41, 150.25, 139.42, 131.78, 130.68, 129.92, 129.90, 126.60, 125.95, 122.77, 122.14, 
116.00, 115.66, 114.11, 113.83, 113.80, 111.92, 110.91, 70.89, 56.56, 55.99, 54.21, 30.40, 28.65, 



















Compound 5.13a was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.72 (d, J = 3.4 Hz, 1H), 7.81 (dd, 
J = 8.9, 2.5 Hz, 1H), 7.79 (d, J = 2.6 Hz, 1H), 7.36 (d, J = 2.5 Hz, 1H), 7.31 – 7.29 (m, 2H), 7.09 
– 7.02 (m, 3H), 6.90 – 6.86 (m, 2H), 4.39-4.37 (m, 2H), 4.32 – 4.29 (m, 1H), 3.88-3.85 (m, 2H), 
3.82 (d, J = 24.8 Hz, 6H), 3.70 (m, 2H), 3.66-3.63 (m, 2H), 2.80 (m, 1H), 2.22 (s, 3H), 2.11-2.09 
(m, 4H), 1.97 (m, 1H), 1.92 – 1.86 (m, 2H), 1.83-1.80 (m, 4H), 1.69 (m, 2H).  13C NMR (126 
MHz, MeOD) δ 162.31, 159.07, 159.02, 157.79, 144.57, 131.71, 129.99, 129.77, 129.19, 128.28, 
127.62, 125.65, 123.02, 123.12, 122.02, 120.31, 117.82, 115.57, 115.35, 114.28, 75.32, 71.07, 
66.69, 58.49, 57.71, 53.69, 52.39, 51.31, 35.24, 31.02, 27.67, 27.39 7.55. HRMS (ESI+), m/z 




























Compound 5.13b was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.82 (d, J = 3.5 Hz, 1H), 7.80 (dd, 
J = 8.6, 2.3 Hz, 1H), 7.75 (d, J = 2.6 Hz, 1H), 7.50 (d, J = 2.3 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.05 
– 7.01 (m, 3H), 6.87 – 6.82 (m, 2H), 4.68 – 4.63 (m, 1H), 4.42-4.38 (m, 2H), 3.90-3.87 (m, 2H), 
3.79 (d, J = 24.8 Hz, 6H), 3.75 (m, 2H), 3.65-3.60 (m, 2H), 3.11 – 3.06 (m, 1H), 2.28 (s, 3H), 
2.10 (d, 4H), 1.99-1.93 (m, 2H), 1.89 – 1.80 (m, 5H), 1.72 (m, 1H), 1.66 (m, 1H). 13C NMR (126 
MHz, MeOD) δ 162.45, 159.35, 159.02, 157.17, 144.02, 131.86, 129.95, 129.45, 129.23, 128.37, 
127.14, 125.01, 123.28, 123.02, 122.09, 120.55, 117.85, 115.51, 115.21, 114.67, 75.34, 71.31, 
66.49, 58.62, 57.51, 53.66, 52.12, 51.14, 35.54, 31.13, 27.56, 27.23 7.55. HRMS (ESI+), m/z 






Compound 5.13c was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.72 (d, J = 3.5 Hz, 1H), 7.89 (dd, 
J = 8.8, 2.5 Hz, 1H), 7.80 (d, J = 2.6 Hz, 1H), 7.33 (d, J = 2.6 Hz, 1H), 7.30 – 7.27 (m, 2H), 7.06 
– 7.01 (m, 3H), 6.86 – 6.80 (m, 2H), 4.55 (s, 1H), 4.38 (t, J = 5.9 Hz, 1H), 4.32 – 4.29 (m, 1H), 
3.88 (q, J = 7.5 Hz, 1H), 3.80 (d, J = 24.7 Hz, 6H), 3.74 (dt, J = 8.3, 4.2 Hz, 1H), 3.67 (dq, J = 
12.9, 4.5, 3.8 Hz, 1H), 2.82 (m, 1H), 2.23 (s, 3H), 2.11 (d, J = 13.2 Hz, 3H), 1.99 (ddd, J = 14.2, 














MeOD) δ 162.01, 159.37, 159.32, 157.72, 144.53, 131.41, 129.97, 129.47, 129.39, 128.48, 
127.32, 125.61, 123.82, 123.02, 122.00, 120.41, 117.85, 115.50, 115.15, 114.22, 75.22, 71.27, 
66.62, 58.19, 57.71, 53.29, 52.39, 51.11, 35.02, 31.72, 27.97, 27.69 7.31. HRMS (ESI+), m/z 





Compound 5.13d was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.80 (d, J = 3.4 Hz, 1H), 7.85 (dd, 
J = 8.8, 2.6 Hz, 1H), 7.79 (d, J = 2.9 Hz, 1H), 7.49 (d, J = 2.4 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.03 
– 7.00 (m, 3H), 6.85 – 6.82 (m, 2H), 4.70 – 4.65 (m, 1H), 4.50 (s, 1H), 4.40 (t, J = 5.9 Hz, 1H), 
3.88 (q, J = 7.6 Hz, 1H), 3.81 (d, J = 24.5 Hz, 6H), 3.76 (dt, J = 8.4, 4.3 Hz, 1H), 3.62 (dq, J = 
12.7, 4.5, 3.7 Hz, 1H), 3.12 – 3.07 (m, 1H), 2.32 (s, 3H), 2.14 (d, 4H), 1.99 (ddd, J = 14.2, 9.4, 
6.0 Hz, 1H), 1.92 – 1.80 (m, 3H), 1.75 (td, J = 11.7, 3.1 Hz, 1H), 1.68 (d, J = 12.4 Hz, 1H). 13C 
NMR (126 MHz, MeOD) δ 162.11, 159.33, 159.02, 157.76, 144.52, 131.44, 129.90, 129.67, 
129.23, 128.67, 127.02, 125.61, 123.22, 123.02, 122.00, 120.11, 117.05, 115.59, 115.45, 114.67, 
75.09, 71.32, 66.45, 58.65, 57.71, 53.48, 52.23, 51.16, 35.12, 31.45, 27.22, 27.13 7.33. HRMS 




















Compound 5.14a was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 7.91 (d, J = 2.4 Hz, 1H), 7.11 – 
7.06 (m, 1H), 7.02 (d, J = 2.4 Hz, 1H), 6.60 (d, J = 3.0 Hz, 1H), 6.55 – 6.46 (m, 2H), 6.35 (ddt, J 
= 8.1, 6.7, 2.2 Hz, 3H), 6.29 – 6.21 (m, 2H), 6.00 (ddd, J = 7.0, 5.1, 3.2 Hz, 1H), 3.56 – 3.42 (m, 
1H), 3.17 (d, J = 1.6 Hz, 3H), 3.11 (d, J = 3.0 Hz, 3H), 2.99 – 2.88 (m, 2H), 2.79 (m, 2H), 2.75 – 
2.68 (m, 2H), 2.63 – 2.58 (m, 2H), 2.50 (s, 3H), 2.48 (dt, J = 3.3, 1.5 Hz, 1H), 2.30 (m, 2H), 1.88 
– 1.76 (m, 1H), 1.62-1.57 (m, 4H), 1.42 – 1.30 (m, 2H), 1.25 (m, 2H), 1.09 – 1.02 (m, 1H). 13C 
NMR (126 MHz, MeOD) δ 165.06, 159.63, 158.41, 149.33, 144.21, 138.74, 130.39, 129.36, 
128.23, 128.07, 125.56, 123.06, 121.59, 114.61, 112.31, 110.98, 70.08, 67.90, 63.52, 55.06, 
54.00, 53.17, 49.37, 40.99, 33.76, 28.48, 7.04. HRMS (ESI+), m/z [M+H+] calculated for 




























Compound 5.14b was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 7.93 (d, J = 2.7 Hz, 1H), 7.20 – 
7.15 (m, 1H), 7.10 (d, J = 2.5 Hz, 1H), 6.66 (d, J = 3.0 Hz, 1H), 6.55 – 6.40 (m, 2H), 6.30 (ddt, J 
= 7.7, 6.3, 2.4 Hz, 3H), 6.21 – 6.17 (m, 2H), 6.09 (ddd, J = 6.4, 5.1, 3.8 Hz, 1H), 3.55 – 3.40 (m, 
1H), 3.10 (s, 3H), 3.06 (s, 3H), 2.95 – 2.89 (m, 2H), 2.77 (m, 2H), 2.73 – 2.68 (m, 2H), 2.60 – 
2.53 (m, 2H), 2.45(s, 3H), 2.30 (dt, J = 3.3, 1.8 Hz, 1H), 2.22 (m, 2H), 1.88 – 1.65 (m, 1H), 1.58 
(m, 4H), 1.39 – 1.28 (m, 2H), 1.22 (m, 2H), 1.13 – 1.06 (m, 1H). 13C NMR (126 MHz, MeOD) δ 
165.53, 159.41, 158.89, 149.05, 144.40, 138.22, 130.44, 129.78, 128.69, 128.19, 125.56, 123.93, 
121.88, 114.23, 112.15, 110.63, 70.78, 67.22, 63.42, 55.06, 54.10, 53.57, 49.27, 40.99, 33.82, 




Compound 5.14c was obtained following the procedure for the synthesis of 5.12c as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 7.95 (d, J = 2.9 Hz, 1H), 7.19 – 
7.15 (m, 1H), 7.05 (d, J = 2.3 Hz, 1H), 6.57 (d, J = 2.7 Hz, 1H), 6.55 – 6.49 (m, 2H), 6.34 (ddt, J 
= 7.7, 6.5, 2.4 Hz, 3H), 6.29 – 6.22 (m, 2H), 6.03 (ddd, J = 6.5, 5.5, 3.6 Hz, 1H), 3.62 (s, 1H), 
3.54 – 3.38 (m, 1H), 3.15 (d, J = 1.8 Hz, 3H), 3.11 (d, J = 3.2 Hz, 3H), 2.98 – 2.86 (m, 1H), 2.77 














1.3 Hz, 1H), 2.40 (dd, J = 8.9, 4.5 Hz, 1H), 1.70 – 1.56 (m, 1H), 1.40 (dd, J = 5.6, 3.4 Hz, 4H), 
1.30 – 1.24 (m, 2H), 1.18 (dddd, J = 17.5, 14.8, 10.3, 4.5 Hz, 2H), 0.99 – 0.84 (m, 1H). 13C NMR 
(126 MHz, MeOD) δ 165.47, 159.47, 158.37, 149.04, 144.19, 138.32, 130.51, 129.49, 128.41, 
128.09, 125.73, 123.58, 121.19, 114.11, 112.61, 110.78, 70.48, 67.09, 63.34, 55.35, 54.82, 53.07, 
49.15, 41.00, 33.72, 28.08, 7.66. HRMS (ESI+), m/z [M+H+] calculated for C36H40N2O7  





Compound 5.14d was obtained following the procedure for the synthesis of 5.12c as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 7.90 (d, J = 2.7 Hz, 1H), 7.09 – 
7.05 (m, 1H), 7.04 (d, J = 2.5 Hz, 1H), 6.56 (d, J = 2.9 Hz, 1H), 6.55 – 6.46 (m, 2H), 6.34 (ddt, J 
= 7.9, 6.7, 2.4 Hz, 3H), 6.30 – 6.22 (m, 2H), 6.09 (ddd, J = 6.8, 5.3, 3.8 Hz, 1H), 3.52 – 3.36 (m, 
1H), 3.05 (d, J = 1.8 Hz, 3H), 3.01 (d, J = 3.2 Hz, 3H), 2.93 – 2.86 (m, 1H), 2.76 (td, J = 5.6, 2.7 
Hz, 1H), 2.73 – 2.68 (m, 1H), 2.67 – 2.58 (m, 1H), 2.54 (d, J = 3.3 Hz, 3H), 2.50 (dt, J = 3.4, 1.6 
Hz, 1H), 2.41 (dd, J = 8.8, 4.7 Hz, 1H), 1.66 – 1.53 (m, 1H), 1.44 (dd, J = 5.8, 3.3 Hz, 4H), 1.32 
– 1.24 (m, 2H), 1.15 (dddd, J = 17.3, 15.0, 10.3, 4.3 Hz, 2H), 0.86 – 0.67 (m, 1H). 13C NMR 
(126 MHz, MeOD) δ 165.57, 159.47, 158.87, 149.07, 144.49, 138.25, 130.54, 129.49, 128.71, 














49.17, 40.94, 33.70, 28.18, 7.64. HRMS (ESI+), m/z [M+H+] calculated for C36H40N2O7  





Compound 5.15c was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.59 (s, 1H), 7.75 (dd, J = 8.6, 2.5 
Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.26 (d, J = 2.3 Hz, 1H), 7.22 – 7.15 (m, 2H), 6.97 – 6.90 (m, 
3H), 6.78 – 6.70 (m, 2H), 4.62, (s, 1H), 4.55 (t, J = 3.1 Hz, 1H), 3.77 (dt, J = 11.8, 4.2 Hz, 2H), 
3.73 (s, 3H), 3.68 (s, 3H), 3.61 (tt, J = 9.1, 4.2 Hz, 1H), 3.27 (ddd, J = 12.1, 10.3, 2.6 Hz, 2H), 
3.05 – 2.92 (m, 1H), 2.19 (s, 3H), 2.09 – 1.98 (m, 2H), 1.69 (m, 4H), 1.60 – 1.47 (m, 2H), 1.37 
(dtd, J = 13.6, 9.7, 4.2 Hz, 2H), 1.31 (dd, J = 7.1, 2.3 Hz, 4H). 13C NMR (126 MHz, MeOD) δ 
165.64, 159.50, 158.86, 156.21, 149.07, 138.22, 130.59, 129.50, 128.73, 127.84, 125.43, 124.76, 
121.59, 114.83, 112.63, 110.75, 109.73, 79.98, 69.68, 59.67, 55.38, 54.81, 53.05, 34.62, 34.47, 





























Compound 5.15d was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.68 (d, J = 2.8 Hz, 1H), 7.83 (dt, 
J = 8.5, 3.2 Hz, 1H), 7.79 (t, J = 3.1 Hz, 1H), 7.30 (m, 2H), 7.04 – 6.97 (m, 4H), 6.81 (ddd, J = 
16.9, 8.8, 4.7 Hz, 2H), 4.65 (s, 1H), 4.62 – 4.56 (m, 1H), 3.85 – 3.70 (m, 2H), 3.55 (ddd, J = 
10.5, 6.6, 3.3 Hz, 2H), 3.25 (dt, J = 3.1, 1.6 Hz, 6H), 3.02 (qd, J = 7.5, 2.9 Hz, 1H), 2.66 (d, J = 
2.6 Hz, 1H), 2.27 (d, J = 3.0 Hz, 3H), 2.14 – 2.04 (m, 2H), 1.83 (d, J = 13.0 Hz, 2H), 1.72 (d, J = 
12.3 Hz, 2H), 1.62 (dd, J = 14.0, 3.1 Hz, 2H), 1.33 (dt, J = 6.7, 2.2 Hz, 2H), 1.29 (dd, J = 6.7, 2.9 
Hz, 2H). 13C NMR (126 MHz, MeOD) δ 165.64, 159.50, 158.86, 156.21, 149.07, 138.22, 
130.59, 129.50, 128.73, 127.84, 125.43, 124.76, 121.59, 114.83, 112.63, 110.75, 109.73, 80.02, 
69.68, 59.67, 55.38, 54.81, 53.05, 34.62, 34.47, 27.46, 24.69, 7.49. HRMS (ESI+), m/z [M+H+] 





Compound 5.15a was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.50 (s, 1H), 7.78 (dd, J = 8.4, 2.2 














3H), 6.76 – 6.70 (m, 2H), 4.50 (t, J = 3.2 Hz, 1H), 3.78 (dt, J = 11.9, 4.0 Hz, 4H), 3.70 (s, 3H), 
3.67 (s, 3H), 3.60 (tt, J = 9.1, 4.2 Hz, 2H), 3.30 (ddd, J = 12.0, 10.1, 2.5 Hz, 4H), 3.05 – 2.92 (m, 
1H), 2.10 (s, 3H), 2.02 – 1.96 (m, 2H), 1.65 (m, 4H), 1.58 – 1.49 (m, 2H), 1.39 (dtd, J = 13.5, 
9.9, 4.2 Hz, 4H) 1.31 (dd, J = 7.1, 2.3 Hz, 4H). 13C NMR (126 MHz, MeOD) δ 165.94, 159.55, 
158.06, 155.71, 149.00, 138.42, 130.51, 129.00, 128.33, 127.14, 125.44, 124.56, 121.50, 114.89, 
112.03, 110.55, 109.43, 79.90, 69.68, 59.63, 55.18, 54.21, 53.15, 34.64, 34.40, 27.56, 24.60, 





Compound 5.15b was obtained following the procedure for the synthesis of 5.12a as a white 
amorphous solid (30%): 1H NMR (500 MHz, Methanol-d4) δ 8.66 (d, J = 2.8 Hz, 1H), 7.82 (dt, 
J = 8.6, 3.0 Hz, 1H), 7.77 (t, J = 2.8 Hz, 1H), 7.28 (m, 2H), 7.01 – 6.92 (m, 4H), 6.80 (ddd, J = 
16.7, 8.9, 4.5 Hz, 2H), 4.60 – 4.51 (m, 1H), 3.83 – 3.72 (m, 4H), 3.50 (ddd, J = 10.7, 6.6, 3.1 Hz, 
4H), 3.27 (d, 6H), 3.02 (qd, J = 7.5, 2.9 Hz, 2H), 2.62 (d, J = 2.8 Hz, 1H), 2.20 (s, 3H), 2.13 – 
2.08 (m, 2H), 1.80 (d, J = 12.8 Hz, 2H), 1.75 (d, J = 12.5 Hz, 2H), 1.60 (dd, J = 14.2, 3.0 Hz, 
2H), 1.35 (dt, J = 6.5, 2.4 Hz, 4H), 1.30 (dd, J = 6.9, 2.6 Hz, 4H). 13C NMR (126 MHz, MeOD) 
δ 165.04, 159.51, 158.82, 156.22, 149.27, 138.52, 130.50, 129.51, 128.70, 127.14, 125.42, 




















Compound 5.50a was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.94 – 
7.87 (m, 2H), 7.39 – 7.30 (m, 2H), 7.13 – 7.10 (m, 1H), 7.10 – 7.05 (m, 2H), 6.93 (ddd, J = 8.3, 
2.6, 0.9 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 4.40 (s, 1H), 4.32 (dt, J = 9.2, 4.9 Hz, 1H), 3.90 (s, 
3H), 3.86 (s, 3H), 2.34 (s, 3H), 2.19 – 2.12 (m, 2H), 1.93 (dq, J = 12.9, 4.5 Hz, 2H), 1.81 – 1.69 
(m, 2H), 1.57 (s, 3H), 1.46 (s, 9H), 1.37 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.40, 159.65, 
159.45, 159.23, 157.20, 149.35, 138.51, 130.94, 129.85, 129.06, 128.04, 126.04, 125.39, 124.28, 
121.92, 121.47, 115.14, 113.22, 113.06, 110.91, 110.58, 55.79, 55.23, 51.07, 28.38, 27.26, 8.32. 























Compound 5.17a was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 9.65 (s, 1H), 8.50 (s, 1H), 8.32 (s, 
1H), 8.01 (dd, J = 8.7, 2.4 Hz, 1H), 7.94 (d, J = 2.4 Hz, 1H), 7.59 (d, J = 8.6 Hz, 1H), 7.38 (t, J = 
7.9 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 7.14 – 7.08 (m, 3H), 6.97 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 
5.76 (s, 1H), 4.71 (s, 1H), 3.89 (s, 3H), 3.82 (s, 3H), 2.21 (s, 3H), 1.88 (td, J = 15.0, 13.3, 9.1 Hz, 
6H), 1.62 (dd, J = 10.2, 5.9 Hz, 2H), 1.33 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.61, 
159.42, 157.05, 150.23, 139.15, 129.86, 126.24, 122.19, 121.67, 95.24, 56.38, 55.57, 53.15, 





Compound 5.50b was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 8.79 (s, 1H), 8.69 (s, 1H), 7.94 – 
7.88 (m, 2H), 7.38 – 7.30 (m, 2H), 7.12 (dt, J = 7.6, 1.1 Hz, 1H), 7.10 – 7.05 (m, 2H), 4.56 (t, J = 
4.2 Hz, 1H), 4.38 (s, 1H), 3.88 (d, J = 19.7 Hz, 5H), 2.34 (s, 3H), 1.95 (d, J = 12.3 Hz, 2H), 1.84 
(dt, J = 9.2, 4.1 Hz, 4H), 1.78 – 1.72 (m, 2H), 1.60 (s, 3H), 1.45 (s, 9H), 1.37 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 165.65, 159.90, 159.71, 159.48, 157.18, 149.61, 138.76, 131.18, 130.10, 
129.31, 128.28, 126.29, 125.72, 124.58, 122.17, 121.67, 115.38, 113.36, 111.16, 110.49, 72.88, 
56.03, 55.47, 51.82, 32.06, 28.63, 26.37, 8.45. HRMS (ESI+), m/z [M+Na+] calculated for 














Compound 5.17b was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Methanol-d4) δ 8.59 (s, 1H), 7.74 (dd, J = 8.6, 2.4 
Hz, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.20 – 7.16 (m, 3H), 6.96 – 6.90 (m, 3H), 6.76 (ddd, J = 8.4, 
2.7, 1.0 Hz, 2H), 4.33 (dt, J = 7.3, 3.7 Hz, 1H), 3.73 (s, 3H), 3.68 (s, 3H), 3.20 (s, 1H), 2.14 (s, 
3H), 1.92 – 1.84 (m, 2H), 1.78 – 1.69 (m, 2H), 1.69 – 1.54 (m, 4H), 1.26 (s, 3H). 13C NMR (126 
MHz, MeOD) δ 165.65, 159.59, 158.98, 156.56, 149.14, 138.32, 130.72, 129.62, 128.87, 127.94, 
125.52, 124.71, 121.73, 121.14, 114.95, 113.19, 112.81, 110.84, 110.31, 73.03, 55.54, 54.98, 




Cyclohex-2-ene-1,4-diyl dimethanesulfonate (5.52). 
Triethylamine (0.07mL, 0.526 mmol) was added to an ice-cooled solution of alcohol 5.5131 
(0.03 g, 0.26 mmol) in anhydrous tetrahydrofuran (2.5 ml), followed by a dropwise addition of 
methanesulfonyl chloride (0.03 ml, 0.39 mmol). The reaction mixture was then allowed to stir at 














organic layers were combined, dried (over Na2SO4), concentrated to yield 5.52 as a white 




yl)oxy)cyclohex-2-en-1-yl methanesulfonate (5.53). 
Compound 5.52 (0.67g, 2.5mmol) was added to a solution of Cs2CO3 (0.65, 2.0mmol), 5.36 
(0.431g, 1.0mmol) in anhydrous DMF (10mL).  The mixture was heated 70oC for 12 h.  The 
reaction was then cooled to rt and worked up with sat. LiCl (3 x 20mL) and EtOAc (30mL).  The 
organic layer was dried and concentrated to yield mesylate 5.53, which was used immediately 




[1,1'-biphenyl]-3-carboxamide  (5.54). 
A mixture of  methanesulfonate ester 5.53 (mg, 1.0 mmol) and sodium azide (mg, 3.0 mmol) 
in anhydrous dimethylformamide was heated at 100 OC. After 12 h, the reaction mixture was 
cooled to rt and concentrated. The residue was diluted with water and extracted with ethyl 
















chromatography (SiO2, 1:20, EtOAc : hexane) to afford 5.54 as a white amorphous solid (60%): 
1H NMR (500 MHz, Methanol-d4) δ 8.60 (s, 1H), 7.76 (dd, J = 8.1, 2.4 Hz, 1H), 7.60 (d, J = 2.3 
Hz, 1H), 7.20 – 7.12 (m, 3H), 6.90 – 6.85 (m, 3H), 6.70 (ddd, J = 8.2, 2.3, 1.2 Hz, 2H), 5.62 (d, 
2H), 4.27-4.20 (m, 1H), 3.86 (s, 3H), 3.82 (s, 3H), 2.25 (m, 1H), 2.21 (m, 1H), 2.11 (s, 3H), 
1.96-1.72 (m, 4H). 13C NMR (126 MHz, MeOD) δ 165.55, 159.39, 158.08, 155.00, 150.32, 
138.79, 130.92, 129.22, 128.45, 127.17, 125.99, 125.05, 124.11, 121.83, 121.14, 114.98, 113.59, 





OsO4 (0.001g, 0.002mmol) was added at rt to a solution of 5.54 (0.01g, 0.02mmol) and NMO 
(0.006g, 0.05mmol) in THF/H2O (1:1, 0.6 mL).  The resulting solution was stirred at rt on.  After 
12 h the THF was evaporated and the residue was extracted with EtOAc (3 x 5mL).  The organic 
layers were collected, dried, concentrated and purified by column chromatography (SiO2, 1:10, 
MeOH: DCM) to give a white solid, which was then dissolved in EtOAc (4 mL). Pd/C (10% 
w/w, 20 mg) was added, the mixture was degassed and flushed with argon, then degassed and 
flushed with hydrogen using a balloon.  After 12 h the reaction was filtered through a pad of 
Celite, washed with EtOAc.  The filtrate was concentrated and purified via column 
chromatography (SiO2, 1:10, MeOH: DCM) to give 5.16 as a white solid (33% yield):  1H NMR 














7.18 – 7.10 (m, 3H), 6.93 – 6.88 (m, 3H), 6.71 (ddd, J = 8.2, 2.4, 1.3 Hz, 2H), 4.07-4.05 (m, 1H), 
3.96-3.94 (m, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.72-3.69 (m, 1H), 2.74 (t, J = 3 Hz, 1H), 2.16 (s, 
3H), 1.94-1.72 (m, 4H). 13C NMR (126 MHz, MeOD) δ 165.87, 159.09, 158.78, 156.16, 149.34, 
138.72, 130.32, 129.62, 128.17, 127.77, 125.55, 124.31, 121.23, 121.04, 114.98, 113.49, 112.31, 
110.34, 73.03, 72.42, 71.06, 55.52, 54.18, 23.89, 23.40, 7.80. HRMS (ESI+), m/z [M+H+] 










Compound 5.64a was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 7.73 (ddd, J = 10.5, 8.3, 2.4 Hz, 


















(t, J = 2.4 Hz, 1H), 6.89 – 6.84 (m, 1H), 6.80 (dd, J = 8.1, 2.3 Hz, 1H), 6.76 (dt, J = 9.5, 2.6 Hz, 
2H), 4.53 (s, 1H), 4.42 (t, J = 3.3 Hz, 1H), 4.33– 4.24 (m, 1H), 3.96 (m, 1H), 3.85 (d, 6H), 3.11 
(dt, J = 10.2, 4.8 Hz, 1H), 2.32 (tt, J = 11.8, 3.6 Hz, 1H), 2.12 (ddt, J = 19.1, 12.5, 3.7 Hz, 4H), 
1.92 (ddd, J = 27.5, 14.0, 3.1 Hz, 2H), 1.86 – 1.73 (m, 6H), 1.58(dtd, J = 18.2, 10.5, 8.3, 4.3 Hz, 
4H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 167.44, 159.67, 159.19, 155.00, 140.93, 
139.33, 131.01, 130.06, 129.79, 128.40, 128.03, 122.12, 116.41, 116.08, 113.66, 113.07, 111.32, 
70.52, 56.16, 55.00, 43.45, 34.19, 33.88, 30.34, 29.15, 28.55, 25.70. HRMS (ESI+), m/z [M+H+] 




[1,1'-biphenyl]-3-carboxamide. (5.18a).  
Compound 5.18a was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 7.75 (ddd, J = 10.7, 8.5, 2.4 Hz, 
1H), 7.64 (dd, J = 10.5, 2.3 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 7.08 (q, J = 9.1, 8.3 Hz, 3H), 7.03 
(t, J = 2.2 Hz, 1H), 6.99 – 6.94 (m, 1H), 6.87 (dd, J = 8.3, 2.5 Hz, 1H), 6.78 (dt, J = 9.8, 2.6 Hz, 
2H), 4.46 (t, J = 3.1 Hz, 1H), 4.30 – 4.23 (m, 1H), 3.96 (ddd, J = 11.9, 7.7, 4.3 Hz, 1H), 3.81 (dt, 
J = 7.1, 3.4 Hz, 6H), 3.09 (dt, J = 10.0, 5.0 Hz, 1H), 2.42 (tt, J = 12.0, 3.4 Hz, 1H), 2.12 (ddt, J = 
19.2, 12.6, 3.3 Hz, 4H), 1.93 (ddd, J = 27.7, 14.2, 3.2 Hz, 2H), 1.84 – 1.72 (m, 6H), 1.56 (dtd, J 
= 18.1, 10.8, 8.1, 4.3 Hz, 4H). 13C NMR (126 MHz, CDCl3) δ 167.49, 159.97, 159.69, 155.90, 











111.62, 70.22, 56.46, 55.99, 43.40, 34.09, 33.86, 30.74, 29.65, 28.45, 25.78. HRMS (ESI+), m/z 





Compound 5.64b was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.80 (ddd, J = 8.4, 6.1, 
2.3 Hz, 1H), 7.65 (t, J = 3.0 Hz, 1H), 7.30 (t, J = 8.1 Hz, 1H), 7.10 – 7.00 (m, 2H), 6.95 (td, J = 
9.2, 6.4 Hz, 2H), 6.87 (dd, J = 8.3, 2.2 Hz, 1H), 6.80 – 6.72 (m, 2H), 4.48 (s, 1H) 4.22 (t, J = 
3.9Hz, 1H), 4.07 (dd, J = 9.5, 4.6 Hz, 1H), 3.91 (ddt, J = 10.8, 7.4, 4.1 Hz, 1H), 3.85 (s, 3H), 
3.81 (s, 3H), 3.10 – 3.01 (m, 1H), 2.55 – 2.40 (m, 1H), 2.22 – 2.09 (m, 4H), 2.03 – 1.96 (m, 1H), 
1.90 – 1.86 (m, 1H), 1.80 – 1.73 (m, 1H), 1.71 – 1.35 (m, 8H), 1.31 (s, 9H). 13C NMR (126 MHz, 
CD2Cl2) δ 159.83, 159.00, 155.18, 139.89, 139.46, 130.57, 129.50, 129.06, 127.45, 122.10, 
116.28, 115.59, 112.08, 111.01, 74.45, 55.65, 55.22, 42.07, 33.45, 29.67, 29.37, 29.02, 28.29. 

















Compound 5.18b was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, Methylene Chloride-d2) δ 7.78 (ddd, J = 8.7, 6.2, 
2.5 Hz, 1H), 7.69 (t, J = 2.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.15 – 7.10 (m, 2H), 7.05 (td, J = 
9.0, 6.2 Hz, 2H), 6.89 (dd, J = 8.3, 2.6 Hz, 1H), 6.84 – 6.78 (m, 2H), 4.26 (t, J = 3.8 Hz, 1H), 
4.17 (dd, J = 9.7, 4.6 Hz, 1H), 3.94 (ddt, J = 11.4, 7.5, 4.3 Hz, 1H), 3.85 (d, J = 2.6 Hz, 3H), 3.82 
(d, J = 2.3 Hz, 3H), 3.13 – 3.07 (m, 1H), 2.52 – 2.42 (m, 1H), 2.23 – 2.05 (m, 5H), 2.01 – 1.96 
(m, 1H), 1.94 – 1.88 (m, 1H), 1.83 – 1.73 (m, 1H), 1.71 – 1.35 (m, 8H). 13C NMR (126 MHz, 
CD2Cl2) δ 159.53, 159.50, 155.78, 139.81, 139.36, 130.51, 129.56, 129.16, 127.85, 122.11, 
116.21, 115.51, 112.88, 111.05, 74.40, 55.85, 55.40, 42.87, 33.41, 29.65, 29.60, 29.12, 28.49. 
























biphenyl]-4-yl)oxy)cyclohexyl)carbamate (5.72a).  
Compound 5.72a was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 8.01 (s, 1H), 7.97 (dt, J = 8.5, 2.4 
Hz, 1H), 7.89 – 7.83 (m, 1H), 7.58 (dd, J = 8.7, 1.8 Hz, 2H), 7.49 – 7.41 (m, 3H), 7.39 (d, J = 8.9 
Hz, 1H), 7.32 (t, J = 7.7 Hz, 1H), 7.22 (dd, J = 8.6, 1.8 Hz, 1H), 7.10 (t, J = 1.4 Hz, 1H), 6.97 (s, 
1H), 6.95 (d, J = 8.9 Hz, 1H), 6.88 (dd, J = 8.4, 2.3 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 4.60 – 4.55 
(m, 1H), 4.32 (dt, J = 9.5, 5.4 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 2.89 (dd, J = 9.7, 3.3 Hz, 1H), 
2.16 – 2.09 (m, 2H), 2.04 – 1.97 (m, 2H), 1.78 – 1.69 (m, 4H), 1.47 (s, 9H). 13C NMR (126 MHz, 
DMSO) δ 164.72, 158.99, 158.74, 138.88, 138.19, 138.17, 129.90, 129.25, 129.12, 127.39, 
127.33, 126.16, 125.93, 121.80, 120.72, 116.11, 115.71, 115.22, 112.59, 111.43, 55.89, 55.13, 
























Compound 5.19a was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, DMSO-d6) δ 10.25 (s, 1H), 8.04 (dt, J = 8.7, 2.2 
Hz, 1H), 8.01 – 7.98 (m, 1H), 7.86 (dd, J = 9.0, 2.1 Hz, 2H), 7.63 – 7.54 (m, 3H), 7.49 (d, J = 8.6 
Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.26 (dd, J = 8.9, 1.5 Hz, 1H), 7.14 (t, J = 1.2 Hz, 1H), 7.12 (s, 
1H), 7.01 (d, J = 8.7 Hz, 1H), 6.95 (dd, J = 8.2, 2.6 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 4.30 (dt, J 
= 9.7, 5.2 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 2.87 (dd, J = 9.5, 3.7 Hz, 1H), 2.13 – 2.06 (m, 1H), 
2.06 – 1.99 (m, 1H), 1.93 (dd, J = 9.5, 4.6 Hz, 1H), 1.60 – 1.27 (m, 4H). 13C NMR (126 MHz, 
DMSO) δ 164.72, 158.99, 158.74, 138.88, 138.19, 138.17, 129.90, 129.25, 129.12, 127.39, 
127.33, 126.16, 125.93, 121.80, 120.72, 116.11, 115.71, 115.22, 112.59, 111.43, 55.89, 55.13, 






Compound 5.72b was obtained following the procedure for the synthesis of 5.1 as a white 
amorphous solid (35%): 1H NMR (500 MHz, Chloroform-d) δ 7.92 (dd, J = 8.6, 2.4 Hz, 1H), 
7.89 (s, 1H), 7.83 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 8.6 Hz, 2H), 7.54 (d, J = 8.6 Hz, 2H), 7.52 – 
7.49 (m, 2H), 7.36 (t, J = 7.9 Hz, 1H), 7.12 (dt, J = 7.6, 1.2 Hz, 1H), 7.09 (dd, J = 2.6, 1.6 Hz, 
1H), 7.05 (d, J = 8.6 Hz, 1H), 6.95 (d, J = 8.8 Hz, 1H), 6.92 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 4.58 












(m, 2H), 1.81 – 1.73 (m, 2H), 1.71 – 1.58 (m, 4H), 1.45 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
165.49, 159.70, 157.18, 155.62, 139.20, 137.22, 133.46, 131.06, 129.93, 129.55, 128.79, 128.28, 
127.56, 122.36, 120.83, 116.66, 115.68, 113.34, 111.43, 71.52, 56.24, 55.72, 53.22, 48.64, 28.83, 






Compound 5.19b was obtained following the procedure for the synthesis of 5.4a as a white 
amorphous solid (70%): 1H NMR (500 MHz, DMSO-d6) δ 10.24 (s, 1H), 8.03 (dd, J = 8.6, 2.4 
Hz, 1H), 7.98 (d, J = 2.4 Hz, 1H), 7.86 – 7.83 (m, 2H), 7.62 – 7.57 (m, 4H), 7.36 (t, J = 7.9 Hz, 
1H), 7.25 (d, J = 8.8 Hz, 1H), 7.12 (dt, J = 7.6, 1.2 Hz, 1H), 7.10 (dd, J = 2.6, 1.5 Hz, 1H), 7.04 
– 7.01 (m, 2H), 6.95 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.62 (dd, J = 4.3, 2.3 Hz, 1H), 3.86 (s, 3H), 
3.80 (s, 3H), 3.10 (td, J = 8.9, 8.2, 4.0 Hz, 1H), 2.01 – 1.93 (m, 2H), 1.79 – 1.59 (m, 6H). 13C 
NMR (126 MHz, DMSO) δ 164.43, 158.68, 158.44, 155.92, 138.56, 137.91, 134.51, 132.02, 
129.58, 128.95, 127.16, 126.62, 125.88, 121.49, 120.42, 116.18, 114.90, 112.30, 111.15, 69.50, 
55.60, 54.83, 47.98, 26.70, 24.84. HRMS (ESI+), m/z [M+H+] calculated for C33H34N2O4 














carboxamide (5.80).  
Compound 5.80 was synthesized following the procedure reported in Chapter 3. 
 
 
4-(Benzyloxy)cyclohexyl 4-methylbenzenesulfonate (5.84a). 
Compound 5.84a and related derivatives (5.84a-d) were synthesized following the procedure 
























Potassium carbonate (30 mg, 0.19 mmol) was added to a solution of 5.80 (45 mg, 0.16 mmol) 
in anhydrous DMF (1 mL) and stirred at rt for 30 min, before 4-(benzyloxy)cyclohexyl 4-
methylbenzenesulfonate (75 mg, 0.19 mmol) and TBAI (7 mg, 0.016 mmol) were added. The 
solution was heated to 90 °C for 16h. Distilled water (3x 5 mL) was added to the mixture and the 
organic layer extracted with EtOAc. After removal of the solvent on a rotorevarporator, the crude 
mixture was purified by column chromatography (SiO2, 1:10, MeOH: DCM) to give 5.20 as a 
white solid in 75% yield: 1H NMR (500 MHz, Chloroform-d) δ 7.68 (dt, J = 8.6, 2.4 Hz, 1H), 
7.57 (dd, J = 3.6, 2.4 Hz, 1H), 7.38 – 7.19 (m, 12H), 7.09 – 6.95 (m, 5H), 6.89 (dddd, J = 11.3, 
8.5, 4.7, 2.0 Hz, 2H), 6.75 (dd, J = 8.6, 2.7 Hz, 1H), 5.90 (dt, J = 6.0, 2.7 Hz, 1H), 4.55 (s, 2H), 
4.35 (dt, J = 6.6, 3.4 Hz, 1H), 4.29 (dt, J = 8.4, 4.2 Hz, 1H), 3.84 (d, J = 4.2 Hz, 6H), 3.53 – 3.42 
(m, 3H), 2.84 (t, J = 7.1 Hz, 2H), 2.13 – 1.96 (m, 2H), 1.94 – 1.86 (m, 1H), 1.74 – 1.66 (m, 2H), 
1.62 – 1.48 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 167.16, 163.87, 161.90, 159.66, 159.29, 
156.51, 156.33, 139.35, 131.37, 130.75, 129.76, 129.46, 128.74, 128.36, 127.86, 127.79, 125.27, 
122.35, 117.97, 116.45, 115.65, 115.64, 113.25, 111.17, 70.55, 70.13, 41.34, 34.71, 32.34, 30.35, 
27.74, 23.11, 21.27, 14.54. HRMS (ESI+), m/z [M+H+] calculated for C42H43FNO5 660.3125; 
















Compound 5.21 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 7.68 (dd, J = 8.6, 2.4 Hz, 1H), 
7.52 (d, J = 2.4 Hz, 1H), 7.48 – 7.43 (m, 3H), 7.37 – 7.31 (m, 1H), 7.30 – 7.27 (m, 1H), 7.22 (dd, 
J = 8.9, 8.1 Hz, 3H), 7.17 (d, J = 8.3 Hz, 1H), 7.10 – 7.07 (m, 1H), 7.02 (ddt, J = 4.2, 2.5, 1.3 Hz, 
2H), 6.96 (d, J = 8.5 Hz, 2H), 6.91 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.82 (dd, J = 8.3, 2.7 Hz, 1H), 
6.71 (d, J = 2.7 Hz, 1H), 5.94 (t, J = 5.8 Hz, 1H), 4.47 (d, J = 7.9 Hz, 3H), 3.85 (d, J = 3.4 Hz, 
6H), 3.78 – 3.65 (m, 2H), 3.50 – 3.40 (m, 3H), 2.83 (t, J = 7.1 Hz, 2H), 2.06 – 2.01 (m, 1H), 2.01 
– 1.95 (m, 1H), 1.93 – 1.83 (m, 2H), 1.76 – 1.65 (m, 6H), 1.63 – 1.51 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 167.19, 163.58, 159.32, 159.11, 154.70, 142.23, 139.05, 138.23, 131.58, 131.54, 
131.26, 130.41, 129.94, 129.42, 129.24, 129.17, 129.08, 128.27, 127.76, 126.79, 124.94, 122.24, 
121.27, 117.27, 116.27, 116.10, 115.58, 115.35, 114.29, 114.12, 112.82, 111.00, 69.56, 69.06, 
41.05, 32.72, 31.98, 30.61, 29.39, 27.62. HRMS (ESI+), m/z [M+H+] calculated for 





Compound 5.22 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 7.68 (dt, J = 8.6, 2.2 Hz, 1H), 












1.4 Hz, 2H), 6.75 (dd, J = 8.3, 2.7 Hz, 1H), 5.95 – 5.88 (m, 1H), 4.51 (s, 2H), 4.35 (dt, J = 6.6, 
3.4 Hz, 1H), 4.31 – 4.24 (m, 1H), 3.84 (d, J = 4.3 Hz, 6H), 3.54 – 3.42 (m, 3H), 2.84 (t, J = 7.1 
Hz, 2H), 2.15 – 1.95 (m, 3H), 1.93 – 1.83 (m, 1H), 1.75 – 1.65 (m, 2H), 1.63 – 1.49 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 166.93, 161.64, 159.39, 159.03, 156.02, 142.19, 139.09, 137.66, 
131.11, 130.49, 129.96, 129.49, 129.20, 128.88, 128.12, 126.98, 125.02, 122.09, 117.71, 116.18, 
115.78, 115.39, 114.31, 112.98, 110.91, 69.54, 69.13, 41.10, 32.08, 30.09, 29.85, 28.45, 27.59, 





Compound 5.23 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%):  1H NMR (500 MHz, Chloroform-d) δ 7.68 (dt, J = 8.6, 2.7 Hz, 1H), 
7.58 (t, J = 2.6 Hz, 1H), 7.39 – 7.29 (m, 2H), 7.24 (dd, J = 8.5, 2.4 Hz, 1H), 7.21 – 7.15 (m, 2H), 
7.09 – 7.03 (m, 3H), 7.03 – 6.99 (m, 1H), 6.97 (d, J = 8.7 Hz, 1H), 6.89 (dddd, J = 8.5, 7.8, 3.9, 
2.3 Hz, 2H), 6.76 (dd, J = 6.6, 2.7 Hz, 1H), 5.94 – 5.90 (m, 1H), 4.53 (s, 2H), 4.35 (dt, J = 6.5, 
3.3 Hz, 1H), 4.29 (ddd, J = 8.6, 4.8, 3.3 Hz, 1H), 3.88 – 3.81 (m, 6H), 3.56 – 3.41 (m, 3H), 2.85 
(t, J = 7.1 Hz, 2H), 2.34 (d, J = 1.8 Hz, 3H), 2.16 – 1.98 (m, 2H), 1.94 – 1.88 (m, 1H), 1.70 (tdd, 
J = 12.9, 6.6, 3.5 Hz, 2H), 1.62 – 1.50 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 167.16, 163.85, 











130.54, 130.20, 129.76, 129.45, 128.76, 128.73, 128.48, 128.36, 128.09, 127.99, 127.25, 126.22, 
126.19, 125.26, 122.34, 117.98, 116.61, 116.44, 116.05, 115.63, 114.54, 114.38, 113.23, 111.16, 
69.16, 68.77, 41.34, 32.33, 30.35, 30.10, 27.77, 19.27, 19.24. HRMS (ESI+), m/z [M+H+] 





Compound 5.24 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%):  1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.95 – 
7.87 (m, 2H), 7.39 – 7.31 (m, 7H), 7.13 (ddd, J = 7.6, 1.6, 1.0 Hz, 1H), 7.11 – 7.04 (m, 2H), 6.93 
(ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 4.57 (s, 2H), 4.45 (dt, J = 7.6, 4.0 Hz, 
1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.57 (dt, J = 7.8, 4.0 Hz, 1H), 2.32 (s, 3H), 2.17 – 2.11 (m, 2H), 
2.10 – 2.03 (m, 2H), 1.70 – 1.59 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 165.64, 159.87, 
159.73, 159.45, 157.45, 149.57, 139.01, 138.74, 131.13, 130.08, 129.32, 128.54, 128.30, 127.62, 
126.25, 125.69, 124.60, 122.14, 121.63, 115.35, 113.29, 111.12, 110.75, 75.18, 74.98, 70.31, 
















Compound 5.25 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.97 – 
7.85 (m, 2H), 7.52 – 7.44 (m, 2H), 7.42 – 7.30 (m, 2H), 7.24 (d, J = 8.3 Hz, 2H), 7.14 – 7.12 (m, 
1H), 7.09 (dd, J = 2.6, 1.6 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.96 (d, J = 0.7 Hz, 1H), 6.93 (ddd, 
J = 8.3, 2.6, 1.0 Hz, 1H), 6.89 (d, J = 8.7 Hz, 1H), 4.51 (s, 2H), 4.49 – 4.43 (m, 2H), 3.90 (s, 
3H), 3.86 (s, 3H), 3.55 (dt, J = 7.8, 4.3 Hz, 1H), 2.32 (s, 3H), 2.17 – 2.10 (m, 2H), 2.09 – 2.00 
(m, 3H), 1.72 – 1.59 (m, 3H).13C NMR (126 MHz, CDCl3) δ 165.65, 159.88, 159.72, 159.45, 
157.40, 149.57, 138.74, 138.06, 131.63, 131.14, 130.08, 129.32, 129.23, 128.98, 128.30, 126.24, 
125.70, 124.59, 122.14, 121.44, 115.35, 113.29, 111.12, 110.73, 75.18, 75.04, 69.59, 34.46, 
32.08, 30.10, 29.85, 27.93, 22.85, 21.01, 14.29, 8.46. HRMS (ESI+), m/z [M+H+] calculated for 
























Compound 5.26 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.97 – 
7.83 (m, 2H), 7.41 – 7.22 (m, 12H), 7.19 – 7.03 (m, 4H), 6.97 – 6.83 (m, 2H), 4.52 (s, 2H), 4.45 
(dt, J = 7.7, 4.0 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.55 (dt, J = 7.8, 4.2 Hz, 1H), 2.32 (s, 3H), 
2.17 – 2.09 (m, 2H), 2.09 – 2.00 (m, 2H), 1.72 – 1.58 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
165.89, 161.07, 160.13, 159.96, 159.70, 157.65, 149.82, 138.99, 137.78, 133.58, 131.39, 130.33, 
129.57, 129.20, 129.15, 128.93, 128.55, 126.49, 125.95, 124.83, 122.40, 121.90, 115.61, 113.63, 
113.54, 111.37, 110.98, 75.42, 75.30, 69.82, 30.35, 30.11, 28.22, 8.71. HRMS (ESI+), m/z 





Compound 5.27 was obtained following the procedure for the synthesis of 5.20 as a white 
amorphous solid (70%): 1H NMR (500 MHz, Chloroform-d) δ 8.80 (s, 1H), 8.70 (s, 1H), 7.96 – 
7.85 (m, 2H), 7.39 – 7.35 (m, 2H), 7.32 (d, J = 8.6 Hz, 1H), 7.22 – 7.15 (m, 4H), 7.13 (dt, J = 
7.6, 1.2 Hz, 1H), 7.09 (dd, J = 2.6, 1.5 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 6.96 – 6.95 (m, 1H), 
6.93 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.88 (d, J = 8.7 Hz, 1H), 4.55 (s, 2H), 4.53 – 4.48 (m, 2H), 
3.90 (s, 3H), 3.86 (s, 3H), 3.56 – 3.48 (m, 1H), 2.35 (d, J = 5.5 Hz, 6H), 2.11 – 2.00 (m, 2H), 
1.95 – 1.87 (m, 2H), 1.8 13C NMR (126 MHz, CDCl3) δ 165.90, 161.11, 160.12, 159.97, 159.70, 











126.51, 126.22, 125.86, 124.84, 122.40, 121.86, 115.60, 113.55, 111.36, 110.77, 75.23, 73.80, 
68.87, 34.71, 32.33, 30.35, 30.11, 28.15, 27.80, 23.10, 21.26, 19.28, 14.54, 8.77. HRMS (ESI+), 
m/z [M+H+] calculated for C39H40NO7 634.2805; found 634.2827. 
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